<?xml version="1.0" standalone="yes"?>
<QueryArticlesSet>
  <T_Query>
    <QueryID>1</QueryID>
    <Name>MavsHuman</Name>
    <ProteinID>1</ProteinID>
    <OrganismID>1</OrganismID>
    <KeywordListID>1</KeywordListID>
    <ResultCount>231</ResultCount>
  </T_Query>
  <T_Protein>
    <ProteinID>1</ProteinID>
    <Protein>Mavs</Protein>
  </T_Protein>
  <T_Organism>
    <OrganismID>1</OrganismID>
    <Organism>Human</Organism>
  </T_Organism>
  <T_Keyword>
    <KeywordID>1</KeywordID>
    <Keyword />
  </T_Keyword>
  <T_QueryArticles>
    <QueryArticleID>1</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>24183820</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>2</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>24128418</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>3</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>24096085</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>4</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>24078691</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>5</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23962476</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>6</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23951545</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>7</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23942572</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>8</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23873628</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>9</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23843640</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>10</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23810392</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>11</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23770038</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>12</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23702035</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>13</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23671700</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>14</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23653683</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>15</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23626834</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>16</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23611287</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>17</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23592984</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>18</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23582325</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>19</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23555725</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>20</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23555247</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>21</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23545497</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>22</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23544010</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>23</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23542348</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>24</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23526820</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>25</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23503762</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>26</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23499490</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>27</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23498958</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>28</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23432157</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>29</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23419645</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>30</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23414438</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>31</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23408632</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>32</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23367207</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>33</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23337771</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>34</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23321557</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>35</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23320079</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>36</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23308256</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>37</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23308066</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>38</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23301932</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>39</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23292079</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>40</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23273991</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>41</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23264040</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>42</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23249700</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>43</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23246644</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>44</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23096996</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>45</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23090998</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>46</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23087404</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>47</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23077300</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>48</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23063572</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>49</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23028806</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>50</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23028469</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>51</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23015697</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>52</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23014529</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>53</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22996173</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>54</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22908223</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>55</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22901541</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>56</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22870331</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>57</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22844514</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>58</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22792062</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>59</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22749352</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>60</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22674996</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>61</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22664327</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>62</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22626058</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>63</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22623799</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>64</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22623778</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>65</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22607805</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>66</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22558311</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>67</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22532683</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>68</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22440325</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>69</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22427742</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>70</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22383950</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>71</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22345667</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>72</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22341464</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>73</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22312431</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>74</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22312267</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>75</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22301138</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>76</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22278390</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>77</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22255022</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>78</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22254549</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>79</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22238314</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>80</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22235281</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>81</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22152002</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>82</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22131337</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>83</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22110409</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>84</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22105485</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>85</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22050228</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>86</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22039483</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>87</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22032846</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>88</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22022264</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>89</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21997372</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>90</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21937652</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>91</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21931545</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>92</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21931357</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>93</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21899695</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>94</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21865020</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>95</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21844353</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>96</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21813773</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>97</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21806875</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>98</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21799518</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>99</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21789793</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>100</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21782231</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>101</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21703540</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>102</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21698224</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>103</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21695240</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>104</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21626268</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>105</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21617692</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>106</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21527281</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>107</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21507982</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>108</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21476879</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>109</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21436888</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>110</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21425308</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>111</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21285412</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>112</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21268286</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>113</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21234810</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>114</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21216621</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>115</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21200404</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>116</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21187438</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>117</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21170385</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>118</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21105190</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>119</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20960373</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>120</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20832207</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>121</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20824343</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>122</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20807553</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>123</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20739519</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>124</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20699406</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>125</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20686657</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>126</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20661427</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>127</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20643110</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>128</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20628368</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>129</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20610716</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>130</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20592086</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>131</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20554965</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>132</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20538852</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>133</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20532218</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>134</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20485506</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>135</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20451243</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>136</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20434986</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>137</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20410276</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>138</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20407122</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>139</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20406818</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>140</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20403326</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>141</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20386371</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>142</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20223737</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>143</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20206303</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>144</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20161788</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>145</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20154210</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>146</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20071582</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>147</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20044805</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>148</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20032188</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>149</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20019757</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>150</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20007272</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>151</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19956647</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>152</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19915568</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>153</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19914245</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>154</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19893624</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>155</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19881509</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>156</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19859543</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>157</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19854139</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>158</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19846534</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>159</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19734229</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>160</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19706715</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>161</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19701189</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>162</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19692591</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>163</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19690333</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>164</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19631370</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>165</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19591957</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>166</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19561593</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>167</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19546225</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>168</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19543380</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>169</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19535268</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>170</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19507289</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>171</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19427399</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>172</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19419966</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>173</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19404494</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>174</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19380815</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>175</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19380491</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>176</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19281641</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>177</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19193793</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>178</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19193783</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>179</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19164550</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>180</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19160540</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>181</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19120474</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>182</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19036819</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>183</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19017982</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>184</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19017631</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>185</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18948594</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>186</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18780793</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>187</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18756281</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>188</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18725224</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>189</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18715932</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>190</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18692023</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>191</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18689426</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>192</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18632970</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>193</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18586328</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>194</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18550535</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>195</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19669308</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>196</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18439848</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>197</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18397740</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>198</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18337166</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>199</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18307765</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>200</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18250407</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>201</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18207245</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>202</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18200010</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>203</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>17602886</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>204</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>17552028</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>205</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>17517627</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>206</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>17473309</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>207</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>17468758</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>208</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>17438296</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>209</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>17392790</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>210</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>17339430</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>211</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>17327220</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>212</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>17142768</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>213</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>17093192</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>214</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>17070177</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>215</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>17020950</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>216</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>16945160</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>217</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>16914100</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>218</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>16876765</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>219</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>16849320</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>220</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>16731946</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>221</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>16707574</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>222</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>16406812</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>223</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>16309964</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>224</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>16301520</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>225</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>16294425</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>226</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>16143094</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>227</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>16125763</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>228</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>11868065</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>229</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>11562841</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>230</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>7793635</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>231</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>6230074</PMID>
  </T_QueryArticles>
  <T_QuerySession>
    <QuerySessionID>1</QuerySessionID>
    <QueryID>1</QueryID>
    <ProteinID>1</ProteinID>
    <DateTime>2013-11-07T13:06:59.7363442-08:00</DateTime>
  </T_QuerySession>
  <T_Article>
    <PMID>24183820</PMID>
    <AuthorListID>1</AuthorListID>
    <Title>Conserved Inhibitory Role of SOCS-1s in IFN Signaling Pathways in Teleost Fish.</Title>
    <PubDate>20131029</PubDate>
    <Language>ENG</Language>
    <doi>10.1016/j.dci.2013.10.007</doi>
    <Abstract>The suppressor of cytokine signaling 1 (SOCS-1) protein is a critical regulator in the immune systems of humans and mammals, which functions classically as an inhibitor of the IFN signaling pathways. However, data on functional characterization of SOCS-1 in ancient vertebrates are limited. In this study, we report the function of teleost SOCS-1s in IFN signaling in fish models (zebrafish and Tetraodon) and human cells. Structurally, teleost SOCS-1s share conserved functional domains with their mammalian counterparts. Functionally, teleost SOCS-1s could be significantly induced upon stimulation with IFN stimulants and zebrafish IFNÏ†1. Overexpression of teleost SOCS-1s could dramatically suppress IFNÏ†1-induced Mx, Viperin and PKZ activation in zebrafish, and IFN-induced ISG15 activation in Hela cells. Furthermore, a SOCS-1 variant that lacks the KIR domain was also characterized. This study demonstrates the conserved negative regulatory role of teleost SOCS-1s in IFN signaling pathways, providing perspective into the functional conservation of SOCS-1 proteins during evolution.Copyright Â© 2013. Published by Elsevier Ltd.</Abstract>
    <JournalRelease>1879-0089</JournalRelease>
    <Pages />
    <Affiliation>College of Life Sciences, Zhejiang University, Hangzhou 310058, People's Republic of China;Key Laboratory for Cell and Gene Engineering of Zhejiang Province, Hangzhou 310058, People's Republic of China;Key Laboratory of Animal Virology of Ministry of Agriculture, Hangzhou 310058, People's Republic of China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=24183820&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>24128418</PMID>
    <AuthorListID>2</AuthorListID>
    <Title>Genetically humanized mice recapitulate the entire hepatitis C virus life cycle.</Title>
    <PubDate>20131012</PubDate>
    <Language>ENG</Language>
    <doi>10.1016/j.jhep.2013.10.005</doi>
    <JournalRelease>1600-0641</JournalRelease>
    <Pages />
    <Affiliation>Inserm U1110, Strasbourg, France; UniversitÃ© de Strasbourg, Strasbourg, France.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=24128418&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>24096085</PMID>
    <AuthorListID>3</AuthorListID>
    <Title>MAVS-dependent IRF3/7 bypass of interferon Î²-induction restricts the response to measles infection in CD150Tg mouse bone marrow-derived dendritic cells.</Title>
    <PubDate>2013103</PubDate>
    <Language>ENG</Language>
    <doi>10.1016/j.molimm.2013.08.007</doi>
    <Abstract>Measles virus (MV) infects CD150Tg/Ifnar (IFN alpha receptor)(-/-) mice but not CD150 (a human MV receptor)-transgenic (Tg) mice. We have shown that bone marrow-derived dendritic cells (BMDCs) from CD150Tg/Ifnar(-/-) mice are permissive to MV in contrast to those from simple CD150Tg mice, which reveals a crucial role of type I interferon (IFN) in natural tropism against MV. Yet, the mechanism whereby BMDCs produce initial type I IFN has not been elucidated in MV infection. RNA virus infection usually allows cells to generate double-stranded RNA and induce activation of IFN regulatory factor (IRF) 3/7 transcription factors, leading to the production of type I IFN through the retinoic acid-inducible gene I (RIG-I)/melanoma differentiation-associated gene 5 (MDA5)-mitochondrial antiviral signaling protein (MAVS) pathway. In mouse experimental BMDCs models, we found CD150Tg/Mavs(-/-)BMDCs, but not CD150Tg/Irf3(-/-)/Irf7(-/-)BMDCs, permissive to MV. IFN-Î±/Î² were not induced in MV-infected CD150Tg/Mavs(-/-)BMDCs, while IFN-Î² was subtly induced in CD150Tg/Irf3(-/-)/Irf7(-/-)BMDCs. In vivo systemic infection was therefore established by transfer of MV-infected CD150Tg/Mavs(-/-) BMDCs to CD150Tg/Ifnar(-/-) mice. These data indicate that MAVS-dependent, IRF3/7-independent IFN-Î² induction triggers the activation of the IFNAR pathway so as to restrict the spread of MV by infected BMDCs. Hence, MAVS participates in the initial induction of type I IFN in BMDCs and IFNAR protects against MV spreading. We also showed the importance of IL-10-producing CD4(+) T cells induced by MV-infected BMDCs in vitro, which may account for immune modulation due to the functional aberration of DCs.Copyright Â© 2013 Elsevier Ltd. All rights reserved.</Abstract>
    <JournalRelease>1872-9142</JournalRelease>
    <Pages>100-110</Pages>
    <Affiliation>Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Kita-ku, Sapporo 060-8638, Japan.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=24096085&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>24078691</PMID>
    <AuthorListID>4</AuthorListID>
    <Title>The MyD88 Pathway in Plasmacytoid and CD4+ Dendritic Cells Primarily Triggers Type I IFN Production against Measles Virus in a Mouse Infection Model.</Title>
    <PubDate>20130927</PubDate>
    <Language>eng</Language>
    <doi>10.4049/jimmunol.1301744</doi>
    <Abstract>Infection by measles virus (MV) induces type I IFN via the retinoic acid-inducible gene I/melanoma differentiation-associated gene 5/mitochondrial antiviral signaling protein (MAVS) pathway in human cells. However, the in vivo role of the MAVS pathway in host defense against MV infection remains undetermined. CD150 transgenic (Tg) mice, which express human CD150, an entry receptor for MV, with the disrupting IFNR gene (Ifnar(-/-)), are susceptible to MV and serve as a model for MV infection. In this study, we generated CD150Tg/Mavs(-/-) mice and examined MV permissiveness compared with that in CD150Tg/Ifnar(-/-) mice. MV replicated mostly in the spleen of i.p.-infected CD150Tg/Ifnar(-/-) mice. Strikingly, CD150Tg/Mavs(-/-) mice were not permissive to MV in vivo because of substantial type I IFN induction. MV barely replicated in any other organs tested. When T cells, B cells, and dendritic cells (DCs) isolated from CD150Tg/Mavs(-/-) splenocytes were cultured with MV in vitro, only the DCs produced type I IFN. In vitro infection analysis using CD150Tg/Mavs(-/-) DC subsets revealed that CD4(+) and plasmacytoid DCs, but not CD8Î±(+) and CD8Î±(-)CD4(-) double negative DCs, were exclusively involved in type I IFN production in response to MV infection. Because CD150Tg/Mavs(-/-) mice turned permissive to MV by anti-IFNAR Ab, type I IFN produced by CD4(+) DCs and plasmacytoid DCs plays a critical role in antiviral protection for neighboring cells expressing IFNAR. Induction of type I IFN in these DC subsets was abolished by the MyD88 inhibitory peptide. Thus, production of type I IFN occurs via the MyD88-dependent and MAVS-independent signaling pathway during MV infection.</Abstract>
    <JournalRelease>1550-6606</JournalRelease>
    <Pages>4740-7</Pages>
    <Affiliation>Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Kita-ku, Sapporo 060-8638, Japan.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=24078691&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23962476</PMID>
    <AuthorListID>5</AuthorListID>
    <Title>The interferon response to intracellular DNA: why so many receptors?</Title>
    <PubDate>20130729</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.imbio.2013.07.007</doi>
    <Abstract>The detection of intracellular DNA has emerged to be a key event in the innate immune response to viruses and intracellular bacteria, and during conditions of sterile inflammation and autoimmunity. One of the consequences of the detection of DNA as a 'stranger' and a 'danger' signal is the production of type I interferons and pro-inflammatory cytokines. Much work has been dedicated to the elucidation of the signalling cascades that activate this DNA-induced gene expression programme. However, while many proteins have been proposed to act as sensors for intracellular DNA in recent years, none has been met with universal acceptance, and a theory linking all the recent observations is, as yet, lacking. This review presents the evidence for the various interferon-inducing DNA receptors proposed to date, and examines the hypotheses that might explain why so many different receptors appear to be involved in the innate immune recognition of intracellular DNA.Copyright Â© 2013 Elsevier GmbH. All rights reserved.</Abstract>
    <JournalRelease>1878-3279</JournalRelease>
    <Pages>1312-21</Pages>
    <Affiliation>Division of Cell Signalling and Immunology, College of Life Sciences, University of Dundee, DD1 5EH, UK. Electronic address: l.unterholzner@dundee.ac.uk.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23962476&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23951545</PMID>
    <AuthorListID>6</AuthorListID>
    <Title>MAVS recruits multiple ubiquitin E3 ligases to activate antiviral signaling cascades.</Title>
    <PubDate>20130814</PubDate>
    <Language>eng</Language>
    <doi>10.7554/eLife.00785</doi>
    <Abstract>RNA virus infections are detected by the RIG-I family of receptors, which induce type-I interferons through the mitochondrial protein MAVS. MAVS forms large prion-like polymers that activate the cytosolic kinases IKK and TBK1, which in turn activate NF-ÎºB and IRF3, respectively, to induce interferons. Here we show that MAVS polymers recruit several TRAF proteins, including TRAF2, TRAF5, and TRAF6, through distinct TRAF-binding motifs. Mutations of these motifs that disrupted MAVS binding to TRAFs abrogated its ability to activate IRF3. IRF3 activation was also abolished in cells lacking TRAF2, 5, and 6. These TRAF proteins promoted ubiquitination reactions that recruited NEMO to the MAVS signaling complex, leading to the activation of IKK and TBK1. These results delineate the mechanism of MAVS signaling and reveal that TRAF2, 5, and 6, which are normally associated with NF-ÎºB activation, also play a crucial role in IRF3 activation in antiviral immune responses. DOI:http://dx.doi.org/10.7554/eLife.00785.001.</Abstract>
    <JournalRelease>2050-084X</JournalRelease>
    <Pages>e00785</Pages>
    <Affiliation>Department of Molecular Biology , University of Texas Southwestern Medical Center , Dallas , United States.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23951545&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23942572</PMID>
    <AuthorListID>7</AuthorListID>
    <Title>IFIT5 potentiates anti-viral response through enhancing innate immune signaling pathways.</Title>
    <PubDate>20130813</PubDate>
    <Language>eng</Language>
    <doi>10.1093/abbs/gmt088</doi>
    <Abstract>Humans have a distinct combination of IFIT (IFN-induced protein with tetratricopeptide repeats) family orthologs, including IFIT1 (ISG56), IFIT2 (ISG54), IFIT3 (ISG60), and IFIT5 (ISG58). The function of IFIT1/IFIT2/IFIT3 has been intensively investigated. However, little is known about the role of IFIT5 in any cellular processes. In this study, we reported that both the mRNA and protein levels of IFIT5 are up-regulated in response to RNA virus infection or polyinosinic-cytidylic acid stimulation. Ectopic expression of IFIT5 could synergize IRF3- and NF-ÎºB-mediated gene expression, whereas knockdown of IFIT5 impairs the transcription of these genes. Consistently, anti-viral responses of host cells are significantly increased or decreased in the presence or absence of IFIT5. Mechanistically, IFIT5 co-localizes partly with mitochondria and interacts with RIG-I and MAVS. Our study identified that IFIT5 is an important enhancer in innate immune response.</Abstract>
    <JournalRelease>1745-7270</JournalRelease>
    <Pages>867-74</Pages>
    <Affiliation>Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, Shanghai 200241, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23942572&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23873628</PMID>
    <AuthorListID>8</AuthorListID>
    <Title>Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells.</Title>
    <PubDate>2013719</PubDate>
    <Language>ENG</Language>
    <doi>10.1002/hep.26626</doi>
    <Abstract>Only humans and chimpanzees are susceptible to chronic infection by hepatitis C virus (HCV). The restricted species tropism of HCV is determined by distinct host factor requirements at different steps of the viral life cycle. In addition, effective innate immune targeting precludes efficient propagation of HCV in nonhuman cells. Species-specificity of HCV host factor usage for cell entry and virus release has been explored. However, the reason for inefficient HCV RNA replication efficiency in mouse liver cells remains elusive. To address this, we generated novel mouse liver-derived cell lines with specific lesions in mitochondrial antiviral signaling protein (MAVS), interferon regulatory factor 3 (IRF3), or Interferon-Î±/Î² receptor (IFNAR) by in vivo immortalization. Blunted innate immune responses in these cells modestly increased HCV RNA replication. However, ectopic expression of liver-specific human microRNA 122 (miR-122) further boosted RNA replication in all knockout cell lines. Remarkably, MAVS(-/-) miR-122 cells sustained vigorous HCV RNA replication, attaining levels comparable to the highly permissive human hepatoma cell line Huh-7.5. RNA replication was dependent on mouse cyclophilin and phosphatidylinositol-4 kinase III alpha (PI4KIIIÎ±) and was also observed after transfection of full-length viral RNA. Additionally, ectopic expression of either human or mouse apolipoprotein E (ApoE) was sufficient to permit release of infectious particles. Finally, expression of human entry cofactors rendered these cells permissive to HCV infection, thus confirming that all steps of the HCV replication cycle can be reconstituted in mouse liver-derived cells. Conclusion: Blunted innate immunity, abundant miR-122, and HCV entry factor expression permits propagation of HCV in mouse liver-derived cell lines. (Hepatology 2013;).Â© 2013 by the American Association for the Study of Liver Diseases.</Abstract>
    <JournalRelease>1527-3350</JournalRelease>
    <Pages />
    <Affiliation>Institute of Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Helmholtz Centre for Infection Research and the Hannover Medical School, Hannover, Germany.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23873628&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23843640</PMID>
    <AuthorListID>9</AuthorListID>
    <Title>Negative regulation of RIG-I-mediated innate antiviral signaling by SEC14L1.</Title>
    <PubDate>20130710</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.01073-13</doi>
    <Abstract>Retinoic acid-inducible gene I (RIG-I) is a key sensor for recognizing nucleic acids derived from RNA viruses and triggers beta interferon (IFN-Î²) production. Because of its important role in antiviral innate immunity, the activity of RIG-I must be tightly controlled. Here, we used yeast two-hybrid screening to identify a SEC14 family member, SEC14L1, as a RIG-I-associated negative regulator. Transfected SEC14L1 interacted with RIG-I, and endogenous SEC14L1 associated with RIG-I in a viral infection-inducible manner. Overexpression of SEC14L1 inhibited transcriptional activity of the IFN-Î² promoter induced by RIG-I but not TANK-binding kinase 1 (TBK1) and interferon regulatory factor 3 (IRF3). Knockdown of endogenous SEC14L1 in both HEK293T cells and HT1080 cells potentiated RIG-I and Sendai virus-triggered IFN-Î² production as well as attenuated the replication of Newcastle disease virus. SEC14L1 interacted with the N-terminal domain of RIG-I (RIG-I caspase activation and recruitment domain [RIG-I-CARD]) and competed with VISA/MAVS/IPS-1/Cardif for RIG-I-CARD binding. Domain mapping further indicated that the PRELI-MSF1 and CRAL-TRIO domains but not the GOLD domain of SEC14L1 are required for interaction and inhibitory function. These findings suggest that SEC14L1 functions as a novel negative regulator of RIG-I-mediated antiviral signaling by preventing RIG-I interaction with the downstream effector.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>10037-46</Pages>
    <Affiliation>The Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, College of Life Sciences, Peking University, Beijing, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23843640&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23810392</PMID>
    <AuthorListID>10</AuthorListID>
    <Title>Negative regulation of RIG-I-mediated antiviral signaling by TRK-fused gene (TFG) protein.</Title>
    <PubDate>20130626</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.bbrc.2013.06.061</doi>
    <Abstract>RIG-I (retinoic acid inducible gene I)-mediated antiviral signaling serves as the first line of defense against viral infection. Upon detection of viral RNA, RIG-I undergoes TRIM25 (tripartite motif protein 25)-mediated K63-linked ubiquitination, leading to type I interferon (IFN) production. In this study, we demonstrate that TRK-fused gene (TFG) protein, previously identified as a TRIM25-interacting protein, binds TRIM25 upon virus infection and negatively regulates RIG-I-mediated type-I IFN signaling. RIG-I-mediated IFN production and nuclear factor (NF)-ÎºB signaling pathways were upregulated by the suppression of TFG expression. Furthermore, vesicular stomatitis virus (VSV) replication was significantly inhibited by small inhibitory hairpin RNA (shRNA)-mediated knockdown of TFG, supporting the suppressive role of TFG in RIG-I-mediated antiviral signaling. Interestingly, suppression of TFG expression increased not only RIG-I-mediated signaling but also MAVS (mitochondrial antiviral signaling protein)-induced signaling, suggesting that TFG plays a pivotal role in negative regulation of RNA-sensing, RIG-I-like receptor (RLR) family signaling pathways.Copyright Â© 2013 Elsevier Inc. All rights reserved.</Abstract>
    <JournalRelease>1090-2104</JournalRelease>
    <Pages>168-72</Pages>
    <Affiliation>Department of Pharmaceutical Science, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23810392&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23770038</PMID>
    <AuthorListID>11</AuthorListID>
    <Title>Independent, parallel pathways to CXCL10 induction in HCV-infected hepatocytes.</Title>
    <PubDate>20130612</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.jhep.2013.06.001</doi>
    <Abstract>The pro-inflammatory chemokine CXCL10 is induced by HCV infection in vitro and in vivo, and is associated with outcome of IFN (interferon)-based therapy. We studied how hepatocyte sensing of early HCV infection via TLR3 (Toll-like receptor 3) and RIG-I (retinoic acid inducible gene I) led to expression of CXCL10.CXCL10, type I IFN, and type III IFN mRNAs and proteins were measured in PHH (primary human hepatocytes) and hepatocyte lines harboring functional or non-functional TLR3 and RIG-I pathways following HCV infection or exposure to receptor-specific stimuli.HuH7 human hepatoma cells expressing both TLR3 and RIG-I produced maximal CXCL10 during early HCV infection. Neutralization of type I and type III IFNs had no impact on virus-induced CXCL10 expression in TLR3+/RIG-I+ HuH7 cells, but reduced CXCL10 expression in PHH. PHH cultures were positive for monocyte, macrophage, and dendritic cell mRNAs. Immunodepletion of non-parenchymal cells (NPCs) eliminated marker expression in PHH cultures, which then showed no IFN requirement for CXCL10 induction during HCV infection. Immunofluorescence studies also revealed a positive correlation between intracellular HCV Core and CXCL10 protein expression (r(2) = 0.88, p â‰¤ 0.001).While CXCL10 induction in hepatocytes during the initial phase of HCV infection is independent of hepatocyte-derived type I and type III IFNs, NPC-derived IFNs contribute to CXCL10 induction during HCV infection in PHH cultures.Copyright Â© 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.</Abstract>
    <JournalRelease>1600-0641</JournalRelease>
    <Pages>701-8</Pages>
    <Affiliation>Department of Global Health, Pathobiology Program, University of Washington, Seattle, WA, United States.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23770038&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23702035</PMID>
    <AuthorListID>12</AuthorListID>
    <Title>MAVS-mediated host cell defense is inhibited by Borna disease virus.</Title>
    <PubDate>20130520</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.biocel.2013.05.012</doi>
    <Abstract>Viruses often have strategies for preventing host cell apoptosis, which antagonizes viral replication. Borna disease virus (BDV) is a neurotropic RNA virus that establishes a non-cytolytic persistent infection. Although BDV suppresses type I Interferon (IFN) through (TANK)-binding kinase 1 (TBK-1) associated BDV P protein, it is still unclear how BDV can survive in the host cell and establish a persistent infection. Recently, it has been recognized that mitochondria-mediated apoptosis through the mitochondrial antiviral signaling protein (MAVS) and the RIG-I-like receptor (RLR) signaling pathway is a crucial component of the innate immune response. In this work we show that BDV X protein colocalizes and interacts with MAVS in the mitochondria to block programmed cell death. BDV X protein-mediated inhibition of apoptosis was independent of type I IFN production and NF-ÎºB activity. The reduction of BDV X expression with RNA interference (RNAi) or the mutation of BDV X enhanced MAVS-induced cell death. Collectively, our data provide novel insights into how BDV X protein inhibits antiviral-associated programmed cell death, through its action of MAVS function.Crown Copyright Â© 2013. Published by Elsevier Ltd. All rights reserved.</Abstract>
    <JournalRelease>1878-5875</JournalRelease>
    <Pages>1546-55</Pages>
    <Affiliation>The Heilongjiang Key Laboratory of Immunity and Infection, Key Laboratory of Pathogenic Biology Heilongjiang Higher Education Institutions, Department of Microbiology, Harbin Medical University, Harbin, Heilongjiang, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23702035&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23671700</PMID>
    <AuthorListID>13</AuthorListID>
    <Title>Analysis of antiviral response in human epithelial cells infected with hepatitis E virus.</Title>
    <PubDate>20130509</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.pone.0063793</doi>
    <Abstract>Hepatitis E virus (HEV) is a major cause of enterically transmitted acute hepatitis in developing nations and occurs in sporadic and epidemic forms. The disease may become severe with high mortality (20%) among pregnant women. Due to lack of efficient cell culture system and small animal model, early molecular events of HEV infection are not yet known. In the present study, human lung epithelial cells, A549, were infected with HEV to monitor expression levels of genes/proteins in antiviral pathways. Both live and UV inactivated virus elicited robust induction of inflammatory cytokines/chemokines such as IL-6, IL-8, TNF-Î±, and RANTES within 12 h of infection. Cells exposed to soluble capsid protein showed no induction suggesting the capsid structure and not the protein being detected as the pathogen pattern by cells. A delayed up-regulation of type I interferon genes only by the live virus at 48 h post HEV infection indicated the need of virus replication. However, absence of secreted interferons till 96 h suggested possible involvement of post-transcriptional regulation of type I IFN expression. HEV infected cells showed activation of both NF-ÎºB and IRF3 transcription factors when seen at protein levels; however, reporter gene assays showed predominant expression via NF-ÎºB promoter as compared to IRF3 promoter. Knockdown experiments done using siRNAs showed involvement of MyD88 and TRIF adaptors in generating antiviral response thus indicating role of TLR2, TLR4 and TLR3 in sensing viral molecules. MAVS knockdown surprisingly enhanced only proinflammatory cytokines and not type I IFNs. This suggested that HEV not only down-regulates RIG-I helicase like receptor mediated IFN induction but also employs MAVS in curtailing host inflammatory response. Our findings uncover an early cellular response in HEV infection and associated molecular mechanisms suggesting the potential role of inflammatory response triggered by HEV infection in host immune response and pathogenesis.</Abstract>
    <JournalRelease>1932-6203</JournalRelease>
    <Pages>e63793</Pages>
    <Affiliation>Hepatitis Division, National Institute of Virology, Microbial Containment Complex, Pashan, Pune, India.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23671700&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23653683</PMID>
    <AuthorListID>14</AuthorListID>
    <Title>RIG-I detects triphosphorylated RNA of Listeria monocytogenes during infection in non-immune cells.</Title>
    <PubDate>20130430</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.pone.0062872</doi>
    <Abstract>The innate immune system senses pathogens by pattern recognition receptors in different cell compartments. In the endosome, bacteria are generally recognized by TLRs; facultative intracellular bacteria such as Listeria, however, can escape the endosome. Once in the cytosol, they become accessible to cytosolic pattern recognition receptors, which recognize components of the bacterial cell wall, metabolites or bacterial nucleic acids and initiate an immune response in the host cell. Current knowledge has been focused on the type I IFN response to Listeria DNA or Listeria-derived second messenger c-di-AMP via the signaling adaptor STING. Our study focused on the recognition of Listeria RNA in the cytosol. With the aid of a novel labeling technique, we have been able to visualize immediate cytosolic delivery of Listeria RNA upon infection. Infection with Listeria as well as transfection of bacterial RNA induced a type-I-IFN response in human monocytes, epithelial cells or hepatocytes. However, in contrast to monocytes, the type-I-IFN response of epithelial cells and hepatocytes was not triggered by bacterial DNA, indicating a STING-independent Listeria recognition pathway. RIG-I and MAVS knock-down resulted in abolishment of the IFN response in epithelial cells, but the IFN response in monocytic cells remained unaffected. By contrast, knockdown of STING in monocytic cells reduced cytosolic Listeria-mediated type-I-IFN induction. Our results show that detection of Listeria RNA by RIG-I represents a non-redundant cytosolic immunorecognition pathway in non-immune cells lacking a functional STING dependent signaling pathway.</Abstract>
    <JournalRelease>1932-6203</JournalRelease>
    <Pages>e62872</Pages>
    <Affiliation>Institute for Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, University of Bonn, Bonn, Germany.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23653683&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23626834</PMID>
    <AuthorListID>15</AuthorListID>
    <Title>Human metapneumovirus glycoprotein G disrupts mitochondrial signaling in airway epithelial cells.</Title>
    <PubDate>20130423</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.pone.0062568</doi>
    <Abstract>Human metapneumovirus (hMPV) is a recently identified RNA virus belonging to the Paramyxoviridae family. It is a common cause of respiratory tract infections in children, adults, and immunocompromised patients, for which no specific treatment or vaccine is available. Recent investigations in our lab identified hMPV glycoprotein G as an important virulence factor, as a recombinant virus lacking the G protein (rhMPV-Î”G) exhibited enhanced production of important immune and antiviral mediators, such as cytokines, chemokines and type I interferon (IFN) in airway epithelial cells, and expression of G protein alone inhibits cellular signaling dependent on retinoic induced gene (RIG)-I, a RNA helicase with a fundamental role in initiating hMPV-induced cellular responses. In this study, we have further investigated the mechanism underlying the inhibitory role of hMPV G protein on RIG-I-dependent signaling. We found that the interaction of hMPV G with RIG-I occurs primarily through the CARD domains of RIG-I N-terminus, preventing RIG-I association with the adaptor protein MAVS (mitochondrial antiviral signaling protein), recruitment of RIG-I to mitochondria, as well as the interaction between mitochondria and mitochondria-associated membrane (MAM) component of the endoplasmic reticulum (ER), which contains STINGS, an important part of the viral-induced RIG-I/MAVS signaling pathway, leading in the end to the inhibition of cytokine, chemokine and type I IFN expression. Mutagenesis analysis showed that hMPV G protein cytoplasmic domain played a major role in the observed inhibitory activity, and recombinant viruses expressing a G protein with amino acid substitution in position 2 and 3 recapitulated most of the phenotype observed with rhMPV-Î”G mutant upon infection of airway epithelial cells.</Abstract>
    <JournalRelease>1932-6203</JournalRelease>
    <Pages>e62568</Pages>
    <Affiliation>Department of Pediatrics, The University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America. xibao@utmb.edu</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23626834&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23611287</PMID>
    <AuthorListID>16</AuthorListID>
    <Title>Intracellular pathogen detection by RIG-I-like receptors.</Title>
    <Language>eng</Language>
    <doi>10.1016/B978-0-12-410524-9.00004-9</doi>
    <Abstract>The RIG-I-like receptors (RLRs) RIG-I, MDA5, and LGP2 trigger innate immune responses against viral infections that serve to limit virus replication and to stimulate adaptive immunity. RLRs are cytosolic sensors for virus-derived RNA and thus responsible for intracellular immune surveillance against infection. RLR signaling requires the adapter protein MAVS to induce type I interferon, interferon-stimulated genes, and proinflammatory cytokines. This review focuses on the molecular and cell biological requirements for RLR signal transduction.Copyright Â© 2013 Elsevier Inc. All rights reserved.</Abstract>
    <JournalRelease>1557-8445</JournalRelease>
    <Pages>99-125</Pages>
    <Affiliation>Harvard Medical School and Division of Gastroenterology, Boston Children's Hospital, Boston, MA, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23611287&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23592984</PMID>
    <AuthorListID>17</AuthorListID>
    <Title>Type I IFN triggers RIG-I/TLR3/NLRP3-dependent inflammasome activation in influenza A virus infected cells.</Title>
    <PubDate>20130411</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.ppat.1003256</doi>
    <Abstract>Influenza A virus (IAV) triggers a contagious and potentially lethal respiratory disease. A protective IL-1Î² response is mediated by innate receptors in macrophages and lung epithelial cells. NLRP3 is crucial in macrophages; however, which sensors elicit IL-1Î² secretion in lung epithelial cells remains undetermined. Here, we describe for the first time the relative roles of the host innate receptors RIG-I (DDX58), TLR3, and NLRP3 in the IL-1Î² response to IAV in primary lung epithelial cells. To activate IL-1Î² secretion, these cells employ partially redundant recognition mechanisms that differ from those described in macrophages. RIG-I had the strongest effect through a MAVS/TRIM25/Riplet-dependent type I IFN signaling pathway upstream of TLR3 and NLRP3. Notably, RIG-I also activated the inflammasome through interaction with caspase 1 and ASC in primary lung epithelial cells. Thus, NS1, an influenza virulence factor that inhibits the RIG-I/type I IFN pathway, strongly modulated the IL-1Î² response in lung epithelial cells and in ferrets. The NS1 protein derived from a highly pathogenic strain resulted in increased interaction with RIG-I and inhibited type I IFN and IL-1Î² responses compared to the least pathogenic virus strains. These findings demonstrate that in IAV-infected lung epithelial cells RIG-I activates the inflammasome both directly and through a type I IFN positive feedback loop.</Abstract>
    <JournalRelease>1553-7374</JournalRelease>
    <Pages>e1003256</Pages>
    <Affiliation>Department of Human Genetics, McGill University, Montreal, Quebec, Canada. julien.pothlichet@pasteur.fr</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23592984&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23582325</PMID>
    <AuthorListID>18</AuthorListID>
    <Title>The adaptor MAVS promotes NLRP3 mitochondrial localization and inflammasome activation.</Title>
    <Language>eng</Language>
    <doi>10.1016/j.cell.2013.02.054</doi>
    <Abstract>NLRP3 is a key component of the macromolecular signaling complex called the inflammasome that promotes caspase 1-dependent production of IL-1Î². The adaptor ASC is necessary for NLRP3-dependent inflammasome function, but it is not known whether ASC is a sufficient partner and whether inflammasome formation occurs in the cytosol or in association with mitochondria is controversial. Here, we show that the mitochondria-associated adaptor molecule, MAVS, is required for optimal NLRP3 inflammasome activity. MAVS mediates recruitment of NLRP3 to mitochondria, promoting production of IL-1Î² and the pathophysiologic activity of the NLRP3 inflammasome in vivo. Our data support a more complex model of NLRP3 inflammasome activation than previously appreciated, with at least two adapters required for maximal function. Because MAVS is a mitochondria-associated molecule previously considered to be uniquely involved in type 1 interferon production, these findings also reveal unexpected polygamous involvement of PYD/CARD-domain-containing adapters in innate immune signaling events.Copyright Â© 2013 Elsevier Inc. All rights reserved.</Abstract>
    <JournalRelease>1097-4172</JournalRelease>
    <Pages>348-61</Pages>
    <Affiliation>Lymphocyte Biology Section, Laboratory of Systems Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. subramaniann@niaid.nih.gov</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23582325&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23555725</PMID>
    <AuthorListID>19</AuthorListID>
    <Title>Targeted induction of interferon-Î» in humanized chimeric mouse liver abrogates hepatotropic virus infection.</Title>
    <PubDate>20130328</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.pone.0059611</doi>
    <Abstract>The interferon (IFN) system plays a critical role in innate antiviral response. We presume that targeted induction of IFN in human liver shows robust antiviral effects on hepatitis C virus (HCV) and hepatitis B virus (HBV).This study used chimeric mice harboring humanized livers and infected with HCV or HBV. This mouse model permitted simultaneous analysis of immune responses by human and mouse hepatocytes in the same liver and exploration of the mechanism of antiviral effect against these viruses. Targeted expression of IFN was induced by treating the animals with a complex comprising a hepatotropic cationic liposome and a synthetic double-stranded RNA analog, pIC (LIC-pIC). Viral replication, IFN gene expression, IFN protein production, and IFN antiviral activity were analyzed (for type I, II and III IFNs) in the livers and sera of these humanized chimeric mice.Following treatment with LIC-pIC, the humanized livers of chimeric mice exhibited increased expression (at the mRNA and protein level) of human IFN-Î»s, resulting in strong antiviral effect on HBV and HCV. Similar increases were not seen for human IFN-Î± or IFN-Î² in these animals. Strong induction of IFN-Î»s by LIC-pIC occurred only in human hepatocytes, and not in mouse hepatocytes nor in human cell lines derived from other (non-hepatic) tissues. LIC-pIC-induced IFN-Î» production was mediated by the immune sensor adaptor molecules mitochondrial antiviral signaling protein (MAVS) and Toll/IL-1R domain-containing adaptor molecule-1 (TICAM-1), suggesting dual recognition of LIC-pIC by both sensor adaptor pathways.These findings demonstrate that the expression and function of various IFNs differ depending on the animal species and tissues under investigation. Chimeric mice harboring humanized livers demonstrate that IFN-Î»s play an important role in the defense against human hepatic virus infection.</Abstract>
    <JournalRelease>1932-6203</JournalRelease>
    <Pages>e59611</Pages>
    <Affiliation>Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23555725&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23555247</PMID>
    <AuthorListID>20</AuthorListID>
    <Title>Enterovirus 71 protease 2Apro targets MAVS to inhibit anti-viral type I interferon responses.</Title>
    <PubDate>20130321</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.ppat.1003231</doi>
    <Abstract>Enterovirus 71 (EV71) is the major causative pathogen of hand, foot, and mouth disease (HFMD). Its pathogenicity is not fully understood, but innate immune evasion is likely a key factor. Strategies to circumvent the initiation and effector phases of anti-viral innate immunity are well known; less well known is whether EV71 evades the signal transduction phase regulated by a sophisticated interplay of cellular and viral proteins. Here, we show that EV71 inhibits anti-viral type I interferon (IFN) responses by targeting the mitochondrial anti-viral signaling (MAVS) protein--a unique adaptor molecule activated upon retinoic acid induced gene-I (RIG-I) and melanoma differentiation associated gene (MDA-5) viral recognition receptor signaling--upstream of type I interferon production. MAVS was cleaved and released from mitochondria during EV71 infection. An in vitro cleavage assay demonstrated that the viral 2A protease (2A(pro)), but not the mutant 2A(pro) (2A(pro)-110) containing an inactivated catalytic site, cleaved MAVS. The Protease-Glo assay revealed that MAVS was cleaved at 3 residues between the proline-rich and transmembrane domains, and the resulting fragmentation effectively inactivated downstream signaling. In addition to MAVS cleavage, we found that EV71 infection also induced morphologic and functional changes to the mitochondria. The EV71 structural protein VP1 was detected on purified mitochondria, suggesting not only a novel role for mitochondria in the EV71 replication cycle but also an explanation of how EV71-derived 2A(pro) could approach MAVS. Taken together, our findings reveal a novel strategy employed by EV71 to escape host anti-viral innate immunity that complements the known EV71-mediated immune-evasion mechanisms.</Abstract>
    <JournalRelease>1553-7374</JournalRelease>
    <Pages>e1003231</Pages>
    <Affiliation>MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, People's Republic of China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23555247&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23545497</PMID>
    <AuthorListID>21</AuthorListID>
    <Title>UBXN1 interferes with Rig-I-like receptor-mediated antiviral immune response by targeting MAVS.</Title>
    <PubDate>20130328</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.celrep.2013.02.027</doi>
    <Abstract>RNA viruses are sensed by RIG-I-like receptors (RLRs), which signal through a mitochondria-associated adaptor molecule, MAVS, resulting in systemic antiviral immune responses. Although RLR signaling is essential for limiting RNA virus replication, it must be stringently controlled to prevent damage from inflammation. We demonstrate here that among all tested UBX-domain-containing protein family members, UBXN1 exhibits the strongest inhibitory effect on RNA-virus-induced type I interferon response. UBXN1 potently inhibits RLR- and MAVS-induced, but not TLR3-, TLR4-, or DNA-virus-induced innate immune responses. Depletion of UBXN1 enhances virus-induced innate immune responses, including those resulting from RNA viruses such as vesicular stomatitis, Sendai, West Nile, and dengue virus infection, repressing viral replication. Following viral infection, UBXN1 is induced, binds to MAVS, interferes with intracellular MAVS oligomerization, and disrupts the MAVS/TRAF3/TRAF6 signalosome. These findings underscore a critical role of UBXN1 in the modulation of a major antiviral signaling pathway.Copyright Â© 2013 The Authors. Published by Elsevier Inc. All rights reserved.</Abstract>
    <JournalRelease>2211-1247</JournalRelease>
    <Pages>1057-70</Pages>
    <Affiliation>Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23545497&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23544010</PMID>
    <AuthorListID>22</AuthorListID>
    <Title>A systems biology approach reveals that tissue tropism to West Nile virus is regulated by antiviral genes and innate immune cellular processes.</Title>
    <PubDate>20130207</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.ppat.1003168</doi>
    <Abstract>The actions of the RIG-I like receptor (RLR) and type I interferon (IFN) signaling pathways are essential for a protective innate immune response against the emerging flavivirus West Nile virus (WNV). In mice lacking RLR or IFN signaling pathways, WNV exhibits enhanced tissue tropism, indicating that specific host factors of innate immune defense restrict WNV infection and dissemination in peripheral tissues. However, the immune mechanisms by which the RLR and IFN pathways coordinate and function to impart restriction of WNV infection are not well defined. Using a systems biology approach, we defined the host innate immune response signature and actions that restrict WNV tissue tropism. Transcriptional profiling and pathway modeling to compare WNV-infected permissive (spleen) and nonpermissive (liver) tissues showed high enrichment for inflammatory responses, including pattern recognition receptors and IFN signaling pathways, that define restriction of WNV replication in the liver. Assessment of infected livers from Mavs(-/-) Ã— Ifnar(-/-) mice revealed the loss of expression of several key components within the natural killer (NK) cell signaling pathway, including genes associated with NK cell activation, inflammatory cytokine production, and NK cell receptor signaling. In vivo analysis of hepatic immune cell infiltrates from WT mice demonstrated that WNV infection leads to an increase in NK cell numbers with enhanced proliferation, maturation, and effector action. In contrast, livers from Mavs(-/-) Ã— Ifnar(-/-) infected mice displayed reduced immune cell infiltration, including a significant reduction in NK cell numbers. Analysis of cocultures of dendritic and NK cells revealed both cell-intrinsic and -extrinsic roles for the RLR and IFN signaling pathways to regulate NK cell effector activity. Taken together, these observations reveal a complex innate immune signaling network, regulated by the RLR and IFN signaling pathways, that drives tissue-specific antiviral effector gene expression and innate immune cellular processes that control tissue tropism to WNV infection.</Abstract>
    <JournalRelease>1553-7374</JournalRelease>
    <Pages>e1003168</Pages>
    <Affiliation>Department of Immunology, University of Washington School of Medicine, Seattle, Washington, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23544010&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23542348</PMID>
    <AuthorListID>23</AuthorListID>
    <Title>Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity.</Title>
    <PubDate>20130328</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.jhep.2013.03.019</doi>
    <Abstract>Hepatitis C virus (HCV) is a major human viral pathogen that causes chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. In most cases, acute HCV infection becomes persistent, at least in part due to viral evasion of host innate immune response. Although HCV genomic RNA contains pathogen-associated molecular pattern (PAMP) that is able to induce host interferon responses, HCV can shut down the responses by using the viral NS3/4A protease to cleave MAVS/VISA and TRIF, two key adaptor molecules essential for the interferon signaling activation. The aim of this study was to explore a novel NS3/4A-independent mechanism HCV utilizes to evade host innate immune responses.We used the interferon promoter-reporter system to screen HCV encoded proteins for their activities to suppress the interferon signaling and to determine the molecular targets of viral proteins. Co-immunoprecipitation, confocal microscopy, and siRNA-based gene silencing were used to investigate the molecular mechanism.We found that, in addition to NS3/4A, NS4B can suppress double-stranded RNA or RNA virus induced interferon activation. NS4B interacts with STING/MITA, an important molecule that mediates the HCV PAMP induced interferon signaling. Mechanistic studies indicated that NS4B disrupts the interactions between STING/MITA and TBK1.In conclusion, we reported an additional mechanism for HCV evasion of host interferon responses in which viral NS4B protein targets STING/MITA to suppress the interferon signaling. Our results present important evidence for the control of interferon response by HCV, and shed more light on the molecular mechanisms underlying the persistence of HCV infection.Copyright Â© 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.</Abstract>
    <JournalRelease>1600-0641</JournalRelease>
    <Pages>52-8</Pages>
    <Affiliation>Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200025, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23542348&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23526820</PMID>
    <AuthorListID>24</AuthorListID>
    <Title>Inflammatory response of mast cells during influenza A virus infection is mediated by active infection and RIG-I signaling.</Title>
    <PubDate>20130322</PubDate>
    <Language>eng</Language>
    <doi>10.4049/jimmunol.1202096</doi>
    <Abstract>Influenza A virus (IAV) is a major respiratory pathogen of both humans and animals. The lung is protected from pathogens by alveolar epithelial cells, tissue-resident alveolar macrophages, dendritic cells, and mast cells. The role of alveolar epithelial cells, endothelial cells, and alveolar macrophages during IAV infection has been studied previously. In this study, we address the role of mast cells during IAV infection. Respiratory infection with A/WSN/33 causes significant disease and immunopathology in C57BL/6 mice but not in B6.Cg-Kit(W-sh) mice, which lack mast cells. During in vitro coculture, A/WSN/33 caused mast cells to release histamine, secrete cytokines and chemokines, and produce leukotrienes. Moreover, when mast cells were infected with IAV, the virus did not replicate within mast cells. Importantly, human H1N1, H3N2, and influenza B virus isolates also could activate mast cells in vitro. Mast cell production of cytokines and chemokines occurs in a RIG-I/MAVS-dependent mechanism; in contrast, histamine production occurred through a RIG-I/MAVS-independent mechanism. Our data highlight that, following IAV infection, the response of mast cells is controlled by multiple receptors. In conclusion, we identified a unique inflammatory cascade activated during IAV infection that could potentially be targeted to limit morbidity following IAV infection.</Abstract>
    <JournalRelease>1550-6606</JournalRelease>
    <Pages>4676-84</Pages>
    <Affiliation>Department of Immunology and Infectious Diseases, Montana State University, Bozeman, MT 59718, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23526820&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23503762</PMID>
    <AuthorListID>25</AuthorListID>
    <Title>Caspase-8 and FLIP regulate RIG-I/MDA5-induced innate immune host responses to picornaviruses.</Title>
    <Language>ENG</Language>
    <doi>10.2217/fvl.12.115</doi>
    <Abstract>Picornaviruses are small, nonenveloped, positive-stranded RNA viruses, which cause a wide range of animal and human diseases, based on their distinct tissue and cell type tropisms. Myocarditis, poliomyelitis, hepatitis and the common cold are the most significant human illnesses caused by picornaviruses. The host response to picornaviruses is complex, and the damage to tissues occurs not only from direct viral replication within infected cells. Picornaviruses exhibit an exceptional ability to evade the early innate immune response, resulting in chronic infection and autoimmunity. This review discusses the detailed aspects of the early innate host response to picornaviruses infection mediated by RIG-I-like helicases, their adaptor, mitochondrial ant iviral signaling protein, innate immune-induced apoptosis, and the role of caspase-8 and its regulatory paralog, FLIP, in these processes.</Abstract>
    <JournalRelease>1746-0794</JournalRelease>
    <Pages>1221-1236</Pages>
    <Affiliation>Department of Pathology, Vermont Center for Immunology &amp; Infectious Diseases, University of Vermont, Burlington, VT 05405, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23503762&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23499490</PMID>
    <AuthorListID>26</AuthorListID>
    <Title>Activation of the innate signaling molecule MAVS by bunyavirus infection upregulates the adaptor protein SARM1, leading to neuronal death.</Title>
    <PubDate>20130314</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.immuni.2013.02.013</doi>
    <Abstract>La Crosse virus (LACV), a zoonotic Bunyavirus, is a major cause of pediatric viral encephalitis in the United States. A hallmark of neurological diseases caused by LACV and other encephalitic viruses is the induction of neuronal cell death. Innate immune responses have been implicated in neuronal damage, but no mechanism has been elucidated. By using inÂ vitro studies in primary neurons and inÂ vivo studies in mice, we have shown that LACV infection induced the RNA helicase, RIG-I, and mitochondrial antiviral signaling protein (MAVS) signaling pathway, resulting in upregulation of the sterile alpha and TIR-containing motif 1 (SARM1), an adaptor molecule that we found to be directly involved in neuronal damage. SARM1-mediated cell death was associated with induced oxidative stress response and mitochondrial damage. These studies provide an innate-immune signaling mechanism for virus-induced neuronal death and reveal potential targets for development of therapeutics to treat encephalitic viral infections.Copyright Â© 2013 Elsevier Inc. All rights reserved.</Abstract>
    <JournalRelease>1097-4180</JournalRelease>
    <Pages>705-16</Pages>
    <Affiliation>Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 903 S. 4th Street, Hamilton, MT 59840, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23499490&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23498958</PMID>
    <AuthorListID>27</AuthorListID>
    <Title>Incoming RNA virus nucleocapsids containing a 5'-triphosphorylated genome activate RIG-I and antiviral signaling.</Title>
    <Language>eng</Language>
    <doi>10.1016/j.chom.2013.01.012</doi>
    <Abstract>Host defense to RNA viruses depends on rapid intracellular recognition of viral RNA by two cytoplasmic RNA helicases: RIG-I and MDA5. RNA transfection experiments indicate that RIG-I responds to naked double-stranded RNAs (dsRNAs) with a triphosphorylated 5' (5'ppp) terminus. However, the identity of the RIG-I stimulating viral structures in an authentic infection context remains unresolved. We show that incoming viral nucleocapsids containing a 5'ppp dsRNA "panhandle" structure trigger antiviral signaling that commences with RIG-I, is mediated through the adaptor protein MAVS, and terminates with transcription factor IRF-3. Independent of mammalian cofactors or viral polymerase activity, RIG-I bound to viral nucleocapsids, underwent a conformational switch, and homo-oligomerized. Enzymatic probing and superresolution microscopy suggest that RIG-I interacts with the panhandle structure of the viral nucleocapsids. These results define cytoplasmic entry of nucleocapsids as the proximal RIG-I-sensitive step during infection and establish viral nucleocapsids withÂ a 5'ppp dsRNA panhandle as a RIG-I activator.Copyright Â© 2013 Elsevier Inc. All rights reserved.</Abstract>
    <JournalRelease>1934-6069</JournalRelease>
    <Pages>336-46</Pages>
    <Affiliation>Institute for Virology, Philipps-University Marburg, 35043 Marburg, Germany.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23498958&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23432157</PMID>
    <AuthorListID>28</AuthorListID>
    <Title>MAVS: a new weapon in the fight against viral infections.</Title>
    <Language>eng</Language>
    <Abstract>In addition to their participation in metabolic processes and control of programmed cell death, the role of mitochondria as a fundamental hub for innate anti-viral immunity is now emerging. The participation of the mitochondrial antiviral signaling protein (MAVS) as a central regulator of a complex signaling cascade, which results in the induction of antiviral and inflammatory responses has been described. A patent based on this role of MAVS is highlighted in this review.</Abstract>
    <JournalRelease>1872-2148</JournalRelease>
    <Pages>115-9</Pages>
    <Affiliation>Servicio de Microbiologia, Hospital Universitario Central de Asturias, 33006 Oviedo, Spain. joseantonio.boga@sespa.princast.es</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23432157&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23419645</PMID>
    <AuthorListID>29</AuthorListID>
    <Title>Prostate cancer-specific thermo-responsive polymer-coated iron oxide nanoparticles.</Title>
    <PubDate>20130215</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.biomaterials.2013.01.062</doi>
    <Abstract>Thermo-responsive poly(N-isopropylacrylamide-acrylamide-allylamine)-coated magnetic nanoparticles (PMNPs) were developed and conjugated with prostate cancer-specific R11 peptides for active targeting and imaging of prostate cancer. The stable nanoparticles with an average diameter of 100Â nm and surface charge ofÂ -27.0Â mV, had a lower critical solution temperature of 40Â Â°C. Magnetic characterization showed that the nanoparticles can be recruited using a magnetic field and possess superparamagnetic behavior even after R11 conjugation. InÂ vitro cell studies demonstrated that R11-conjugated PMNPs (R11-PMNPs) were compatible with human dermal fibroblasts and normal prostate epithelial cells to all tested concentrations up to 500Â Î¼g/ml after 24Â h of incubation. Moreover, the nanoparticles were taken up by prostate cancer cells (PC3 and LNCaP) in a dose-dependent manner, which was higher in case of R11-PMNPs than PMNPs. Further, inÂ vivo biodistribution of the nanoparticles showed significantly more R11-PMNPs accumulation in tumors than other vital organs unlike PMNPs without R11 conjugation. Moreover, R11-PMNPs decreased 30% magnetic resonance T2 signal intensity in tumors inÂ vivo compared to 0% decrease with PMNPs. These results indicate great potential of R11-PMPs as platform technology to target and monitor prostate cancers for diagnostic and therapeutic applications.Copyright Â© 2013 Elsevier Ltd. All rights reserved.</Abstract>
    <JournalRelease>1878-5905</JournalRelease>
    <Pages>3618-25</Pages>
    <Affiliation>Department of Bioengineering, The University of Texas at Arlington, Arlington, TX 76019, USA. aniket.wadajkar@mavs.uta.edu</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23419645&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23414438</PMID>
    <AuthorListID>30</AuthorListID>
    <Title>Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancer.</Title>
    <PubDate>20130218</PubDate>
    <Language>eng</Language>
    <doi>10.1517/14728222.2013.765407</doi>
    <Abstract>Many forms of RNA duplexes with agonistic activity for pattern-recognition receptors have been reported, some of which are candidates for adjuvant immunotherapy for cancer. These RNA duplexes induce cytokines, interferons (IFNs) and cellular effectors mainly via two distinct pathways, TLR3/TICAM-1 and MDA5/MAVS.We determined which pathway of innate immunity predominantly participates in evoking tumor immunity in response to RNA adjuvants.In knockout (KO) mouse studies, robust cytokine or IFN production is dependent on systemic activation of the MAVS pathway, whereas maturation of dendritic cells (DCs) to drive cellular effectors (i.e., NK and CTL) depends on the TICAM-1 pathway in DCs. MAVS activation often causes endotoxin-like cytokinemia, while the TICAM-1 activation does not. Unlike the TLR/MyD88 pathway, this TICAM-1 pathway barely accelerates tumor progression. Although the therapeutic effect in human patients of MAVS-activating or TICAM-1-activating RNA duplexes remains undetermined, the design of a TLR3 agonist with optimized toxicity and dose is an important goal for human immunotherapy. Here we summarize current knowledge on available RNA duplex formulations, and offer a possible approach to developing a promising RNA duplex for clinical tests.</Abstract>
    <JournalRelease>1744-7631</JournalRelease>
    <Pages>533-44</Pages>
    <Affiliation>Hokkaido University, Graduate School of Medicine, Department of Microbiology and Immunology, Sapporo, 060-8638 , Japan. seya-tu@pop.med.hokudai.ac.jp</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23414438&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23408632</PMID>
    <AuthorListID>31</AuthorListID>
    <Title>RNA helicase signaling is critical for type i interferon production and protection against Rift Valley fever virus during mucosal challenge.</Title>
    <PubDate>20130213</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.01997-12</doi>
    <Abstract>Rift Valley fever virus (RVFV) is an emerging RNA virus with devastating economic and social consequences. Clinically, RVFV induces a gamut of symptoms ranging from febrile illness to retinitis, hepatic necrosis, hemorrhagic fever, and death. It is known that type I interferon (IFN) responses can be protective against severe pathology; however, it is unknown which innate immune receptor pathways are crucial for mounting this response. Using both in vitro assays and in vivo mucosal mouse challenge, we demonstrate here that RNA helicases are critical for IFN production by immune cells and that signaling through the helicase adaptor molecule MAVS (mitochondrial antiviral signaling) is protective against mortality and more subtle pathology during RVFV infection. In addition, we demonstrate that Toll-like-receptor-mediated signaling is not involved in IFN production, further emphasizing the importance of the RNA cellular helicases in type I IFN responses to RVFV.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>4846-60</Pages>
    <Affiliation>Center for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23408632&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23367207</PMID>
    <AuthorListID>32</AuthorListID>
    <Title>An investigation of simultaneous variations in cerebral blood flow velocity and arterial blood pressure during sleep apnea.</Title>
    <Language>eng</Language>
    <doi>10.1109/EMBC.2012.6347272</doi>
    <Abstract>Obstructive Sleep Apnea (OSA) is a major sleep disorder with a prevalence of about 15 % among US adult population and can lead to cardiovascular diseases and stroke. In this study, we have investigated the OSA-induced concurrent rise in cerebral blood flow velocity and blood pressure in 5 positively diagnosed sleep apnea subjects. The subject population had a mean AHI of 57.94Â±25.73 and BMI of 33.66Â±7.27 kg/m(2). The results of this preliminary study yielded a relatively high correlation between rise in blood pressure and rise in cerebral blood flow velocity during apnea episodes (r=0.61Â±0.16) compared to normal breathing (r=0.28Â±0.26). These findings suggest that cerebral autoregulation may be less effective during apnea episodes.</Abstract>
    <JournalRelease>1557-170X</JournalRelease>
    <Pages>5634-7</Pages>
    <Affiliation>Bioengineering Department, University of Texas at Arlington, Arlington, TX 76010, USA. raichelmary.alex@ mavs.uta.edu</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23367207&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23337771</PMID>
    <AuthorListID>33</AuthorListID>
    <Title>A structural perspective of the MAVS-regulatory mechanism on the mitochondrial outer membrane using bioluminescence resonance energy transfer.</Title>
    <PubDate>20130118</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.bbamcr.2013.01.010</doi>
    <Abstract>In most eukaryotic cells, mitochondria have various essential roles for proper cell function, such as energy production, and in mammals mitochondria also act as a platform for antiviral innate immunity. Mitochondrial-mediated antiviral immunity depends on the activation of the cytoplasmic retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) signaling pathway, and on the participation of mitochondrial antiviral signaling (MAVS), which is localized on the mitochondrial outer membrane. After RNA virus infection, RLRs translocate to the mitochondrial surface to interact with MAVS, and the adaptor protein undergoes a conformational change that is essential for downstream signaling, although its structural features are poorly understood. Here we examined the MAVS-regulatory mechanism on the mitochondrial outer membrane using bioluminescence resonance energy transfer (BRET) in live cells. Using a combination of BRET and functional analysis, we found that the activated MAVS conformation is a highly ordered oligomer, at least more than three molecules per complex unit on the membrane. Hepatitis C virus NS3/4A protease and mitofusin 2, which are known MAVS inhibitors, interfere with MAVS homotypic oligomerization in a distinct manner, each differentially altering the active conformation of MAVS. Our results reveal structural features underlying the precise regulation of MAVS signaling on the mitochondrial outer membrane, and may provide insight into other signaling systems involving organelles.Copyright Â© 2013 Elsevier B.V. All rights reserved.</Abstract>
    <JournalRelease>0006-3002</JournalRelease>
    <Pages>1017-27</Pages>
    <Affiliation>Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23337771&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23321557</PMID>
    <AuthorListID>34</AuthorListID>
    <Title>The NLR protein, NLRX1, and its partner, TUFM, reduce type I interferon, and enhance autophagy.</Title>
    <PubDate>20130115</PubDate>
    <Language>eng</Language>
    <doi>10.4161/auto.23026</doi>
    <Abstract>The NLR (nucleotide-binding domain leucine-rich repeat containing) proteins serve as regulators of inflammatory signaling pathways. NLRX1, a mitochondria-localized NLR protein, has been previously shown to negatively regulate inflammatory cytokine production activated via the MAVS-DDX58 (RIG-I) pathway. The literature also indicates that DDX58 has a negative impact upon autophagy. Consistent with the inhibitory role of NLRX1 on DDX58, our recent study indicates a role of NLRX1 in augmenting virus-induced autophagy. This effect is through its interaction with another mitochondrial protein TUFM (Tu translation elongation factor, mitochondrial, also known as EF-TuMT, COXPD4, and P43). TUFM also reduces DDX58-activated cytokines but augments autophagy. Additionally it interacts with ATG12-ATG5-ATG16L1 to form a molecular complex that modulates autophagy. The work shows that both NLRX1 and TUFM work in concert to reduce cytokine response and augment autophagy.</Abstract>
    <JournalRelease>1554-8635</JournalRelease>
    <Pages>432-3</Pages>
    <Affiliation>Department of Diagnostic Sciences, School of Dental Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23321557&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23320079</PMID>
    <AuthorListID>35</AuthorListID>
    <Title>Japanese encephalitis virus activates autophagy as a viral immune evasion strategy.</Title>
    <PubDate>20130108</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.pone.0052909</doi>
    <Abstract>In addition to manipulating cellular homeostasis and survivability, autophagy also plays a crucial role in numerous viral infections. In this study, we discover that Japanese encephalitis virus (JEV) infection results in the accumulation of microtubule-associated protein 1 light chain 3-II (LC3-II) protein and GFP-LC3 puncta in vitro and an increase in autophagosomes/autolysosomes in vivo. The fusion between autophagosomes and lysosomes is essential for virus replication. Knockdown of autophagy-related genes reduced JEV replication in vitro, as indicated by viral RNA and protein levels. We also note that JEV infection in autophagy-impaired cells displayed active caspases cleavage and cell death. Moreover, we find that JEV induces higher type I interferon (IFN) activation in cells deficient in autophagy-related genes as the cells exhibited increased phosphorylation and dimerization of interferon regulatory factor 3 (IRF3) and mitochondrial antiviral signaling protein (MAVS) aggregation. Finally, we find that autophagy is indispensable for efficient JEV replication even in an IFN-defective background. Overall, our studies provide the first description of the mechanism of the autophagic innate immune signaling pathway during JEV infection.</Abstract>
    <JournalRelease>1932-6203</JournalRelease>
    <Pages>e52909</Pages>
    <Affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23320079&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23308256</PMID>
    <AuthorListID>36</AuthorListID>
    <Title>Functional characterization of domains of IPS-1 using an inducible oligomerization system.</Title>
    <PubDate>20130107</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.pone.0053578</doi>
    <Abstract>The innate immune system recognizes viral nucleic acids and stimulates cellular antiviral responses. Intracellular detection of viral RNA is mediated by the Retinoic acid inducible gene (RIG)-I Like Receptor (RLR), leading to production of type I interferon (IFN) and pro-inflammatory cytokines. Once cells are infected with a virus, RIG-I and MDA5 bind to viral RNA and undergo conformational change to transmit a signal through direct interaction with downstream CARD-containing adaptor protein, IFN-Î² promoter stimulator-1 (IPS-1, also referred as MAVS/VISA/Cardif). IPS-1 is composed of N-terminal Caspase Activation and Recruitment Domain (CARD), proline-rich domain, intermediate domain, and C-terminal transmembrane (TM) domain. The TM domain of IPS-1 anchors it to the mitochondrial outer membrane. It has been hypothesized that activated RLR triggers the accumulation of IPS-1, which forms oligomer as a scaffold for downstream signal proteins. However, the exact mechanisms of IPS-1-mediated signaling remain controversial. In this study, to reveal the details of IPS-1 signaling, we used an artificial oligomerization system to induce oligomerization of IPS-1 in cells. Artificial oligomerization of IPS-1 activated antiviral signaling without a viral infection. Using this system, we investigated the domain-requirement of IPS-1 for its signaling. We discovered that artificial oligomerization of IPS-1 could overcome the requirement of CARD and the TM domain. Moreover, from deletion- and point-mutant analyses, the C-terminal Tumor necrosis factor Receptor-Associated Factor (TRAF) binding motif of IPS-1 (aa. 453-460) present in the intermediate domain is critical for downstream signal transduction. Our results suggest that IPS-1 oligomerization is essential for the formation of a multiprotein signaling complex and enables downstream activation of transcription factors, Interferon Regulatory Factor 3 (IRF3) and Nuclear Factor-ÎºB (NF-ÎºB), leading to type I IFN and pro-inflammatory cytokine production.</Abstract>
    <JournalRelease>1932-6203</JournalRelease>
    <Pages>e53578</Pages>
    <Affiliation>Laboratory of Molecular Genetics, Institute for Virus Research, Kyoto University, Kyoto, Japan.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23308256&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23308066</PMID>
    <AuthorListID>37</AuthorListID>
    <Title>COX5B regulates MAVS-mediated antiviral signaling through interaction with ATG5 and repressing ROS production.</Title>
    <PubDate>20121220</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.ppat.1003086</doi>
    <Abstract>Innate antiviral immunity is the first line of the host defense system that rapidly detects invading viruses. Mitochondria function as platforms for innate antiviral signal transduction in mammals through the adaptor protein, MAVS. Excessive activation of MAVS-mediated antiviral signaling leads to dysfunction of mitochondria and cell apoptosis that likely causes the pathogenesis of autoimmunity. However, the mechanism of how MAVS is regulated at mitochondria remains unknown. Here we show that the Cytochrome c Oxidase (CcO) complex subunit COX5B physically interacts with MAVS and negatively regulates the MAVS-mediated antiviral pathway. Mechanistically, we find that while activation of MAVS leads to increased ROS production and COX5B expression, COX5B down-regulated MAVS signaling by repressing ROS production. Importantly, our study reveals that COX5B coordinates with the autophagy pathway to control MAVS aggregation, thereby balancing the antiviral signaling activity. Thus, our study provides novel insights into the link between mitochondrial electron transport system and the autophagy pathway in regulating innate antiviral immunity.</Abstract>
    <JournalRelease>1553-7374</JournalRelease>
    <Pages>e1003086</Pages>
    <Affiliation>State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Chaoyang District, Beijing, P.R. China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23308066&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23301932</PMID>
    <AuthorListID>38</AuthorListID>
    <Title>What leads non-U.S.-Born Latinos to access mental health care?</Title>
    <Language>eng</Language>
    <doi>10.1080/00981389.2012.733326</doi>
    <Abstract>Latinos underutilize mental health care services. Of those who do, about 70% do not return after the initial visit. This study's purposes were: (1) to identify factors that led non-U.S.-born Latinos to utilize services from a nonprofit clinic in Texas and (2) to assess whether acculturation played a role in accessing mental health care. Data were collected over a 10-week period using an interview schedule and the Bidimensional Acculturation Scale for Latinos. Results indicate acculturation does not play a significant role in access, but patient knowledge of mental health care issues does. Specifically, the main barriers to access were: (1) lack of knowledge that there was a mental health issue; and (2) lack of knowledge of where to go for mental health services.</Abstract>
    <JournalRelease>1541-034X</JournalRelease>
    <Pages>1-19</Pages>
    <Affiliation>School of Social Work, University of Texas at Arlington, Arlington, Texas 76016, USA. Erika.Ruiz@mavs.uta.edu</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23301932&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23292079</PMID>
    <AuthorListID>39</AuthorListID>
    <Title>Multi-step regulation of interferon induction by hepatitis C virus.</Title>
    <PubDate>20130105</PubDate>
    <Language>eng</Language>
    <doi>10.1007/s00005-012-0214-x</doi>
    <Abstract>Acute hepatitis C virus (HCV) infection evokes several distinct innate immune responses in host, but the virus usually propagates by circumventing these responses. Although a replication intermediate double-stranded RNA is produced in infected cells, type I interferon (IFN) induction and immediate cell death are largely blocked in infected cells. In vitro studies suggested that type I and III IFNs are mainly produced in HCV-infected hepatocytes if the MAVS pathway is functional, and dysfunction of this pathway may lead to cellular permissiveness to HCV replication and production. Cellular immunity, including natural killer cell activation and antigen-specific CD8 T-cell proliferation, occurs following innate immune activation in response to HCV, but is often ineffective for eradication of HCV. Constitutive dsRNA stimulation differs in output from type I IFN therapy, which has been an authentic therapy for patients with HCV. Host innate immune responses to HCV RNA/proteins may be associated with progressive hepatic fibrosis and carcinogenesis once persistent HCV infection is established in opposition to the IFN system. Hence, innate RNA sensing exerts pivotal functions against HCV genome replication and host pathogenesis through modulation of the IFN system. Molecules participating in the RIG-I and Toll-like receptor 3 pathways are the main targets for HCV, disabling the anti-viral functions of these IFN-inducing molecules. We discuss the mechanisms that abolish type I and type III IFN production in HCV-infected cells, which may contribute to understanding the mechanism of virus persistence and resistance to the IFN therapy.</Abstract>
    <JournalRelease>1661-4917</JournalRelease>
    <Pages>127-38</Pages>
    <Affiliation>Department of Microbiology and Immunology, Hokkaido University Graduate School of Medicine, Kita, Sapporo 060-8638, Japan.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23292079&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23273991</PMID>
    <AuthorListID>40</AuthorListID>
    <Title>Structural basis for dsRNA recognition, filament formation, and antiviral signal activation by MDA5.</Title>
    <PubDate>20121227</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.cell.2012.11.048</doi>
    <Abstract>MDA5, a viral double-stranded RNA (dsRNA) receptor, shares sequence similarity and signaling pathways with RIG-I yet plays essential functions in antiviral immunity through distinct specificity for viral RNA. Revealing the molecular basis for the functional divergence, we report here the crystal structure ofÂ MDA5 bound to dsRNA, which shows how, using the same domain architecture, MDA5 recognizes the internal duplex structure, whereas RIG-I recognizes the terminus of dsRNA. We further show that MDA5 uses direct protein-protein contacts to stack along dsRNA in a head-to-tail arrangement, and that the signaling domain (tandem CARD), which decorates the outside of the core MDA5 filament, also has an intrinsic propensity to oligomerize into an elongated structure that activates the signaling adaptor, MAVS. These data support a model in which MDA5 uses long dsRNA as a signaling platform to cooperatively assemble the core filament, which in turn promotes stochastic assembly of the tandem CARD oligomers for signaling.Copyright Â© 2013 Elsevier Inc. All rights reserved.</Abstract>
    <JournalRelease>1097-4172</JournalRelease>
    <Pages>276-89</Pages>
    <Affiliation>Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23273991&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23264040</PMID>
    <AuthorListID>41</AuthorListID>
    <Title>Structural and biochemical studies of RIG-I antiviral signaling.</Title>
    <PubDate>20121220</PubDate>
    <Language>eng</Language>
    <doi>10.1007/s13238-012-2088-4</doi>
    <Abstract>Retinoic acid-inducible gene I (RIG-I) is an important pattern recognition receptor that detects viral RNA and triggers the production of type-I interferons through the downstream adaptor MAVS (also called IPS-1, CARDIF, or VISA). A series of structural studies have elaborated some of the mechanisms of dsRNA recognition and activation of RIG-I. Recent studies have proposed that K63-linked ubiquitination of, or unanchored K63-linked polyubiquitin binding to RIG-I positively regulates MAVS-mediated antiviral signaling. Conversely phosphorylation of RIG-I appears to play an inhibitory role in controlling RIG-I antiviral signal transduction. Here we performed a combined structural and biochemical study to further define the regulatory features of RIG-I signaling. ATP and dsRNA binding triggered dimerization of RIG-I with conformational rearrangements of the tandem CARD domains. Full length RIG-I appeared to form a complex with dsRNA in a 2:2 molar ratio. Compared with the previously reported crystal structures of RIG-I in inactive state, our electron microscopic structure of full length RIG-I in complex with blunt-ended dsRNA, for the first time, revealed an exposed active conformation of the CARD domains. Moreover, we found that purified recombinant RIG-I proteins could bind to the CARD domain of MAVS independently of dsRNA, while S8E and T170E phosphorylation-mimicking mutants of RIG-I were defective in binding E3 ligase TRIM25, unanchored K63-linked polyubiquitin, and MAVS regardless of dsRNA. These findings suggested that phosphorylation of RIG inhibited downstream signaling by impairing RIG-I binding with polyubiquitin and its interaction with MAVS.</Abstract>
    <JournalRelease>1674-8018</JournalRelease>
    <Pages>142-54</Pages>
    <Affiliation>State Key Laboratory of Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23264040&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23249700</PMID>
    <AuthorListID>42</AuthorListID>
    <Title>Over-expression of mitochondrial antiviral signaling protein inhibits coxsackievirus B3 infection by enhancing type-I interferons production.</Title>
    <PubDate>20121219</PubDate>
    <Language>eng</Language>
    <doi>10.1186/1743-422X-9-312</doi>
    <Abstract>Recent studies have revealed that Mitochondrial Antiviral Signaling (MAVS) protein plays an essential role in the inhibition of viral infection through type I interferon (IFN) pathway. It has been shown that 3C (pro) cysteine protease of coxsackievirus B3 (CVB3) cleaves MAVS to inhibit type I IFNs induction. Other workers also found that MAVS knock-out mice suffered CVB3 susceptibility and severe histopathological change. Accordingly,our experiments were designed to explore the protection of over-expressing MAVS against CVB3 infection and the possible mechanism.In this study, HeLa cells (transfected with MAVS constructs pre- or post- exposure to CVB3) were used to analyze the function of exogenous MAVS on CVB3 infection. The results revealed that though CVB3 infection induced production of type I IFNs, viral replication and cell death were not effectively inhibited. Similarly, exogenous MAVS increased type I IFNs moderately. Morever, we observed robust production of type I IFNs in CVB3 post-infected HeLa cells thereby successfully inhibiting CVB3 infection, as well formation of cytopathic effect (CPE) and cell death. Finally, introduction of exogenous MAVS into CVB3 pre-infected cells also restricted viral infection efficiently by greatly up-regulating IFNs.In summary, exogenous MAVS effectively prevents and controls CVB3 infection by modulating and promoting the production of type I IFNs. The IFNs level in MAVS over-expressing cells is still tightly regulated by CVB3 infection. Thus, the factors that up-regulate MAVS might be an alternative prescription in CVB3-related syndromes by enhancing IFNs production.</Abstract>
    <JournalRelease>1743-422X</JournalRelease>
    <Pages>312</Pages>
    <Affiliation>Key Laboratory of Immunity and Infection, Pathogenic Biology, Heilongjiang province, Department of Microbiology, Harbin Medical University, 150081, Harbin, People's Republic of China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23249700&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23246644</PMID>
    <AuthorListID>43</AuthorListID>
    <Title>Influenza A polymerase subunit PB2 possesses overlapping binding sites for polymerase subunit PB1 and human MAVS proteins.</Title>
    <PubDate>20121212</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.virusres.2012.12.003</doi>
    <Abstract>Influenza A virus is an important human pathogen accounting for widespread morbidity and mortality, with new strains emerging from animal reservoirs possessing the potential to cause pandemics. The influenza A RNA-dependent RNA polymerase complex consists of three subunits (PA, PB1, and PB2) and catalyzes viral RNA replication and transcription activities in the nuclei of infected host cells. The PB2 subunit has been implicated in pathogenicity and host adaptation. This includes the inhibition of type I interferon induction through interaction with the host's mitochondrial antiviral signaling protein (MAVS), an adaptor molecule of RIG-I-like helicases. This study reports the identification of the cognate PB2 and MAVS interaction domains necessary for complex formation. Specifically, MAVS residues 1-150, containing both the CARD domain and the N-terminal portion of the proline rich-region, and PB2 residues 1-37 are essential for PB2-MAVS virus-host protein-protein complex formation. The three Î±-helices constituting PB2 (1-37) were tested to determine their relative influence in complex formation, and Helix3 was observed to promote the primary interaction with MAVS. The PB2 MAVS-binding domain unexpectedly coincided with its PB1-binding domain, indicating an important dual functionality for this region of PB2. Analysis of these interaction domains suggests both virus and host properties that may contribute to host tropism. Additionally, the results of this study suggest a new strategy to develop influenza A therapeutics by simultaneously blocking PB2-MAVS and PB2-PB1 protein-protein interactions and their resulting activities.Copyright Â© 2012 Elsevier B.V. All rights reserved.</Abstract>
    <JournalRelease>1872-7492</JournalRelease>
    <Pages>75-80</Pages>
    <Affiliation>Hauptman-Woodward Medical Research Institute, 700 Ellicott Street, Buffalo, NY 14203, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23246644&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23096996</PMID>
    <AuthorListID>44</AuthorListID>
    <Title>Hepatitis C virus NS2 protease inhibits host cell antiviral response by inhibiting IKKÎµ and TBK1 functions.</Title>
    <PubDate>20121023</PubDate>
    <Language>eng</Language>
    <doi>10.1002/jmv.23442</doi>
    <Abstract>Hepatitis C virus (HCV) encodes for several proteins that can interfere with host cell signaling and antiviral response. Previously, serine protease NS3/4A was shown to block host cell interferon (IFN) production by proteolytic cleavage of MAVS and TRIF, the adaptor molecules of the RIG-I and TLR3 signaling pathways, respectively. This study shows that another HCV protease, NS2 can interfere efficiently with cytokine gene expression. NS2 and its proteolytically inactive mutant forms were able to inhibit type I and type III IFN, CCL5 and CXCL10 gene promoters activated by Sendai virus infection. However, the CXCL8 gene promoter was not inhibited by NS2. In addition, constitutively active RIG-I (Î”RIG-I), MAVS, TRIF, IKKÎµ, and TBK1-induced activation of IFN-Î² promoter was inhibited by NS2. Cotransfection experiments with IKKÎµ or TBK1 together with interferon regulatory factor 3 (IRF3) and HCV expression constructs revealed that NS2 in a dose-dependent manner inhibited IKKÎµ and especially TBK1-induced IRF3 phosphorylation. GST pull-down experiments with GST-NS2 and in vitro-translated and cell-expressed IKKÎµ and TBK1 demonstrated direct physical interactions of the kinases with NS2. Further evidence that the IKKÎµ/TBK1 kinase complex is the target for NS2 was obtained from the observation that the constitutively active form of IRF3 (IRF3-5D) activated readily IFN-Î² promoter in the presence of NS2. The present study identified HCV NS2 as a potent interferon antagonist, and describes an explanation of how NS2 downregulates the major signaling pathways involved in the development of host innate antiviral responses.Copyright Â© 2012 Wiley Periodicals, Inc.</Abstract>
    <JournalRelease>1096-9071</JournalRelease>
    <Pages>71-82</Pages>
    <Affiliation>Virology Unit, Department of Infectious Disease Surveillance and Control, National Institute for Health and Welfare (THL), Helsinki, Finland. pasi.kaukinen@helsinki.fi</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23096996&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23090998</PMID>
    <AuthorListID>45</AuthorListID>
    <Title>MDA5 assembles into a polar helical filament on dsRNA.</Title>
    <PubDate>20121022</PubDate>
    <Language>eng</Language>
    <doi>10.1073/pnas.1212186109</doi>
    <Abstract>Melanoma differentiation-associated protein 5 (MDA5) detects viral dsRNA in the cytoplasm. On binding of RNA, MDA5 forms polymers, which trigger assembly of the signaling adaptor mitochondrial antiviral-signaling protein (MAVS) into its active fibril form. The molecular mechanism of MDA5 signaling is not well understood, however. Here we show that MDA5 forms helical filaments on dsRNA and report the 3D structure of the filaments using electron microscopy (EM) and image reconstruction. MDA5 assembles into a polar, single-start helix around the RNA. Fitting of an MDA5 homology model into the structure suggests a key role for the MDA5 C-terminal domain in cooperative filament assembly. Our study supports a signal transduction mechanism in which the helical array of MDA5 within filaments nucleates the assembly of MAVS fibrils. We conclude that MDA5 is a polymerization-dependent signaling platform that uses the amyloid-like self-propagating properties of MAVS to amplify signaling.</Abstract>
    <JournalRelease>1091-6490</JournalRelease>
    <Pages>18437-41</Pages>
    <Affiliation>Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06520, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23090998&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23087404</PMID>
    <AuthorListID>46</AuthorListID>
    <Title>Ndfip1 negatively regulates RIG-I-dependent immune signaling by enhancing E3 ligase Smurf1-mediated MAVS degradation.</Title>
    <PubDate>20121019</PubDate>
    <Language>eng</Language>
    <doi>10.4049/jimmunol.1201445</doi>
    <Abstract>Ndfip1 functions as both a recruiter and an activator of multiple HECT domain E3 ubiquitin ligases of the Nedd4 family. In this study, we demonstrate that Ndfip1 is involved in the ubiquitin-mediated degradation of mitochondrial antiviral signaling (MAVS), which is a key adaptor protein in RIG-I-like receptor-mediated immune signaling. We found that overexpression of Ndfip1 severely impaired MAVS and Sendai virus-mediated activation of IFN-stimulated response element, NF-ÎºB, IFN-Î² promoter, and polyinosinic-polycytidylic acid or influenza virus RNA-stimulated IRF-3 phosphorylation, as well as the transcription of IFN-Î². This functional interaction was confirmed by knockdown of Ndfip1, which facilitated MAVS-mediated downstream signaling and elevated MAVS protein levels. Further analysis indicated that Ndfip1 enhances both self-ubiquitination of HECT domain-containing E3 ubiquitin ligase Smurf1 and its interaction with MAVS, and eventually promotes MAVS degradation. In addition, the activation of IFN-Î² by MAVS, influenza virus RNA, polyinosinic-polycytidylic acid, and Sendai virus was enhanced in Ndfip1 knockdown cells. These results reveal that Ndfip1 is a potent inhibitor of MAVS-mediated antiviral response.</Abstract>
    <JournalRelease>1550-6606</JournalRelease>
    <Pages>5304-13</Pages>
    <Affiliation>Center for Molecular Immunology, Chinese Academy of Sciences Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23087404&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23077300</PMID>
    <AuthorListID>47</AuthorListID>
    <Title>TRIM protein-mediated regulation of inflammatory and innate immune signaling and its association with antiretroviral activity.</Title>
    <PubDate>20121017</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.01804-12</doi>
    <Abstract>Members of the tripartite interaction motif (TRIM) family of E3 ligases are emerging as critical regulators of innate immunity. To identify new regulators, we carried out a screen of 43 human TRIM proteins for the ability to activate NF-ÎºB, AP-1, and interferon, hallmarks of many innate immune signaling pathways. We identified 16 TRIM proteins that induced NF-ÎºB and/or AP-1. We found that one of these, TRIM62, functions in the TRIF branch of the TLR4 signaling pathway. Knockdown of TRIM62 in primary macrophages led to a defect in TRIF-mediated late NF-ÎºB, AP-1, and interferon production after lipopolysaccharide challenge. We also discovered a role for TRIM15 in the RIG-I-mediated interferon pathway upstream of MAVS. Knockdown of TRIM15 limited virus/RIG-I ligand-induced interferon production and enhanced vesicular stomatitis virus replication. In addition, most TRIM proteins previously identified to inhibit murine leukemia virus (MLV) demonstrated an ability to induce NF-ÎºB/AP-1. Interfering with the NF-ÎºB and AP-1 signaling induced by the antiretroviral TRIM1 and TRIM62 proteins rescued MLV release. In contrast, human immunodeficiency virus type 1 (HIV-1) gene expression was increased by TRIM proteins that induce NF-ÎºB. HIV-1 resistance to inflammatory TRIM proteins mapped to the NF-ÎºB sites in the HIV-1 long terminal repeat (LTR) U3 and could be transferred to MLV. Thus, our work identifies new TRIM proteins involved in innate immune signaling and reinforces the striking ability of HIV-1 to exploit innate immune signaling for the purpose of viral replication.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>257-72</Pages>
    <Affiliation>Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23077300&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23063572</PMID>
    <AuthorListID>48</AuthorListID>
    <Title>Innate immunity and HCV.</Title>
    <PubDate>20121011</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.jhep.2012.10.005</doi>
    <Abstract>Hepatitis C virus (HCV) infections become chronic in the majority of infected individuals, and chronic hepatitis C (CHC) can lead to cirrhosis and hepatocellular carcinoma. The innate immune system is central to host-virus interactions during the entire natural course of the disease. The HCV NS3/4A protease efficiently cleaves and inactivates two important signaling molecules in the sensory pathways that react to HCV pathogen-associated molecular patterns (PAMPs) to induce interferons (IFNs), i.e., mitochondrial antiviral signaling protein (MAVS) and Toll-IL-1 receptor domain-containing adaptor inducing IFN-Î² (TRIF). Despite this viral escape mechanism, the innate immune system strongly reacts to HCV within the first days after infection. The sensory pathways, the type(s) of IFNs involved and the cellular source of IFNs are largely unknown. After 4-8weeks, HCV specific T cells are recruited to the liver. IFN-Î³-stimulated genes get strongly expressed in the liver. In about 30% of patients, the virus is eliminated during the acute phase of the infection by T cell-mediated antiviral mechanisms. In the remaining 70% of patients, HCV persists for decades. During this phase, T cell-derived IFN-Î³ cannot be detected any more in liver biopsies. Instead, in about half of the patients, hundreds of type I or III IFN-stimulated genes become again strongly expressed. However, this innate immune reaction is ineffective against HCV. Moreover, patients with constitutive IFN-stimulated gene (ISG) expression have a poor response to treatment with pegylated IFN-Î± (PegIFN-Î±) and ribavirin. The viral escape mechanisms that protect HCV from IFN-mediated innate immune reactions are not entirely understood, but might involve blockade of ISG protein translation at the ribosome, localization of viral replication to cells with refractory IFN signal transduction pathways or to cell compartments that are not accessible to antiviral IFN-stimulated effector systems. Recently, genetic variations near the IL28B (IFN-Î»3) were found to be strongly associated with spontaneous clearance of HCV and response to treatment with PegIFN-Î± and ribavirin. The finding supports a central role of the innate immune response in host-viral interactions. The signaling pathways that link genetic variants of IL28B with immune answers to HCV remain to be elucidated. The present review article attempts to summarize current knowledge of some central aspects of the interactions of HCV with the innate immune system.Copyright Â© 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.</Abstract>
    <JournalRelease>1600-0641</JournalRelease>
    <Pages>564-74</Pages>
    <Affiliation>Division of Gastroenterology and Hepatology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland. markus.heim@unibas.ch</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23063572&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23028806</PMID>
    <AuthorListID>49</AuthorListID>
    <Title>Foreign RNA induces the degradation of mitochondrial antiviral signaling protein (MAVS): the role of intracellular antiviral factors.</Title>
    <PubDate>20120917</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.pone.0045136</doi>
    <Abstract>Mitochondrial antiviral signaling protein (MAVS) is an essential adaptor molecule that is responsible for antiviral signaling triggered by retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs), leading to the induction of type I interferon in innate immunity. Previous studies have shown that certain viruses evade the innate immune response by cleaving the MAVS protein. However, little is known about how MAVS is regulated in response to foreign RNA, including both single-stranded (ss) and double-stranded (ds) RNA, because most previous reports have shown that the cleavage of MAVS is executed by proteases that are induced or activated by the invading RNA viruses. Here, we report that MAVS mRNA is degraded in response to polyinosinic-polycytidylic acid (polyI:C), a synthetic dsRNA, in A549 cells. RNA interference (RNAi) experiments revealed that both ssRNA- and dsRNA-associated pattern-recognition receptors (PRRs) were not involved in the degradation of MAVS mRNA. Foreign RNA also induced the transient degradation of the MAVS protein. In the resting state, the MAVS protein was protected from degradation by interferon regulatory factor 3 (IRF3); moreover, the dimerization of IRF3 appeared to be correlated with the rescue of protein degradation in response to polyI:C. The overexpression of MAVS enhanced interferon-Î² (IFN-Î²) expression in response to polyI:C, suggesting that the degradation of MAVS contributes to the suppression of the hyper-immune reaction in late-phase antiviral signaling. Taken together, these results suggest that the comprehensive regulation of MAVS in response to foreign RNA may be essential to antiviral host defenses.</Abstract>
    <JournalRelease>1932-6203</JournalRelease>
    <Pages>e45136</Pages>
    <Affiliation>Department of Vascular Biology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23028806&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23028469</PMID>
    <AuthorListID>50</AuthorListID>
    <Title>NEMO binds ubiquitinated TANK-binding kinase 1 (TBK1) to regulate innate immune responses to RNA viruses.</Title>
    <PubDate>20120918</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.pone.0043756</doi>
    <Abstract>RIG-I-like receptors (RLR) are intracellular sensors utilized by nearly all cell types for recognition of viral RNA, initiation of antiviral defense, and induction of type I interferons (IFN). TBK1 is a critical kinase implicated in RLR-dependent IFN transcription. Posttranslational modification of TBK1 by K63-linked ubiquitin is required for RLR driven signaling. However, the TBK1 ubiquitin acceptor sites and the function of ubiquitinated TBK1 in the signaling cascade are unknown. We now show that TBK1 is ubiquitinated on residues K69, K154, and K372 in response to infection with RNA virus. The K69 and K154 residues are critical for innate antiviral responses and IFN production. Ubiquitinated TBK1 recruits the downstream adaptor NEMO through ubiquitin binding domains. The assembly of the NEMO/TBK1 complex on the mitochondrial protein MAVS leads to activation of TBK1 kinase activity and phosphorylation of the transcription factor, interferon response factor 3. The combined results refine current views of RLR signaling, define the role of TBK1 polyubiquitination, and detail the mechanisms involved in signalosome assembly.</Abstract>
    <JournalRelease>1932-6203</JournalRelease>
    <Pages>e43756</Pages>
    <Affiliation>Department of Microbiology &amp; Immunobiology, Harvard Medical School, Boston, Massachusetts, United States of America.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23028469&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23015697</PMID>
    <AuthorListID>51</AuthorListID>
    <Title>Human metapneumovirus M2-2 protein inhibits innate cellular signaling by targeting MAVS.</Title>
    <PubDate>20120926</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.01248-12</doi>
    <Abstract>Human metapneumovirus (hMPV) is a leading cause of respiratory infections in pediatric populations globally, with no prophylactic or therapeutic measures. Recently, a recombinant hMPV lacking the M2-2 protein (rhMPV-Î”M2-2) demonstrated reduced replication in the respiratory tract of animal models, making it a promising live vaccine candidate. However, the exact nature of the interaction between the M2-2 protein and host cells that regulates viral infection/propagation is largely unknown. By taking advantage of the available reverse genetics system and ectopic expression system for viral protein, we found that M2-2 not only promotes viral gene transcription and replication but subverts host innate immunity, therefore identifying M2-2 as a novel virulence factor, in addition to the previously described hMPV G protein. Since we have shown that the RIG-I/MAVS pathway plays an important role in hMPV-induced signaling in airway epithelial cells, we investigated whether M2-2 antagonizes the host cellular responses by targeting this pathway. Reporter gene assays and coimmunoprecipitation studies indicated that M2-2 targets MAVS, an inhibitory mechanism different from what we previously reported for hMPV G, which affects RIG-I- but not MAVS-dependent gene transcription. In addition, we found that the domains of M2-2 responsible for the regulation of viral gene transcription and antiviral signaling are different. Our findings collectively demonstrate that M2-2 contributes to hMPV immune evasion through the inhibition of MAVS-dependent cellular responses.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>13049-61</Pages>
    <Affiliation>Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23015697&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23014529</PMID>
    <AuthorListID>52</AuthorListID>
    <Title>TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles.</Title>
    <PubDate>20120926</PubDate>
    <Language>eng</Language>
    <doi>10.1158/1078-0432.CCR-12-1595</doi>
    <Abstract>The treatment of cancer with oncolytic viruses primarily depends on the selective viral replication in cancer cells. However, a replication-incompetent hemagglutinating virus of Japan (HVJ; Sendai virus) envelope (HVJ-E) suppresses the growth of human cancer cells as effectively as replication-competent live HVJ without producing toxic effects in nonmalignant cells. Here, we analyze the molecular mechanism of the oncolytic activity of HVJ-E.The molecules responsible for HVJ-E-induced cancer cell death were elucidated in prostate cancer cell lines, and the effect of HVJ-E on orthotopic prostate cancers was evaluated in nonobese diabetic-severe combined immunodeficient (NOD-SCID) mice.The liposome-mediated transfer of viral RNA genome fragments from HVJ-E suppressed the viability of prostate cancer cells but not the viability of the noncancerous prostate epithelium. Knockdown experiments using siRNAs showed that the cancer cell-selective killing induced by HVJ-E was mediated by retinoic acid-inducible gene I (RIG-I) and mitochondrial antiviral signaling protein (MAVS). Downstream of the RIG-I/MAVS pathway, both TNF-related apoptosis-inducing ligand (TRAIL) and Noxa were upregulated by HVJ-E in the castration-resistant prostate cancer cell line PC3 but not in the noncancerous prostate epithelial cell line PNT2. TRAIL siRNA but not Noxa siRNA significantly inhibited HVJ-E-induced cell death in PC3 cells. However, Noxa siRNA effectively suppressed HVJ-E-induced cell death in DU145 cells, another castration-resistant prostate cancer cell line, in which Noxa but not TRAIL was upregulated by HVJ-E. Furthermore, the orthotopic prostate cancers were dramatically eradicated in immunodeficient mice injected with HVJ-E.The RIG-I/MAVS signaling pathway represents an attractive target for cancer therapy.Â©2012 AACR.</Abstract>
    <JournalRelease>1078-0432</JournalRelease>
    <Pages>6271-83</Pages>
    <Affiliation>Division of Gene Therapy Science, Departments of Urology and Pediatric Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23014529&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22996173</PMID>
    <AuthorListID>53</AuthorListID>
    <Title>The essential adaptors of innate immune signaling.</Title>
    <PubDate>20120921</PubDate>
    <Language>eng</Language>
    <doi>10.1007/s13238-012-2063-0</doi>
    <Abstract>Microbial components and the endogenous molecules released from damaged cells can stimulate germ-line-encoded pattern recognition receptors (PRRs) to transduce signals to the hub of the innate immune signaling network-the adaptor proteins MyD88/TRIF/MAVS/STING/Caspase-1, where integrated signals relay to the relevant transcription factors IRF3/IRF7/NF-ÎºB/ AP-1 and the signal transducer and activator of transcription 6 (STAT6) to trigger the expression of type I interferons and inflammatory cytokines or the assembly of inflammasomes. Most pleiotropic cytokines are secreted and bind to specific receptors, activating the signaling pathways including JAK-STAT for the proliferation, differentiation and functional capacity of immune cells. This review focuses on several critical adaptors in innate immune signaling cascades and recent progress in their molecular mechanisms.</Abstract>
    <JournalRelease>1674-8018</JournalRelease>
    <Pages>27-39</Pages>
    <Affiliation>School of Life Sciences, Peking University, Beijing, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22996173&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22908223</PMID>
    <AuthorListID>54</AuthorListID>
    <Title>Tetraspanin 6 (TSPAN6) negatively regulates retinoic acid-inducible gene I-like receptor-mediated immune signaling in a ubiquitination-dependent manner.</Title>
    <PubDate>20120820</PubDate>
    <Language>eng</Language>
    <doi>10.1074/jbc.M112.390401</doi>
    <Abstract>The recognition between retinoic acid-inducible gene I-like receptors (RLRs) and viral RNA triggers an intracellular cascade of signaling to induce the expression of type I IFNs. Both positive and negative regulation of the RLR signaling pathway are important for the host antiviral immune response. Here, we demonstrate that the tetraspanin protein TSPAN6 inhibits RLR signaling by affecting the formation of the adaptor MAVS (mitochondrial antiviral signaling)-centered signalosome. We found that overexpression of TSPAN6 impaired RLR-mediated activation of IFN-stimulated response element, NF-ÎºB, and IFN-Î² promoters, whereas knockdown of TSPAN6 enhanced the RLR-mediated signaling pathway. Interestingly, as the RLR pathway was activated, TSPAN6 underwent Lys-63-linked ubiquitination, which promoted its association with MAVS. The interaction of TSPAN6 and MAVS interfered with the recruitment of RLR downstream molecules TRAF3, MITA, and IRF3 to MAVS. Further study revealed that the first transmembrane domain of TSPAN6 is critical for its ubiquitination and association with MAVS as well as its inhibitory effect on RLR signaling. We concluded that TSPAN6 functions as a negative regulator of the RLR pathway by interacting with MAVS in a ubiquitination-dependent manner.</Abstract>
    <JournalRelease>1083-351X</JournalRelease>
    <Pages>34626-34</Pages>
    <Affiliation>CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22908223&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22901541</PMID>
    <AuthorListID>55</AuthorListID>
    <Title>Linear ubiquitination of NEMO negatively regulates the interferon antiviral response through disruption of the MAVS-TRAF3 complex.</Title>
    <Language>eng</Language>
    <doi>10.1016/j.chom.2012.06.009</doi>
    <Abstract>The RIG-I/Mda5 sensors recognize viral intracellular RNA and trigger host antiviral responses. RIG-I signals through the adaptor protein MAVS, which engages various TRAF family members and results in type I interferon (IFNs) and proinflammatory cytokine production via activation of IRFs and NF-ÎºB, respectively. Both the IRF and NF-ÎºB pathways also require the adaptor protein NEMO. We determined that the RIG-I pathway is differentially regulated by the linear ubiquitin assembly complex (LUBAC), which consists of the E3 ligases HOIL-1L, HOIP, and the accessory protein SHARPIN. LUBAC downregulated virus-mediated IFN induction by targeting NEMO for linear ubiquitination. Linear ubiquitinated NEMO associated with TRAF3 and disrupted the MAVS-TRAF3 complex, which inhibited IFN activation while stimulating NF-ÎºB-dependent signaling. In SHARPIN-deficient MEFs, vesicular stomatitis virus replication was decreased due to increased IFN production. Linear ubiquitination thus switches NEMO from a positive to a negative regulator of RIG-I signaling, resulting in an attenuated IFN response.Copyright Â© 2012 Elsevier Inc. All rights reserved.</Abstract>
    <JournalRelease>1934-6069</JournalRelease>
    <Pages>211-22</Pages>
    <Affiliation>Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22901541&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22870331</PMID>
    <AuthorListID>56</AuthorListID>
    <Title>Canine hepacivirus NS3 serine protease can cleave the human adaptor proteins MAVS and TRIF.</Title>
    <PubDate>20120801</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.pone.0042481</doi>
    <Abstract>Canine hepacivirus (CHV) was recently identified in domestic dogs and horses. The finding that CHV is genetically the virus most closely related to hepatitis C virus (HCV) has raised the question of whether HCV might have evolved as the result of close contact between dogs and/or horses and humans. The aim of this study was to investigate whether the NS3/4A serine protease of CHV specifically cleaves human mitochondrial antiviral signaling protein (MAVS) and Toll-IL-1 receptor domain-containing adaptor inducing interferon-beta (TRIF). The proteolytic activity of CHV NS3/4A was evaluated using a bacteriophage lambda genetic screen. Human MAVS- and TRIF-specific cleavage sites were engineered into the lambda cI repressor. Upon infection of Escherichia coli cells coexpressing these repressors and a CHV NS3/4A construct, lambda phage replicated up to 2000-fold more efficiently than in cells expressing a CHV protease variant carrying the inactivating substitution S139A. Comparable results were obtained when several HCV NS3/4A constructs of genotype 1b were assayed. This indicates that CHV can disrupt the human innate antiviral defense signaling pathway and suggests a possible evolutionary relationship between CHV and HCV.</Abstract>
    <JournalRelease>1932-6203</JournalRelease>
    <Pages>e42481</Pages>
    <Affiliation>FundaciÃ³ irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat AutÃ²noma de Barcelona (UAB), Badalona, Spain.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22870331&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22844514</PMID>
    <AuthorListID>57</AuthorListID>
    <Title>Identification of tyrosine-9 of MAVS as critical target for inducible phosphorylation that determines activation.</Title>
    <PubDate>20120726</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.pone.0041687</doi>
    <Abstract>Innate immunity to viruses involves receptors such as RIG-I, which senses viral RNA and triggers an IFN-Î² signaling pathway involving the outer mitochondrial membrane protein MAVS. However, the functional status of MAVS phosphorylation remains elusive.Here we demonstrate for the first time that MAVS undergoes extensive tyrosine phosphorylation upon viral infection, indicating that MAVS phosphorylation might play an important role in MAVS function. A tyrosine-scanning mutational analysis revealed that MAVS tyrosine-9 (Y9) is a phosphorylation site that is required for IFN-Î² signaling. Indeed, MAVS Y9F mutation severely impaired TRAF3/TRAF6 recruitment and displayed decreased tyrosine phosphorylation in response to VSV infection compared to wild type MAVS. Functionally, MAVS Y9 phosphorylation contributed to MAVS antiviral function without interfering with its apoptosis property.These experiments identify a novel residue of MAVS that is crucially involved in the recruitment of TRAF3/TRAF6 and in downstream propagation of MAVS signaling.</Abstract>
    <JournalRelease>1932-6203</JournalRelease>
    <Pages>e41687</Pages>
    <Affiliation>Hainan Branch of Chinese PLA General Hospital Sanya City, Hainan, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22844514&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22792062</PMID>
    <AuthorListID>58</AuthorListID>
    <Title>Proteomic profiling of the TRAF3 interactome network reveals a new role for the ER-to-Golgi transport compartments in innate immunity.</Title>
    <PubDate>20120705</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.ppat.1002747</doi>
    <Abstract>Tumor Necrosis Factor receptor-associated factor-3 (TRAF3) is a central mediator important for inducing type I interferon (IFN) production in response to intracellular double-stranded RNA (dsRNA). Here, we report the identification of Sec16A and p115, two proteins of the ER-to-Golgi vesicular transport system, as novel components of the TRAF3 interactome network. Notably, in non-infected cells, TRAF3 was found associated with markers of the ER-Exit-Sites (ERES), ER-to-Golgi intermediate compartment (ERGIC) and the cis-Golgi apparatus. Upon dsRNA and dsDNA sensing however, the Golgi apparatus fragmented into cytoplasmic punctated structures containing TRAF3 allowing its colocalization and interaction with Mitochondrial AntiViral Signaling (MAVS), the essential mitochondria-bound RIG-I-like Helicase (RLH) adaptor. In contrast, retention of TRAF3 at the ER-to-Golgi vesicular transport system blunted the ability of TRAF3 to interact with MAVS upon viral infection and consequently decreased type I IFN response. Moreover, depletion of Sec16A and p115 led to a drastic disorganization of the Golgi paralleled by the relocalization of TRAF3, which under these conditions was unable to associate with MAVS. Consequently, upon dsRNA and dsDNA sensing, ablation of Sec16A and p115 was found to inhibit IRF3 activation and anti-viral gene expression. Reciprocally, mild overexpression of Sec16A or p115 in Hec1B cells increased the activation of IFNÎ², ISG56 and NF-ÎºB -dependent promoters following viral infection and ectopic expression of MAVS and Tank-binding kinase-1 (TBK1). In line with these results, TRAF3 was found enriched in immunocomplexes composed of p115, Sec16A and TBK1 upon infection. Hence, we propose a model where dsDNA and dsRNA sensing induces the formation of membrane-bound compartments originating from the Golgi, which mediate the dynamic association of TRAF3 with MAVS leading to an optimal induction of innate immune responses.</Abstract>
    <JournalRelease>1553-7374</JournalRelease>
    <Pages>e1002747</Pages>
    <Affiliation>Faculty of Pharmacy, UniversitÃ© de MontrÃ©al, MontrÃ©al, QuÃ©bec Canada.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22792062&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22749352</PMID>
    <AuthorListID>59</AuthorListID>
    <Title>The mitochondrial proteins NLRX1 and TUFM form a complex that regulates type I interferon and autophagy.</Title>
    <Language>eng</Language>
    <doi>10.1016/j.immuni.2012.03.025</doi>
    <Abstract>The mitochondrial protein MAVS (also known as IPS-1, VISA, and CARDIF) interacts with RIG-I-like receptors (RLRs) to induce type I interferon (IFN-I). NLRX1 is a mitochondrial nucleotide-binding, leucine-rich repeats (NLR)-containing protein that attenuates MAVS-RLR signaling. Using Nlrx1(-/-) cells, we confirmed that NLRX1 attenuated IFN-I production, but additionally promoted autophagy during viral infection. This dual function of NLRX1 paralleled the previously described functions of the autophagy-related proteins Atg5-Atg12, but NLRX1 did not associate with Atg5-Atg12. High-throughput quantitative mass spectrometry and endogenous protein-protein interaction revealed an NLRX1-interacting partner, mitochondrial Tu translation elongation factor (TUFM). TUFM interacted with Atg5-Atg12 and Atg16L1 and has similar functions as NLRX1 by inhibiting RLR-induced IFN-I but promoting autophagy. In the absence of NLRX1, increased IFN-I and decreased autophagy provide an advantage for host defense against vesicular stomatitis virus. This study establishes a link between an NLR protein and the viral-induced autophagic machinery via an intermediary partner, TUFM.Copyright Â© 2012 Elsevier Inc. All rights reserved.</Abstract>
    <JournalRelease>1097-4180</JournalRelease>
    <Pages>933-46</Pages>
    <Affiliation>The Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22749352&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22674996</PMID>
    <AuthorListID>60</AuthorListID>
    <Title>Influenza virus protein PB1-F2 inhibits the induction of type I interferon by binding to MAVS and decreasing mitochondrial membrane potential.</Title>
    <PubDate>20120606</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.01122-12</doi>
    <Abstract>PB1-F2 is a small, 87- to 90-amino-acid-long protein encoded by the +1 alternate open reading frame of the PB1 gene of most influenza A virus strains. It has been shown to contribute to viral pathogenicity in a host- and strain-dependent manner, and we have previously discovered that a serine at position 66 (66S) in the PB1-F2 protein increases virulence of the 1918 and H5N1 pandemic viruses. Recently, we have shown that PB1-F2 inhibits the induction of type I interferon (IFN) at the level of the MAVS adaptor protein. However, the molecular mechanism for the IFN antagonist function of PB1-F2 has remained unclear. In the present study, we demonstrated that the C-terminal portion of the PB1-F2 protein binds to MAVS in a region that contains the transmembrane domain. Strikingly, PB1-F2 66S was observed to bind to MAVS more efficiently than PB1-F2 66N. We also tested the effect of PB1-F2 on the IFN antagonist functions of the polymerase proteins PB1, PB2, and PA and observed enhanced IFN inhibition by the PB1 and PB2 proteins in combination with PB1-F2 but not by the PA protein. Using a flow cytometry-based assay, we demonstrate that the PB1-F2 protein inhibits MAVS-mediated IFN synthesis by decreasing the mitochondrial membrane potential (MMP). Interestingly, PB1-F2 66S affected the MMP more efficiently than wild-type PB1-F2. In summary, the results of our study identify the molecular mechanism by which the influenza virus PB1-F2 N66S protein increases virulence.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>8359-66</Pages>
    <Affiliation>Department of Microbiology, Mount Sinai School of Medicine, New York, New York, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22674996&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22664327</PMID>
    <AuthorListID>61</AuthorListID>
    <Title>Mitochondrial anti-viral immunity.</Title>
    <PubDate>20120601</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.biocel.2012.05.018</doi>
    <Abstract>In the cytosol, the sensing of RNA viruses by the RIG-I-like receptors (RLRs) triggers a complex signaling cascade where the mitochondrial antiviral signaling protein (MAVS) plays a crucial role in orchestrating the innate host response through the induction of antiviral and inflammatory responses. Hence, in addition to their known roles in the metabolic processes and the control of programmed cell death, mitochondria are now emerging as a fundamental hub for innate anti-viral immunity. This review summarizes the findings related to the MAVS adapter and mitochondria in the innate immune response to RNA viruses.Copyright Â© 2012 Elsevier Ltd. All rights reserved.</Abstract>
    <JournalRelease>1878-5875</JournalRelease>
    <Pages>1473-6</Pages>
    <Affiliation>INSERM UMR_S 1014, HÃ´pital Paul Brousse, BÃ¢timent Lavoisier, Villejuif Cedex, France.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22664327&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22626058</PMID>
    <AuthorListID>62</AuthorListID>
    <Title>MAVS ubiquitination by the E3 ligase TRIM25 and degradation by the proteasome is involved in type I interferon production after activation of the antiviral RIG-I-like receptors.</Title>
    <PubDate>20120524</PubDate>
    <Language>eng</Language>
    <doi>10.1186/1741-7007-10-44</doi>
    <Abstract>During a viral infection, the intracellular RIG-I-like receptors (RLRs) sense viral RNA and signal through the mitochondrial antiviral signaling adaptor MAVS (also known as IPS-1, Cardif and VISA) whose activation triggers a rapid production of type I interferons (IFN) and of pro-inflammatory cytokines through the transcription factors IRF3/IRF7 and NF-ÎºB, respectively. While MAVS is essential for this signaling and known to operate through the scaffold protein NEMO and the protein kinase TBK1 that phosphorylates IRF3, its mechanism of action and regulation remain unclear.We report here that RLR activation triggers MAVS ubiquitination on lysine 7 and 10 by the E3 ubiquitin ligase TRIM25 and marks it for proteasomal degradation concomitantly with downstream signaling. Inhibition of this MAVS degradation with a proteasome inhibitor does not affect NF-ÎºB signaling but it hampers IRF3 activation, and NEMO and TBK1, two essential mediators in type I IFN production, are retained at the mitochondria.These results suggest that MAVS functions as a recruitment platform that assembles a signaling complex involving NEMO and TBK1, and that the proteasome-mediated MAVS degradation is required to release the signaling complex into the cytosol, allowing IRF3 phosphorylation by TBK1.</Abstract>
    <JournalRelease>1741-7007</JournalRelease>
    <Pages>44</Pages>
    <Affiliation>INSERM UMR_S 1014, HÃ´pital Paul Brousse, BÃ¢timent Lavoisier, 14 avenue Paul Vaillant Couturier, 94807 Villejuif cedex, France.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22626058&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22623799</PMID>
    <AuthorListID>63</AuthorListID>
    <Title>Suppression of the interferon and NF-ÎºB responses by severe fever with thrombocytopenia syndrome virus.</Title>
    <PubDate>20120523</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.00612-12</doi>
    <Abstract>Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease characterized by high fever, thrombocytopenia, multiorgan dysfunction, and a high fatality rate between 12 and 30%. It is caused by SFTS virus (SFTSV), a novel Phlebovirus in family Bunyaviridae. Although the viral pathogenesis remains largely unknown, hemopoietic cells appear to be targeted by the virus. In this study we report that human monocytes were susceptible to SFTSV, which replicated efficiently, as shown by an immunofluorescence assay and real-time reverse transcription-PCR. We examined host responses in the infected cells and found that antiviral interferon (IFN) and IFN-inducible proteins were induced upon infection. However, our data also indicated that downregulation of key molecules such as mitochondrial antiviral signaling protein (MAVS) or weakened activation of interferon regulatory factor (IRF) and NF-ÎºB responses may contribute to a restricted innate immunity against the infection. NSs, the nonstructural protein encoded by the S segment, suppressed the beta interferon (IFN-Î²) and NF-ÎºB promoter activities, although NF-ÎºB activation appears to facilitate SFTSV replication in human monocytes. NSs was found to be associated with TBK1 and may inhibit the activation of downstream IRF and NF-ÎºB signaling through this interaction. Interestingly, we demonstrated that the nucleoprotein (N), also encoded by the S segment, exhibited a suppressive effect on the activation of IFN-Î² and NF-ÎºB signaling as well. Infected monocytes, mainly intact and free of apoptosis, may likely be implicated in persistent viral infection, spreading the virus to the circulation and causing primary viremia. Our findings provide the first evidence in dissecting the host responses in monocytes and understanding viral pathogenesis in humans infected with a novel deadly Bunyavirus.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>8388-401</Pages>
    <Affiliation>The State Key Laboratory of Pharmaceutical Biotechnology and Medical School, Nanjing University, Nanjing, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22623799&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22623778</PMID>
    <AuthorListID>64</AuthorListID>
    <Title>Human respiratory syncytial virus nucleoprotein and inclusion bodies antagonize the innate immune response mediated by MDA5 and MAVS.</Title>
    <PubDate>20120523</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.00215-12</doi>
    <Abstract>Currently, the spatial distribution of human respiratory syncytial virus (hRSV) proteins and RNAs in infected cells is still under investigation, with many unanswered questions regarding the interaction of virus-induced structures and the innate immune system. Very few studies of hRSV have used subcellular imaging as a means to explore the changes in localization of retinoic-acid-inducible gene-I (RIG-I)-like receptors or the mitochondrial antiviral signaling (MAVS) protein, in response to the infection and formation of viral structures. In this investigation, we found that both RIG-I and melanoma differentiation-associated gene 5 (MDA5) colocalized with viral genomic RNA and the nucleoprotein (N) as early as 6 h postinfection (hpi). By 12 hpi, MDA5 and MAVS were observed within large viral inclusion bodies (IB). We used a proximity ligation assay (PLA) and determined that the N protein was in close proximity to MDA5 and MAVS in IBs throughout the course of the infection. Similar results were found with the transient coexpression of N and the phosphoprotein (P). Additionally, we demonstrated that the localization of MDA5 and MAVS in IBs inhibited the expression of interferon Î² mRNA 27-fold following Newcastle disease virus infection. From these data, we concluded that the N likely interacts with MDA5, is in close proximity to MAVS, and localizes these molecules within IBs in order to attenuate the interferon response. To our knowledge, this is the first report of a specific function for hRSV IBs and of the hRSV N protein as a modulator of the innate immune response.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>8245-58</Pages>
    <Affiliation>Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22623778&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22607805</PMID>
    <AuthorListID>65</AuthorListID>
    <Title>The mitochondrial targeting chaperone 14-3-3Îµ regulates a RIG-I translocon that mediates membrane association and innate antiviral immunity.</Title>
    <Language>eng</Language>
    <doi>10.1016/j.chom.2012.04.006</doi>
    <Abstract>RIG-I is a cytosolic pathogen recognition receptor that initiates immune responses against RNA viruses. Upon viral RNA recognition, antiviral signaling requires RIG-I redistribution from the cytosol to membranes where it binds the adaptor protein, MAVS. Here we identify the mitochondrial targeting chaperone protein, 14-3-3Îµ, as a RIG-I-binding partner and essential component of a translocation complex or "translocon" containing RIG-I, 14-3-3Îµ, and the TRIM25 ubiquitin ligase. The RIG-I translocon directs RIG-I redistribution from the cytosol to membranes where it mediates MAVS-dependent innate immune signaling during acute RNA virus infection. 14-3-3Îµ is essential for the stable interaction of RIG-I with TRIM25, which facilitates RIG-I ubiquitination and initiation of innate immunity against hepatitis C virus and other pathogenic RNA viruses. Our results define 14-3-3Îµ as a key component of a RIG-I translocon required for innate antiviral immunity.Copyright Â© 2012 Elsevier Inc. All rights reserved.</Abstract>
    <JournalRelease>1934-6069</JournalRelease>
    <Pages>528-37</Pages>
    <Affiliation>Department of Immunology, University of Washington School of Medicine, Seattle, WA 98195-7950, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22607805&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22558311</PMID>
    <AuthorListID>66</AuthorListID>
    <Title>Bile acids specifically increase hepatitis C virus RNA-replication.</Title>
    <PubDate>20120425</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.pone.0036029</doi>
    <Abstract>Hepatitis C virus (HCV) patients with high serum levels of bile acids (BAs) respond poorly to IFN therapy. BAs have been shown to increase RNA-replication of genotype 1 but not genotype 2a replicons. Since BAs modulate lipid metabolism including lipoprotein secretion and as HCV depends on lipids and lipoproteins during RNA-replication, virus production and cell entry, BAs may affect multiple steps of the HCV life cycle. Therefore, we analyzed the influence of BAs on individual steps of virus replication.We measured replication of subgenomic genotype (GT) 1b and 2a RNAs as well as full-length GT2a genomes in the presence of BAs using quantitative RT-PCR and luciferase assays. Cell entry was determined using HCV pseudoparticles (HCVpp). Virus assembly and release were quantified using a core-specific ELISA. Replicon chimeras were employed to characterize genotype-specific modulation of HCV by BAs. Lunet CD81/GFP-NLS-MAVS cells were used to determine infection of Con1 particles.BAs increased RNA-replication of GT1b replicons up to 10-fold but had no effect on subgenomic GT2a replicons both in Huh-7 and HuH6 cells. They did not increase viral RNA translation, virus assembly and release or cell entry. Lowering replication efficiency of GT2a replicons rendered them susceptible to stimulation by BAs. Moreover, replication of full length GT1b with or without replication enhancing mutations and GT2a genomes were also stimulated by BAs.Bile acids specifically enhance RNA-replication. This is not limited to GT1, but also holds true for GT2a full length genomes and subgenomic replicons with low replication capacity. The increase of HCV replication by BAs may influence the efficacy of antiviral treatment in vivo and may improve replication of primary HCV genomes in cell culture.</Abstract>
    <JournalRelease>1932-6203</JournalRelease>
    <Pages>e36029</Pages>
    <Affiliation>Department of Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research; a joint venture between Medical School Hannover and Helmholtz Centre for Infection Research, Hannover, Germany.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22558311&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22532683</PMID>
    <AuthorListID>67</AuthorListID>
    <Title>Arenavirus nucleoprotein targets interferon regulatory factor-activating kinase IKKÎµ.</Title>
    <PubDate>20120424</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.00187-12</doi>
    <Abstract>Arenaviruses perturb innate antiviral defense by blocking induction of type I interferon (IFN) production. Accordingly, the arenavirus nucleoprotein (NP) was shown to block activation and nuclear translocation of interferon regulatory factor 3 (IRF3) in response to virus infection. Here, we sought to identify cellular factors involved in innate antiviral signaling targeted by arenavirus NP. Consistent with previous studies, infection with the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV) prevented phosphorylation of IRF3 in response to infection with Sendai virus, a strong inducer of the retinoic acid-inducible gene I (RIG-I)/mitochondrial antiviral signaling (MAVS) pathway of innate antiviral signaling. Using a combination of coimmunoprecipitation and confocal microscopy, we found that LCMV NP associates with the IÎºB kinase (IKK)-related kinase IKKÎµ but that, rather unexpectedly, LCMV NP did not bind to the closely related TANK-binding kinase 1 (TBK-1). The NP-IKKÎµ interaction was highly conserved among arenaviruses from different clades. In LCMV-infected cells, IKKÎµ colocalized with NP but not with MAVS located on the outer membrane of mitochondria. LCMV NP bound the kinase domain (KD) of IKKÎµ (IKBKE) and blocked its autocatalytic activity and its ability to phosphorylate IRF3, without undergoing phosphorylation. Together, our data identify IKKÎµ as a novel target of arenavirus NP. Engagement of NP seems to sequester IKKÎµ in an inactive complex. Considering the important functions of IKKÎµ in innate antiviral immunity and other cellular processes, the NP-IKKÎµ interaction likely plays a crucial role in arenavirus-host interaction.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>7728-38</Pages>
    <Affiliation>Institute of Microbiology University Hospital Center and University of Lausanne, Lausanne, Switzerland.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22532683&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22440325</PMID>
    <AuthorListID>68</AuthorListID>
    <Title>Mitochondrial-mediated antiviral immunity.</Title>
    <PubDate>20120313</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.bbamcr.2012.03.005</doi>
    <Abstract>Mitochondria, cellular powerhouses of eukaryotes, are known to act as central hubs for multiple signal transductions. Recent research reveals that mitochondria are involved in cellular innate antiviral immunity in vertebrates, particularly mammals. Mitochondrial-mediated antiviral immunity depends on the activation of the retinoic acid-inducible gene I (RIG-I)-like receptors signal transduction pathway and on the participation of a mitochondrial outer membrane adaptor protein, called the "mitochondrial antiviral signaling (MAVS)". In this review, we discuss unexpected discoveries that are revealing how the organelles contribute to the innate immune response against RNA viruses. This article is part of a Special Issue entitled: Mitochondrial dynamics and physiology.Copyright Â© 2012 Elsevier B.V. All rights reserved.</Abstract>
    <JournalRelease>0006-3002</JournalRelease>
    <Pages>225-32</Pages>
    <Affiliation>Department of Biology, Kyushu University, Higashi-ku, Fukuoka, Japan. koshiba@kyudai.jp</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22440325&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22427742</PMID>
    <AuthorListID>69</AuthorListID>
    <Title>Convergent evolution of escape from hepaciviral antagonism in primates.</Title>
    <PubDate>20120313</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.pbio.1001282</doi>
    <Abstract>The ability to mount an interferon response on sensing viral infection is a critical component of mammalian innate immunity. Several viruses directly antagonize viral sensing pathways to block activation of the host immune response. Here, we show that recurrent viral antagonism has shaped the evolution of the host protein MAVS--a crucial component of the viral-sensing pathway in primates. From sequencing and phylogenetic analyses of MAVS from 21 simian primates, we found that MAVS has evolved under strong positive selection. We focused on how this positive selection has shaped MAVS' susceptibility to Hepatitis C virus (HCV). We functionally tested MAVS proteins from diverse primate species for their ability to resist antagonism by HCV, which uses its protease NS3/4A to cleave human MAVS. We found that MAVS from multiple primates are resistant to inhibition by the HCV protease. This resistance maps to single changes within the protease cleavage site in MAVS, which protect MAVS from getting cleaved by the HCV protease. Remarkably, most of these changes have been independently acquired at a single residue 506 that evolved under positive selection. We show that "escape" mutations lower affinity of the NS3 protease for MAVS and allow it to better restrict HCV replication. We further show that NS3 proteases from all other primate hepaciviruses, including the highly divergent GBV-A and GBV-C viruses, are functionally similar to HCV. We conclude that convergent evolution at residue 506 in multiple primates has resulted in escape from antagonism by hepaciviruses. Our study provides a model whereby insights into the ancient history of viral infections in primates can be gained using extant host and virus genes. Our analyses also provide a means by which primates might clear infections by extant hepaciviruses like HCV.</Abstract>
    <JournalRelease>1545-7885</JournalRelease>
    <Pages>e1001282</Pages>
    <Affiliation>Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22427742&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22383950</PMID>
    <AuthorListID>70</AuthorListID>
    <Title>Respiratory syncytial virus NS1 protein colocalizes with mitochondrial antiviral signaling protein MAVS following infection.</Title>
    <PubDate>20120227</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.pone.0029386</doi>
    <Abstract>Respiratory syncytial virus (RSV) nonstructural protein 1(NS1) attenuates type-I interferon (IFN) production during RSV infection; however the precise role of RSV NS1 protein in orchestrating the early host-virus interaction during infection is poorly understood. Since NS1 constitutes the first RSV gene transcribed and the production of IFN depends upon RLR (RIG-I-like receptor) signaling, we reasoned that NS1 may interfere with this signaling. Herein, we report that NS1 is localized to mitochondria and binds to mitochondrial antiviral signaling protein (MAVS). Live-cell imaging of rgRSV-infected A549 human epithelial cells showed that RSV replication and transcription occurs in proximity to mitochondria. NS1 localization to mitochondria was directly visualized by confocal microscopy using a cell-permeable chemical probe for His(6)-NS1. Further, NS1 colocalization with MAVS in A549 cells infected with RSV was shown by confocal laser microscopy and immuno-electron microscopy. NS1 protein is present in the mitochondrial fraction and co-immunoprecipitates with MAVS in total cell lysatesof A549 cells transfected with the plasmid pNS1-Flag. By immunoprecipitation with anti-RIG-I antibody, RSV NS1 was shown to associate with MAVS at an early stage of RSV infection, and to disrupt MAVS interaction with RIG-I (retinoic acid inducible gene) and the downstream IFN antiviral and inflammatory response. Together, these results demonstrate that NS1 binds to MAVS and that this binding inhibits the MAVS-RIG-I interaction required for IFN production.</Abstract>
    <JournalRelease>1932-6203</JournalRelease>
    <Pages>e29386</Pages>
    <Affiliation>James A Haley Veteran's Administration Hospital, Tampa, Florida, United States of America.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22383950&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22345667</PMID>
    <AuthorListID>71</AuthorListID>
    <Title>Characterization of a PIAS4 homologue from zebrafish: insights into its conserved negative regulatory mechanism in the TRIF, MAVS, and IFN signaling pathways during vertebrate evolution.</Title>
    <PubDate>20120217</PubDate>
    <Language>eng</Language>
    <doi>10.4049/jimmunol.1100959</doi>
    <Abstract>Members of the protein inhibitor of activated STAT (PIAS) family are key regulators of various human and mammalian signaling pathways, but data on their occurrence and functions in ancient vertebrates are limited. This study characterizes for the first time to our knowledge a PIAS4 homologue (PIAS4a) from zebrafish. Structurally, this zebrafish PIAS4a (zfPIAS4a) shares a number of conserved functional domains with mammalian PIAS4 proteins, including the scaffold attachment factor A/B/acinus/PIAS box, PINIT, and RING-finger-like zinc-binding domains and a highly acidic domain in the C-terminal region. Subcellular localization analysis shows that zfPIAS4a is a nuclear-localized protein and that the C terminus of the molecule harbors strict nuclear localization signals. Functionally, zfPIAS4a expression can be dramatically induced by the stimulation of polyinosinic-polycytidylic acid and zebrafish IFN1. It acts as a critical negative regulator of the TIR domain-containing adapter inducing IFN-Î², mitochondrial antiviral signaling (MAVS), and IFN signaling pathways, and it is the first PIAS protein that plays a role in the MAVS-mediated pathway to be identified. The structure and functionality of PIAS4 seem highly conserved from zebrafish to mammals, making zebrafish an attractive model for screens designed to uncover genes involved in IFN- and inflammatory cytokine-induced signaling pathways. This study provides preliminary evidence that the PIAS regulatory mechanism already existed in fish during vertebrate evolution. It presents valuable clues for improving the understanding of not only the negative regulation of cytokine signaling in fish but also the evolutionary history of the PIAS family from fish to mammals as a whole.</Abstract>
    <JournalRelease>1550-6606</JournalRelease>
    <Pages>2653-68</Pages>
    <Affiliation>College of Life Sciences, Zhejiang University, Hangzhou 310058, People's Republic of China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22345667&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22341464</PMID>
    <AuthorListID>72</AuthorListID>
    <Title>Focal adhesion kinase is a component of antiviral RIG-I-like receptor signaling.</Title>
    <Language>eng</Language>
    <doi>10.1016/j.chom.2012.01.008</doi>
    <Abstract>Viruses modulate the actin cytoskeleton at almost every step of their cellular journey from entry toÂ egress. Cellular sensing of these cytoskeletal changes may function in the recognition of viral infection. Here we show that focal adhesion kinase (FAK), a focal adhesion localized tyrosine kinase that transmits signals between the extracellular matrix and the cytoplasm, serves as a RIG-I-like receptor antiviral signaling component by directing mitochondrial antiviral signaling adaptor (MAVS) activation. Cells deficient in FAK are highly susceptible to RNA virusÂ infection and attenuated in antiviral signaling. We show that FAK interacts with MAVS at the mitochondrial membrane in a virus infection-dependent manner and potentiates MAVS-mediated signaling via a kinase-independent mechanism. A cysteine protease encoded by enteroviruses cleaves FAK to suppress its role in innate immune signaling. These findings suggest that FAK serves as a link between cytoskeletal perturbations that occur during virus infection and activation of innate immune signaling.Copyright Ã‚Â© 2012 Elsevier Inc. All rights reserved.</Abstract>
    <JournalRelease>1934-6069</JournalRelease>
    <Pages>153-66</Pages>
    <Affiliation>Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA 15219, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22341464&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22312431</PMID>
    <AuthorListID>73</AuthorListID>
    <Title>Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling.</Title>
    <PubDate>20120201</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.pone.0030802</doi>
    <Abstract>Viruses have evolved elaborate mechanisms to evade or inactivate the complex system of sensors and signaling molecules that make up the host innate immune response. Here we show that human coronavirus (HCoV) NL63 and severe acute respiratory syndrome (SARS) CoV papain-like proteases (PLP) antagonize innate immune signaling mediated by STING (stimulator of interferon genes, also known as MITA/ERIS/MYPS). STING resides in the endoplasmic reticulum and upon activation, forms dimers which assemble with MAVS, TBK-1 and IKKÎµ, leading to IRF-3 activation and subsequent induction of interferon (IFN). We found that expression of the membrane anchored PLP domain from human HCoV-NL63 (PLP2-TM) or SARS-CoV (PLpro-TM) inhibits STING-mediated activation of IRF-3 nuclear translocation and induction of IRF-3 dependent promoters. Both catalytically active and inactive forms of CoV PLPs co-immunoprecipitated with STING, and viral replicase proteins co-localize with STING in HCoV-NL63-infected cells. Ectopic expression of catalytically active PLP2-TM blocks STING dimer formation and negatively regulates assembly of STING-MAVS-TBK1/IKKÎµ complexes required for activation of IRF-3. STING dimerization was also substantially reduced in cells infected with SARS-CoV. Furthermore, the level of ubiquitinated forms of STING, RIG-I, TBK1 and IRF-3 are reduced in cells expressing wild type or catalytic mutants of PLP2-TM, likely contributing to disruption of signaling required for IFN induction. These results describe a new mechanism used by CoVs in which CoV PLPs negatively regulate antiviral defenses by disrupting the STING-mediated IFN induction.</Abstract>
    <JournalRelease>1932-6203</JournalRelease>
    <Pages>e30802</Pages>
    <Affiliation>Division of Infection and Immunity, Department of Electromagnetic and Laser Biology, Beijing Institute of Radiation Medicine, Beijing, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22312431&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22312267</PMID>
    <AuthorListID>74</AuthorListID>
    <Title>Molecular Cloning and Functional Characterization of Tibetan Porcine STING.</Title>
    <PubDate>20120104</PubDate>
    <Language>eng</Language>
    <doi>10.3390/ijms13010506</doi>
    <Abstract>Tibetan pig is well known for its strong disease resistance. However, little is known about the molecular basis of its strong resistance to disease. Stimulator of interferon (IFN) genes (STING), also known as MPYS/MITA/ERIS/TMEM173, is an adaptor that functions downstream of RIG-I and MAVS and upstream of TBK1 and plays a critical role in type I IFN induction. Here we report the first cloning and characterization of STING gene from Tibetan pig. The entire open reading frame (ORF) of the Tibetan porcine STING is 1137 bp, with a higher degree of sequence similarity with Landrace pig (98%) and cattle (88%) than with chimpanzee (84%), human (83%) or mouse (77%). The predicted protein is composed of 378 amino acids and has 4 putative transmembrane domains. Real-time quantitative PCR analysis indicated that Tibetan pig STING mRNA was most abundant in the lung and heart. Overexpression of Tibetan porcine STING led to upregulation of IFN-Î² and IFN-stimulated gene 15 (ISG15) in porcine jejunal epithelial cell line IPEC-J2 cells. This is the first study investigating the biological role of STING in intestinal epithelial cells, which lays a foundation for the further study of STING in intestinal innate immunity.</Abstract>
    <JournalRelease>1422-0067</JournalRelease>
    <Pages>506-15</Pages>
    <Affiliation>Key Laboratory for Animal Disease-Resistance Nutrition of Sichuan Province, Institute of Animal Nutrition, Sichuan Agricultural University, Yaan, Sichuan 625014, China; E-Mails: zqhuang@sicau.edu.cn (Z.H.); xlchen@sicau.edu.cn (X.C.); zkeying@yahoo.com (K.Z.); bingyucn@yahoo.com (B.Y.); xiangbingm@hotmail.com (X.M.); ye_zhao@yahoo.com (Y.Z.).</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22312267&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22301138</PMID>
    <AuthorListID>75</AuthorListID>
    <Title>Herpes simplex virus 1 tegument protein US11 downmodulates the RLR signaling pathway via direct interaction with RIG-I and MDA-5.</Title>
    <PubDate>20120201</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.06713-11</doi>
    <Abstract>The interferon (IFN)-mediated antiviral response is a major defense of the host immune system. In order to complete their life cycle, viruses must modulate host IFN-mediated immune responses. Herpes simplex virus 1 (HSV-1) is a large DNA virus containing more than 80 genes, many of which encode proteins that are involved in virus-host interactions and show immune modulatory capabilities. In this study, we demonstrate that the US11 protein, an RNA binding tegument protein of HSV-1, is a novel antagonist of the beta IFN (IFN-Î²) pathway. US11 significantly inhibited Sendai virus (SeV)-induced IFN-Î² production, and its double-stranded RNA (dsRNA) binding domain was indispensable for this inhibition activity. Additionally, wild-type HSV-1 coinfection showed stronger inhibition than US11 mutant HSV-1 in SeV-induced IFN-Î² production. Coimmunoprecipitation analysis demonstrated that the US11 protein in HSV-1-infected cells interacts with endogenous RIG-I and MDA-5 through its C-terminal RNA-binding domain, which was RNA independent. Expression of US11 in both transfected and HSV-1-infected cells interferes with the interaction between MAVS and RIG-I or MDA-5. Finally, US11 dampens SeV-mediated IRF3 activation. Taken together, the combined data indicate that HSV-1 US11 binds to RIG-I and MDA-5 and inhibits their downstream signaling pathway, preventing the production of IFN-Î², which may contribute to the pathogenesis of HSV-1 infection.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>3528-40</Pages>
    <Affiliation>Institut fÃ¼r Klinische und Molekulare Virologie, UniversitÃ¤tsklinikum, Friedrich Alexander UniversitÃ¤t, Erlangen, Germany.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22301138&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22278390</PMID>
    <AuthorListID>76</AuthorListID>
    <Title>Relationship between decreased swimming velocity and muscle activity during 200-m front crawl.</Title>
    <PubDate>20120126</PubDate>
    <Language>eng</Language>
    <doi>10.1007/s00421-012-2321-0</doi>
    <Abstract>The aims of this study were (1) to evaluate changes in muscle activity associated with physiological fatigue and decreased swimming velocity (SV) during 200 m of front crawl swimming, and (2) to examine the relationship between the decreased SV and changes in kinematic or electromyogram parameters. Twenty swimmers participated in a 4 Ã— 50-m swim test. The surface EMG of 11 muscles (7 in the upper limbs and 4 in the lower limbs) was measured and the mean amplitude value (MAV) for one stroke cycle was obtained. The SV and arm angular velocity (AAV) of shoulder flexion during the first (early stroke) and second (late stroke) half of the underwater arm stroke were analyzed using an underwater camera. The AAV, the MAV of flexor carpi ulnaris (FCU), biceps brachii (BB), and triceps brachii during the early stroke, and the MAV of rectus femoris decreased along with a decrease in SV. In contrast, the MAV of the pectoralis major (PM) increased significantly in the final 50 m. The rate of change in MAVs (Î”MAVs) of FCU, BB and latissimus dorsi during the early stroke, and Î”MAV of biceps femoris were significantly correlated with Î”SV and/or Î”AAV. Positive correlations were identified between Î”MAVs of several muscles. However, no negative correlations were observed between Î”MAVs. These results suggest that the decrease in SV was related to decreases in the activities of several muscles that coordinated with each other, and that a compensating strategy occurred between PM and other muscles in the final 50 m.</Abstract>
    <JournalRelease>1439-6327</JournalRelease>
    <Pages>3417-29</Pages>
    <Affiliation>Graduate School of Human and Environmental Studies, Kyoto University, Yoshida-nihonmatsu-cho, Sakyo-ku, Kyoto, 606-8501, Japan. yasushi@cc.osaka-kyoiku.ac.jp</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22278390&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22255022</PMID>
    <AuthorListID>77</AuthorListID>
    <Title>Concurrent variations of cerebral blood flow and arterial blood pressure in simulated sleep apnea.</Title>
    <Language>eng</Language>
    <doi>10.1109/IEMBS.2011.6090873</doi>
    <Abstract>Obstructive Sleep Apnea (OSA) is one of the most common sleep disordered breathing which affects about 15 % of US adult population. OSA is considered to be an important risk factor for the development of cardiac dysfunction and stroke. In this paper, we present the initial results of our investigation of the relationship between arterial blood pressure and cerebral blood flow velocity in simulated apnea. Sixteen healthy subjects (9 male, 7 female) of 29 Â± 4.89 yrs age and body mass index of 24.07 Â± 4.84 kg/m(2) participated in the study. Our findings indicate that cerebral blood flow velocity variations has a relatively high correlation to changes in blood pressure during simulated apnea (r = 0.74 Â± 0.06), suggesting that cerebral autoregulation may not compensate for the pressure changes during apnea.</Abstract>
    <JournalRelease>1557-170X</JournalRelease>
    <Pages>3209-12</Pages>
    <Affiliation>Bioengineering Department, University of Texas at Arlington, TX 76010, USA. raichelmary.alex@ mavs.uta.edu</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22255022&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22254549</PMID>
    <AuthorListID>78</AuthorListID>
    <Title>Generation of complex motor patterns in american grasshopper via current-controlled thoracic electrical interfacing.</Title>
    <Language>eng</Language>
    <doi>10.1109/IEMBS.2011.6090300</doi>
    <Abstract>Micro-air vehicles (MAVs) have attracted attention for their potential application to military applications, environmental sensing, and search and rescue missions. While progress is being made toward fabrication of a completely human-engineered MAV, another promising approach seeks to interface to, and take control of, an insect's nervous system. Cyborg insects take advantage of their innate exquisite loco-motor, navigation, and sensing abilities. Recently, several groups have demonstrated the feasibility of radio-controlled flight in the hawkmoth and beetle via electrical neural interfaces. Here, we report a method for eliciting the "jump" response in the American grasshopper (S. Americana). We found that stimulating the metathoracic T3 ganglion with constant-current square wave pulses with amplitude 186 Â± 40 Î¼A and frequency 190 Â± 13 Hz reproducibly evoked (â‰¥95% success rate) the desired motor activity in N=3 test subjects. To the best of our knowledge, this is the first report of an insect cyborg with a synchronous neuromuscular system.</Abstract>
    <JournalRelease>1557-170X</JournalRelease>
    <Pages>1275-8</Pages>
    <Affiliation>Washington and Lee University, 204 W Washington Street, Lexington, VA 24450, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22254549&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22238314</PMID>
    <AuthorListID>79</AuthorListID>
    <Title>Control of innate immune signaling and membrane targeting by the Hepatitis C virus NS3/4A protease are governed by the NS3 helix Î±0.</Title>
    <PubDate>20120111</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.06727-11</doi>
    <Abstract>Hepatitis C virus (HCV) infection is sensed in the host cell by the cytosolic pathogen recognition receptor RIG-I. RIG-I signaling is propagated through its signaling adaptor protein MAVS to drive activation of innate immunity. However, HCV blocks RIG-I signaling through viral NS3/4A protease cleavage of MAVS on the mitochondrion-associated endoplasmic reticulum (ER) membrane (MAM). The multifunctional HCV NS3/4A serine protease is associated with intracellular membranes, including the MAM, through membrane-targeting domains within NS4A and also at the amphipathic helix Î±(0) of NS3. The serine protease domain of NS3 is required for both cleavage of MAVS, a tail-anchored membrane protein, and processing the HCV polyprotein. Here, we show that hydrophobic amino acids in the NS3 helix Î±(0) are required for selective cleavage of membrane-anchored portions of the HCV polyprotein and for cleavage of MAVS for control of RIG-I pathway signaling of innate immunity. Further, we found that the hydrophobic composition of NS3 helix Î±(0) is essential to establish HCV replication and infection. Alanine substitution of individual hydrophobic amino acids in the NS3 helix Î±(0) impaired HCV RNA replication in cells with a functional RIG-I pathway, but viral RNA replication was rescued in cells lacking RIG-I signaling. Therefore, the hydrophobic amphipathic helix Î±(0) of NS3 is required for NS3/4A control of RIG-I signaling and HCV replication by directing the membrane targeting of both viral and cellular substrates.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>3112-20</Pages>
    <Affiliation>Department of Immunology, University of Washington, Seattle, Washington, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22238314&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22235281</PMID>
    <AuthorListID>80</AuthorListID>
    <Title>Genomic HIV RNA induces innate immune responses through RIG-I-dependent sensing of secondary-structured RNA.</Title>
    <PubDate>20120103</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.pone.0029291</doi>
    <Abstract>Innate immune responses have recently been appreciated to play an important role in the pathogenesis of HIV infection. Whereas inadequate innate immune sensing of HIV during acute infection may contribute to failure to control and eradicate infection, persistent inflammatory responses later during infection contribute in driving chronic immune activation and development of immunodeficiency. However, knowledge on specific HIV PAMPs and cellular PRRs responsible for inducing innate immune responses remains sparse.Here we demonstrate a major role for RIG-I and the adaptor protein MAVS in induction of innate immune responses to HIV genomic RNA. We found that secondary structured HIV-derived RNAs induced a response similar to genomic RNA. In primary human peripheral blood mononuclear cells and primary human macrophages, HIV RNA induced expression of IFN-stimulated genes, whereas only low levels of type I IFN and tumor necrosis factor Î± were produced. Furthermore, secondary structured HIV-derived RNA activated pathways to NF-ÎºB, MAP kinases, and IRF3 and co-localized with peroxisomes, suggesting a role for this organelle in RIG-I-mediated innate immune sensing of HIV RNA.These results establish RIG-I as an innate immune sensor of cytosolic HIV genomic RNA with secondary structure, thereby expanding current knowledge on HIV molecules capable of stimulating the innate immune system.</Abstract>
    <JournalRelease>1932-6203</JournalRelease>
    <Pages>e29291</Pages>
    <Affiliation>Department of Infectious Diseases, Aarhus University Hospital-Skejby, Aarhus, Denmark.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22235281&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22152002</PMID>
    <AuthorListID>81</AuthorListID>
    <Title>Rotavirus nonstructural protein 1 antagonizes innate immune response by interacting with retinoic acid inducible gene I.</Title>
    <PubDate>20111208</PubDate>
    <Language>eng</Language>
    <doi>10.1186/1743-422X-8-526</doi>
    <Abstract>The nonstructural protein 1 (NSP1) of rotavirus has been reported to block interferon (IFN) signaling by mediating proteasome-dependent degradation of IFN-regulatory factors (IRFs) and (or) the Î²-transducin repeat containing protein (Î²-TrCP). However, in addition to these targets, NSP1 may subvert innate immune responses via other mechanisms.The NSP1 of rotavirus OSU strain as well as the IRF3 binding domain truncated NSP1 of rotavirus SA11 strain are unable to degrade IRFs, but can still inhibit host IFN response, indicating that NSP1 may target alternative host factor(s) other than IRFs. Overexpression of NSP1 can block IFN-Î² promoter activation induced by the retinoic acid inducible gene I (RIG-I), but does not inhibit IFN-Î² activation induced by the mitochondrial antiviral-signaling protein (MAVS), indicating that NSP1 may target RIG-I. Immunoprecipitation experiments show that NSP1 interacts with RIG-I independent of IRF3 binding domain. In addition, NSP1 induces down-regulation of RIG-I in a proteasome-independent way.Our findings demonstrate that inhibition of RIG-I mediated type I IFN responses by NSP1 may contribute to the immune evasion of rotavirus.</Abstract>
    <JournalRelease>1743-422X</JournalRelease>
    <Pages>526</Pages>
    <Affiliation>State Key Laboratory of Molecular Virology and Genetic Engineering, Institute of Pathogen Biology, Peking Union Medical College &amp; Chinese Academy of Medical Sciences, # 9 Dong Dan San Tiao, Dongcheng District, Beijing 100730, PR China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22152002&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22131337</PMID>
    <AuthorListID>82</AuthorListID>
    <Title>UXT-V1 facilitates the formation of MAVS antiviral signalosome on mitochondria.</Title>
    <PubDate>20111130</PubDate>
    <Language>eng</Language>
    <doi>10.4049/jimmunol.1102079</doi>
    <Abstract>Virus infection induces the MAVS-TNFR-associated factor (TRAF) 3 signaling axis on mitochondria. It remains to elucidate the corresponding regulatory processes. In this study, we identify UXT-V1 as a novel TRAF3-binding protein. UXT-V1 is critical for the virus-induced activation of NF-ÎºB and IFN regulatory factor 3. Reduction of UXT-V1 impairs the induction of IFN-Î² and attenuates the host antiviral responses. The N-terminal TRAF-binding motif of UXT-V1 binds to the C-terminal TRAF domain of TRAF3, thus facilitating the interaction between TRAF3 and MAVS. Notably, TRAF3 and TNFR-associated death domain protein are recruited onto mitochondria upon virus infection. These translocations are blocked when knocking down UXT-V1. Thus, UXT-V1 represents a novel integral component of the MAVS signalosome on mitochondria, mediating the innate antiviral signal transduction.</Abstract>
    <JournalRelease>1550-6606</JournalRelease>
    <Pages>358-66</Pages>
    <Affiliation>Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22131337&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22110409</PMID>
    <AuthorListID>83</AuthorListID>
    <Title>Murine gamma herpesvirus 68 hijacks MAVS and IKKÎ² to abrogate NFÎºB activation and antiviral cytokine production.</Title>
    <PubDate>20111110</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.ppat.1002336</doi>
    <Abstract>Upon viral infection, mitochondrial antiviral signaling (MAVS) protein serves as a key adaptor to promote cytokine production. We report here that murine gamma herpesvirus 68 (Î³HV68), a model virus for oncogenic human gamma herpesviruses, subverts cytokine production via the MAVS adaptor. During early infection, Î³HV68 hijacks MAVS and IKKÎ² to induce the site-specific phosphorylation of RelA, a crucial subunit of the transcriptionally active NFÎºB dimer, which primes RelA for the proteasome-mediated degradation. As such, Î³HV68 efficiently abrogated NFÎºB activation and cytokine gene expression. Conversely, uncoupling RelA degradation from Î³HV68 infection promoted NFÎºB activation and elevated cytokine production. Loss of MAVS increased cytokine production and immune cell infiltration in the lungs of Î³HV68-infected mice. Moreover, exogenous expression of the phosphorylation- and degradation-resistant RelA variant restored Î³HV68-induced cytokine production. Our findings uncover an intricate strategy whereby signaling via the upstream MAVS adaptor is intercepted by a pathogen to nullify the immediate downstream effector, RelA, of the innate immune pathway.</Abstract>
    <JournalRelease>1553-7374</JournalRelease>
    <Pages>e1002336</Pages>
    <Affiliation>Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22110409&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22105485</PMID>
    <AuthorListID>84</AuthorListID>
    <Title>Poly(C)-binding protein 1 (PCBP1) mediates housekeeping degradation of mitochondrial antiviral signaling (MAVS).</Title>
    <PubDate>20111122</PubDate>
    <Language>eng</Language>
    <doi>10.1038/cr.2011.184</doi>
    <Abstract>Mitochondrial antiviral signaling (MAVS) is a key adaptor in cellular antiviral innate immunity. We previously identified poly(C)-binding protein 2 (PCBP2) as a feedback inhibitor of MAVS that facilitates its degradation after viral infection, but little is known about the regulatory potential of poly(C)-binding protein 1 (PCBP1), which highly resembles PCBP2. Here we report that PCBP1 mediates housekeeping degradation of MAVS using the same mechanism as PCBP2 employs. Overexpression of PCBP1 impairs MAVS-mediated antiviral responses, while knockdown of PCBP1 exerts the opposite effect. The suppression is due to PCBP1-induced MAVS degradation. We observe that PCBP1 and PCBP2 show synergy in MAVS inhibition, but their expression patterns are distinct: PCBP1 is stably and abundantly expressed, while PCBP2 shows low basal expression with rapid induction after infection. Individual knockdown and subcellular fractionation analyses reveal that unlike the postinfection inhibitor PCBP2, PCBP1 continuously eliminates cellular MAVS. Our findings unravel a critical role of PCBP1 in regulating MAVS for both fine-tuning the antiviral immunity and preventing inflammation.</Abstract>
    <JournalRelease>1748-7838</JournalRelease>
    <Pages>717-27</Pages>
    <Affiliation>State Key Laboratory of Protein and Plant Gene Research, Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking University, Beijing, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22105485&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22050228</PMID>
    <AuthorListID>85</AuthorListID>
    <Title>The influenza virus PB1-F2 protein has interferon antagonistic activity.</Title>
    <Language>eng</Language>
    <doi>10.1515/BC.2011.174</doi>
    <Abstract>PB1-F2 is a nonstructural protein of influenza viruses encoded by the PB1 gene segment from a +1 open reading frame. It has been shown that PB1-F2 contributes to viral pathogenicity, although the underlying mechanisms are still unclear. Induction of type I interferon (IFN) and the innate immune response are the first line of defense against viral infection. Here we show that influenza A viruses (IAVs) lacking the PB1-F2 protein induce an enhanced expression of IFN-Î² and IFN-stimulated genes in infected epithelial cells. Studying molecular mechanisms underlying the PB1-F2-mediated IFN antagonistic activity showed that PB1-F2 interferes with the RIG-I/MAVS protein complex thereby inhibiting the activation of the downstream transcription factor IFN regulatory factor 3. These findings were also reflected in in vivo studies demonstrating that infection with PR8 wild-type (wt) virus resulted in higher lung titers and a more severe onset of disease compared with infection with its PB1-F2-deficient counterpart. Accordingly, a much more pronounced infiltration of lungs with immune cells was detected in mice infected with the PB1-F2 wt virus. In summary, we demonstrate that the PB1-F2 protein of IAVs exhibits a type I IFN-antagonistic function by interfering with the RIG-I/MAVS complex, which contributes to an enhanced pathogenicity in vivo.</Abstract>
    <JournalRelease>1437-4315</JournalRelease>
    <Pages>1135-44</Pages>
    <Affiliation>Institute of Molecular Virology, Centre for Molecular Biology of Inflammation, WestfÃ¤lische Wilhelms University, D-48149 MÃ¼nster, Germany.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22050228&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22039483</PMID>
    <AuthorListID>86</AuthorListID>
    <Title>Relative quantification of protein-protein interactions using a dual luciferase reporter pull-down assay system.</Title>
    <PubDate>20111019</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.pone.0026414</doi>
    <Abstract>The identification and quantitative analysis of protein-protein interactions are essential to the functional characterization of proteins in the post-proteomics era. The methods currently available are generally time-consuming, technically complicated, insensitive and/or semi-quantitative. The lack of simple, sensitive approaches to precisely quantify protein-protein interactions still prevents our understanding of the functions of many proteins. Here, we develop a novel dual luciferase reporter pull-down assay by combining a biotinylated Firefly luciferase pull-down assay with a dual luciferase reporter assay. The biotinylated Firefly luciferase-tagged protein enables rapid and efficient isolation of a putative Renilla luciferase-tagged binding protein from a relatively small amount of sample. Both of these proteins can be quantitatively detected using the dual luciferase reporter assay system. Protein-protein interactions, including Fos-Jun located in the nucleus; MAVS-TRAF3 in cytoplasm; inducible IRF3 dimerization; viral protein-regulated interactions, such as MAVS-MAVS and MAVS-TRAF3; IRF3 dimerization; and protein interaction domain mapping, are studied using this novel assay system. Herein, we demonstrate that this dual luciferase reporter pull-down assay enables the quantification of the relative amounts of interacting proteins that bind to streptavidin-coupled beads for protein purification. This study provides a simple, rapid, sensitive, and efficient approach to identify and quantify relative protein-protein interactions. Importantly, the dual luciferase reporter pull-down method will facilitate the functional determination of proteins.</Abstract>
    <JournalRelease>1932-6203</JournalRelease>
    <Pages>e26414</Pages>
    <Affiliation>Beijing Institute of Transfusion Medicine, Beijing, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22039483&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22032846</PMID>
    <AuthorListID>87</AuthorListID>
    <Title>Translocase of outer mitochondrial membrane 70 induces interferon response and is impaired by hepatitis C virus NS3.</Title>
    <PubDate>20111020</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.virusres.2011.10.009</doi>
    <Abstract>Hepatitis C virus (HCV) elevated expression of the translocase of outer mitochondrial membrane 70 (Tom70). Interestingly, overexpression of Tom70 induces interferon (IFN) synthesis in hepatocytes, and it was impaired by HCV. Here, we addressed the mechanism of this impairment. The HCV NS3/4A protein induced Tom70 expression. The HCV NS3 protein interacted in cells, and cleaved the adapter protein mitochondrial anti-viral signaling (MAVS). Ectopic overexpression of Tom70 could not inhibit this cleavage. As a result, IRF-3 phosphorylation was impaired and IFN-Î² induction was suppressed. These results indicate that MAVS works upstream of Tom70 and the cleavage of MAVS by HCV NS3 protease suppresses signaling of IFN induction.Copyright Â© 2011 Elsevier B.V. All rights reserved.</Abstract>
    <JournalRelease>1872-7492</JournalRelease>
    <Pages>405-9</Pages>
    <Affiliation>Department of Experimental Phylaxiology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo Kumamoto City, Kumamoto 860-8556, Japan.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22032846&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22022264</PMID>
    <AuthorListID>88</AuthorListID>
    <Title>Hepatitis C virus reveals a novel early control in acute immune response.</Title>
    <PubDate>20111013</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.ppat.1002289</doi>
    <Abstract>Recognition of viral RNA structures by the intracytosolic RNA helicase RIG-I triggers induction of innate immunity. Efficient induction requires RIG-I ubiquitination by the E3 ligase TRIM25, its interaction with the mitochondria-bound MAVS protein, recruitment of TRAF3, IRF3- and NF-ÎºB-kinases and transcription of Interferon (IFN). In addition, IRF3 alone induces some of the Interferon-Stimulated Genes (ISGs), referred to as early ISGs. Infection of hepatocytes with Hepatitis C virus (HCV) results in poor production of IFN despite recognition of the viral RNA by RIG-I but can lead to induction of early ISGs. HCV was shown to inhibit IFN production by cleaving MAVS through its NS3/4A protease and by controlling cellular translation through activation of PKR, an eIF2Î±-kinase containing dsRNA-binding domains (DRBD). Here, we have identified a third mode of control of IFN induction by HCV. Using HCVcc and the Huh7.25.CD81 cells, we found that HCV controls RIG-I ubiquitination through the di-ubiquitine-like protein ISG15, one of the early ISGs. A transcriptome analysis performed on Huh7.25.CD81 cells silenced or not for PKR and infected with JFH1 revealed that HCV infection leads to induction of 49 PKR-dependent genes, including ISG15 and several early ISGs. Silencing experiments revealed that this novel PKR-dependent pathway involves MAVS, TRAF3 and IRF3 but not RIG-I, and that it does not induce IFN. Use of PKR inhibitors showed that this pathway requires the DRBD but not the kinase activity of PKR. We then demonstrated that PKR interacts with HCV RNA and MAVS prior to RIG-I. In conclusion, HCV recruits PKR early in infection as a sensor to trigger induction of several IRF3-dependent genes. Among those, ISG15 acts to negatively control the RIG-I/MAVS pathway, at the level of RIG-I ubiquitination.These data give novel insights in the machinery involved in the early events of innate immune response.</Abstract>
    <JournalRelease>1553-7374</JournalRelease>
    <Pages>e1002289</Pages>
    <Affiliation>Institut Pasteur, Hepacivirus and Innate Immunity, Paris, France.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22022264&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21997372</PMID>
    <AuthorListID>89</AuthorListID>
    <Title>IFN-Î±/Î² and autophagy: tug-of-war between HCV and the host.</Title>
    <PubDate>20111101</PubDate>
    <Language>eng</Language>
    <doi>10.4161/auto.7.11.17514</doi>
    <Abstract>Hepatitis C virus (HCV) infects approximately 130 million people worldwide. The clinical sequelae of this chronic disease include cirrhosis, functional failure and carcinoma of the liver. HCV induces autophagy, a fundamental cellular process for maintaining homeostasis and mediating innate immune response, and also inhibits autophagic protein degradation and suppresses antiviral immunity. In addition to this ploy, the HCV serine protease composed of the viral non-structural proteins 3/4A (NS3/4A) can enzymatically digest two cellular proteins, mitochondria-associated anti-viral signaling protein (MAVS) and Toll/interleukin-1 receptor domain containing adaptor inducing IFN-Î² (TRIF). Since these two proteins are the adaptor molecules in the retinoic acid-inducible gene I (RIG-I) and TLR3 pathways, respectively, their cleavage has been suggested as a pivotal mechanism by which HCV blunts the IFN-Î±/Î² signaling and antiviral responses. Thus far, how HCV perturbs autophagy and copes with IFN-Î±/Î² in the liver remains unclear.</Abstract>
    <JournalRelease>1554-8635</JournalRelease>
    <Pages>1394-6</Pages>
    <Affiliation>Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX, USA. jisun@utmb.edu</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21997372&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21937652</PMID>
    <AuthorListID>90</AuthorListID>
    <Title>The virion host shutoff protein of herpes simplex virus 1 blocks the replication-independent activation of NF-ÎºB in dendritic cells in the absence of type I interferon signaling.</Title>
    <PubDate>20110921</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.05557-11</doi>
    <Abstract>Immune evasion is a defining feature of the virus-host relationship. During infection, herpes simplex virus type 1 (HSV-1) utilizes multiple proteins to manipulate the host immune response. In the present study, we investigated the mechanism by which the virion host shutoff (vhs) protein blocks the activation of dendritic cells (DCs). Previously, we found that coinfection of wild-type HSV-1 with a panel of RNA viruses resulted in a block to DC activation that was attributable to vhs. These observations led us to hypothesize that the vhs-mediated inhibition was dependent on signaling through the RIG-I-like receptor (RLR) signaling pathway. By examining DCs generated from MAVS (IPS-1) knockout (KO) mice, we determined that RLR/MAVS signaling is not essential for the DC response to HSV-1. We also evaluated the requirement for the type I interferon (IFN) signaling pathway in DC activation following infection with HSV-1 and found that stimulation of DCs with wild-type HSV-1 required intact type I IFN signaling for the production of cytokines, whereas the vhs deletion (vhs(-)) mutant virus activated DCs without the need for exogenous IFN signaling. Comparisons of transcription factor activation in DCs infected with wild-type HSV and the vhs(-) mutant virus revealed that NF-ÎºB activation was inhibited by vhs in the early phase of the infection. In contrast, IRF3 activation was not influenced by vhs. In these studies, measurement of proinflammatory cytokines and type I IFN release from the infected DCs reflected the activation status of these transcription factors. Taken together, the work presented here (i) describes a novel role for the vhs protein as an inhibitor of the early activation of NF-ÎºB during HSV-1 infection of DCs and (ii) offers a mechanistic explanation of how this protein interferes with DC activation.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>12662-72</Pages>
    <Affiliation>Department of Microbiology and Immunology Institute, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21937652&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21931545</PMID>
    <AuthorListID>91</AuthorListID>
    <Title>Disruption of TLR3 signaling due to cleavage of TRIF by the hepatitis A virus protease-polymerase processing intermediate, 3CD.</Title>
    <PubDate>20110908</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.ppat.1002169</doi>
    <Abstract>Toll-like receptor 3 (TLR3) and cytosolic RIG-I-like helicases (RIG-I and MDA5) sense viral RNAs and activate innate immune signaling pathways that induce expression of interferon (IFN) through specific adaptor proteins, TIR domain-containing adaptor inducing interferon-Î² (TRIF), and mitochondrial antiviral signaling protein (MAVS), respectively. Previously, we demonstrated that hepatitis A virus (HAV), a unique hepatotropic human picornavirus, disrupts RIG-I/MDA5 signaling by targeting MAVS for cleavage by 3ABC, a precursor of the sole HAV protease, 3C(pro), that is derived by auto-processing of the P3 (3ABCD) segment of the viral polyprotein. Here, we show that HAV also disrupts TLR3 signaling, inhibiting poly(I:C)-stimulated dimerization of IFN regulatory factor 3 (IRF-3), IRF-3 translocation to the nucleus, and IFN-Î² promoter activation, by targeting TRIF for degradation by a distinct 3ABCD processing intermediate, the 3CD protease-polymerase precursor. TRIF is proteolytically cleaved by 3CD, but not by the mature 3C(pro) protease or the 3ABC precursor that degrades MAVS. 3CD-mediated degradation of TRIF depends on both the cysteine protease activity of 3C(pro) and downstream 3D(pol) sequence, but not 3D(pol) polymerase activity. Cleavage occurs at two non-canonical 3C(pro) recognition sequences in TRIF, and involves a hierarchical process in which primary cleavage at Gln-554 is a prerequisite for scission at Gln-190. The results of mutational studies indicate that 3D(pol) sequence modulates the substrate specificity of the upstream 3C(pro) protease when fused to it in cis in 3CD, allowing 3CD to target cleavage sites not normally recognized by 3C(pro). HAV thus disrupts both RIG-I/MDA5 and TLR3 signaling pathways through cleavage of essential adaptor proteins by two distinct protease precursors derived from the common 3ABCD polyprotein processing intermediate.</Abstract>
    <JournalRelease>1553-7374</JournalRelease>
    <Pages>e1002169</Pages>
    <Affiliation>Lineberger Comprehensive Cancer Center and the Division of Infectious Diseases, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21931545&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21931357</PMID>
    <AuthorListID>92</AuthorListID>
    <Title>Prion-like behavior of MAVS in RIG-I signaling.</Title>
    <PubDate>20110920</PubDate>
    <Language>eng</Language>
    <doi>10.1038/cr.2011.155</doi>
    <JournalRelease>1748-7838</JournalRelease>
    <Pages>1643-5</Pages>
    <Affiliation>Department of Genetics, The Scripps Research Institute, La Jolla, CA 92037, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21931357&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21899695</PMID>
    <AuthorListID>93</AuthorListID>
    <Title>Phosphatidylinositol-3-kinase (PI3K) is activated by influenza virus vRNA via the pathogen pattern receptor Rig-I to promote efficient type I interferon production.</Title>
    <PubDate>20111011</PubDate>
    <Language>eng</Language>
    <doi>10.1111/j.1462-5822.2011.01680.x</doi>
    <Abstract>The phosphatidylinositol-3-kinase (PI3K) was identified to be activated upon influenza A virus (IAV) infection. An early and transient induction of PI3K signalling is caused by viral attachment to cells and promotes virus entry. In later phases of infection the kinase is activated by the viral NS1 protein to prevent premature apoptosis. Besides these virus supporting functions, it was suggested that PI3K signalling is involved in dsRNA and IAV induced antiviral responses by enhancing the activity of interferon regulatory factor-3 (IRF-3). However, molecular mechanisms of activation remained obscure. Here we show that accumulation of vRNA in cells infected with influenza A or B viruses results in PI3K activation. Furthermore, expression of the RNA receptors Rig-I and MDA5 was increased upon stimulation with virion extracted vRNA or IAV infection. Using siRNA approaches, Rig-I was identified as pathogen receptor necessary for influenza virus vRNA sensing and subsequent PI3K activation in a TRIM25 and MAVS signalling dependent manner. Rig-I induced PI3K signalling was further shown to be essential for complete IRF-3 activation and consequently induction of the type I interferon response. These data identify PI3K as factor that is activated as part of the Rig-I mediated anti-pathogen response to enhance expression of type I interferons.Â© 2011 Blackwell Publishing Ltd.</Abstract>
    <JournalRelease>1462-5822</JournalRelease>
    <Pages>1907-19</Pages>
    <Affiliation>Institute of Molecular Virology, ZMBE, Von Esmarch-Str. 56, D-48149 Muenster, Germany.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21899695&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21865020</PMID>
    <AuthorListID>94</AuthorListID>
    <Title>Orchestrating the interferon antiviral response through the mitochondrial antiviral signaling (MAVS) adapter.</Title>
    <PubDate>20110822</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.coi.2011.08.001</doi>
    <Abstract>Sensing of RNA virus infection by the RIG-I-like receptors (RLRs) engages a complex signaling cascade that utilizes the mitochondrial antiviral signaling (MAVS) adapter protein to orchestrate the innate host response to pathogen, ultimately leading to the induction of antiviral and inflammatory responses mediated by type I interferon (IFN) and NF-ÎºB pathways. MAVS is localized to the outer mitochondrial membrane, and has been associated with peroxisomes, the endoplasmic reticulum and autophagosomes, where it coordinates signaling events downstream of RLRs. MAVS not only plays a pivotal role in the induction of antiviral and inflammatory pathways but is also involved in the coordination of apoptotic and metabolic functions. This review summarizes recent findings related to the MAVS adapter and its essential role in the innate immune response to RNA viruses.Copyright Â© 2011 Elsevier Ltd. All rights reserved.</Abstract>
    <JournalRelease>1879-0372</JournalRelease>
    <Pages>564-72</Pages>
    <Affiliation>Terry Fox Molecular Oncology Group, Lady Davis Institute, Jewish General Hospital, Canada.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21865020&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21844353</PMID>
    <AuthorListID>95</AuthorListID>
    <Title>Mitochondrial-associated endoplasmic reticulum membranes (MAM) form innate immune synapses and are targeted by hepatitis C virus.</Title>
    <PubDate>20110815</PubDate>
    <Language>eng</Language>
    <doi>10.1073/pnas.1110133108</doi>
    <Abstract>RIG-I is a cytosolic pathogen recognition receptor that engages viral RNA in infected cells to trigger innate immune defenses through its adaptor protein MAVS. MAVS resides on mitochondria and peroxisomes, but how its signaling is coordinated among these organelles has not been defined. Here we show that a major site of MAVS signaling is the mitochondrial-associated membrane (MAM), a distinct membrane compartment that links the endoplasmic reticulum to mitochondria. During RNA virus infection, RIG-I is recruited to the MAM to bind MAVS. Dynamic MAM tethering to mitochondria and peroxisomes then coordinates MAVS localization to form a signaling synapse between membranes. Importantly, the hepatitis C virus NS3/4A protease, which cleaves MAVS to support persistent infection, targets this synapse for MAVS proteolysis from the MAM, but not from mitochondria, to ablate RIG-I signaling of immune defenses. Thus, the MAM mediates an intracellular immune synapse that directs antiviral innate immunity.</Abstract>
    <JournalRelease>1091-6490</JournalRelease>
    <Pages>14590-5</Pages>
    <Affiliation>Department of Immunology, University of Washington School of Medicine, Seattle, WA 98195, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21844353&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21813773</PMID>
    <AuthorListID>96</AuthorListID>
    <Title>IFN-induced TPR protein IFIT3 potentiates antiviral signaling by bridging MAVS and TBK1.</Title>
    <PubDate>20110803</PubDate>
    <Language>eng</Language>
    <doi>10.4049/jimmunol.1100963</doi>
    <Abstract>Intracellular RNA viruses are sensed by receptors retinoic acid-inducible gene I/MDA5, which trigger formation of the mitochondrial antiviral signaling (MAVS) complex on mitochondria. Consequently, this leads to the activation of TNFR-associated factor family member-associated NF-ÎºB activator-binding kinase 1 (TBK1) and phosphorylation of IFN regulatory factor 3 (IRF3). It remains to be elucidated how MAVS activates TBK1/IRF3. In this study, we report that IFN-induced protein with tetratricopeptide repeats 3 (IFIT3) is significantly induced upon RNA virus infection. Ectopic expression or knockdown of IFIT3 could, respectively, enhance or impair IRF3-mediated gene expression. Mechanistically, the tetratrico-peptide repeat motif (E164/E165) of IFIT3 interacts with the N terminus (K38) of TBK1, thus bridging TBK1 to MAVS on the mitochondrion. Disruption of this interaction markedly attenuates the activation of TBK1 and IRF3. Furthermore, host antiviral responses are significantly boosted or crippled in the presence or absence of IFIT3. Collectively, our study characterizes IFIT3 as an important modulator in innate immunity, revealing a new function of the IFIT family proteins (IFN-induced protein with tetratricopeptide repeats).</Abstract>
    <JournalRelease>1550-6606</JournalRelease>
    <Pages>2559-68</Pages>
    <Affiliation>Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21813773&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21806875</PMID>
    <AuthorListID>97</AuthorListID>
    <Title>[Regulation of MAVS-mediated pathway by p21].</Title>
    <Language>chi</Language>
    <Abstract>To study the interaction between MAVS and p21 regulates MAVS-mediated pathway.Firstly, we cloned full-length p21 gene by PCR. And then the interaction between MAVS and p21 was further demonstrated by co-immunoprecipitation. The regulation of MAVS-mediated pathway by p21 was analyzed by luciferase reporter assays.There are interaction between p21 and MAVS in 293T cells. p21 downregulates activity of MAVS.It is shown that p21 inhibits MAVS-mediated activation of NF-ÎºB and IFN-Î² by Luciferase reporter assays. Overall, these results laid the foundation for further investigating the function of p21 in MAVS-mediated pathway.</Abstract>
    <JournalRelease>1007-8738</JournalRelease>
    <Pages>832-4</Pages>
    <Affiliation>Laboratory Medical College, Beihua University, Jilin , China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21806875&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21799518</PMID>
    <AuthorListID>98</AuthorListID>
    <Title>Mitochondria in innate immunity.</Title>
    <PubDate>20110901</PubDate>
    <Language>eng</Language>
    <doi>10.1038/embor.2011.157</doi>
    <Abstract>Mitochondria are cellular organelles involved in host-cell metabolic processes and the control of programmed cell death. A direct link between mitochondria and innate immune signalling was first highlighted with the identification of MAVS-a crucial adaptor for RIGI-like receptor signalling-as a mitochondria-anchored protein. Recently, other innate immune molecules, such as NLRX1, TRAF6, NLRP3 and IRGM have been functionally associated with mitochondria. Furthermore, mitochondrial alarmins-such as mitochondrial DNA and formyl peptides-can be released by damaged mitochondria and trigger inflammation. Therefore, mitochondria emerge as a fundamental hub for innate immune signalling.</Abstract>
    <JournalRelease>1469-3178</JournalRelease>
    <Pages>901-10</Pages>
    <Affiliation>INSERM U, Hopital Paul Brousse, Batiment Lavoisier, Villejuif, France.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21799518&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21789793</PMID>
    <AuthorListID>99</AuthorListID>
    <Title>Addendum to "Strain-to-strain difference of V protein of measles virus affects MDA5-mediated IFN-Î²-inducing potential" [Mol. Immunol. 48(4) (2011) 497-504].</Title>
    <Language>eng</Language>
    <Abstract>Measles virus (MV) V protein blocks type I IFN signaling in MV-infected cells. Previous studies suggested that some MV strains could release the V protein-mediated type I IFN suppression in affected cells by two distinct modes: V protein mutation and production of DI RNA. These two modes of type I interferon regulation involves the IPS-1 (MAVS, Cardif, VISA) pathway (Takaki et al., 2011. Mol. Immunol. 48(4), 497â€“504). We add the comment to this previous issue that the release of the V protein-mediated suppression of type I IFN occurs only by a laboratory-adapted strain of Edmonston.</Abstract>
    <JournalRelease>1872-9142</JournalRelease>
    <Pages>1589-90</Pages>
    <Affiliation>Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Kita-ku, Sapporo 060-8638, Japan. seya-tu@pop.med.hokudai.ac.jp</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21789793&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21782231</PMID>
    <AuthorListID>100</AuthorListID>
    <Title>MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response.</Title>
    <PubDate>20110721</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.cell.2011.06.041</doi>
    <Abstract>In response to viral infection, RIG-I-like RNA helicases bind to viral RNA and activate the mitochondrial protein MAVS, which in turn activates the transcription factors IRF3 and NF-ÎºB to induce type I interferons. [corrected] We have previously shown that RIG-I binds to unanchored lysine-63 (K63) polyubiquitin chains and that this binding is important for MAVS activation; however, the mechanism underlying MAVS activation is not understood. Here, we show that viral infection induces the formation of very large MAVS aggregates, which potently activate IRF3 in the cytosol. We find that a fraction of recombinant MAVS protein forms fibrils that are capable of activating IRF3. Remarkably, the MAVS fibrils behave like prions and effectively convert endogenous MAVS into functional aggregates. We also show that, in the presence of K63 ubiquitin chains, RIG-I catalyzes the conversion of MAVS on the mitochondrial membrane to prion-like aggregates. These results suggest that a prion-like conformational switch of MAVS activates and propagates the antiviral signaling cascade.Copyright Â© 2011 Elsevier Inc. All rights reserved.</Abstract>
    <JournalRelease>1097-4172</JournalRelease>
    <Pages>448-61</Pages>
    <Affiliation>Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9148, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21782231&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21703540</PMID>
    <AuthorListID>101</AuthorListID>
    <Title>NLRX1 protein attenuates inflammatory responses to infection by interfering with the RIG-I-MAVS and TRAF6-NF-ÎºB signaling pathways.</Title>
    <Language>eng</Language>
    <doi>10.1016/j.immuni.2011.03.026</doi>
    <Abstract>The nucleotide-binding domain and leucine-rich-repeat-containing (NLR) proteins regulate innate immunity. Although the positive regulatory impact of NLRs is clear, their inhibitory roles are not well defined. We showed that Nlrx1(-/-) mice exhibited increased expression of antiviral signaling molecules IFN-Î², STAT2, OAS1, and IL-6 after influenza virus infection. Consistent with increased inflammation, Nlrx1(-/-) mice exhibited marked morbidity and histopathology. Infection of these mice with an influenza strain that carries a mutated NS-1 protein, which normally prevents IFN induction by interaction withÂ RNA and the intracellular RNA sensor RIG-I, further exacerbated IL-6 and type I IFN signaling. NLRX1 also weakened cytokine responses to the 2009 H1N1 pandemic influenza virus in human cells.Â Mechanistically, Nlrx1 deletion led to constitutive interaction of MAVS and RIG-I. Additionally, an inhibitory function is identified for NLRX1 during LPS activation of macrophages where the MAVS-RIG-I pathway was not involved. NLRX1 interacts with TRAF6 and inhibits NF-ÎºB activation. Thus, NLRX1 functions as a checkpoint of overzealous inflammation.Copyright Â© 2011 Elsevier Inc. All rights reserved.</Abstract>
    <JournalRelease>1097-4180</JournalRelease>
    <Pages>854-65</Pages>
    <Affiliation>The Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21703540&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21698224</PMID>
    <AuthorListID>102</AuthorListID>
    <Title>Induction of Noxa-mediated apoptosis by modified vaccinia virus Ankara depends on viral recognition by cytosolic helicases, leading to IRF-3/IFN-Î²-dependent induction of pro-apoptotic Noxa.</Title>
    <PubDate>20110616</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.ppat.1002083</doi>
    <Abstract>Viral infection is a stimulus for apoptosis, and in order to sustain viral replication many viruses are known to carry genes encoding apoptosis inhibitors. F1L, encoded by the orthopoxvirus modified vaccinia virus Ankara (MVA) has a Bcl-2-like structure. An MVA mutant lacking F1L (MVAÎ”F1L) induces apoptosis, indicating that MVA infection activates and F1L functions to inhibit the apoptotic pathway. In this study we investigated the events leading to apoptosis upon infection by MVAÎ”F1L. Apoptosis largely proceeded through the pro-apoptotic Bcl-2 family protein Bak with some contribution from Bax. Of the family of pro-apoptotic BH3-only proteins, only the loss of Noxa provided substantial protection, while the loss of Bim had a minor effect. In mice, MVA preferentially infected macrophages and DCs in vivo. In both cell types wt MVA induced apoptosis albeit more weakly than MVAÎ”F1L. The loss of Noxa had a significant protective effect in macrophages, DC and primary lymphocytes, and the combined loss of Bim and Noxa provided strong protection. Noxa protein was induced during infection, and the induction of Noxa protein and apoptosis induction required transcription factor IRF3 and type I interferon signalling. We further observed that helicases RIG-I and MDA5 and their signalling adapter MAVS contribute to Noxa induction and apoptosis in response to MVA infection. RNA isolated from MVA-infected cells induced Noxa expression and apoptosis when transfected in the absence of viral infection. We thus here describe a pathway leading from the detection of viral RNA during MVA infection by the cytosolic helicase-pathway, to the up-regulation of Noxa and apoptosis via IRF3 and type I IFN signalling.</Abstract>
    <JournalRelease>1553-7374</JournalRelease>
    <Pages>e1002083</Pages>
    <Affiliation>Institute of Medical Microbiology, Immunology and Hygiene, Technische UniversitÃ¤t MÃ¼nchen, Munich, Germany.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21698224&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21695240</PMID>
    <AuthorListID>103</AuthorListID>
    <Title>The influenza virus protein PB1-F2 inhibits the induction of type I interferon at the level of the MAVS adaptor protein.</Title>
    <PubDate>20110609</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.ppat.1002067</doi>
    <Abstract>PB1-F2 is a 90 amino acid protein that is expressed from the +1 open reading frame in the PB1 gene of some influenza A viruses and has been shown to contribute to viral pathogenicity. Notably, a serine at position 66 (66S) in PB1-F2 is known to increase virulence compared to an isogenic virus with an asparagine (66N) at this position. Recently, we found that an influenza virus expressing PB1-F2 N66S suppresses interferon (IFN)-stimulated genes in mice. To characterize this phenomenon, we employed several in vitro assays. Overexpression of the A/Puerto Rico/8/1934 (PR8) PB1-F2 protein in 293T cells decreased RIG-I mediated activation of an IFN-Î² reporter and secretion of IFN as determined by bioassay. Of note, the PB1-F2 N66S protein showed enhanced IFN antagonism activity compared to PB1-F2 wildtype. Similar observations were found in the context of viral infection with a PR8 PB1-F2 N66S virus. To understand the relationship between NS1, a previously described influenza virus protein involved in suppression of IFN synthesis, and PB1-F2, we investigated the induction of IFN when NS1 and PB1-F2 were co-expressed in an in vitro transfection system. In this assay we found that PB1-F2 N66S further reduced IFN induction in the presence of NS1. By inducing the IFN-Î² reporter at different levels in the signaling cascade, we found that PB1-F2 inhibited IFN production at the level of the mitochondrial antiviral signaling protein (MAVS). Furthermore, immunofluorescence studies revealed that PB1-F2 co-localizes with MAVS. In summary, we have characterized the anti-interferon function of PB1-F2 and we suggest that this activity contributes to the enhanced pathogenicity seen with PB1-F2 N66S- expressing influenza viruses.</Abstract>
    <JournalRelease>1553-7374</JournalRelease>
    <Pages>e1002067</Pages>
    <Affiliation>Department of Microbiology, Mount Sinai School of Medicine, New York City, New York, United States of America.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21695240&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21626268</PMID>
    <AuthorListID>104</AuthorListID>
    <Title>Retinoic acid inducible gene-I, more than a virus sensor.</Title>
    <PubDate>20110528</PubDate>
    <Language>eng</Language>
    <doi>10.1007/s13238-011-1045-y</doi>
    <Abstract>Retinoic acid inducible gene-I (RIG-I) is a caspase recruitment domain (CARD) containing protein that acts as an intracellular RNA receptor and senses virus infection. After binding to double stranded RNA (dsRNA) or 5'-triphosphate single stranded RNA (ssRNA), RIG-I transforms into an open conformation, translocates onto mitochondria, and interacts with the downstream adaptor mitochondrial antiviral signaling (MAVS) to induce the production of type I interferon and inflammatory factors via IRF3/7 and NF-ÎºB pathways, respectively. Recently, accumulating evidence suggests that RIG-I could function in non-viral systems and participate in a series of biological events, such as inflammation and inflammation related diseases, cell proliferation, apoptosis and even senescence. Here we review recent advances in antiviral study of RIG-I as well as the functions of RIG-I in other fields.</Abstract>
    <JournalRelease>1674-8018</JournalRelease>
    <Pages>351-7</Pages>
    <Affiliation>National Key Laboratory of Protein Engineering and Plant Gene Engineering, LSC, Peking University, Beijing, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21626268&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21617692</PMID>
    <AuthorListID>105</AuthorListID>
    <Title>NLRX1/NOD5 deficiency does not affect MAVS signalling.</Title>
    <PubDate>20110527</PubDate>
    <Language>eng</Language>
    <doi>10.1038/cdd.2011.64</doi>
    <JournalRelease>1476-5403</JournalRelease>
    <Pages>1387</Pages>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21617692&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21527281</PMID>
    <AuthorListID>106</AuthorListID>
    <Title>Characterization of a TnMAVS protein from Tetraodon nigroviridis.</Title>
    <PubDate>20110419</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.dci.2011.03.029</doi>
    <Abstract>A growing family of cellular proteins encoding for caspase activation and the recruitment domain (CARD) plays a crucial role in immunity by sensing viral infections and signaling antiviral immune defenses. We obtained a MAVS-like protein (named TnMAVS) from Tetradon nigroviridis, which contains a CARD domain, a pro-rich domain, and a TM domain similar to human MAVS. A fluorescence assay showed that TnMAVS was located in the cytoplasm and near by the membrane, and not the mitochondria in FHM cells. As such, it was considered as a new member of MAVS. The TnMAVS was highly expressed in the liver and muscle of T. nigroviridis. In the spleen, TnMAVS was down-regulated when the fish was treated with polyinosinic:polycytidylic acid or challenged with ISKNV, but was not affected by PGN or LPS. The dual luciferase reporter assay revealed that TnMAVS overexpression resulted in the activation of the interferon-sensitive response element and NF-ÎºB signal pathways. In addition, a characteristic TRAF3-associated peptide PVQD was found in the TnMAVS sequence. Co-immunoprecipitation assays indicated that TnMAVS could interact with zfTRAF3 in eukaryotic cells.Copyright Â© 2011 Elsevier Ltd. All rights reserved.</Abstract>
    <JournalRelease>1879-0089</JournalRelease>
    <Pages>1103-15</Pages>
    <Affiliation>State Key Laboratory for Biocontrol, School of Life Sciences, Sun Yat-sen University, 135 Xingang Road West, Guangzhou, 510275, PR China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21527281&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21507982</PMID>
    <AuthorListID>107</AuthorListID>
    <Title>Molecular mechanisms of viral and host cell substrate recognition by hepatitis C virus NS3/4A protease.</Title>
    <PubDate>20110420</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.00377-11</doi>
    <Abstract>Hepatitis C NS3/4A protease is a prime therapeutic target that is responsible for cleaving the viral polyprotein at junctions 3-4A, 4A4B, 4B5A, and 5A5B and two host cell adaptor proteins of the innate immune response, TRIF and MAVS. In this study, NS3/4A crystal structures of both host cell cleavage sites were determined and compared to the crystal structures of viral substrates. Two distinct protease conformations were observed and correlated with substrate specificity: (i) 3-4A, 4A4B, 5A5B, and MAVS, which are processed more efficiently by the protease, form extensive electrostatic networks when in complex with the protease, and (ii) TRIF and 4B5A, which contain polyproline motifs in their full-length sequences, do not form electrostatic networks in their crystal complexes. These findings provide mechanistic insights into NS3/4A substrate recognition, which may assist in a more rational approach to inhibitor design in the face of the rapid acquisition of resistance.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>6106-16</Pages>
    <Affiliation>University of Massachusetts Medical School, Department of Biochemistry and Molecular Pharmacology, 364 Plantation Street, Worcester, MA 01605, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21507982&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21476879</PMID>
    <AuthorListID>108</AuthorListID>
    <Title>Mitochondrion: an emerging platform critical for host antiviral signaling.</Title>
    <PubDate>20110226</PubDate>
    <Language>eng</Language>
    <doi>10.1517/14728222.2011.561321</doi>
    <Abstract>Toll-like receptors (TLRs) and cytoplasmic retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) are the two major receptor systems for detecting RNA viruses. RLRs play essential roles within the cytosol of various cell types. The signaling pathways converge at the mitochondrial antiviral signalling protein (MAVS) on the outer membrane of mitochondria. Recent research has surprisingly shown that many mitochondrial intrinsic factors play novel functions in RLR signaling, conferring a new perspective of therapeutic drug design to inhibit viral infection.This review covers the literature of the past 6 years and summarizes the components, regulation and mechanisms of RLR signaling, highlighting the function and regulation of mitochondrial proteins, such as MAVS and translocase of outer membrane (Tom)70 in this process. The authors attempt to delineate the complicated cross-talk among subcellular organelles in the context of intracellular antiviral signaling.It is imperative to elucidate the specific roles and mechanisms of post-translational modifications in MAVS signaling. The sub-cellular dynamics of regulatory proteins should be correlated with their multiple functions. Animal models are needed to further probe the integration of mitochondria with innate immunity evolutionarily; they will be instrumental for identifying novel antiviral targets and, ultimately, for developing specific clinical drugs.</Abstract>
    <JournalRelease>1744-7631</JournalRelease>
    <Pages>647-65</Pages>
    <Affiliation>Shanghai Institutes for Biological Sciences-Institute of Biochemistry and Cell Biology, Shanghai, China. cwang01@sibs.ac.cn</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21476879&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21436888</PMID>
    <AuthorListID>109</AuthorListID>
    <Title>The coxsackievirus B 3C protease cleaves MAVS and TRIF to attenuate host type I interferon and apoptotic signaling.</Title>
    <PubDate>20110310</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.ppat.1001311</doi>
    <Abstract>The host innate immune response to viral infections often involves the activation of parallel pattern recognition receptor (PRR) pathways that converge on the induction of type I interferons (IFNs). Several viruses have evolved sophisticated mechanisms to attenuate antiviral host signaling by directly interfering with the activation and/or downstream signaling events associated with PRR signal propagation. Here we show that the 3C(pro) cysteine protease of coxsackievirus B3 (CVB3) cleaves the innate immune adaptor molecules mitochondrial antiviral signaling protein (MAVS) and Toll/IL-1 receptor domain-containing adaptor inducing interferon-beta (TRIF) as a mechanism to escape host immunity. We found that MAVS and TRIF were cleaved in CVB3-infected cells in culture. CVB3-induced cleavage of MAVS and TRIF required the cysteine protease activity of 3C(pro), occurred at specific sites and within specialized domains of each molecule, and inhibited both the type I IFN and apoptotic signaling downstream of these adaptors. 3C(pro)-mediated MAVS cleavage occurred within its proline-rich region, led to its relocalization from the mitochondrial membrane, and ablated its downstream signaling. We further show that 3C(pro) cleaves both the N- and C-terminal domains of TRIF and localizes with TRIF to signalosome complexes within the cytoplasm. Taken together, these data show that CVB3 has evolved a mechanism to suppress host antiviral signal propagation by directly cleaving two key adaptor molecules associated with innate immune recognition.</Abstract>
    <JournalRelease>1553-7374</JournalRelease>
    <Pages>e1001311</Pages>
    <Affiliation>Department of Cell Biology and Physiology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21436888&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21425308</PMID>
    <AuthorListID>110</AuthorListID>
    <Title>Mitochondrial antiviral signaling protein defect links impaired antiviral response and liver injury in steatohepatitis in mice.</Title>
    <PubDate>20110502</PubDate>
    <Language>eng</Language>
    <doi>10.1002/hep.24301</doi>
    <Abstract>Mitochondrial dysfunction is a pathogenic feature of nonalcoholic steatohepatitis (NASH). NASH complicates hepatotropic viral disease. The mitochondrial antiviral signaling protein (MAVS) is the adapter of helicase receptors involved in sensing double-stranded RNA (dsRNA). We hypothesized that impaired MAVS function may contribute to insufficient antiviral response and liver damage in steatohepatitis. We identified reduced MAVS protein levels and increased MAVS association with the proteasome subunit alpha type 7 (PSMA7) in livers from mice given a methionine-choline-deficient (MCD) diet. Decreased association of MAVS with mitochondria and increased cytosolic cytochrome c indicated mitochondrial damage in steatohepatitis. In vivo administration of the synthetic dsRNA polyinosinic:polycytidylic acid [poly(I:C)], but not lipopolysaccharide or cytidine-phosphate-guanosine-rich DNA, resulted in impaired induction of type I interferons (IFNs) and proinflammatory cytokines in steatohepatitis. Consistent with a defect in helicase receptor-induced signaling, there was loss of poly(I:C)-induced translocation of MAVS to the cytosol and decreased IFN regulatory factor 3 phosphorylation. Caspases 1 and 8, both of which cleave MAVS, were increased in MCD diet-fed mice. At baseline, steatohepatitis was associated with increased serum alanine aminotransferase (ALT), apoptosis and caspase 3 activation compared with controls. In contrast to apoptosis in controls, necrosis was induced by poly(I:C) stimulation in steatohepatitis. Hepatocyte necrosis was indicated by elevated serum high-mobility group box protein-1 and ALT and was correlated with increased expression of receptor-interacting protein 3 (RIP3), a master regulator of necrosis. Increased expression of MAVS, PSMA7, and RIP3 messenger RNA was also present in human NASH livers.Our novel findings suggest that mitochondrial damage in steatohepatitis extends to MAVS, an adapter of helicase receptors, resulting in inefficient type I IFN and inflammatory cytokine response but increased hepatocyte necrosis and RIP3 induction in response to a dsRNA viral challenge. These mechanisms may contribute to progressive liver damage and impaired viral clearance in NASH.Copyright Â© 2011 American Association for the Study of Liver Diseases.</Abstract>
    <JournalRelease>1527-3350</JournalRelease>
    <Pages>1917-31</Pages>
    <Affiliation>Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21425308&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21285412</PMID>
    <AuthorListID>111</AuthorListID>
    <Title>Mitochondrial membrane potential is required for MAVS-mediated antiviral signaling.</Title>
    <PubDate>20110201</PubDate>
    <Language>eng</Language>
    <doi>10.1126/scisignal.2001147</doi>
    <Abstract>Mitochondria, dynamic organelles that undergo cycles of fusion and fission, are the powerhouses of eukaryotic cells and are also involved in cellular innate antiviral immunity in mammals. Mitochondrial antiviral immunity depends on activation of the cytoplasmic retinoic acid-inducible gene I (RIG-I)-like receptor (RLR) signaling pathway and the participation of a mitochondrial outer membrane adaptor protein called MAVS (mitochondrial antiviral signaling). We found that cells that lack the ability to undergo mitochondrial fusion as a result of targeted deletion of both mitofusin 1 (Mfn1) and mitofusin 2 (Mfn2) exhibited impaired induction of interferons and proinflammatory cytokines in response to viral infection, resulting in increased viral replication. In contrast, cells with null mutations in either Mfn1 or Mfn2 retained their RLR-induced antiviral responses. We also found that a reduced mitochondrial membrane potential (Î”Î¨(m)) correlated with the reduced antiviral response. The dissipation in Î”Î¨(m) did not affect the activation of the transcription factor interferon regulatory factor 3 downstream of MAVS, which suggests that Î”Î¨(m) and MAVS are coupled at the same stage in the RLR signaling pathway. Our results provide evidence that the physiological function of mitochondria plays a key role in innate antiviral immunity.</Abstract>
    <JournalRelease>1937-9145</JournalRelease>
    <Pages>ra7</Pages>
    <Affiliation>1Department of Biology, Faculty of Sciences, Kyushu University, 6-10-1 Hakozaki, Higashi-ku, Fukuoka 812-8581, Japan. koshiba@kyudai.jp</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21285412&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21268286</PMID>
    <AuthorListID>112</AuthorListID>
    <Title>A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients.</Title>
    <PubDate>20110126</PubDate>
    <Language>eng</Language>
    <doi>10.1002/emmm.201000120</doi>
    <Abstract>Dysregulation of the antiviral immune response may contribute to autoimmune diseases. Here, we hypothesized that altered expression or function of MAVS, a key molecule downstream of the viral sensors RIG-I and MDA-5, may impair antiviral cell signalling and thereby influence the risk for systemic lupus erythematosus (SLE), the prototype autoimmune disease. We used molecular techniques to screen non-synonymous single nucleotide polymorphisms (SNPs) in the MAVS gene for functional significance in human cell lines and identified one critical loss-of-function variant (C79F, rs11905552). This SNP substantially reduced expression of type I interferon (IFN) and other proinflammatory mediators and was found almost exclusively in the African-American population. Importantly, in African-American SLE patients, the C79F allele was associated with low type I IFN production and absence of anti-RNA-binding protein autoantibodies. These serologic associations were not related to a distinct, functionally neutral, MAVS SNP Q198K. Hence, this is the first demonstration that an uncommon genetic variant in the MAVS gene has a functional impact upon the anti-viral IFN pathway in vivo in humans and is associated with a novel sub-phenotype in SLE. This study demonstrates the utility of functional data in selecting rare variants for genetic association studies, allowing for fewer comparisons requiring statistical correction and for alternate lines of evidence implicating the particular variant in disease.Copyright Â© 2011 EMBO Molecular Medicine.</Abstract>
    <JournalRelease>1757-4684</JournalRelease>
    <Pages>142-52</Pages>
    <Affiliation>Institut Pasteur, UnitÃ© de DÃ©fense InnÃ©e et Inflammation, Paris, France; Inserm U874, Paris, France.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21268286&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21234810</PMID>
    <AuthorListID>113</AuthorListID>
    <Title>Antiviral signaling through retinoic acid-inducible gene-I-like receptors.</Title>
    <PubDate>20110114</PubDate>
    <Language>eng</Language>
    <doi>10.1007/s00005-010-0107-9</doi>
    <Abstract>The innate immune system is essential for the first line of host defense against micropathogens. In virus-infected cells, exposed viral nucleotides are sensed by pattern recognition receptors (PRRs), resulting in the induction of type I interferon. Retinoic acid-inducible gene-I-like receptors (RLRs) are a member of PRRs and are known to be crucial molecules in innate immune responses. Upon viral recognition, RLRs recruit their specific adaptor molecules, leading to the activation of antiviral signaling molecules including interferon regulatory factor-3 and nuclear factor-ÎºB. Mitochondrial antiviral signaling (MAVS) protein is also known as one of the adaptor molecules responsible for antiviral signaling triggered by RLRs. Recent reports have identified numerous intracellular molecules involved in the antiviral responses mediated by RLRs/MAVS. Several viral proteins interfere with the RLR/MAVS signaling, allowing the virus to evade the host defense. In this review, we comprehensively update RLR-dependent antiviral signaling with special reference to the RLRs/MAVS-mediated responses.</Abstract>
    <JournalRelease>1661-4917</JournalRelease>
    <Pages>41-8</Pages>
    <Affiliation>Department of Vascular Biology, Institute of Brain Science, Graduate School of Medicine, Hirosaki University, 5 Zaifu-cho, Hirosaki City, Aomori, 036-8562, Japan. tomo1027@cc.hirosaki-u.ac.jp</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21234810&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21216621</PMID>
    <AuthorListID>114</AuthorListID>
    <Title>Comparison in lower leg neuromuscular activity between runners with unilateral mid-portion Achilles tendinopathy and healthy individuals.</Title>
    <PubDate>20110108</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.jelekin.2010.11.010</doi>
    <Abstract>Neuromuscular control in functional situations and possible impairments due to Achilles tendinopathy are not well understood. Thirty controls (CO) and 30 runners with Achilles tendinopathy (AT) were tested on a treadmill at 3.33 ms(-1) (12 km h(-1)). Neuromuscular activity of the lower leg (tibialis anterior, peroneal, and gastrocnemius muscle) was measured by surface electromyography. Mean amplitude values (MAV) for the gait cycle phases preactivation, weight acceptance and push-off were calculated and normalised to the mean activity of the entire gait cycle. MAVs of the tibialis anterior did not differ between CO and AT in any gait cycle phase. The activation of the peroneal muscle was lower in AT in weight acceptance (p=0.006), whereas no difference between CO and AT was found in preactivation (p=0.71) and push-off (p=0.83). Also, MAVs of the gastrocnemius muscle did not differ between AT and CO in preactivity (p=0.71) but were reduced in AT during weight acceptance (p=0.001) and push-off (p=0.04). Achilles tendinopathy does not seem to alter pre-programmed neural control but might induce mechanical deficits of the lower extremity during weight bearing (joint stability). This should be addressed in the therapy process of AT.Copyright Â© 2010 Elsevier Ltd. All rights reserved.</Abstract>
    <JournalRelease>1873-5711</JournalRelease>
    <Pages>499-505</Pages>
    <Affiliation>University Outpatient Clinic, Sports Medicine and Sports Orthopaedics, University of Potsdam, Am Neuen Palais 10 - Haus 12, 14469 Potsdam, Germany. hbaur@uni-potsdam.de</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21216621&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21200404</PMID>
    <AuthorListID>115</AuthorListID>
    <Title>A functional C-terminal TRAF3-binding site in MAVS participates in positive and negative regulation of the IFN antiviral response.</Title>
    <PubDate>20110104</PubDate>
    <Language>eng</Language>
    <doi>10.1038/cr.2011.2</doi>
    <Abstract>Recognition of viral RNA structures by the cytosolic sensor retinoic acid-inducible gene-I (RIG-I) results in the activation of signaling cascades that culminate with the generation of the type I interferon (IFN) antiviral response. Onset of antiviral and inflammatory responses to viral pathogens necessitates the regulated spatiotemporal recruitment of signaling adapters, kinases and transcriptional proteins to the mitochondrial antiviral signaling protein (MAVS). We previously demonstrated that the serine/threonine kinase IKKÎµ is recruited to the C-terminal region of MAVS following Sendai or vesicular stomatitis virus (VSV) infection, mediated by Lys63-linked polyubiquitination of MAVS at Lys500, resulting in inhibition of downstream IFN signaling (Paz et al, Mol Cell Biol, 2009). In this study, we demonstrate that C-terminus of MAVS harbors a novel TRAF3-binding site in the aa450-468 region of MAVS. A consensus TRAF-interacting motif (TIM), 455-PEENEY-460, within this site is required for TRAF3 binding and activation of IFN antiviral response genes, whereas mutation of the TIM eliminates TRAF3 binding and the downstream IFN response. Reconstitution of MAVS(-/-) mouse embryo fibroblasts with a construct expressing a TIM-mutated version of MAVS failed to restore the antiviral response or block VSV replication, whereas wild-type MAVS reconstituted antiviral inhibition of VSV replication. Furthermore, recruitment of IKKÎµ to an adjacent C-terminal site (aa 468-540) in MAVS via Lys500 ubiquitination decreased TRAF3 binding and protein stability, thus contributing to IKKÎµ-mediated shutdown of the IFN response. This study demonstrates that MAVS harbors a functional C-terminal TRAF3-binding site that participates in positive and negative regulation of the IFN antiviral response.</Abstract>
    <JournalRelease>1748-7838</JournalRelease>
    <Pages>895-910</Pages>
    <Affiliation>Terry Fox Molecular Oncology Group, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec H3T1E2, Canada.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21200404&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21187438</PMID>
    <AuthorListID>116</AuthorListID>
    <Title>RIG-I/MDA5/MAVS are required to signal a protective IFN response in rotavirus-infected intestinal epithelium.</Title>
    <PubDate>20101227</PubDate>
    <Language>eng</Language>
    <doi>10.4049/jimmunol.1002862</doi>
    <Abstract>Rotavirus is a dsRNA virus that infects epithelial cells that line the surface of the small intestine. It causes severe diarrheal illness in children and âˆ¼500,000 deaths per year worldwide. We studied the mechanisms by which intestinal epithelial cells (IECs) sense rotavirus infection and signal IFN-Î² production, and investigated the importance of IFN-Î² production by IECs for controlling rotavirus production by intestinal epithelium and virus excretion in the feces. In contrast with most RNA viruses, which interact with either retinoic acid-inducible gene I (RIG-I) or melanoma differentiation-associated gene 5 (MDA5) inside cells, rotavirus was sensed by both RIG-I and MDA5, alone and in combination. Rotavirus did not signal IFN-Î² through either of the dsRNA sensors TLR3 or dsRNA-activated protein kinase (PKR). Silencing RIG-I or MDA5, or their common adaptor protein mitochondrial antiviral signaling protein (MAVS), significantly decreased IFN-Î² production and increased rotavirus titers in infected IECs. Overexpression of laboratory of genetics and physiology 2, a RIG-I-like receptor that interacts with viral RNA but lacks the caspase activation and recruitment domains required for signaling through MAVS, significantly decreased IFN-Î² production and increased rotavirus titers in infected IECs. Rotavirus-infected mice lacking MAVS, but not those lacking TLR3, TRIF, or PKR, produced significantly less IFN-Î² and increased amounts of virus in the intestinal epithelium, and shed increased quantities of virus in the feces. We conclude that RIG-I or MDA5 signaling through MAVS is required for the activation of IFN-Î² production by rotavirus-infected IECs and has a functionally important role in determining the magnitude of rotavirus replication in the intestinal epithelium.</Abstract>
    <JournalRelease>1550-6606</JournalRelease>
    <Pages>1618-26</Pages>
    <Affiliation>Laboratory of Mucosal Immunology, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21187438&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21170385</PMID>
    <AuthorListID>117</AuthorListID>
    <Title>Hepatitis C virus core protein abrogates the DDX3 function that enhances IPS-1-mediated IFN-beta induction.</Title>
    <PubDate>20101208</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.pone.0014258</doi>
    <Abstract>The DEAD box helicase DDX3 assembles IPS-1 (also called Cardif, MAVS, or VISA) in non-infected human cells where minimal amounts of the RIG-I-like receptor (RLR) protein are expressed. DDX3 C-terminal regions directly bind the IPS-1 CARD-like domain as well as the N-terminal hepatitis C virus (HCV) core protein. DDX3 physically binds viral RNA to form IPS-1-containing spots, that are visible by confocal microscopy. HCV polyU/UC induced IPS-1-mediated interferon (IFN)-beta promoter activation, which was augmented by co-transfected DDX3. DDX3 spots localized near the lipid droplets (LDs) where HCV particles were generated. Here, we report that HCV core protein interferes with DDX3-enhanced IPS-1 signaling in HEK293 cells and in hepatocyte Oc cells. Unlike the DEAD box helicases RIG-I and MDA5, DDX3 was constitutively expressed and colocalized with IPS-1 around mitochondria. In hepatocytes (O cells) with the HCV replicon, however, DDX3/IPS-1-enhanced IFN-beta-induction was largely abrogated even when DDX3 was co-expressed. DDX3 spots barely merged with IPS-1, and partly assembled in the HCV core protein located near the LD in O cells, though in some O cells IPS-1 was diminished or disseminated apart from mitochondria. Expression of DDX3 in replicon-negative or core-less replicon-positive cells failed to cause complex formation or LD association. HCV core protein and DDX3 partially colocalized only in replicon-expressing cells. Since the HCV core protein has been reported to promote HCV replication through binding to DDX3, the core protein appears to switch DDX3 from an IFN-inducing mode to an HCV-replication mode. The results enable us to conclude that HCV infection is promoted by modulating the dual function of DDX3.</Abstract>
    <JournalRelease>1932-6203</JournalRelease>
    <Pages>e14258</Pages>
    <Affiliation>Department of Microbiology and Immunology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21170385&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21105190</PMID>
    <AuthorListID>118</AuthorListID>
    <Title>Screening compounds against HCV based on MAVS/IFN-Î² pathway in a replicon model.</Title>
    <Language>eng</Language>
    <Abstract>To develop a sensitive assay for screening compounds against hepatitis C virus (HCV).The proteolytic cleavage of NS3/4A on enhanced yellow fluorescent protein (eYFP)-mitochondrial antiviral signaling protein (MAVS) was examined by reporter enzyme secreted placental alkaline phosphatase (SEAP), which enabled us to perform ongoing monitoring of anti-HCV drugs through repeated chemiluminescence. Subcellular localization of eYFP-MAVS was assessed by fluorescence microscopy. Cellular localization and protein levels were examined by Western blotting.HCV NS3/4A protease cleaved eYFP-MAVS from mitochondria to block the activation of interferon (IFN)-Î² promoter, thus resulting in downregulation of SEAP activity. The decrease in SEAP activity was proportional to the dose of active NS3/4A protease. Also this reporter assay was used to detect anti-HCV activity of IFN-Î± and cyclosporine A.Our data show that this reporter system is a sensitive and quantitative reporter of anti-HCV inhibitors. This system will constitute a new tool to allow the efficient screening of HCV inhibitors.</Abstract>
    <JournalRelease>1007-9327</JournalRelease>
    <Pages>5582-7</Pages>
    <Affiliation>Laboratory of Blood-Borne Virus, Beijing Institute of Transfusion Medicine, 27(9) Tai Ping Road, Beijing 100850, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21105190&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20960373</PMID>
    <AuthorListID>119</AuthorListID>
    <Title>Hepatitis A and hepatitis C viruses: divergent infection outcomes marked by similarities in induction and evasion of interferon responses.</Title>
    <PubDate>20101019</PubDate>
    <Language>eng</Language>
    <doi>10.1055/s-0030-1267534</doi>
    <Abstract>Hepatitis A and hepatitis C viruses (HAV and HCV) are both positive-strand ribonucleic acid (RNA) viruses with hepatotropic lifestyles. Despite several important differences, they share many biological and molecular features and similar genome replication schemes. Despite this, HAV infections are usually effectively controlled by the host with elimination of the virus, whereas HCV most often is able to establish lifelong persistent infection. The mechanisms underlying this difference are unknown. The cellular helicases RIG-I and MDA5, and Toll-like receptor 3, are pattern recognition receptors that sense virus-derived RNAs within hepatocytes in the liver. Activation of these receptors leads to their interaction with specific adaptor proteins, mitochondrial antiviral signaling protein (MAVS) and TIR-domain-containing adapter-inducing interferon-Î² (TRIF), respectively, which engage downstream kinases to activate two crucial transcription factors, nuclear factor kappa B (NF-ÎºB) and interferon regulatory factor 3 (IRF3). This results in the induction of interferons (IFNs) and IFN-stimulated genes that ultimately establish an antiviral state. These signaling pathways are central to host antiviral defense and thus frequent targets for viral interference. Both HAV and HCV express proteases that target signal transduction through these pathways and that block the induction of IFNs upon sensing of viral RNA by these receptors. An understanding of the differences and similarities in the early innate immune responses to these infections is likely to provide important insights into the mechanism underlying the long-term persistence of HCV.Â© Thieme Medical Publishers.</Abstract>
    <JournalRelease>1098-8971</JournalRelease>
    <Pages>319-32</Pages>
    <Affiliation>Department of Medicine, The University of North Carolina, Chapel Hill, NC, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20960373&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20832207</PMID>
    <AuthorListID>120</AuthorListID>
    <Title>Matrix-assisted laser desorption/ionization-time of flight-mass spectrometry profiling of trace constituents of condom lubricants in the presence of biological fluids.</Title>
    <PubDate>20100915</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.forsciint.2010.08.010</doi>
    <Abstract>The use of condoms in sexual assault cases has become increasingly common due to the heightened awareness of the use of DNA as evidence in criminal investigations. The ability to identify and differentiate the polymers and additives found in lubricant residues can provide investigators leads and insights as to the perpetrator of a sexual assault. Matrix-assisted laser desorption/ionization-time of flight-mass spectrometry (MALDI-TOF-MS) is ideal for detecting condom lubricants and additives; the instrument is capable of surveying analytes across a wide mass range and is a preferred technique for the analysis of polymers. Three MALDI-TOF-MS methods directed toward the detection and differentiation of condom and personal lubricant residues, as well as their mixtures with biological fluids, were developed and compared: (a) a sample premixed with aqueous matrix; (b) a sample premixed with an ionic liquid matrix; and (c) a layering method that incorporates a cationization reagent. Of the three, the layered method that utilized sodium chloride as a cationization reagent showed the best sensitivity and selectivity. This method allowed for the segregation of the various lubricant formulas into a discrete number of groups. Infrared spectroscopy was used to support and clarify the MALDI data. Principal component analysis was used to further demonstrate the ability of this method to segregate various lubricant types into a limited number of classes. Additionally, lubricant residues could be detected in the presence of biological fluids down to a fraction of a percent.Copyright Â© 2010 Elsevier Ireland Ltd. All rights reserved.</Abstract>
    <JournalRelease>1872-6283</JournalRelease>
    <Pages>19-26</Pages>
    <Affiliation>Department of Chemistry &amp; Biochemistry, The University of Texas at Arlington, 700 Planetarium Place, Arlington, TX 76019, USA. sandra.spencer@mavs.uta.edu</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20832207&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20824343</PMID>
    <AuthorListID>121</AuthorListID>
    <Title>A wireless system for monitoring transcranial motor evoked potentials.</Title>
    <PubDate>20100908</PubDate>
    <Language>eng</Language>
    <doi>10.1007/s10439-010-0152-x</doi>
    <Abstract>Intraoperative neurophysiological monitoring (IONM) is commonly used as an attempt to minimize neurological morbidity from operative manipulations. The goal of IONM is to identify changes in the central and peripheral nervous system function prior to irreversible damage. Intraoperative monitoring also has been effective in localizing anatomical structures, including peripheral nerves and sensorimotor cortex, which helps guide the surgeon during dissection. As part of IONM, transcranial motor evoked potentials (TcMEPs), and somatosensory evoked potentials (SSEPs) are routinely monitored. However, current wired systems are cumbersome as the wires contribute to the crowded conditions in the operating room and in doing so not only it limits the maneuverability of the surgeon and assistants, but also places certain demand in the total anesthesia required during surgery, due to setup preoperative time needed for proper electrode placement, due to the number and length of the wires, and critical identification of the lead wires needed for stimulation and recording. To address these limitations, we have developed a wireless TcMEP IONM system as a first step toward a multimodality IONM system. Bench-top and animal experiments in rodents demonstrated that the wireless method reproduced with high fidelity, and even increased the frequency bandwidth of the TcMEP signals, compared to wired systems. This wireless system will reduce the preoperative time required for IONM setup, add convenience for surgical staff, and reduce wire-related risks for patients during the operation.</Abstract>
    <JournalRelease>1573-9686</JournalRelease>
    <Pages>517-23</Pages>
    <Affiliation>Department of Bioengineering, University of Texas at Arlington, 701 S. Nedderman Dr., Arlington, TX 76019, USA. aydin.farajidavar@mavs.uta.edu</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20824343&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20807553</PMID>
    <AuthorListID>122</AuthorListID>
    <Title>Mitochondrial localization of viral proteins as a means to subvert host defense.</Title>
    <PubDate>20100831</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.bbamcr.2010.08.009</doi>
    <Abstract>Viruses have developed a battery of distinct strategies to overcome the very sophisticated defense mechanisms of the infected host. Throughout the process of pathogen-host co-evolution, viruses have therefore acquired the capability to prevent host cell apoptosis because elimination of infected cells via apoptosis is one of the most ancestral defense mechanism against infection. Conversely, induction of apoptosis may favor viral dissemination as a result of the dismantlement of the infected cells. Mitochondria have been long recognized for their key role in the modulation of apoptosis but more recently, mitochondria have been shown to serve as a crucial platform for innate immune signaling as illustrated by the identification of MAVS. Thus, it is therefore not surprising that this organelle represents a recurrent target for viruses, aiming to manipulate the fate of the infected host cell or to inhibit innate immune response. In this review, we highlight the viral proteins that are specifically targeted to the mitochondria to subvert host defense. This article is part of a Special Issue entitled Mitochondria: the deadly organelle.Copyright Â© 2010 Elsevier B.V. All rights reserved.</Abstract>
    <JournalRelease>0006-3002</JournalRelease>
    <Pages>575-83</Pages>
    <Affiliation>INSERM U1014, Hopital Paul Brousse, Batiment Lavoisier, 14 avenue Paul Vaillant Couturier, 94807 Villejuif cedex, France.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20807553&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20739519</PMID>
    <AuthorListID>123</AuthorListID>
    <Title>Early innate recognition of herpes simplex virus in human primary macrophages is mediated via the MDA5/MAVS-dependent and MDA5/MAVS/RNA polymerase III-independent pathways.</Title>
    <PubDate>20100825</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.01106-10</doi>
    <Abstract>Innate recognition of viruses is mediated by pattern recognition receptors (PRRs) triggering expression of antiviral interferons (IFNs) and proinflammatory cytokines. In mice, Toll-like receptor 2 (TLR2) and TLR9 as well as intracellular nucleotide-sensing pathways have been shown to recognize herpes simplex virus (HSV). Here, we describe how human primary macrophages recognize early HSV infection via intracellular pathways. A number of inflammatory cytokines, IFNs, and IFN-stimulated genes were upregulated after HSV infection. We show that early recognition of HSV and induction of IFNs and inflammatory cytokines are independent of TLR2 and TLR9, since inhibition of TLR2 using TLR2 neutralizing antibodies did not affect virus-induced responses and the macrophages were unresponsive to TLR9 stimulation. Instead, HSV recognition involves intracellular recognition systems, since induction of tumor necrosis factor alpha (TNF-Î±) and IFNs was dependent on virus entry and replication. Importantly, expression of IFNs was strongly inhibited by small interfering RNA (siRNA) knockdown of MAVS, but this MAVS-dependent IFN induction occurred independently of the recently discovered polymerase III (Pol III)/RIG-I DNA sensing system. In contrast, induction of TNF-Î± was largely independent of MAVS, suggesting that induction of inflammatory cytokines during HSV infection proceeds via a novel pathway. Transfection with ODN2006, a broad inhibitor of intracellular nucleotide recognition, revealed that nucleotide-sensing systems are employed to induce both IFNs and TNF-Î±. Finally, using siRNA knockdown, we found that MDA5, but not RIG-I, was the primary mediator of HSV recognition. Thus, innate recognition of HSV by human primary macrophages occurs via two distinct intracellular nucleotide-sensing pathways responsible for induction of IFNs and inflammatory cytokine expression, respectively.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>11350-8</Pages>
    <Affiliation>Department of Infectious Diseases, Aarhus University Hospital Skejby, and Department of Medical Microbiology and Immunology, University of Aarhus, Brendstrupgaardsvej 100, DK-8200 Aarhus N, Denmark. jespmelc@rm.dk</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20739519&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20699406</PMID>
    <AuthorListID>124</AuthorListID>
    <Title>Ingroup identification and group-level narcissism as predictors of U.S. citizens' attitudes and behavior toward Arab immigrants.</Title>
    <PubDate>20100810</PubDate>
    <Language>eng</Language>
    <doi>10.1177/0146167210380604</doi>
    <Abstract>In four studies, the authors explored factors contributing to negative attitudes and behavior toward Arab immigrants in the United States. In Study 1, Americans reported greater threat from Arabs, compared to other groups (e.g., Latino, Asian). In Study 2, they tested the effects of ingroup identification and group-level narcissism on attitudes toward Arab, Latino, Asian, and European immigrants. Identification interacted with group narcissism in predicting attitudes toward Arab (but not other) immigrants, such that identification predicted negative attitudes toward Arab immigrants only at mean and high levels of group narcissism. Study 3 explored the convergent and discriminant validity of the group narcissism construct. In Study 4, the authors added a behavioral dependent measure. Again, ingroup identification predicted negative behavior and attitudes toward an Arab immigrant group (but not comparison groups) only at mean and high levels of group narcissism. Theoretical and practical implications are discussed.</Abstract>
    <JournalRelease>1552-7433</JournalRelease>
    <Pages>1267-80</Pages>
    <Affiliation>University of Texas at Arlington, Arlington, TX 76019, USA. patricia.lyons@mavs.uta.edu</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20699406&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20686657</PMID>
    <AuthorListID>125</AuthorListID>
    <Title>Murine gamma-herpesvirus 68 hijacks MAVS and IKKbeta to initiate lytic replication.</Title>
    <PubDate>20100729</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.ppat.1001001</doi>
    <Abstract>Upon viral infection, the mitochondrial antiviral signaling (MAVS)-IKKbeta pathway is activated to restrict viral replication. Manipulation of immune signaling events by pathogens has been an outstanding theme of host-pathogen interaction. Here we report that the loss of MAVS or IKKbeta impaired the lytic replication of gamma-herpesvirus 68 (gammaHV68), a model herpesvirus for human Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus. gammaHV68 infection activated IKKbeta in a MAVS-dependent manner; however, IKKbeta phosphorylated and promoted the transcriptional activation of the gammaHV68 replication and transcription activator (RTA). Mutational analyses identified IKKbeta phosphorylation sites, through which RTA-mediated transcription was increased by IKKbeta, within the transactivation domain of RTA. Moreover, the lytic replication of recombinant gammaHV68 carrying mutations within the IKKbeta phosphorylation sites was greatly impaired. These findings support the conclusion that gammaHV68 hijacks the antiviral MAVS-IKKbeta pathway to promote viral transcription and lytic infection, representing an example whereby viral replication is coupled to host immune activation.</Abstract>
    <JournalRelease>1553-7374</JournalRelease>
    <Pages>e1001001</Pages>
    <Affiliation>Department of Microbiology, UT Southwestern Medical Center, Dallas, Texas, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20686657&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20661427</PMID>
    <AuthorListID>126</AuthorListID>
    <Title>Virus-infection or 5'ppp-RNA activates antiviral signal through redistribution of IPS-1 mediated by MFN1.</Title>
    <PubDate>20100722</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.ppat.1001012</doi>
    <Abstract>In virus-infected cells, RIG-I-like receptor (RLR) recognizes cytoplasmic viral RNA and triggers innate immune responses including production of type I and III interferon (IFN) and the subsequent expression of IFN-inducible genes. Interferon-beta promoter stimulator 1 (IPS-1, also known as MAVS, VISA and Cardif) is a downstream molecule of RLR and is expressed on the outer membrane of mitochondria. While it is known that the location of IPS-1 is essential to its function, its underlying mechanism is unknown. Our aim in this study was to delineate the function of mitochondria so as to identify more precisely its role in innate immunity. In doing so we discovered that viral infection as well as transfection with 5'ppp-RNA resulted in the redistribution of IPS-1 to form speckle-like aggregates in cells. We further found that Mitofusin 1 (MFN1), a key regulator of mitochondrial fusion and a protein associated with IPS-1 on the outer membrane of mitochondria, positively regulates RLR-mediated innate antiviral responses. Conversely, specific knockdown of MFN1 abrogates both the virus-induced redistribution of IPS-1 and IFN production. Our study suggests that mitochondria participate in the segregation of IPS-1 through their fusion processes.</Abstract>
    <JournalRelease>1553-7374</JournalRelease>
    <Pages>e1001012</Pages>
    <Affiliation>Department of Molecular Genetics, Institute for Virus Research, Kyoto University, Kyoto, Japan.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20661427&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20643110</PMID>
    <AuthorListID>127</AuthorListID>
    <Title>The protein Nod2: an innate receptor more complex than previously assumed.</Title>
    <PubDate>20100717</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.bcp.2010.07.016</doi>
    <Abstract>For almost 10 years, Nod2 has been known as a cytosolic innate receptor able to sense peptidoglycan from Gram-positive and -negative bacteria and to trigger RIP2- and NF-ÎºB-mediated pro-inflammatory and antibacterial response. Mutations in the gene encoding Nod2 in humans have been associated with Crohn's disease (CD). Mechanisms by which Nod2 variants can lead to CD development are still under investigation. The most admitted hypothesis suggests that the impaired function of Nod2 variants in intestinal epithelial and phagocytic cells results in deficiencies in epithelial-barrier function which subsequently lead to increased bacterial invasion and inflammation at intestinal sites. Very recent results have just reinforced this hypothesis by demonstrating that Nod2 wild-type (unlike Nod2 variants) could mediate autophagy, allowing an efficient bacterial clearance and adaptative immune response. Other recent data have attributed new roles to Nod2. Indeed, Nod2 has been shown to activate antiviral innate immune responses involving IRF3-dependent IFN-Î² production after viral ssRNA recognition through a RIP2-independent mechanism requiring the mitochondrial adaptor protein MAVS. Recently, Nod2 has been also shown to be exquisitely tuned to detect mycobacterial infections and mount a protective immunity against these pathogens.Copyright Â© 2010 Elsevier Inc. All rights reserved.</Abstract>
    <JournalRelease>1873-2968</JournalRelease>
    <Pages>2021-31</Pages>
    <Affiliation>Laboratory of Virology and Immunology, GIGA-Research, GIGA B34, University of LiÃ¨ge, 4000 LiÃ¨ge, Belgium.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20643110&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20628368</PMID>
    <AuthorListID>128</AuthorListID>
    <Title>Tom70 mediates activation of interferon regulatory factor 3 on mitochondria.</Title>
    <PubDate>20100713</PubDate>
    <Language>eng</Language>
    <doi>10.1038/cr.2010.103</doi>
    <Abstract>Intracellular RNA viruses are sensed by receptors retinoic acid-inducible gene 1 (RIG-I)/melanoma differentiation-associated gene 5 (MDA5) that trigger the formation of MAVS signal complex on mitochondria. Consequently, this leads to the activation of TANK-binding kinase 1 (TBK1) and phosphorylation of interferon regulatory factor 3 (IRF3), both of which constitutively associate with cytosolic chaperone Hsp90. It remains largely unknown how MAVS activates TBK1/IRF3. In this study, we identified translocases of outer membrane 70 (Tom70), a mitochondrial import receptor, to interact with MAVS upon RNA virus infection. Ectopic expression or knockdown of Tom70 could enhance or impair IRF3-mediated gene expression, respectively. Mechanistically, the clamp domain (R192) of Tom70 interacts with the C-terminal motif (EEVD) of Hsp90, thus recruiting TBK1/IRF3 to mitochondria. Disruption of this interaction or mislocation of Tom70 sharply impairs activation of TBK1 and IRF3. Furthermore, host antiviral responses are significantly boosted or crippled in the presence or absence of Tom70. Collectively, our study characterizes Tom70 as a critical adaptor linking MAVS to TBK1/IRF3, revealing that mitochondrion is evolutionarily integrated with innate immunity.</Abstract>
    <JournalRelease>1748-7838</JournalRelease>
    <Pages>994-1011</Pages>
    <Affiliation>Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20628368&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20610716</PMID>
    <AuthorListID>129</AuthorListID>
    <Title>Different strains of Theiler's murine encephalomyelitis virus antagonize different sites in the type I interferon pathway.</Title>
    <PubDate>20100707</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.00603-10</doi>
    <Abstract>The DA strain of Theiler's murine encephalomyelitis virus (TMEV), a member of the Cardiovirus genus of the family Picornaviridae, causes persistent infection in susceptible mice, associated with restricted expression of viral proteins, and induces a demyelinating disease of the central nervous system. DA-induced demyelinating disease serves as a model of human multiple sclerosis because of similarities in pathology and because host immune responses contribute to pathogenesis in both disorders. In contrast, the GDVII strain of TMEV causes acute lethal encephalitis with no virus persistence. Cardiovirus L is a multifunctional protein that blocks beta interferon (IFN-beta) gene transcription. We show that both DA L and GDVII L disrupt IFN-beta gene transcription induction by IFN regulatory factor 3 (IRF-3) but do so at different points in the signaling pathway. DA L blocks IFN-beta gene transcription downstream of mitochondrial antiviral signaling protein (MAVS) but upstream of IRF-3 activation, while GDVII L acts downstream of IRF-3 activation. Both DA L and GDVII L block IFN-beta gene transcription in infected mice; however, IFN-beta mRNA is expressed at low levels in the central nervous systems of mice persistently infected with DA. The particular level of IFN-beta mRNA expression set by DA L as well as other factors in the IRF-3 pathway may play a role in virus persistence, inflammation, and the restricted expression of viral proteins during the late stage of demyelinating disease.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>9181-9</Pages>
    <Affiliation>Committee of Microbiology, the University of Chicago Medical Center, 5841 S. Maryland Ave., Chicago, Illinois 60637, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20610716&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20592086</PMID>
    <AuthorListID>130</AuthorListID>
    <Title>Induction and inhibition of type I interferon responses by distinct components of lymphocytic choriomeningitis virus.</Title>
    <PubDate>20100630</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.00155-10</doi>
    <Abstract>Type I interferons (IFNs) play a critical role in the host defense against viruses. Lymphocytic choriomeningitis virus (LCMV) infection induces robust type I IFN production in its natural host, the mouse. However, the mechanisms underlying the induction of type I IFNs in response to LCMV infection have not yet been clearly defined. In the present study, we demonstrate that IRF7 is required for both the early phase (day 1 postinfection) and the late phase (day 2 postinfection) of the type I IFN response to LCMV, and melanoma differentiation-associated gene 5 (MDA5)/mitochondrial antiviral signaling protein (MAVS) signaling is crucial for the late phase of the type I IFN response to LCMV. We further demonstrate that LCMV genomic RNA itself (without other LCMV components) is able to induce type I IFN responses in various cell types by activation of the RNA helicases retinoic acid-inducible gene I (RIG-I) and MDA5. We also show that expression of the LCMV nucleoprotein (NP) inhibits the type I IFN response induced by LCMV RNA and other RIG-I/MDA5 ligands. These virus-host interactions may play important roles in the pathogeneses of LCMV and other human arenavirus diseases.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>9452-62</Pages>
    <Affiliation>Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20592086&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20554965</PMID>
    <AuthorListID>131</AuthorListID>
    <Title>The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein.</Title>
    <PubDate>20100616</PubDate>
    <Language>eng</Language>
    <doi>10.4049/jimmunol.0903874</doi>
    <Abstract>Previous studies have shown that both hepatitis A virus and hepatitis C virus inhibit innate immunity by cleaving the mitochondrial antiviral signaling (MAVS) protein, an essential component of the virus-activated signaling pathway that activates NF-kappaB and IFN regulatory factor-3 to induce the production of type I IFN. For human hepatitis B virus (HBV), hepatitis B s-Ag, hepatitis B e-Ag, or HBV virions have been shown to suppress TLR-induced antiviral activity with reduced IFN-beta production and subsequent induction of IFN-stimulated genes. However, HBV-mediated suppression of the RIG-I-MDA5 pathway is unknown. In this study, we found that HBV suppressed poly(deoxyadenylate-thymidylate)-activated IFN-beta production in hepatocytes. Specifically, hepatitis B virus X (HBX) interacted with MAVS and promoted the degradation of MAVS through Lys(136) ubiquitin in MAVS protein, thus preventing the induction of IFN-beta. Further analysis of clinical samples revealed that MAVS protein was downregulated in hepatocellular carcinomas of HBV origin, which correlated with increased sensitivities of primary murine hepatocytes isolated from HBX knock-in transgenic mice upon vesicular stomatitis virus infections. By establishing a link between MAVS and HBX, this study suggests that HBV can target the RIG-I signaling by HBX-mediated MAVS downregulation, thereby attenuating the antiviral response of the innate immune system.</Abstract>
    <JournalRelease>1550-6606</JournalRelease>
    <Pages>1158-68</Pages>
    <Affiliation>Beijing Institute of Biotechnology, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20554965&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20538852</PMID>
    <AuthorListID>132</AuthorListID>
    <Title>The PB2 subunit of the influenza virus RNA polymerase affects virulence by interacting with the mitochondrial antiviral signaling protein and inhibiting expression of beta interferon.</Title>
    <PubDate>20100610</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.00879-10</doi>
    <Abstract>The PB2 subunit of the influenza virus RNA polymerase is a major virulence determinant of influenza viruses. However, the molecular mechanisms involved remain unknown. It was previously shown that the PB2 protein, in addition to its nuclear localization, also accumulates in the mitochondria. Here, we demonstrate that the PB2 protein interacts with the mitochondrial antiviral signaling protein, MAVS (also known as IPS-1, VISA, or Cardif), and inhibits MAVS-mediated beta interferon (IFN-beta) expression. In addition, we show that PB2 proteins of influenza viruses differ in their abilities to associate with the mitochondria. In particular, the PB2 proteins of seasonal human influenza viruses localize to the mitochondria while PB2 proteins of avian influenza viruses are nonmitochondrial. This difference in localization is caused by a single amino acid polymorphism in the PB2 mitochondrial targeting signal. In order to address the functional significance of the mitochondrial localization of the PB2 protein in vivo, we have generated two recombinant human influenza viruses encoding either mitochondrial or nonmitochondrial PB2 proteins. We found that the difference in the mitochondrial localization of the PB2 proteins does not affect the growth of these viruses in cell culture. However, the virus encoding the nonmitochondrial PB2 protein induces higher levels of IFN-beta and, in an animal model, is attenuated compared to the isogenic virus encoding a mitochondrial PB2. Overall this study implicates the PB2 protein in the regulation of host antiviral innate immune pathways and suggests an important role for the mitochondrial association of the PB2 protein in determining virulence.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>8433-45</Pages>
    <Affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health,Bethesda, Maryland 20892-3203, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20538852&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20532218</PMID>
    <AuthorListID>133</AuthorListID>
    <Title>Requirement of NOX2 and reactive oxygen species for efficient RIG-I-mediated antiviral response through regulation of MAVS expression.</Title>
    <PubDate>20100603</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.ppat.1000930</doi>
    <Abstract>The innate immune response is essential to the host defense against viruses, through restriction of virus replication and coordination of the adaptive immune response. Induction of antiviral genes is a tightly regulated process initiated mainly through sensing of invading virus nucleic acids in the cytoplasm by RIG-I like helicases, RIG-I or Mda5, which transmit the signal through a common mitochondria-associated adaptor, MAVS. Although major breakthroughs have recently been made, much remains unknown about the mechanisms that translate virus recognition into antiviral genes expression. Beside the reputed detrimental role, reactive oxygen species (ROS) act as modulators of cellular signaling and gene regulation. NADPH oxidase (NOX) enzymes are a main source of deliberate cellular ROS production. Here, we found that NOX2 and ROS are required for the host cell to trigger an efficient RIG-I-mediated IRF-3 activation and downstream antiviral IFNbeta and IFIT1 gene expression. Additionally, we provide evidence that NOX2 is critical for the expression of the central mitochondria-associated adaptor MAVS. Taken together these data reveal a new facet to the regulation of the innate host defense against viruses through the identification of an unrecognized role of NOX2 and ROS.</Abstract>
    <JournalRelease>1553-7374</JournalRelease>
    <Pages>e1000930</Pages>
    <Affiliation>CRCHUM - Centre Hospitalier de l'UniversitÃ© de MontrÃ©al, MontrÃ©al, QuÃ©bec, Canada.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20532218&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20485506</PMID>
    <AuthorListID>134</AuthorListID>
    <Title>Hepatitis C virus controls interferon production through PKR activation.</Title>
    <PubDate>20100511</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.pone.0010575</doi>
    <Abstract>Hepatitis C virus is a poor inducer of interferon (IFN), although its structured viral RNA can bind the RNA helicase RIG-I, and activate the IFN-induction pathway. Low IFN induction has been attributed to HCV NS3/4A protease-mediated cleavage of the mitochondria-adapter MAVS. Here, we have investigated the early events of IFN induction upon HCV infection, using the cell-cultured HCV JFH1 strain and the new HCV-permissive hepatoma-derived Huh7.25.CD81 cell subclone. These cells depend on ectopic expression of the RIG-I ubiquitinating enzyme TRIM25 to induce IFN through the RIG-I/MAVS pathway. We observed induction of IFN during the first 12 hrs of HCV infection, after which a decline occurred which was more abrupt at the protein than at the RNA level, revealing a novel HCV-mediated control of IFN induction at the level of translation. The cellular protein kinase PKR is an important regulator of translation, through the phosphorylation of its substrate the eIF2alpha initiation factor. A comparison of the expression of luciferase placed under the control of an eIF2alpha-dependent (IRES(EMCV)) or independent (IRES(HCV)) RNA showed a specific HCV-mediated inhibition of eIF2alpha-dependent translation. We demonstrated that HCV infection triggers the phosphorylation of both PKR and eIF2alpha at 12 and 15 hrs post-infection. PKR silencing, as well as treatment with PKR pharmacological inhibitors, restored IFN induction in JFH1-infected cells, at least until 18 hrs post-infection, at which time a decrease in IFN expression could be attributed to NS3/4A-mediated MAVS cleavage. Importantly, both PKR silencing and PKR inhibitors led to inhibition of HCV yields in cells that express functional RIG-I/MAVS. In conclusion, here we provide the first evidence that HCV uses PKR to restrain its ability to induce IFN through the RIG-I/MAVS pathway. This opens up new possibilities to assay PKR chemical inhibitors for their potential to boost innate immunity in HCV infection.</Abstract>
    <JournalRelease>1932-6203</JournalRelease>
    <Pages>e10575</Pages>
    <Affiliation>Institut Pasteur, UnitÃ© HÃ©pacivirus et ImmunitÃ© InnÃ©e, Paris, France.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20485506&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20451243</PMID>
    <AuthorListID>135</AuthorListID>
    <Title>Peroxisomes are signaling platforms for antiviral innate immunity.</Title>
    <PubDate>20100506</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.cell.2010.04.018</doi>
    <Abstract>Peroxisomes have long been established to play a central role in regulating various metabolic activities in mammalian cells. These organelles act in concert with mitochondria to control the metabolism of lipids and reactive oxygen species. However, while mitochondria have emerged as an important site of antiviral signal transduction, a role for peroxisomes in immune defense is unknown. Here, we report that the RIG-I-like receptor (RLR) adaptor protein MAVS is located on peroxisomes and mitochondria. We find that peroxisomal and mitochondrial MAVS act sequentially to create an antiviral cellular state. Upon viral infection, peroxisomal MAVS induces the rapid interferon-independent expression of defense factors that provide short-term protection, whereas mitochondrial MAVS activates an interferon-dependent signaling pathway with delayed kinetics, which amplifies and stabilizes the antiviral response. The interferon regulatory factor IRF1 plays a crucial role in regulating MAVS-dependent signaling from peroxisomes. These results establish that peroxisomes are an important site of antiviral signal transduction.Copyright (c) 2010 Elsevier Inc. All rights reserved.</Abstract>
    <JournalRelease>1097-4172</JournalRelease>
    <Pages>668-81</Pages>
    <Affiliation>Division of Gastroenterology, Children's Hospital Boston, Harvard Medical School, Boston, MA 02115, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20451243&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20434986</PMID>
    <AuthorListID>136</AuthorListID>
    <Title>NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways.</Title>
    <Language>eng</Language>
    <doi>10.1016/j.cell.2010.03.040</doi>
    <Abstract>Stringent control of the NF-kappaB and type I interferon signaling pathways is critical to effective host immune responses, yet the molecular mechanisms that negatively regulate these pathways are poorly understood. Here, we show that NLRC5, a member of the highly conserved NOD-like protein family, can inhibit the IKK complex and RIG-I/MDA5 function. NLRC5 inhibited NF-kappaB-dependent responses by interacting with IKKalpha and IKKbeta and blocking their phosphorylation. It also interacted with RIG-I and MDA5, but not with MAVS, to inhibit RLR-mediated type I interferon responses. Consistent with these observations, NLRC5-specific siRNA knockdown not only enhanced the activation of NF-kappaB and its responsive genes, TNF-alpha and IL-6, but also promoted type I interferon signaling and antiviral immunity. Our findings identify NLRC5 as a negative regulator that blocks two central components of the NF-kappaB and type I interferon signaling pathways and suggest an important role for NLRC5 in homeostatic control of innate immunity.2010 Elsevier Inc. All rights reserved.</Abstract>
    <JournalRelease>1097-4172</JournalRelease>
    <Pages>483-96</Pages>
    <Affiliation>Center for Cell and Gene Therapy, and Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas 77030, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20434986&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20410276</PMID>
    <AuthorListID>137</AuthorListID>
    <Title>Respiratory syncytial virus-mediated NF-kappa B p65 phosphorylation at serine 536 is dependent on RIG-I, TRAF6, and IKK beta.</Title>
    <PubDate>20100421</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.00142-10</doi>
    <Abstract>Respiratory syncytial virus (RSV) is the etiological agent of acute respiratory diseases, such as bronchiolitis and pneumonia. The exacerbated production of proinflammatory cytokines and chemokines in the airways in response to RSV is an important pillar in the development of these pathologies. As such, a keen understanding of the mechanisms that modulate the inflammatory response during RSV infection is of pivotal importance to developing effective treatment. The NF-kappaB transcription factor is a major regulator of proinflammatory cytokine and chemokine genes. However, RSV-mediated activation of NF-kappaB is far from characterized. We recently demonstrated that aside from the well-characterized IkappaBalpha phosphorylation and degradation, the phosphorylation of p65 at Ser536 is an essential event regulating the RSV-mediated NF-kappaB-dependent promoter transactivation. In the present study, using small interfering RNA and pharmacological inhibitors, we now demonstrate that RSV sensing by the RIG-I cytoplasmic receptor triggers a signaling cascade involving the MAVS and TRAF6 adaptors that ultimately leads to p65ser536 phosphorylation by the IKKbeta kinase. In a previous study, we highlighted a critical role of the NOX2-containing NADPH oxidase enzyme as an upstream regulator of both the IkappaBalphaSer32 and p65Ser536 in human airway epithelial cells. Here, we demonstrate that inhibition of NOX2 significantly decreases IKKbeta activation. Taken together, our data identify a new RIG-I/MAVS/TRAF6/IKKbeta/p65Ser536 pathway placed under the control of NOX2, thus characterizing a novel regulatory pathway involved in NF-kappaB-driven proinflammatory response in the context of RSV infection.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>7267-77</Pages>
    <Affiliation>Centre de recherche du CHUM-HÃ´pital St Luc, 264 RenÃ© Levesque-Est, PEA 311, MontrÃ©al, Quebec H2X 1P1, Canada.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20410276&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20407122</PMID>
    <AuthorListID>138</AuthorListID>
    <Title>TRIM proteins: another class of viral victims.</Title>
    <PubDate>20100420</PubDate>
    <Language>eng</Language>
    <doi>10.1126/scisignal.3118jc2</doi>
    <Abstract>TRIM (tripartite motif) proteins are a family of RING (really interesting new gene) domain-containing proteins comprising more than 70 human members, with new members still being described. In addition to their involvement in cell proliferation, differentiation, development, morphogenesis, and apoptosis, roles in immune signaling and antiviral functions are emerging. In response to viral infection, TRIM25 ubiquitinates the N terminus of the viral RNA receptor retinoic acid-inducible gene-I (RIG-I), and this modification is essential for RIG-I to interact with its downstream partner mitochondrial antiviral signaling (MAVS). TRIM25 activity thus leads to activation of the RIG-I signaling pathway, which results in type I interferon production to limit viral replication. Recently, it has been demonstrated that influenza A viruses target TRIM25 and disable its antiviral function, thereby suppressing the host interferon response. This Journal Club article highlights the emerging roles of TRIM proteins in antiviral defense mechanisms and an immune evasion strategy in which influenza viruses target a member of the TRIM family.</Abstract>
    <JournalRelease>1937-9145</JournalRelease>
    <Pages>jc2</Pages>
    <Affiliation>Joint Research and Development Unit for Virology, Immunobiology, and Parasitology of the National Veterinary Institute (SVA) and Swedish University of Agricultural Sciences (SLU), Department of Biomedical Sciences and Veterinary Public Health, Division of Microbiology and Food Safety, SLU, 2B, SE-751 89 Uppsala, Sweden. muhammad.munir@bvf.slu.se</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20407122&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20406818</PMID>
    <AuthorListID>139</AuthorListID>
    <Title>Negative role of RIG-I serine 8 phosphorylation in the regulation of interferon-beta production.</Title>
    <PubDate>20100420</PubDate>
    <Language>eng</Language>
    <doi>10.1074/jbc.M109.089912</doi>
    <Abstract>RIG-I (retinoic acid-inducible gene I) and TRIM25 (tripartite motif protein 25) have emerged as key regulatory factors to induce interferon (IFN)-mediated innate immune responses to limit viral replication. Upon recognition of viral RNA, TRIM25 E3 ligase binds the first caspase recruitment domain (CARD) of RIG-I and subsequently induces lysine 172 ubiquitination of the second CARD of RIG-I, which is essential for the interaction with downstream MAVS/IPS-1/CARDIF/VISA and, thereby, IFN-beta mRNA production. Although ubiquitination has emerged as a major factor involved in RIG-I activation, the potential contribution of other post-translational modifications, such as phosphorylation, to the regulation of RIG-I activity has not been addressed. Here, we report the identification of serine 8 phosphorylation at the first CARD of RIG-I as a negative regulatory mechanism of RIG-I-mediated IFN-beta production. Immunoblot analysis with a phosphospecific antibody showed that RIG-I serine 8 phosphorylation steady-state levels were decreased upon stimulation of cells with IFN-beta or virus infection. Substitution of serine 8 in the CARD RIG-I functional domain with phosphomimetic aspartate or glutamate results in decreased TRIM25 binding, RIG-I ubiquitination, MAVS binding, and downstream signaling. Finally, sequence comparison reveals that only primate species carry serine 8, whereas other animal species carry an asparagine, indicating that serine 8 phosphorylation may represent a primate-specific regulation of RIG-I activation. Collectively, these data suggest that the phosphorylation of RIG-I serine 8 operates as a negative switch of RIG-I activation by suppressing TRIM25 interaction, further underscoring the importance of RIG-I and TRIM25 connection in type I IFN signal transduction.</Abstract>
    <JournalRelease>1083-351X</JournalRelease>
    <Pages>20252-61</Pages>
    <Affiliation>Department of Microbiology, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1124, New York, NY 10029, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20406818&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20403326</PMID>
    <AuthorListID>140</AuthorListID>
    <Title>Reconstitution of the RIG-I pathway reveals a signaling role of unanchored polyubiquitin chains in innate immunity.</Title>
    <Language>eng</Language>
    <doi>10.1016/j.cell.2010.03.029</doi>
    <Abstract>RIG-I detects invading viral RNA and activates the transcription factors NF-kappaB and IRF3 through the mitochondrial protein MAVS. Here we show that RNA bearing 5'-triphosphate strongly activates the RIG-I-IRF3 signaling cascade in a reconstituted system composed of RIG-I, mitochondria, and cytosol. Activation of RIG-I requires not only RNA but also polyubiquitin chains linked through lysine 63 (K63) of ubiquitin. RIG-I binds specifically to K63-polyubiquitin chains through its tandem CARD domains in a manner that depends on RNA and ATP. Mutations in the CARD domains that abrogate ubiquitin binding also impair RIG-I activation. Remarkably, unanchored K63-ubiquitin chains, which are not conjugated to any target protein, potently activate RIG-I. These ubiquitin chains function as an endogenous ligand of RIG-I in human cells. Our results delineate the mechanism of RIG-I activation, identify CARD domains as a ubiquitin sensor, and demonstrate that unanchored K63-polyubiquitin chains are signaling molecules in antiviral innate immunity.Copyright 2010 Elsevier Inc. All rights reserved.</Abstract>
    <JournalRelease>1097-4172</JournalRelease>
    <Pages>315-30</Pages>
    <Affiliation>Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9148, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20403326&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20386371</PMID>
    <AuthorListID>141</AuthorListID>
    <Title>PPHN: is sildenafil the new nitric? A review of the literature.</Title>
    <Language>eng</Language>
    <doi>10.1097/ANC.0b013e3181d5c501</doi>
    <Abstract>Persistent pulmonary hypertension of the newborn (PPHN) is a life-threatening neonatal pathology resulting from poor hemodynamic and respiratory transition to extrauterine life. Inhaled nitric oxide (iNO) is a current, commonly used treatment of PPHN. However, some infants with PPHN do not respond to iNO therapy. Because of the significant morbidity and mortality associated with PPHN, it is useful to look at other possible therapies. This article explores the use of sildenafil in the treatment of PPHN, either as a supplement to iNO or as an alternative to iNO. Current research, including a case study, is reviewed. An emphasis is placed on the administration and efficacy of sildenafil in synergy with, and in lieu of, current iNO therapy in the treatment of PPHN.</Abstract>
    <JournalRelease>1536-0911</JournalRelease>
    <Pages>69-74</Pages>
    <Affiliation>Baylor University Medical Center, and Baylor University Louise Herrington School of Nursing, Dallas, Texas, USA. jana.spillers@mavs.uta.edu</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20386371&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20223737</PMID>
    <AuthorListID>142</AuthorListID>
    <Title>An algorithm for the reconstruction of consensus sequences of ancient segmental duplications and transposon copies in eukaryotic genomes.</Title>
    <Language>eng</Language>
    <Abstract>Interspersed repeats, mostly resulting from the activity and accumulation of transposable elements, occupy a significant fraction of many eukaryotic genomes. More than half of human genomic sequence consists of known repeats, however a very large part has not yet been associated with neither repetitive structures nor functional units. We have postulated that most of the seemingly unique content of mammalian genomes is also a result of transposon activity, written software to look for weak signals which would help us reconstruct the ancient elements with substantially mutated copies, and integrated it into a system for de novo identification and classification of interspersed repeats. In this manuscript we describe our approach, and report on our methods for building the consensus sequences of these transposons.</Abstract>
    <JournalRelease>1744-5485</JournalRelease>
    <Pages>147-62</Pages>
    <Affiliation>Department of Computer Science and Engineering, University of Texas, Arlington, TX 76019, USA. abanish.singh@mavs.uta.edu</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20223737&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20206303</PMID>
    <AuthorListID>143</AuthorListID>
    <Title>The role of mitochondria in the mammalian antiviral defense system.</Title>
    <PubDate>20100302</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.mito.2010.02.005</doi>
    <Abstract>Innate immunity is a crucial defense system against viral and bacterial pathogens, providing a rapid response to mitigate the effects of microbial attack. While more readily associated with respiration and metabolism, recent research has surprisingly identified a number of mitochondrial factors in the mammalian innate immune system. This review summarizes the novel mitochondrial proteins, such as MAVS and NLRX1, involved in this process and attempts to reconcile this new mitochondrial function with our previous knowledge of the organelle.Published by Elsevier B.V.</Abstract>
    <JournalRelease>1872-8278</JournalRelease>
    <Pages>316-20</Pages>
    <Affiliation>Molecular Biology Section, Translational Medicine Branch, National Heart Lung and Blood Institute, Building 10-CRC, Room 5-3216, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA. scotti@mail.nih.gov</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20206303&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20161788</PMID>
    <AuthorListID>144</AuthorListID>
    <Title>TRAF5 is a downstream target of MAVS in antiviral innate immune signaling.</Title>
    <PubDate>20100211</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.pone.0009172</doi>
    <Abstract>The recognition of nucleic acids by the innate immune system during viral infection results in the production of type I interferons and the activation of antiviral immune responses. The RNA helicases RIG-I and MDA-5 recognize distinct types of cytosolic RNA species and signal through the mitochondrial protein MAVS to stimulate the phosphorylation and activation of the transcription factors IRF3 and IRF7, thereby inducing type I interferon expression. Alternatively, the activation of NF-kappaB leads to proinflammatory cytokine production. The function of MAVS is dependent on both its C-terminal transmembrane (TM) domain and N-terminal caspase recruitment domain (CARD). The TM domain mediates MAVS dimerization in response to viral RNA, allowing the CARD to bind to and activate the downstream effector TRAF3. Notably, dimerization of the MAVS CARD alone is sufficient to activate IRF3, IRF7, and NF-kappaB. However, TRAF3-deficient cells display only a partial reduction in interferon production in response to RNA virus infection and are not defective in NF-kappaB activation. Here we find that the related ubiquitin ligase TRAF5 is a downstream target of MAVS that mediates both IRF3 and NF-kappaB activation. The TM domain of MAVS allows it to dimerize and thereby associate with TRAF5 and induce its ubiquitination in a CARD-dependent manner. Also, NEMO is recruited to the dimerized MAVS CARD domain in a TRAF3 and TRAF5-dependent manner. Thus, our findings reveal a possible function for TRAF5 in mediating the activation of IRF3 and NF-kappaB downstream of MAVS through the recruitment of NEMO. TRAF5 may be a key molecule in the innate response against viral infection.</Abstract>
    <JournalRelease>1932-6203</JournalRelease>
    <Pages>e9172</Pages>
    <Affiliation>Laboratory of Molecular Signalling, Division of Oral Biology and Medicine, University of California Los Angeles School of Dentistry, Los Angeles, California, United States of America.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20161788&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20154210</PMID>
    <AuthorListID>145</AuthorListID>
    <Title>Essential role of mitochondrial antiviral signaling, IFN regulatory factor (IRF)3, and IRF7 in Chlamydophila pneumoniae-mediated IFN-beta response and control of bacterial replication in human endothelial cells.</Title>
    <PubDate>20100212</PubDate>
    <Language>eng</Language>
    <doi>10.4049/jimmunol.0902947</doi>
    <Abstract>Chlamydophila pneumoniae infection of the vascular wall as well as activation of the transcription factor IFN regulatory factor (IRF)3 have been linked to development of chronic vascular lesions and atherosclerosis. The innate immune system detects invading pathogens by use of pattern recognition receptors, some of which are able to stimulate IRF3/7 activation and subsequent type I IFN production (e. g., IFN-beta). In this study, we show that infection of human endothelial cells with C. pneumoniae-induced production of IFN-beta, a cytokine that so far has been mainly associated with antiviral immunity. Moreover, C. pneumoniae infection led to IRF3 and IRF7 nuclear translocation in HUVECs and RNA interference experiments showed that IRF3 and IRF7 as well as the mitochondrial antiviral signaling (MAVS) were essential for IFN-beta induction. Finally, C. pneumoniae replication was enhanced in endothelial cells in which IRF3, IRF7, or MAVS expression was inhibited by small interfering RNA and attenuated by IFN-beta treatment. In conclusion, C. pneumoniae infection of endothelial cells activates an MAVS-, IRF3-, and IRF7-dependent signaling, which controls bacterial growth and might modulate development of vascular lesions.</Abstract>
    <JournalRelease>1550-6606</JournalRelease>
    <Pages>3072-8</Pages>
    <Affiliation>Division of Infectious Diseases and Pulmonary Medicine, Department of Internal Medicine, CharitÃ© UniversitÃ¤tsmedizin Berlin, Berlin, Germany.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20154210&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20071582</PMID>
    <AuthorListID>146</AuthorListID>
    <Title>Phosphorylation-mediated negative regulation of RIG-I antiviral activity.</Title>
    <PubDate>20100113</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.02241-09</doi>
    <Abstract>Recognition of invading viruses by the host is elicited by cellular sensors which trigger signaling cascades that lead to type I interferon (IFN) gene expression. Retinoic acid-inducible gene I (RIG-I) has emerged as a key receptor for the detection of viral RNA in the cytosol, inducing IFN-mediated innate immune responses to limit viral replication through its interaction with MAVS (also called IPS-1, CARDIF, or VISA). Upon the recognition of viral RNA, the Lys-172 residue of RIG-I undergoes ubiquitination induced by tripartite motif protein 25 (TRIM25), an essential protein for antiviral signal transduction. Here we demonstrate that phosphorylation represents another regulatory mechanism for RIG-I-mediated antiviral activity. Using protein purification and mass spectrometry analysis, we identified three phosphorylation sites in the amino-terminal caspase recruitment domains (CARDs) of RIG-I. One of these residues, Thr-170, is located in close proximity to Lys-172, and we speculated that its phosphorylation may affect Lys-172 ubiquitination and functional activation of RIG-I. Indeed, a RIG-I mutant carrying a phosphomimetic Glu residue in place of Thr-170 loses TRIM25 binding, Lys-172 ubiquitination, MAVS binding, and downstream signaling ability. This suggests that phosphorylation of RIG-I at Thr-170 inhibits RIG-I-mediated antiviral signal transduction. Immunoblot analysis with a phospho-specific antibody showed that the phosphorylation of the RIG-I Thr-170 residue is present under normal conditions but rapidly declines upon viral infection. Our results indicate that Thr-170 phosphorylation and TRIM25-mediated Lys-172 ubiquitination of RIG-I functionally antagonize each other. While Thr-170 phosphorylation keeps RIG-I latent, Lys-172 ubiquitination enables RIG-I to form a stable complex with MAVS, thereby inducing IFN signal transduction.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>3220-9</Pages>
    <Affiliation>Department of Microbiology and Molecular Genetics, New England Primate Research Center, Harvard Medical School, One Pine Hill Drive, Box 9102, Southborough, MA 01772-9102, USA. michaela_gack@hms.harvard.edu</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20071582&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20044805</PMID>
    <AuthorListID>147</AuthorListID>
    <Title>Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system.</Title>
    <Language>eng</Language>
    <doi>10.1002/hep.23426</doi>
    <Abstract>Hepatitis C virus (HCV) infection induces the endogenous interferon (IFN) system in the liver in some but not all patients with chronic hepatitis C (CHC). Patients with a pre-activated IFN system are less likely to respond to the current standard therapy with pegylated IFN-alpha. Mitochondrial antiviral signaling protein (MAVS) is an important adaptor molecule in a signal transduction pathway that senses viral infections and transcriptionally activates IFN-beta. The HCV NS3-4A protease can cleave and thereby inactivate MAVS in vitro, and, therefore, might be crucial in determining the activation status of the IFN system in the liver of infected patients. We analyzed liver biopsies from 129 patients with CHC to investigate whether MAVS is cleaved in vivo and whether cleavage prevents the induction of the endogenous IFN system. Cleavage of MAVS was detected in 62 of the 129 samples (48%) and was more extensive in patients with a high HCV viral load. MAVS was cleaved by all HCV genotypes (GTs), but more efficiently by GTs 2 and 3 than by GTs 1 and 4. The IFN-induced Janus kinase (Jak)-signal transducer and activator of transcription protein (STAT) pathway was less frequently activated in patients with cleaved MAVS, and there was a significant inverse correlation between cleavage of MAVS and the expression level of the IFN-stimulated genes IFI44L, Viperin, IFI27, USP18, and STAT1. We conclude that the pre-activation status of the endogenous IFN system in the liver of patients with CHC is in part regulated by cleavage of MAVS.</Abstract>
    <JournalRelease>1527-3350</JournalRelease>
    <Pages>1127-36</Pages>
    <Affiliation>Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20044805&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20032188</PMID>
    <AuthorListID>148</AuthorListID>
    <Title>The interferon stimulator mitochondrial antiviral signaling protein facilitates cell death by disrupting the mitochondrial membrane potential and by activating caspases.</Title>
    <PubDate>20091223</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.02174-09</doi>
    <Abstract>Interferon (IFN) signaling is initiated by the recognition of viral components by host pattern recognition receptors. Dengue virus (DEN) triggers IFN-beta induction through a molecular mechanism involving the cellular RIG-I/MAVS signaling pathway. Here we report that the MAVS protein level is reduced in DEN-infected cells and that caspase-1 and caspase-3 cleave MAVS at residue D429. In addition to its well-known function in IFN induction, MAVS is also a proapoptotic molecule that triggers disruption of the mitochondrial membrane potential and activation of caspases. Although different domains are required for the induction of cytotoxicity and IFN, caspase cleavage at residue 429 abolished both functions of MAVS. The apoptotic role of MAVS in viral infection and double-stranded RNA (dsRNA) stimulation was demonstrated in cells with reduced endogenous MAVS expression induced by RNA interference. Even though IFN-beta promoter activation was largely suppressed, DEN production was not affected greatly in MAVS knockdown cells. Instead, DEN- and dsRNA-induced cell death and caspase activation were delayed and attenuated in the cells with reduced levels of MAVS. These results reveal a new role of MAVS in the regulation of cell death beyond its well-known function of IFN induction in antiviral innate immunity.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>2421-31</Pages>
    <Affiliation>Institute of Biomedical Sciences, Academia Sinica, Taiwan, Republic of China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20032188&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20019757</PMID>
    <AuthorListID>149</AuthorListID>
    <Title>Mitochondrial dynamics regulate the RIG-I-like receptor antiviral pathway.</Title>
    <PubDate>20091218</PubDate>
    <Language>eng</Language>
    <doi>10.1038/embor.2009.258</doi>
    <Abstract>The intracellular retinoic acid-inducible gene I-like receptors (RLRs) sense viral ribonucleic acid and signal through the mitochondrial protein mitochondrial antiviral signalling (MAVS) to trigger the production of type I interferons and proinflammatory cytokines. In this study, we report that RLR activation promotes elongation of the mitochondrial network. Mimicking this elongation enhances signalling downstream from MAVS and favours the binding of MAVS to stimulator of interferon genes, an endoplasmic reticulum (ER) protein involved in the RLR pathway. By contrast, enforced mitochondrial fragmentation dampens signalling and reduces the association between both proteins. Our finding that MAVS is associated with a pool of mitofusin 1, a protein of the mitochondrial fusion machinery, suggests that MAVS is capable of regulating mitochondrial dynamics to facilitate the mitochondria-ER association required for signal transduction. Importantly, we observed that viral mitochondria-localized inhibitor of apoptosis, a cytomegalovirus (CMV) antiapoptotic protein that promotes mitochondrial fragmentation, inhibits signalling downstream from MAVS, suggesting a possible new immune modulation strategy of the CMV.</Abstract>
    <JournalRelease>1469-3178</JournalRelease>
    <Pages>133-8</Pages>
    <Affiliation>INSERM U542, HÃ´pital Paul Brousse, BÃ¢timent Lavoisier, UniversitÃ© Paris-Sud, 14 Avenue Paul Vaillant Couturier, Villejuif Cedex 94807, France.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20019757&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20007272</PMID>
    <AuthorListID>150</AuthorListID>
    <Title>Z proteins of New World arenaviruses bind RIG-I and interfere with type I interferon induction.</Title>
    <PubDate>20091209</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.01362-09</doi>
    <Abstract>The retinoic acid-inducible gene I product (RIG-I) is a cellular sensor of RNA virus infection that regulates the cellular beta interferon (IFN-beta) response. The nucleoproteins (NP) of arenaviruses are reported to antagonize the IFN response by inhibiting interferon regulatory factor 3 (IRF-3). Here, we demonstrate that the Z proteins of four New World (NW) arenaviruses, Guanarito virus (GTOV), Junin virus (JUNV), Machupo virus (MAVC), and Sabia virus (SABV), bind to RIG-I, resulting in downregulation of the IFN-beta response. We show that expression of the four NW arenavirus Z proteins inhibits IFN-beta mRNA induction in A549 cells in response to RNA bearing 5' phosphates (5'pppRNA). NW arenavirus Z proteins interact with RIG-I in coimmunoprecipitation studies and colocalize with RIG-I. Furthermore, expression of Z proteins interferes with the interaction between RIG-I and MAVS. Z expression also impedes the nuclear factor kappa light chain enhancer of activated B cells (NF-kappaB) and IRF-3 activation. Our results indicate that NW arenavirus Z proteins, but not Z protein of the Old World (OW) arenavirus lymphocytic choriomeningitis virus (LCMV) or Lassa virus, bind to RIG-I and inhibit downstream activation of the RIG-I signaling pathway, preventing the transcriptional induction of IFN-beta.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>1785-91</Pages>
    <Affiliation>Center for Infection and Immunity, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20007272&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19956647</PMID>
    <AuthorListID>151</AuthorListID>
    <Title>Expression of an IKKgamma splice variant determines IRF3 and canonical NF-kappaB pathway utilization in ssRNA virus infection.</Title>
    <PubDate>20091126</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.pone.0008079</doi>
    <Abstract>Single stranded RNA (ssRNA) virus infection activates the retinoic acid inducible gene I (RIG-I)- mitochondrial antiviral signaling (MAVS) complex, a complex that coordinates the host innate immune response via the NF-kappaB and IRF3 pathways. Recent work has shown that the IkappaB kinase (IKK)gamma scaffolding protein is the final common adapter protein required by RIG-I.MAVS to activate divergent rate-limiting kinases downstream controlling the NF-kappaB and IRF3 pathways. Previously we discovered a ubiquitous IKKgamma splice-variant, IKKgammaDelta, that exhibits distinct signaling properties.We examined the regulation and function of IKKgamma splice forms in response to ssRNA virus infection, a condition that preferentially induces full length IKKgamma-WT mRNA expression. In IKKgammaDelta-expressing cells, we found increased viral translation and cytopathic effect compared to those expressing full length IKKgamma-WT. IKKgammaDelta fails to support viral-induced IRF3 activation in response to ssRNA infections; consequently type I IFN production and the induction of anti-viral interferon stimulated genes (ISGs) are significantly attenuated. By contrast, ectopic RIG-I.MAVS or TNFalpha-induced canonical NF-kappaB activation is preserved in IKKgammaDelta expressing cells. Increasing relative levels of IKKgamma-WT to IKKgammaDelta (while keeping total IKKgamma constant) results in increased type I IFN expression. Conversely, overexpressing IKKgammaDelta (in a background of constant IKKgamma-WT expression) shows IKKgammaDelta functions as a dominant-negative IRF3 signaling inhibitor. IKKgammaDelta binds both IKK-alpha and beta, but not TANK and IKKepsilon, indicating that exon 5 encodes an essential TANK binding domain. Finally, IKKgammaDelta displaces IKKgammaWT from MAVS explaining its domainant negative effect.Relative endogenous IKKgammaDelta expression affects cellular selection of inflammatory/anti-viral pathway responses to ssRNA viral infection.</Abstract>
    <JournalRelease>1932-6203</JournalRelease>
    <Pages>e8079</Pages>
    <Affiliation>Department of Medicine, University of Texas Medical Branch (UTMB), Galveston, Texas, United States of America.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19956647&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19915568</PMID>
    <AuthorListID>152</AuthorListID>
    <Title>Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production.</Title>
    <PubDate>20091115</PubDate>
    <Language>eng</Language>
    <doi>10.1038/ni.1824</doi>
    <Abstract>Interleukin 1 beta (IL-1 beta) is a potent proinflammatory factor during viral infection. Its production is tightly controlled by transcription of Il1b dependent on the transcription factor NF-kappaB and subsequent processing of pro-IL-1 beta by an inflammasome. However, the sensors and mechanisms that facilitate RNA virus-induced production of IL-1 beta are not well defined. Here we report a dual role for the RNA helicase RIG-I in RNA virus-induced proinflammatory responses. Whereas RIG-I-mediated activation of NF-kappaB required the signaling adaptor MAVS and a complex of the adaptors CARD9 and Bcl-10, RIG-I also bound to the adaptor ASC to trigger caspase-1-dependent inflammasome activation by a mechanism independent of MAVS, CARD9 and the Nod-like receptor protein NLRP3. Our results identify the CARD9-Bcl-10 module as an essential component of the RIG-I-dependent proinflammatory response and establish RIG-I as a sensor able to activate the inflammasome in response to certain RNA viruses.</Abstract>
    <JournalRelease>1529-2916</JournalRelease>
    <Pages>63-9</Pages>
    <Affiliation>III. Medizinische Klinik, Klinikum rechts der Isar, Technische UniversitÃ¤t MÃ¼nchen, Munich, Germany.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19915568&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19914245</PMID>
    <AuthorListID>153</AuthorListID>
    <Title>c-Abl tyrosine kinase interacts with MAVS and regulates innate immune response.</Title>
    <Language>eng</Language>
    <doi>10.1016/j.febslet.2009.11.025</doi>
    <Abstract>The tyrosine kinase, c-Abl, plays important roles in many aspects of cellular function. Previous reports showed that c-Abl is involved in NF-kappaB signaling. However, the functions of c-Abl in innate immunity are still unknown. Here we demonstrate that the mitochondrial antiviral signaling (MAVS) protein can be physically associated with c-Abl in vivo and in vitro. MAVS interacted with c-Abl through its Card and TM domain. A phosphotyrosine-specific antibody indicated that MAVS was phosphorylated by c-Abl. Functional impairment of c-Abl attenuated MAVS or VSV induced type-I IFN production. Importantly, c-Abl knockdown in MCF7 cells displayed impaired MAVS-mediated NF-kappaB and IRF3 activation. Taken together, our results suggest that c-Abl modulates innate immune response through MAVS.</Abstract>
    <JournalRelease>1873-3468</JournalRelease>
    <Pages>33-8</Pages>
    <Affiliation>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Biotechnology, Haidian District, Beijing, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19914245&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19893624</PMID>
    <AuthorListID>154</AuthorListID>
    <Title>The E3 ubiquitin ligase Triad3A negatively regulates the RIG-I/MAVS signaling pathway by targeting TRAF3 for degradation.</Title>
    <PubDate>20091106</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.ppat.1000650</doi>
    <Abstract>The primary role of the innate immune response is to limit the spread of infectious pathogens, with activation of Toll-like receptor (TLR) and RIG-like receptor (RLR) pathways resulting in a pro-inflammatory response required to combat infection. Limiting the activation of these signaling pathways is likewise essential to prevent tissue injury in the host. Triad3A is an E3 ubiquitin ligase that interacts with several components of TLR signaling and modulates TLR activity. In the present study, we demonstrate that Triad3A negatively regulates the RIG-I RNA sensing pathway through Lys48-linked, ubiquitin-mediated degradation of the tumor necrosis factor receptor-associated factor 3 (TRAF3) adapter. Triad3A was induced following dsRNA exposure or virus infection and decreased TRAF3 levels in a dose-dependent manner; moreover, Triad3A expression blocked IRF-3 activation by Ser-396 phosphorylation and inhibited the expression of type 1 interferon and antiviral genes. Lys48-linked ubiquitination of TRAF3 by Triad3A increased TRAF3 turnover, whereas reduction of Triad3A expression by stable shRNA expression correlated with an increase in TRAF3 protein expression and enhancement of the antiviral response following VSV or Sendai virus infection. Triad3A and TRAF3 physically interacted together, and TRAF3 residues Y440 and Q442--previously shown to be important for association with the MAVS adapter--were also critical for Triad3A. Point mutation of the TRAF-Interacting-Motif (TIM) of Triad3A abrogated its ability to interact with TRAF3 and modulate RIG-I signaling. TRAF3 appears to undergo sequential ubiquitin "immuno-editing" following virus infection that is crucial for regulation of RIG-I-dependent signaling to the antiviral response. Thus, Triad3A represents a versatile E3 ubiquitin ligase that negatively regulates RIG-like receptor signaling by targeting TRAF3 for degradation following RNA virus infection.</Abstract>
    <JournalRelease>1553-7374</JournalRelease>
    <Pages>e1000650</Pages>
    <Affiliation>The Terry Fox Molecular Oncology Group, Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19893624&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19881509</PMID>
    <AuthorListID>155</AuthorListID>
    <Title>PCBP2 mediates degradation of the adaptor MAVS via the HECT ubiquitin ligase AIP4.</Title>
    <PubDate>20091101</PubDate>
    <Language>eng</Language>
    <doi>10.1038/ni.1815</doi>
    <Abstract>MAVS is critical in innate antiviral immunity as the sole adaptor for RIG-I-like helicases. MAVS regulation is essential for the prevention of excessive harmful immune responses. Here we identify PCBP2 as a negative regulator in MAVS-mediated signaling. Overexpression of PCBP2 abrogated cellular responses to viral infection, whereas knockdown of PCBP2 exerted the opposite effect. PCBP2 was induced after viral infection, and its interaction with MAVS led to proteasomal degradation of MAVS. PCBP2 recruited the HECT domain-containing E3 ligase AIP4 to polyubiquitinate and degrade MAVS. MAVS was degraded after viral infection in wild-type mouse embryonic fibroblasts but remained stable in AIP4-deficient (Itch(-/-)) mouse embryonic fibroblasts, coupled with greatly exaggerated and prolonged antiviral responses. The PCBP2-AIP4 axis defines a new signaling cascade for MAVS degradation and 'fine tuning' of antiviral innate immunity.</Abstract>
    <JournalRelease>1529-2916</JournalRelease>
    <Pages>1300-8</Pages>
    <Affiliation>The Education Ministry Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking University, Beijing, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19881509&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19859543</PMID>
    <AuthorListID>156</AuthorListID>
    <Title>Study of human RIG-I polymorphisms identifies two variants with an opposite impact on the antiviral immune response.</Title>
    <PubDate>20091027</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.pone.0007582</doi>
    <Abstract>RIG-I is a pivotal receptor that detects numerous RNA and DNA viruses. Thus, its defectiveness may strongly impair the host antiviral immunity. Remarkably, very little information is available on RIG-I single-nucleotide polymorphisms (SNPs) presenting a functional impact on the host response.Here, we studied all non-synonymous SNPs of RIG-I using biochemical and structural modeling approaches. We identified two important variants: (i) a frameshift mutation (P(229)fs) that generates a truncated, constitutively active receptor and (ii) a serine to isoleucine mutation (S(183)I), which drastically inhibits antiviral signaling and exerts a down-regulatory effect, due to unintended stable complexes of RIG-I with itself and with MAVS, a key downstream adapter protein.Hence, this study characterized P(229)fs and S(183)I SNPs as major functional RIG-I variants and potential genetic determinants of viral susceptibility. This work also demonstrated that serine 183 is a residue that critically regulates RIG-I-induced antiviral signaling.</Abstract>
    <JournalRelease>1932-6203</JournalRelease>
    <Pages>e7582</Pages>
    <Affiliation>Institut Pasteur, UnitÃ© de DÃ©fense InnÃ©e et Inflammation, Paris, France.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19859543&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19854139</PMID>
    <AuthorListID>157</AuthorListID>
    <Title>Key role of Ubc5 and lysine-63 polyubiquitination in viral activation of IRF3.</Title>
    <Language>eng</Language>
    <doi>10.1016/j.molcel.2009.09.037</doi>
    <Abstract>The mitochondrial antiviral signaling protein (MAVS; also known as IPS-1, VISA, and CARDIF) is essential for innate immune response against RNA viruses. MAVS transduces signals from the cytosolic RIG-I-like receptors, which bind to viral RNAs. But how MAVS activates downstream transcription factors such as IRF3 to induce type-I interferons is not well understood. We have established a cell-free system in which mitochondria derived from virus-infected cells activate IRF3 in the cytosol. Fractionation of the cytosol led to the identification of Ubc5 as a ubiquitin-conjugating enzyme (E2) required for IRF3 activation. Using an inducible RNAi strategy, we demonstrate that catalytically active Ubc5 is required for IRF3 activation by viral infection. The activation of IRF3 also requires two ubiquitin-binding domains of NEMO. Furthermore, we show that replacement of endogenous ubiquitin with its K63R mutant abolishes viral activation of IRF3, demonstrating that K63 polyubiquitination plays a key role in IRF3 activation.</Abstract>
    <JournalRelease>1097-4164</JournalRelease>
    <Pages>315-25</Pages>
    <Affiliation>Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9148, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19854139&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19846534</PMID>
    <AuthorListID>158</AuthorListID>
    <Title>MDA5 and MAVS mediate type I interferon responses to coxsackie B virus.</Title>
    <Language>eng</Language>
    <doi>10.1128/JVI.00631-09</doi>
    <Abstract>Coxsackie B viruses (CVB) are enteroviruses that have been associated with a variety of human diseases, including myocarditis. In the present study, we found that MDA5 and its adaptor molecule MAVS are critical for type I interferon responses to CVB, since the absence of either MAVS or MDA5 leads to deficient type I interferon production and early mortality in mice infected with CVB. Pancreatic and hepatic necrosis were observed on histopathological examination of MAVS and MDA5 knockout mice infected with CVB. Inflammatory cytokine production in response to systemic CVB infection was independent of MAVS. Surprisingly, virus titers were not elevated in MAVS-deficient mice, despite significant reductions in type I interferon levels. These data highlight the importance of type I interferon in host defense and provide insight on the mechanisms of innate immune responses following coxsackievirus infection.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>254-60</Pages>
    <Affiliation>Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA. Jennifer.wang@umassmed.edu</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19846534&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19734229</PMID>
    <AuthorListID>159</AuthorListID>
    <Title>Negative regulation of MAVS-mediated innate immune response by PSMA7.</Title>
    <PubDate>20090904</PubDate>
    <Language>eng</Language>
    <doi>10.4049/jimmunol.0901646</doi>
    <Abstract>Innate immunity to viruses involves receptors such as Retinoic Acid Induced Gene-1 (RIG-I), which senses viral RNA and triggers a signaling pathway involving the outer mitochondrial membrane protein mitochondrial antiviral signaling (MAVS). Recent work has identified that NLRX1, a member of another class of innate immune receptors, sequesters MAVS away from RIG-I and thereby prevents mitochondrial antiviral immunity. In this study, we demonstrate that the proteasome PSMA7 (alpha4) subunit associates with MAVS in vivo and in vitro. Expression of PSMA7 results in a potent inhibition of RIG-1 and MAVS-mediated IFN-beta promoter activity; conversely, depletion of PSMA7 with small interference RNA enhances virus-induced type I IFN production, with consequent reduction of virus replication. Furthermore, a striking reduction in the abundance of endogenous MAVS with overexpressed PSMA7 was found and virus infection leads to transient increase in the endogenous PSMA7 protein level. Cumulatively, these results suggest that PSMA7 is a negative regulator of the MAVS-mediated innate immunity that probably serves to attenuate the establishment of an antiviral state during viral infection, highlighting the biological significance of PSMA7-MAVS association as an important cellular regulatory control.</Abstract>
    <JournalRelease>1550-6606</JournalRelease>
    <Pages>4241-8</Pages>
    <Affiliation>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Biotechnology, Beijing, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19734229&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19706715</PMID>
    <AuthorListID>160</AuthorListID>
    <Title>Respiratory syncytial virus infection induces a reactive oxygen species-MSK1-phospho-Ser-276 RelA pathway required for cytokine expression.</Title>
    <PubDate>20090812</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.01090-09</doi>
    <Abstract>Respiratory syncytial virus (RSV) is a human pathogen that induces airway inflammation, at least in part, by modulating gene expression programs in airway epithelial cells. The presence of RSV replication is detected by the intracellular retinoic acid-inducible gene I (RIG-I) RNA helicase that forms a productive signaling complex with the mitochondrion-anchored MAVS protein, resulting in nuclear translocation of the NF-kappaB transcription factor. Although nuclear translocation is a prerequisite for activation of the innate inflammatory response, recent studies show that separate pathways governing RelA activation are also required for target gene expression. In this study, we examine the mechanism of RelA phosphorylation and its requirement for RSV-induced gene expression. RSV infection produced a time-dependent RelA phosphorylation on serine (Ser) residues Ser-276 and Ser-536 in parallel with enhanced reactive oxygen species (ROS) stress. Inhibition of RSV-induced ROS inhibited formation of phospho-Ser-276 RelA without affecting phospho-Ser-536 RelA formation. RSV potently induced activation of cytoplasmic mitogen- and stress-related kinase 1 (MSK1) in an ROS-dependent manner. Inhibition of MSK1 using H89 and small interfering RNA knockdown both reduced RSV-induced phospho-Ser-276 RelA formation and expression of a subset of NF-kappaB-dependent genes. Direct examination of the role of phospho-Ser-276 in target gene expression by expression of a RelA Ser-276-to-Ala site mutation in RelA(-/-) mouse embryonic fibroblasts showed that the mutation was unable to mediate RSV-induced NF-kappaB-dependent gene expression. We conclude that RSV induces RelA activation in the innate inflammatory response via a pathway separate from that controlling RelA cytoplasmic release, mediated by ROS signaling to cytoplasmic MSK1 activation and RelA Ser-276 phosphorylation.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>10605-15</Pages>
    <Affiliation>Institute for Translational Sciences, University of Texas Medical Branch (UTMB), Galveston, TX 77555-1060, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19706715&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19701189</PMID>
    <AuthorListID>161</AuthorListID>
    <Title>Activation of innate immune antiviral responses by Nod2.</Title>
    <PubDate>20090823</PubDate>
    <Language>eng</Language>
    <doi>10.1038/ni.1782</doi>
    <Abstract>Pattern-recognition receptors (PRRs), including Toll-like receptors (TLRs) and RIG-like helicase (RLH) receptors, are involved in innate immune antiviral responses. Here we show that nucleotide-binding oligomerization domain 2 (Nod2) can also function as a cytoplasmic viral PRR by triggering activation of interferon-regulatory factor 3 (IRF3) and production of interferon-beta (IFN-beta). After recognition of a viral ssRNA genome, Nod2 used the adaptor protein MAVS to activate IRF3. Nod2-deficient mice failed to produce interferon efficiently and showed enhanced susceptibility to virus-induced pathogenesis. Thus, the function of Nod2 as a viral PRR highlights the important function of Nod2 in host antiviral defense mechanisms.</Abstract>
    <JournalRelease>1529-2916</JournalRelease>
    <Pages>1073-80</Pages>
    <Affiliation>Department of Microbiology and Immunology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19701189&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19692591</PMID>
    <AuthorListID>162</AuthorListID>
    <Title>An N-terminal addressing sequence targets NLRX1 to the mitochondrial matrix.</Title>
    <Language>eng</Language>
    <doi>10.1242/jcs.051193</doi>
    <Abstract>NLRX1 is the only member of the Nod-like receptor (NLR) family that is targeted to the mitochondria, and its overexpression induces the generation of reactive oxygen species (ROS), thus impacting on NFkappaB- and JNK-dependent signaling cascades. In addition, NLRX1 has been shown to interact with MAVS (also known as IPS-1, VISA and Cardif) at the mitochondrial outer membrane and to modulate antiviral responses. Here we report that NLRX1 has a functional leader sequence and fully translocates to the mitochondrial matrix via a mechanism requiring the mitochondrial inner-membrane potential, DeltaPsim. Importantly, we failed to detect NLRX1 at the mitochondrial outer membrane. We also show that the leader sequence of NLRX1 is removed, which generates a mature protein lacking the first 39 amino acids through a maturation process that is common for mitochondrial-matrix proteins. Finally, we identified UQCRC2, a matrix-facing protein of the respiratory chain complex III, as an NLRX1-interacting molecule, thus providing a molecular basis for the role of NLRX1 in ROS generation. These results provide the first identification of a protein belonging to the NLR family that is targeted to the mitochondrial matrix.</Abstract>
    <JournalRelease>1477-9137</JournalRelease>
    <Pages>3161-8</Pages>
    <Affiliation>INSERM U542, HÃ´pital Paul Brousse, Batiment Lavoisier, Villejuif Cedex, France. Damien.arnoult@inserm.fr</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19692591&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19690333</PMID>
    <AuthorListID>163</AuthorListID>
    <Title>Mitofusin 2 inhibits mitochondrial antiviral signaling.</Title>
    <PubDate>20090818</PubDate>
    <Language>eng</Language>
    <doi>10.1126/scisignal.2000287</doi>
    <Abstract>The innate immune response to viral infection involves the activation of multiple signaling steps that culminate in the production of type I interferons (IFNs). Mitochondrial antiviral signaling (MAVS), a mitochondrial outer membrane adaptor protein, plays an important role in this process. Here, we report that mitofusin 2 (Mfn2), a mediator of mitochondrial fusion, interacts with MAVS to modulate antiviral immunity. Overexpression of Mfn2 resulted in the inhibition of retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated gene 5 (MDA-5), two cytosolic sensors of viral RNA, as well as of MAVS-mediated activation of the transcription factors interferon regulatory factor 3 (IRF-3) and nuclear factor kappaB (NF-kappaB). In contrast, loss of endogenous Mfn2 enhanced virus-induced production of IFN-beta and thereby decreased viral replication. Structure-function analysis revealed that Mfn2 interacted with the carboxyl-terminal region of MAVS through a heptad repeat region, providing a structural perspective on the regulation of the mitochondrial antiviral response. Our results suggest that Mfn2 acts as an inhibitor of antiviral signaling, a function that may be distinct from its role in mitochondrial dynamics.</Abstract>
    <JournalRelease>1937-9145</JournalRelease>
    <Pages>ra47</Pages>
    <Affiliation>Department of Biology, Kyushu University, Hakozaki, Higashi-ku, Fukuoka, Japan.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19690333&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19631370</PMID>
    <AuthorListID>164</AuthorListID>
    <Title>RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway.</Title>
    <PubDate>20090723</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.cell.2009.06.015</doi>
    <Abstract>Type I interferons (IFNs) are important for antiviral and autoimmune responses. Retinoic acid-induced gene I (RIG-I) and mitochondrial antiviral signaling (MAVS) proteins mediate IFN production in response to cytosolic double-stranded RNA or single-stranded RNA containing 5'-triphosphate (5'-ppp). Cytosolic B form double-stranded DNA, such as poly(dA-dT)*poly(dA-dT) [poly(dA-dT)], can also induce IFN-beta, but the underlying mechanism is unknown. Here, we show that the cytosolic poly(dA-dT) DNA is converted into 5'-ppp RNA to induce IFN-beta through the RIG-I pathway. Biochemical purification led to the identification of DNA-dependent RNA polymerase III (Pol-III) as the enzyme responsible for synthesizing 5'-ppp RNA from the poly(dA-dT) template. Inhibition of RNA Pol-III prevents IFN-beta induction by transfection of DNA or infection with DNA viruses. Furthermore, Pol-III inhibition abrogates IFN-beta induction by the intracellular bacterium Legionella pneumophila and promotes the bacterial growth. These results suggest that RNA Pol-III is a cytosolic DNA sensor involved in innate immune responses.</Abstract>
    <JournalRelease>1097-4172</JournalRelease>
    <Pages>576-91</Pages>
    <Affiliation>Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9148, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19631370&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19591957</PMID>
    <AuthorListID>165</AuthorListID>
    <Title>Degradation of RIG-I following cytomegalovirus infection is independent of apoptosis.</Title>
    <PubDate>20090708</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.micinf.2009.07.001</doi>
    <Abstract>Many viruses have evolved strategies to either evade or hijack host cell immune programs, as a means of promoting their own reproduction. For example, the human cytomegalovirus (HCMV) immediate-early protein vMIA/UL37ex1 inhibits host cell apoptosis, and its expression during infection aids virus replication. Here it is shown that stable expression of vMIA/UL37ex1 reduces cleavage of the innate immune response-proteins MAVS and RIG-I by caspases during apoptosis. Unexpectedly, it is demonstrated that RIG-I, but not MAVS, is degraded during HCMV infection. This process occurs in a non-apoptotic manner, and provides new evidence that HCMV may have evolved a unique strategy to evade RIG-I-mediated immune responses.</Abstract>
    <JournalRelease>1769-714X</JournalRelease>
    <Pages>973-9</Pages>
    <Affiliation>Biochemistry Section, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892, USA. scotti@mail.nih.gov</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19591957&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19561593</PMID>
    <AuthorListID>166</AuthorListID>
    <Title>Regulation of the innate immune response by threonine-phosphatase of Eyes absent.</Title>
    <PubDate>20090628</PubDate>
    <Language>eng</Language>
    <doi>10.1038/nature08138</doi>
    <Abstract>Innate immunity is stimulated not only by viral or bacterial components, but also by non-microbial danger signals (damage-associated molecular patterns). One of the damage-associated molecular patterns is chromosomal DNA that escapes degradation. In programmed cell death and erythropoiesis, DNA from dead cells or nuclei expelled from erythroblasts is digested by DNase II in the macrophages after they are engulfed. DNase II(-/-) (also known as Dnase2a(-/-)) mice suffer from severe anaemia or chronic arthritis due to interferon-beta (IFN-beta) and tumour necrosis factor-alpha (TNF-alpha) produced from the macrophages carrying undigested DNA in a Toll-like receptor (TLR)-independent mechanism. Here we show that Eyes absent 4 (EYA4), originally identified as a co-transcription factor, stimulates the expression of IFN-beta and CXCL10 in response to the undigested DNA of apoptotic cells. EYA4 enhanced the innate immune response against viruses (Newcastle disease virus and vesicular stomatitis virus), and could associate with signalling molecules (IPS-1 (also known as MAVS), STING (TMEM173) and NLRX1). Three groups have previously shown that EYA has phosphatase activity. We found that mouse EYA family members act as a phosphatase for both phosphotyrosine and phosphothreonine. The haloacid dehalogenase domain at the carboxy terminus contained the tyrosine-phosphatase, and the amino-terminal half carried the threonine-phosphatase. Mutations of the threonine-phosphatase, but not the tyrosine-phosphatase, abolished the ability of EYA4 to enhance the innate immune response, suggesting that EYA regulates the innate immune response by modulating the phosphorylation state of signal transducers for the intracellular pathogens.</Abstract>
    <JournalRelease>1476-4687</JournalRelease>
    <Pages>520-4</Pages>
    <Affiliation>Department of Medical Chemistry, Graduate School of Medicine, Kyoto University, Yoshida-Konoe, Kyoto 606-8501, Japan.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19561593&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19546225</PMID>
    <AuthorListID>167</AuthorListID>
    <Title>Polo-like kinase 1 (PLK1) regulates interferon (IFN) induction by MAVS.</Title>
    <PubDate>20090622</PubDate>
    <Language>eng</Language>
    <doi>10.1074/jbc.M109.018275</doi>
    <Abstract>The mitochondria-bound adapter MAVS participates in IFN induction by recruitment of downstream partners such as members of the TRAF family, leading to activation of NF-kappaB, and the IRF3 pathways. A yeast two-hybrid search for MAVS-interacting proteins yielded the Polo-box domain (PBD) of the mitotic Polo-like kinase PLK1. We showed that PBD associates with two different domains of MAVS in both dependent and independent phosphorylation events. The phosphodependent association requires the phosphopeptide binding ability of PBD. It takes place downstream of the proline-rich domain of MAVS, within an STP motif, characteristic of the binding of PLK1 to its targets, where the central Thr234 residue is phosphorylated. Its phosphoindependent association takes place at the C terminus of MAVS. PLK1 strongly inhibits the ability of MAVS to activate the IRF3 and NF-kappaB pathways and to induce IFN. Reciprocally, depletion of PLK1 can increase IFN induction in response to RIG-I/SeV or RIG-I/poly(I)-poly(C) treatments. This inhibition is dependent on the phosphoindependent association of PBD at the C terminus of MAVS where it disrupts the association of MAVS with its downstream partner TRAF3. IFN induction was strongly inhibited in cells arrested in G2/M by nocodazole, which provokes increased expression of endogenous PLK1. Interestingly, depletion of PLK1 from these nocodazole-treated cells could restore, at least partially, IFN induction. Altogether, these data demonstrate a new function for PLK1 as a regulator of IFN induction and provide the basis for the development of inhibitors preventing the PLK1/MAVS association to sustain innate immunity.</Abstract>
    <JournalRelease>0021-9258</JournalRelease>
    <Pages>21797-809</Pages>
    <Affiliation>Unit of Hepacivirus and Innate Immunity, Laboratory of Viral Genomics and Vaccination, Institut Pasteur, Paris, France.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19546225&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19543380</PMID>
    <AuthorListID>168</AuthorListID>
    <Title>Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome.</Title>
    <PubDate>20090619</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.ppat.1000480</doi>
    <Abstract>Modified vaccinia virus Ankara (MVA) is an attenuated double-stranded DNA poxvirus currently developed as a vaccine vector against HIV/AIDS. Profiling of the innate immune responses induced by MVA is essential for the design of vaccine vectors and for anticipating potential adverse interactions between naturally acquired and vaccine-induced immune responses. Here we report on innate immune sensing of MVA and cytokine responses in human THP-1 cells, primary human macrophages and mouse bone marrow-derived macrophages (BMDMs). The innate immune responses elicited by MVA in human macrophages were characterized by a robust chemokine production and a fairly weak pro-inflammatory cytokine response. Analyses of the cytokine production profile of macrophages isolated from knockout mice deficient in Toll-like receptors (TLRs) or in the adapter molecules MyD88 and TRIF revealed a critical role for TLR2, TLR6 and MyD88 in the production of IFNbeta-independent chemokines. MVA induced a marked up-regulation of the expression of RIG-I like receptors (RLR) and the IPS-1 adapter (also known as Cardif, MAVS or VISA). Reduced expression of RIG-I, MDA-5 and IPS-1 by shRNAs indicated that sensing of MVA by RLR and production of IFNbeta and IFNbeta-dependent chemokines was controlled by the MDA-5 and IPS-1 pathway in the macrophage. Crosstalk between TLR2-MyD88 and the NALP3 inflammasome was essential for expression and processing of IL-1beta. Transcription of the Il1b gene was markedly impaired in TLR2(-/-) and MyD88(-/-) BMDM, whereas mature and secreted IL-1beta was massively reduced in NALP3(-/-) BMDMs or in human THP-1 macrophages with reduced expression of NALP3, ASC or caspase-1 by shRNAs. Innate immune sensing of MVA and production of chemokines, IFNbeta and IL-1beta by macrophages is mediated by the TLR2-TLR6-MyD88, MDA-5-IPS-1 and NALP3 inflammasome pathways. Delineation of the host response induced by MVA is critical for improving our understanding of poxvirus antiviral escape mechanisms and for designing new MVA vaccine vectors with improved immunogenicity.</Abstract>
    <JournalRelease>1553-7374</JournalRelease>
    <Pages>e1000480</Pages>
    <Affiliation>Department of Medicine, Infectious Diseases Service, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19543380&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19535268</PMID>
    <AuthorListID>169</AuthorListID>
    <Title>The role of mitochondria in cellular defense against microbial infection.</Title>
    <PubDate>20090616</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.smim.2009.05.009</doi>
    <Abstract>Mitochondria have been long recognized for their key role in the modulation of cell death pathways. Thus, it is therefore not surprising that this organelle represents a recurrent target for pathogenic microbes, aiming to manipulate the fate of the infected host cell. More recently, mitochondria have been shown to serve as a crucial platform for innate immune signaling, as illustrated by the identification of MAVS (also known as IPS-1, VISA and Cardif), NLRX1 and STING as mitochondrial proteins. This review discusses the tight interplay between microbial infection, innate immune signaling and mitochondria.</Abstract>
    <JournalRelease>1096-3618</JournalRelease>
    <Pages>223-32</Pages>
    <Affiliation>INSERM U542, Hopital Paul Brousse, Batiment Lavoisier, Villejuif Cedex, France. Damien.arnoult@inserm.fr</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19535268&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19507289</PMID>
    <AuthorListID>170</AuthorListID>
    <Title>Peak detection in mass spectrometry by Gabor filters and envelope analysis.</Title>
    <Language>eng</Language>
    <Abstract>Mass Spectrometry (MS) is increasingly being used to discover diseases-related proteomic patterns. The peak detection step is one of the most important steps in the typical analysis of MS data. Recently, many new algorithms have been proposed to increase true position rate with low false discovery rate in peak detection. Most of them follow two approaches: one is the denoising approach and the other is the decomposing approach. In the previous studies, the decomposition of MS data method shows more potential than the first one. In this paper, we propose two novel methods, named GaborLocal and GaborEnvelop, both of which can detect more true peaks with a lower false discovery rate than previous methods. We employ the method of Gaussian local maxima to detect peaks, because it is robust to noise in signals. A new approach, peak rank, is defined for the first time to identify peaks instead of using the signal-to-noise ratio. Meanwhile, the Gabor filter is used to amplify important information and compress noise in the raw MS signal. Moreover, we also propose the envelope analysis to improve the quantification of peaks and remove more false peaks. The proposed methods have been performed on the real SELDI-TOF spectrum with known polypeptide positions. The experimental results demonstrate that our methods outperform other commonly used methods in the Receiver Operating Characteristic (ROC) curve.</Abstract>
    <JournalRelease>0219-7200</JournalRelease>
    <Pages>547-69</Pages>
    <Affiliation>Department of Computer Science and Engineering, University of Texas at Arlington, TX 76019, USA. nha.nguyen@mavs.uta.edu</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19507289&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19427399</PMID>
    <AuthorListID>171</AuthorListID>
    <Title>Mitochondrial factors in the regulation of innate immunity.</Title>
    <PubDate>20090507</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.micinf.2009.04.022</doi>
    <Abstract>Viral infection stimulates multiple signalling pathways in the innate immune system, leading to type 1 interferon production. Recent research has identified the mitochondrial protein MAVS as a key component of one intracellular pathway, definitively linking mitochondria to the mammalian antiviral defence system for the first time.</Abstract>
    <JournalRelease>1769-714X</JournalRelease>
    <Pages>729-36</Pages>
    <Affiliation>Molecular Biology Section, Translational Medicine Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA. scotti@mail.nih.gov</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19427399&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19419966</PMID>
    <AuthorListID>172</AuthorListID>
    <Title>The tyrosine kinase c-Src enhances RIG-I (retinoic acid-inducible gene I)-elicited antiviral signaling.</Title>
    <PubDate>20090506</PubDate>
    <Language>eng</Language>
    <doi>10.1074/jbc.M808233200</doi>
    <Abstract>Antiviral immune responses are initiated through Toll-like receptors (TLRs) and RIG-I (retinoic acid-inducible gene-I)-like RNA helicases that recognize nucleic acids from distinct viruses. In this study, we show that the tyrosine kinase c-Src participates in antiviral responses induced by the cytoplasmic RNA helicase RIG-I. Sendai virus (SV), which is recognized by RIG-I, induced c-Src phosphorylation. Functional impairment of c-Src through chemical inhibition or transient expression of a c-Src kinase-inactive mutant attenuated production of endogenous antiviral proteins after SV infection or after expression of RIG-I or its adapter protein MAVS. Importantly, SV-stimulated synthesis of antiviral proteins was significantly impaired in cells treated with c-Src small interfering RNA and in cells from c-Src-deficient mice. In addition, we found that c-Src interacted with components of the RIG-I pathway: RIG-I, MAVS, and TRAF3 (tumor necrosis factor receptor-associated factor-3). The interaction between c-Src and TRAF3 was found to occur within the RING domain of TRAF3. Taken together, our results suggest that c-Src enhances RIG-I-mediated signaling, acting at the level of TRAF3.</Abstract>
    <JournalRelease>0021-9258</JournalRelease>
    <Pages>19122-31</Pages>
    <Affiliation>Department of Laboratory Medicine, Children's and Women's Health, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim N-7006, Norway.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19419966&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19404494</PMID>
    <AuthorListID>173</AuthorListID>
    <Title>MAVS-mediated apoptosis and its inhibition by viral proteins.</Title>
    <PubDate>20090307</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.pone.0005466</doi>
    <Abstract>Host responses to viral infection include both immune activation and programmed cell death. The mitochondrial antiviral signaling adaptor, MAVS (IPS-1, VISA or Cardif) is critical for host defenses to viral infection by inducing type-1 interferons (IFN-I), however its role in virus-induced apoptotic responses has not been elucidated.We show that MAVS causes apoptosis independent of its function in initiating IFN-I production. MAVS-induced cell death requires mitochondrial localization, is caspase dependent, and displays hallmarks of apoptosis. Furthermore, MAVS(-/-) fibroblasts are resistant to Sendai virus-induced apoptosis. A functional screen identifies the hepatitis C virus NS3/4A and the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) nonstructural protein (NSP15) as inhibitors of MAVS-induced apoptosis, possibly as a method of immune evasion.This study describes a novel role for MAVS in controlling viral infections through the induction of apoptosis, and identifies viral proteins which inhibit this host response.</Abstract>
    <JournalRelease>1932-6203</JournalRelease>
    <Pages>e5466</Pages>
    <Affiliation>Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19404494&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19380815</PMID>
    <AuthorListID>174</AuthorListID>
    <Title>Actin and RIG-I/MAVS signaling components translocate to mitochondria upon influenza A virus infection of human primary macrophages.</Title>
    <Language>eng</Language>
    <doi>10.4049/jimmunol.0803093</doi>
    <Abstract>Influenza A virus is one of the most important causes of respiratory infection. During viral infection, multiple cell signaling cascades are activated, resulting in the production of antiviral cytokines and initiation of programmed cell death of virus-infected cells. In the present study, we have used subcellular proteomics to reveal the host response to influenza A infection at the protein level in human macrophages. Macrophages were infected with influenza A virus, after which the cytosolic and mitochondrial cell fractions were prepared and analyzed by using two-dimensional electrophoresis for protein separation and mass spectrometry for protein identification. In cytosolic proteomes, the level of several heat shock proteins and fragments of cytoskeletal proteins was clearly up-regulated during influenza A virus infection. In mitochondrial proteomes, simultaneously with the expression of viral proteins, the level of intact actin and tubulin was highly up-regulated. This was followed by translocation of the components of antiviral RNA recognition machinery, including RIG-I (retinoic acid-inducible protein I), TRADD (TNFR1-associated death domain protein), TRIM25 (tripartite motif protein 25), and IKKepsilon (inducible IkappaB kinase), onto the mitochondria. Cytochalasin D, a potent inhibitor of actin polymerization, clearly inhibited influenza A virus-induced expression of IFN-beta, IL-29, and TNF-alpha, suggesting that intact actin cytoskeleton structure is crucial for proper activation of antiviral response. At late phases of infection mitochondrial fragmentation of actin was seen, indicating that actin fragments, fractins, are involved in disruption of mitochondrial membranes during apoptosis of virus-infected cells. In conclusion, our results suggest that actin network interacts with mitochondria to regulate both antiviral and cell death signals during influenza A virus infection.</Abstract>
    <JournalRelease>1550-6606</JournalRelease>
    <Pages>5682-92</Pages>
    <Affiliation>Protein Chemistry Research Group, Institute of Biotechnology, University of Helsinki, Helsinki, Finland.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19380815&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19380491</PMID>
    <AuthorListID>175</AuthorListID>
    <Title>Ubiquitin-regulated recruitment of IkappaB kinase epsilon to the MAVS interferon signaling adapter.</Title>
    <PubDate>20090420</PubDate>
    <Language>eng</Language>
    <doi>10.1128/MCB.00880-08</doi>
    <Abstract>Induction of the antiviral interferon response is initiated upon recognition of viral RNA structures by the RIG-I or Mda-5 DEX(D/H) helicases. A complex signaling cascade then converges at the mitochondrial adapter MAVS, culminating in the activation of the IRF and NF-kappaB transcription factors and the induction of interferon gene expression. We have previously shown that MAVS recruits IkappaB kinase epsilon (IKKepsilon) but not TBK-1 to the mitochondria following viral infection. Here we map the interaction of MAVS and IKKepsilon to the C-terminal region of MAVS and demonstrate that this interaction is ubiquitin dependent. MAVS is ubiquitinated following Sendai virus infection, and K63-linked ubiquitination of lysine 500 (K500) of MAVS mediates recruitment of IKKepsilon to the mitochondria. Real-time PCR analysis reveals that a K500R mutant of MAVS increases the mRNA level of several interferon-stimulated genes and correlates with increased NF-kappaB activation. Thus, recruitment of IKKepsilon to the mitochondria upon MAVS K500 ubiquitination plays a modulatory role in the cascade leading to NF-kappaB activation and expression of inflammatory and antiviral genes. These results provide further support for the differential role of IKKepsilon and TBK-1 in the RIG-I/Mda5 pathway.</Abstract>
    <JournalRelease>1098-5549</JournalRelease>
    <Pages>3401-12</Pages>
    <Affiliation>Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Cote Ste. Catherine, Montreal, Quebec, Canada H3T 1E2.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19380491&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19281641</PMID>
    <AuthorListID>176</AuthorListID>
    <Title>Systematic method for the kinetic modeling of temporally resolved hyperspectral microscope images of fluorescently labeled cells.</Title>
    <Language>eng</Language>
    <Abstract>In this paper we report the application of a novel method for fitting kinetic models to temporally resolved hyperspectral images of fluorescently labeled cells to mathematically resolve pure-component spatial images, pure-component spectra, and pure-component reaction profiles. The method is demonstrated on one simulated image and two experimental cell images, including human embryonic kidney cells (HEK 293) and human A549 pulmonary type II epithelial cells. In both cell images, inhibitor kappa B kinase alpha (IKK(alpha)) and mitochondrial antiviral signaling protein (MAVS) were labeled with green and yellow fluorescent protein, respectively. Kinetic modeling was performed on the compressed images by using a separable least squares method. A combination of several first-order decays were needed to adequately model the photobleaching processes for each fluorophore observed in these images, consistent with the hypothesis that each fluorophore was found in several different environments within the cells. Numerous plausible mechanisms for kinetic modeling of the photobleaching processes in these images were tested and a method for selecting the most parsimonious and statistically sufficient model was used to prepare spatial maps of each fluorophore.</Abstract>
    <JournalRelease>0003-7028</JournalRelease>
    <Pages>261-70</Pages>
    <Affiliation>Department of Chemistry, East Carolina University, Greenville, North Carolina 27858, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19281641&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19193793</PMID>
    <AuthorListID>177</AuthorListID>
    <Title>Human respiratory syncytial virus nonstructural protein NS2 antagonizes the activation of beta interferon transcription by interacting with RIG-I.</Title>
    <PubDate>20090204</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.02434-08</doi>
    <Abstract>A wide variety of RNA viruses have been shown to produce proteins that inhibit interferon (IFN) production and signaling. For human respiratory syncytial virus (RSV), the nonstructural NS1 and NS2 proteins have been shown to block IFN signaling by causing the proteasomal degradation of STAT2. In addition, recombinant RSVs lacking either NS1 or NS2 induce more IFN production than wild-type (wt) RSV in infected cells. However, the mechanisms by which the NS proteins perform this function are unknown. In this study, we focused on defining the mechanism by which NS2 inhibits the induction of IFN transcription. We find that NS2 is required for the early inhibition of IFN transcription since the infection of cells with NS2-deletion RSV resulted in a higher level of IRF3 activation at early time points postinfection compared with that of wt or NS1-deletion RSV infection. In addition, NS2 expression inhibits IFN transcription induced by both the RIG-I and TLR3 pathways. Furthermore, we show that NS2 inhibits RIG-I-mediated IFN promoter activation by binding to the N-terminal CARD of RIG-I and inhibiting its interaction with the downstream component MAVS (IPS-1, VISA, Cardif). Thus, the RSV NS2 protein is a multifunctional IFN antagonist that targets specific components of both the IFN induction and IFN signaling pathways.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>3734-42</Pages>
    <Affiliation>Department of Biochemistry and Molecular Biology, Pennsylvania State University, 406 Althouse, University Park, PA 16802, USA. MNT2@psu.edu</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19193793&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19193783</PMID>
    <AuthorListID>178</AuthorListID>
    <Title>MAVS self-association mediates antiviral innate immune signaling.</Title>
    <PubDate>20090204</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.02623-08</doi>
    <Abstract>The innate immune system recognizes nucleic acids during viral infection and stimulates cellular antiviral responses. Intracellular detection of RNA virus infection is mediated by the RNA helicases RIG-I (retinoic acid inducible gene I) and MDA-5, which recognize viral RNA and signal through the adaptor molecule MAVS (mitochondrial antiviral signaling) to stimulate the phosphorylation and activation of the transcription factors IRF3 (interferon regulatory factor 3) and IRF7. Once activated, IRF3 and IRF7 turn on the expression of type I interferons, such as beta interferon. Interestingly, unlike other signaling molecules identified in this pathway, MAVS contains a C-terminal transmembrane (TM) domain that is essential for both type I interferon induction and localization of MAVS to the mitochondrial outer membrane. However, the role the MAVS TM domain plays in signaling remains unclear. Here we report the identification of a function for the TM domain in mediating MAVS self-association. The activation of RIG-I/MDA-5 leads to the TM-dependent dimerization of the MAVS N-terminal caspase recruitment domain, thereby providing an interface for direct binding to and activation of the downstream effector TRAF3 (tumor necrosis factor receptor-associated factor 3). Our results reveal a role for MAVS self-association in antiviral innate immunity signaling and provide a molecular mechanism for downstream signal transduction.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>3420-8</Pages>
    <Affiliation>Laboratory of Molecular Signaling, Division of Oral Biology and Medicine, UCLA School of Dentistry, Los Angeles, California 90095, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19193783&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19164550</PMID>
    <AuthorListID>179</AuthorListID>
    <Title>Inhibition of RIG-I and MDA5-dependent antiviral response by gC1qR at mitochondria.</Title>
    <PubDate>20090121</PubDate>
    <Language>eng</Language>
    <doi>10.1073/pnas.0811029106</doi>
    <Abstract>gC1qR is one of the C1q receptors implicated in the regulation of innate and adaptive immunity. We found that gC1qR inhibits RIG-I and MDA5-dependent antiviral signaling. Double stranded RNA and virus trigger the translocation of gC1qR to the mitochondrial outer membrane leading to the interaction of gC1qR with the RIG-I and MDA5 adaptor, VISA/MAVS/IPS-1/Cardif. The interaction of gC1qR with VISA/MAVS/IPS-1/Cardif at mitochondria results in the disruption of RIG-I and MDA5 signaling and the promotion of virus replication. Knockdown of endogenous gC1qR enhances RIG-I-dependent antiviral signaling, and augments the inhibition of virus proliferation. Therefore, gC1qR is a physiological inhibitor of the RIG-I and MDA5-mediated antiviral signaling pathway. These data uncover a new viral mechanism used to negatively control antiviral signaling in host cells.</Abstract>
    <JournalRelease>1091-6490</JournalRelease>
    <Pages>1530-5</Pages>
    <Affiliation>National Key Laboratory of Protein Engineering and Plant Gene Engineering, College of Life Sciences, Peking University, Beijing, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19164550&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19160540</PMID>
    <AuthorListID>180</AuthorListID>
    <Title>The IKK-related kinases: from innate immunity to oncogenesis.</Title>
    <Language>eng</Language>
    <doi>10.1038/cr.2008.273</doi>
    <Abstract>Over the past four years, the field of the innate immune response has been highly influenced by the discovery of the IkappaB kinase (IKK)-related kinases, TANK Binding Kinase 1 (TBK1) and IKKi, which regulate the activity of interferon regulatory factor (IRF)-3/IRF-7 and NF-kappaB transcription factors. More recently, additional essential components of the signaling pathways that activate these IKK homologues have been discovered. These include the RNA helicases RIGi and MDA5, and the downstream mitochondrial effector known as CARDIF/MAVS/VISA/IPS-1. In addition to their essential functions in controlling the innate immune response, recent studies have highlighted a role of these kinases in cell proliferation and oncogenesis. The canonical IKKs are well recognized to be a bridge linking chronic inflammation to cancer. New findings now suggest that the IKK-related kinases TBK1 and IKKi also participate in signaling pathways that impact on cell transformation and tumor progression. This review will therefore summarize and discuss the role of TBK1 and IKKi in cellular transformation and oncogenesis by focusing on their regulation and substrate specificity.</Abstract>
    <JournalRelease>1001-0602</JournalRelease>
    <Pages>889-99</Pages>
    <Affiliation>FacultÃ© de Pharmacie, UniversitÃ© de MontrÃ©al, C.P. 6128, succursale Centre-Ville, MontrÃ©al, QuÃ©bec, Canada H3C 3J7.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19160540&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19120474</PMID>
    <AuthorListID>181</AuthorListID>
    <Title>Functional evolution of the TICAM-1 pathway for extrinsic RNA sensing.</Title>
    <Language>eng</Language>
    <doi>10.1111/j.1600-065X.2008.00723.x</doi>
    <Abstract>The type I interferon (IFN) is a host defense factor against microbial pathogens in vertebrates. In mammals, retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated gene 5 (MDA5) in the cytoplasm are regarded as sensors for double-stranded RNA (dsRNA) and trigger IFN regulatory factor-3 (IRF-3) activation followed by type I IFN induction through the mitochondrial antiviral signaling (MAVS) adapter. This intrinsic pathway appears to link the main protective responses against RNA virus infection in mammals. On the other hand, human Toll-like receptor 3 (TLR3) is localized in the endosomal membrane or cell surface and signals the presence of extrinsic dsRNA. In response to RNA stimulation, TLR3 recruits the Toll-interleukin 1 receptor domain (TIR)-containing adapter molecule 1 (TICAM-1) adapter and induces IRF-3 activation followed by IFN-beta promoter activation. Human TLR3 is localized limitedly extent in myeloid dendritic cells, fibroblasts, and epithelial cells. The TICAM-1 and cytoplasmic MAVS pathways converge at the IRF-3-activating kinase in human cells. The reason for the involvement of this extrinsic mode of IFN-inducing pathways in the dsRNA response remains unknown. In fish, two TLRs, i.e. endoplasmic TLR3 and cell surface TLR22, participate in teleost IFN production without the activation of IRF-3. TLR22 is distinct from mammalian TLR3 in terms of cellular localization, ligand selection, and tissue distribution. TLR22 may be a functional substitute for human cell surface TLR3 and may serve as a surveillance molecule for detecting dsRNA virus infection and alerting the immune system for antiviral protection in fish. In this review, we discuss the fundamentals of the extrinsic dsRNA recognition system, which has evolved to induce cellular effectors to cope with dsRNA virus infection across different vertebrate species.</Abstract>
    <JournalRelease>1600-065X</JournalRelease>
    <Pages>44-53</Pages>
    <Affiliation>Department of Microbiology and Immunology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. seya-tu@pop.med.hokudai.ac.jp</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19120474&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19036819</PMID>
    <AuthorListID>182</AuthorListID>
    <Title>MAVS dimer is a crucial signaling component of innate immunity and the target of hepatitis C virus NS3/4A protease.</Title>
    <PubDate>20081126</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.01659-08</doi>
    <Abstract>The mitochondrial antiviral signaling (MAVS) protein plays a central role in innate antiviral immunity. Upon recognition of a virus, intracellular receptors of the RIG-I-like helicase family interact with MAVS to trigger a signaling cascade. In this study, we investigate the requirement of the MAVS structure for enabling its signaling by structure-function analyses and resonance energy transfer approaches in live cells. We now report the essential role of the MAVS oligomer in signal transduction and map the transmembrane domain as the main determinant of dimerization. A combination of mutagenesis and computational methods identified a cluster of residues making favorable van der Waals interactions at the MAVS dimer interface. We also correlated the activation of IRF3 and NF-kappaB with MAVS oligomerization rather than its mitochondrial localization. Finally, we demonstrated that MAVS oligomerization is disrupted upon expression of HCV NS3/4A protease, suggesting a mechanism for the loss of antiviral signaling. Altogether, our data suggest that the MAVS oligomer is essential in the formation of a multiprotein membrane-associated signaling complex and enables downstream activation of IRF3 and NF-kappaB in antiviral innate immunity.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>1299-311</Pages>
    <Affiliation>Institut de Recherche en Immunologie et en CancÃ©rologie (IRIC), MontrÃ©al, QuÃ©bec, Canada.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19036819&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19017982</PMID>
    <AuthorListID>183</AuthorListID>
    <Title>A novel IFN regulatory factor 3-dependent pathway activated by trypanosomes triggers IFN-beta in macrophages and fibroblasts.</Title>
    <Language>eng</Language>
    <Abstract>Innate immune recognition of intracellular pathogens involves both extracellular and cytosolic surveillance mechanisms. The intracellular protozoan parasite Trypanosoma cruzi triggers a robust type I IFN response in both immune and nonimmune cell types. In this study, we report that signaling through TBK1 and IFN regulatory factor 3 is required for T. cruzi-mediated expression of IFN-beta. The TLR adaptors MyD88 and TRIF, as well as TLR4 and TLR3, were found to be dispensable, demonstrating that T. cruzi induces IFN-beta expression in a TLR-independent manner. The potential role for cytosolic dsRNA sensing pathways acting through RIG-I and MDA5 was ruled out because T. cruzi was shown to trigger robust expression of IFN-beta in macrophages lacking the MAVS/IPS1/VISA/CARDif adaptor protein. The failure of T. cruzi to activate HEK293-IFN-beta-luciferase cells, which are highly sensitive to cytosolic triggers of IFN-beta expression including Listeria, Sendai virus, and transfected dsRNA and dsDNA, further indicates that the parasite does not engage currently recognized cytosolic surveillance pathways. Together, these findings identify the existence of a novel TLR-independent pathogen-sensing mechanism in immune and nonimmune cells that converges on TBK1 and IFN regulatory factor 3 for activation of IFN-beta gene expression.</Abstract>
    <JournalRelease>1550-6606</JournalRelease>
    <Pages>7917-24</Pages>
    <Affiliation>Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19017982&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19017631</PMID>
    <AuthorListID>184</AuthorListID>
    <Title>Riplet/RNF135, a RING finger protein, ubiquitinates RIG-I to promote interferon-beta induction during the early phase of viral infection.</Title>
    <PubDate>20081118</PubDate>
    <Language>eng</Language>
    <doi>10.1074/jbc.M804259200</doi>
    <Abstract>RIG-I (retinoic acid-inducible gene-I), a cytoplasmic RNA helicase, interacts with IPS-1/MAVS/Cardif/VISA, a protein on the outer membrane of mitochondria, to signal the presence of virus-derived RNA and induce type I interferon production. Activation of RIG-I requires the ubiquitin ligase, TRIM25, which mediates lysine 63-linked polyubiquitination of the RIG-I N-terminal CARD-like region. However, how this modification proceeds for activation of IPS-1 by RIG-I remains unclear. Here we identify an alternative factor, Riplet/RNF135, that promotes RIG-I activation independent of TRIM25. The Riplet/RNF135 protein consists of an N-terminal RING finger domain, C-terminal SPRY and PRY motifs, and shows sequence similarity to TRIM25. Immunoprecipitation analyses demonstrated that the C-terminal helicase and repressor domains of RIG-I interact with the Riplet/RNF135 C-terminal region, whereas the CARD-like region of RIG-I is dispensable for this interaction. Riplet/RNF135 promotes lysine 63-linked polyubiquitination of the C-terminal region of RIG-I, modification of which differs from the N-terminal ubiquitination by TRIM25. Overexpression and knockdown analyses revealed that Riplet/RNF135 promotes RIG-I-mediated interferon-beta promoter activation and inhibits propagation of the negative-strand RNA virus, vesicular stomatitis virus. Our data suggest that Riplet/RNF135 is a novel factor of the RIG-I pathway that is involved in the evoking of human innate immunity against RNA virus infection, and activates RIG-I through ubiquitination of its C-terminal region. We infer that a variety of RIG-I-ubiquitinating molecular complexes sustain RIG-I activation to modulate RNA virus replication in the cytoplasm.</Abstract>
    <JournalRelease>0021-9258</JournalRelease>
    <Pages>807-17</Pages>
    <Affiliation>Department of Microbiology and Immunology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19017631&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18948594</PMID>
    <AuthorListID>185</AuthorListID>
    <Title>Roles of RIG-I N-terminal tandem CARD and splice variant in TRIM25-mediated antiviral signal transduction.</Title>
    <PubDate>20081023</PubDate>
    <Language>eng</Language>
    <doi>10.1073/pnas.0804947105</doi>
    <Abstract>The caspase recruitment domain (CARD) of intracellular adaptors and sensors plays a critical role in the assembly of signaling complexes involved in innate host defense against pathogens and in the regulation of inflammatory responses. The cytosolic receptor retinoic acid-inducible gene-I (RIG-I) recognizes viral RNA in a 5'-triphosphate-dependent manner and initiates an antiviral signaling cascade. Upon viral infection, the N-terminal CARDs of RIG-I undergo the K(63)-linked ubiquitination induced by tripartite motif protein 25 (TRIM25), critical for the interaction of RIG-I with its downstream signaling partner MAVS/VISA/IPS-1/Cardif. Here, we demonstrate the distinct roles of RIG-I first and second CARD in TRIM25-mediated RIG-I ubiquitination: TRIM25 binds the RIG-I first CARD and subsequently ubiquitinates its second CARD. The T(55)I mutation in RIG-I first CARD abolishes TRIM25 interaction, whereas the K(172)R mutation in the second CARD eliminates polyubiquitin attachment. The necessity of the intact tandem CARD for RIG-I function is further evidenced by a RIG-I splice variant (SV) whose expression is robustly up-regulated upon viral infection. The RIG-I SV carries a short deletion (amino acids 36-80) within the first CARD and thereby loses TRIM25 binding, CARD ubiquitination, and downstream signaling ability. Furthermore, because of its robust inhibition of virus-induced RIG-I multimerization and RIG-I-MAVS signaling complex formation, this SV effectively suppresses the RIG-I-mediated IFN-beta production. This study not only elucidates the vital role of the intact tandem CARD for TRIM25-mediated RIG-I activation but also identifies the RIG-I SV as an off-switch regulator of its own signaling pathway.</Abstract>
    <JournalRelease>1091-6490</JournalRelease>
    <Pages>16743-8</Pages>
    <Affiliation>Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Harlyne J. Norris Cancer Research Tower, 1450 Biggy Street, Los Angeles, CA 90033, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18948594&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18780793</PMID>
    <AuthorListID>186</AuthorListID>
    <Title>MAVS and MyD88 are essential for innate immunity but not cytotoxic T lymphocyte response against respiratory syncytial virus.</Title>
    <PubDate>20080909</PubDate>
    <Language>eng</Language>
    <doi>10.1073/pnas.0804717105</doi>
    <Abstract>Infection by RNA viruses is detected by the host through Toll-like receptors or RIG-I-like receptors. Toll-like receptors and RIG-I-like receptors signal through the adaptors MyD88 and MAVS, respectively, to induce type I IFNs (IFN-I) and other antiviral molecules, which are thought to be essential for activating the adaptive immune system. We investigated the role of these adaptors in innate and adaptive immune responses against respiratory syncytial virus (RSV), a common human pathogen. Deletion of Mavs abolished the induction of IFN-I and other proinflammatory cytokines by RSV. Genome-wide expression profiling in the lung showed that the vast majority of RSV-induced genes depended on MAVS. Although Myd88 deficiency did not affect most RSV-induced genes, mice lacking both adaptors harbored a higher and more prolonged viral load and exhibited more severe pulmonary disease than those lacking either adaptor alone. Surprisingly, Myd88(-/-)Mavs(-/-) mice were able to activate a subset of pulmonary dendritic cells that traffic to the draining lymph node in response to RSV. These mice subsequently mounted a normal cytotoxic T-lymphocyte response and demonstrated delayed but effective viral clearance. These results provide an example of a normal and effective adaptive immune response in the absence of innate immunity mediated by MAVS and MyD88.</Abstract>
    <JournalRelease>1091-6490</JournalRelease>
    <Pages>14046-51</Pages>
    <Affiliation>Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9148, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18780793&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18756281</PMID>
    <AuthorListID>187</AuthorListID>
    <Title>The antiviral adaptor proteins Cardif and Trif are processed and inactivated by caspases.</Title>
    <PubDate>20080829</PubDate>
    <Language>eng</Language>
    <doi>10.1038/cdd.2008.119</doi>
    <Abstract>The outcome of a viral infection depends on the interplay between the host's capacity to trigger potent antiviral responses and viral mechanisms that counteract them. Although Toll-like receptor (TLR)-3, which recognizes virally derived double-stranded (ds) RNA, transmits downstream antiviral signaling through the TIR adaptor Trif (TICAM-1), viral RNA-sensing RIG-like helicases (RLHs) use the mitochondrial-bound CARD protein Cardif (IPS-1/MAVS/VISA). The importance of these two antiviral signaling pathways is reflected by the fact that both adaptors are inhibited through specific cleavage triggered by the hepatitis C virus serine protease NS3-4A. Here, we show that inactivation can also occur through cellular caspases activated by various pro-apoptotic signals. Upon caspase-dependent cleavage both adaptors loose their capacity to activate the transcription factors interferon regulatory factors (IRF) and NF-kappaB. Importantly, poliovirus infection triggers a caspase-dependent cleavage of Cardif, suggesting that some viruses may activate caspases not only as a mean to facilitate shedding and replication, but also to impair antiviral responses.</Abstract>
    <JournalRelease>1350-9047</JournalRelease>
    <Pages>1804-11</Pages>
    <Affiliation>Department of Biochemistry, University of Lausanne, Epalinges, Switzerland.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18756281&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18725224</PMID>
    <AuthorListID>188</AuthorListID>
    <Title>Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors.</Title>
    <PubDate>20080722</PubDate>
    <Language>eng</Language>
    <doi>10.1053/j.gastro.2008.07.023</doi>
    <Abstract>Expression of the nonstructural protein (NS)3/4A protease in cells infected with hepatitis C virus (HCV) results in cleavage of the mitochondrial antiviral-signaling protein (MAVS) and disruption of signaling pathways that lead to viral activation of interferon regulatory factor 3 (IRF-3) and synthesis of type 1 interferons (IFN-alpha/beta). High concentrations of inhibitors of NS3/4A reverse this signaling defect, but quantitative analyses of this potential therapeutic effect are lacking. This study quantitatively assessed the rescue of IRF-3 signaling by NS3/4A inhibitors, compared with in vitro antiviral activity.Antiviral activities of 2 NS3/4A protease inhibitors (TMC435350 and an analog, TMC380765) and a nonnucleoside polymerase inhibitor (Tib-3) were determined in HCV replicon cells and in cells infected with genotype 1a and 2a viruses. The capacity to rescue IRF-3 activation in these cells was assessed by monitoring IFN-beta promoter activity following challenge with Sendai virus. Inhibitor-induced changes in NS3 and MAVS expression were assessed in immunoblots.Both protease inhibitors were capable of rescuing IFN-beta promoter activation but only at concentrations approximately 100-fold the antiviral 50% effective concentration (EC(50)) for genotype 1 virus. No rescue was observed with the polymerase inhibitor, even at a concentration 600-fold greater than the EC(50). IRF-3 activation did not correlate with reductions in NS3/4A levels or detection of full-length MAVS. Overexpression of the product of NS3/4A cleavage of MAVS did not result in a dominant-negative effect on signaling.NS3/4A protease inhibitors can restore IRF-3 signaling in HCV-infected cells but only at concentrations far in excess of the antiviral EC(50).</Abstract>
    <JournalRelease>1528-0012</JournalRelease>
    <Pages>1710-1718.e2</Pages>
    <Affiliation>Center for Hepatitis Research, Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas 77555-1073, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18725224&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18715932</PMID>
    <AuthorListID>189</AuthorListID>
    <Title>Vaccinia virus subverts a mitochondrial antiviral signaling protein-dependent innate immune response in keratinocytes through its double-stranded RNA binding protein, E3.</Title>
    <PubDate>20080820</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.01305-08</doi>
    <Abstract>Skin keratinocytes provide a first line of defense against invading microorganisms in two ways: (i) by acting as a physical barrier to pathogen entry and (ii) by initiating a vigorous innate immune response upon sensing danger signals. How keratinocytes detect virus infections and generate antiviral immune responses is not well understood. Orthopoxviruses are dermatotropic DNA viruses that cause lethal disease in humans. Virulence in animal models depends on the virus-encoded bifunctional Z-DNA/double-stranded RNA (dsRNA)-binding protein E3. Here, we report that infection of mouse primary keratinocytes with a vaccinia DeltaE3L mutant virus triggers the production of beta interferon (IFN-beta), interleukin-6 (IL-6), CCL4, and CCL5. None of these immune mediators is produced by keratinocytes infected with wild-type vaccinia virus. The dsRNA-binding domain of E3 suffices to prevent activation of the innate immune response. DeltaE3L induction of IFN-beta, IL-6, CCL4, and CCL5 secretion requires mitochondrial antiviral signaling protein (MAVS; an adaptor for the cytoplasmic viral RNA sensors RIG-I and MDA5) and the transcription factor IRF3. IRF3 phosphorylation is induced in keratinocytes infected with DeltaE3L, an event that depends on MAVS. The response of keratinocytes to DeltaE3L is unaffected by genetic ablation of Toll-like receptor 3 (TLR3), TRIF, TLR9, and MyD88.</Abstract>
    <JournalRelease>1098-5514</JournalRelease>
    <Pages>10735-46</Pages>
    <Affiliation>Department of Medicine, Dermatology Service, Molecular Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. dengl@mskcc.org</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18715932&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18692023</PMID>
    <AuthorListID>190</AuthorListID>
    <Title>The mitochondrial antiviral signaling protein, MAVS, is cleaved during apoptosis.</Title>
    <PubDate>20080808</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.bbrc.2008.07.147</doi>
    <Abstract>Apoptosis of virus-infected cells is one important host strategy used to limit viral infection. Recently a member of the innate immune signaling pathway, MAVS, was localized to mitochondria, an organelle important for apoptosis regulation. Here we investigate what role MAVS may play in apoptosis. Induction of cell death led to the rapid cleavage of MAVS, resulting in its release from the outer mitochondrial membrane. This cleavage is blocked in cells incubated with proteasome or caspase inhibitors. Transfection of synthetic viral dsRNA and dsDNA also led to cleavage of MAVS, indicating that this process may be important during infection. Preventing apoptosis by over-expression of anti-apoptotic Bcl-xL blocks MAVS cleavage, placing this process downstream of caspase activation in the apoptotic program.</Abstract>
    <JournalRelease>1090-2104</JournalRelease>
    <Pages>101-6</Pages>
    <Affiliation>Biochemistry Section, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Room 2C-1014, Building 35, 9000 Rockville Pike, Bethesda, MD 20892, USA. scotti@ninds.nih.gov</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18692023&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18689426</PMID>
    <AuthorListID>191</AuthorListID>
    <Title>Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes.</Title>
    <PubDate>20080808</PubDate>
    <Language>eng</Language>
    <doi>10.1136/gut.2007.147264</doi>
    <Abstract>Hepatitis C virus (HCV) effectively establishes persistent infection in human livers. The non-structural (NS) 3/4A complex participates in this process by cleavage of interferon beta (IFN beta) promoter stimulator-1 (IPS-1; also termed Cardif/MAVS/VISA), which inhibits responses to double stranded (ds) RNA. However, it is not known whether this effect extends beyond innate responses.To test if HCV NS3/4A affects innate and adaptive immune responses in vivo.NS3 levels were semi-quantified in human liver biopsies, transfected cells, and in transgenic (Tg) mouse livers by western blot. The effect of NS3/4A on dsRNA-mediated signalling and on the integrity of IPS-1 was analysed using in vitro translation, transfected cells and Tg mice. Cytotoxic T cell (CTL)-mediated clearance of transient firefly luciferase (FLuc)- and/or NS3/4A-Tg hepatocytes was determined using in vivo imaging and western blot.NS3 protein levels were in a comparable range (0.1-49 microg/g tissue) in infected human livers and Tg mouse livers. Importantly, these levels of NS3/4A reduced murine innate responses to synthetic dsRNA in vivo, supporting the possibility that this occurs also in infected humans. The likely explanation for this was the NS3/4A-mediated cleavage of mouse IPS-1, albeit less efficiently than human IPS-1. Despite this, FLuc- and/or NS3/4A-expressing murine hepatocytes were effectively eliminated by hepatic CTLs, utilising the classical molecules for virus-infected cell lysis, including CD8, IFN gamma, perforin and FasL.Although HCV NS3/4A inhibits the innate immunity, this does not prevent CTL-mediated clearance of NS3/4A-expressing hepatocytes in vivo. Thus, other HCV proteins are most likely responsible for interfering with the adaptive immunity.</Abstract>
    <JournalRelease>1468-3288</JournalRelease>
    <Pages>560-9</Pages>
    <Affiliation>Division of Clinical Microbiology, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18689426&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18632970</PMID>
    <AuthorListID>192</AuthorListID>
    <Title>Role of retinoic acid inducible gene-I in human metapneumovirus-induced cellular signalling.</Title>
    <Language>eng</Language>
    <doi>10.1099/vir.0.2008/000778-0</doi>
    <Abstract>Human metapneumovirus (HMPV) is a recently discovered pathogen that causes a significant proportion of respiratory infections in young infants, the elderly and immunocompromised patients. Very little is known regarding the cellular signalling elicited by this virus in airway epithelial cells, the target of HMPV infection. In this study, we investigated the role of the RNA helicases retinoic acid inducible gene-I (RIG-I) and melanoma differentiation-associated gene-5 (MDA-5) as the main pattern recognition receptors (PRRs) involved in viral detection and subsequent expression of proinflammatory and antiviral genes. HMPV infection readily induced RIG-I and MDA-5 gene and protein expression in A549 cells, a type II-like alveolar epithelial cell line. Expression of dominant-negative (DN) RIG-I or downregulation of RIG-I gene expression using small interfering RNA (siRNA) significantly decreased HMPV-induced beta interferon (IFN-beta), interleukin (IL)-8 and RANTES gene transcription, by inhibiting viral-induced activation of nuclear factor (NF)-kappaB and interferon regulatory factor (IRF), leading to enhanced viral replication. On the other hand, MDA-5 did not seem to play a significant role in HMPV-induced cellular responses. Mitochondrial antiviral signalling protein (MAVS), an adaptor protein linking both RIG-I and MDA-5 to downstream activation of IRF-3 and NF-kappaB, was also necessary for HMPV-induced cellular signalling. Expression of a DN MAVS significantly reduced IFN-beta and chemokine gene transcription, by inhibiting NF-kappaB- and IRF-dependent gene transcription, in response to HMPV infection. Our results show that HMPV activates the RIG-I-MAVS signalling pathway in airway epithelial cells, leading to the expression of important proinflammatory and antiviral molecules involved in the innate immune response to viruses.</Abstract>
    <JournalRelease>0022-1317</JournalRelease>
    <Pages>1978-86</Pages>
    <Affiliation>Department of Pediatrics, University of Texas Medical Branch, Galveston, TX, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18632970&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18586328</PMID>
    <AuthorListID>193</AuthorListID>
    <Title>Molecular cloning and functional characterization of porcine IFN-beta promoter stimulator 1 (IPS-1).</Title>
    <PubDate>20080528</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.vetimm.2008.05.018</doi>
    <Abstract>The IFN-beta promoter stimulator 1 (IPS-1), also known as MAVS/VISA/Cardif, is an adaptor molecule for the retinoic-acid-inducible protein I (RIG-I) or melanoma-differentiation-associated gene 5 (MDA5) that recognizes intracellular double-stranded RNA (dsRNA) and triggers a signal for producing type I IFN. In the present study, porcine IPS-1 cDNA was cloned, using RT-PCR coupled with rapid amplification of cDNA ends (RACE)-PCR, from porcine peripheral blood mononuclear cells. The open reading frame of porcine IPS-1 consists of 1575bp encoding 524 amino acids. The putative porcine IPS-1 protein contains a N-terminal CARD-like domain, a central proline-rich domain, a C-terminal transmembrane domain, and exhibits similarity to mouse, rat, monkey, human and cattle counterparts, ranging from 59% to 79%. Semi-quantitative RT-PCR showed that porcine IPS-1 mRNA was widely expressed in different tissues. Porcine kidney (PK-15) cells transfected with a DNA construct encoding porcine IPS-1 produced type I IFN, and activated IRF3 and NF-kappaB. Deletion mutant analyses further revealed that both the CARD-like domain and transmembrane domain are essential for these functions. In addition, poly(I:C)-induced porcine IFN-beta promoter activation in PK-15 cells was significantly reduced by siRNA targeting IPS-1, indicating that IPS-1 is an important immunoregulator in the porcine innate immune system. The availability of porcine IPS-1 and establishment of its function in the type I IFN signaling pathway provides a useful molecule for defining its role during the course of pig infectious diseases.</Abstract>
    <JournalRelease>0165-2427</JournalRelease>
    <Pages>344-53</Pages>
    <Affiliation>State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan, PR China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18586328&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18550535</PMID>
    <AuthorListID>194</AuthorListID>
    <Title>Respiratory syncytial virus induces RelA release from cytoplasmic 100-kDa NF-kappa B2 complexes via a novel retinoic acid-inducible gene-I{middle dot}NF- kappa B-inducing kinase signaling pathway.</Title>
    <PubDate>20080612</PubDate>
    <Language>eng</Language>
    <doi>10.1074/jbc.M802729200</doi>
    <Abstract>Respiratory syncytial virus (RSV) is a primary cause of severe lower respiratory tract infection in children worldwide. RSV infects airway epithelial cells, where it activates inflammatory genes via the NF-kappaB pathway. NF-kappaB is controlled by two pathways, a canonical pathway that releases sequestered RelA complexes from the IkappaBalpha inhibitor, and a second, the noncanonical pathway, that releases RelB from the 100-kDa NF-kappaB2 complex. Recently we found that the retinoic acid-inducible gene I (RIG-I) is a major intracellular RSV sensor upstream of the canonical pathway. In this study, we surprisingly found that RIG-I silencing also inhibited p100 processing to 52-kDa NF-kappaB2 ("p52"), suggesting that RIG-I was functionally upstream of the noncanonical regulatory kinase complex composed of NIK.IKKalpha subunits. Co-immunoprecipitation experiments not only demonstrated that NIK associated with RIG-I and its downstream adaptor, mitochondrial antiviral signaling (MAVS), but also showed the association between IKKalpha and MAVS. To further understand the role of the NIK.IKKalpha pathway, we compared RSV-induced NF-kappaB activation using wild type, Ikkgamma(-/-), Nik(-/-), and Ikkalpha(-/-)-deficient MEF cells. Interestingly, we found that in canonical pathway-defective Ikkgamma(-/-) cells, RSV induced RelA by liberation from p100 complexes. RSV was still able to activate IP10, Rantes, and Grobeta gene expression in Ikkgamma(-/-) cells, and this induction was inhibited by small interfering RNA-mediated RelA knockdown but not RelB silencing. These data suggest that part of the RelA activation in response to RSV infection was induced by a "cross-talk" pathway involving the noncanonical NIK.IKKalpha complex downstream of RIG-I.MAVS. This pathway may be a potential target for RSV treatment.</Abstract>
    <JournalRelease>0021-9258</JournalRelease>
    <Pages>23169-78</Pages>
    <Affiliation>Department of Medicine, University of Texas Medical Branch, Galveston, TX 77555-1060, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18550535&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19669308</PMID>
    <AuthorListID>195</AuthorListID>
    <Title>Increased expression of Toll-like receptor 3 in intrahepatic biliary epithelial cells at sites of ductular reaction in diseased livers.</Title>
    <PubDate>20080326</PubDate>
    <Language>eng</Language>
    <doi>10.1007/s12072-008-9055-4</doi>
    <Abstract>Background Toll-like receptors (TLRs) may play active roles in both innate and adaptive immune responses in human intrahepatic biliary epithelial cells (HIBECs). The role of TLR3 expressed by HIBECs, however, remains unclear. Methods We determined the in vivo expression of TLRs in biopsy specimens derived from diseased livers immunohistochemically using a panel of monoclonal antibodies against human TLRs. We then examined the response of cultured HIBECs to a TLR3 ligand, polyinosinic-polycytidylic acid (polyI:C). Using siRNAs specific for Toll-IL-1R homology domain-containing adaptor molecule 1 (TICAM-1) and mitochondrial antiviral signaling protein (MAVS), we studied signaling pathways inducing IFN-beta expression. Results The expression of TLR3 was markedly increased in biliary epithelial cells at sites of ductular reaction in diseased livers, including primary biliary cirrhosis (PBC), autoimmune hepatitis (AIH), and chronic viral hepatitis (CH) as compared to nondiseased livers. Although cultured HIBECs constitutively expressed TLR3 at both the protein and mRNA levels in vitro, the addition of polyI:C to culture media induced only minimal increases in IFN-beta mRNA. In contrast, transfection of HIBECs with polyI:C induced a marked increase in mRNAs encoding a variety of chemokines/cytokines, including IFN-beta, IL-6, and TNF-alpha. The induction of IFN-beta mRNA was efficiently inhibited by an siRNA against MAVS but not against TICAM-1, indicating that the main signaling pathway for IFN-beta induction following polyI:C transfection is via retinoic acid-inducible gene I (RIG-I)/melanoma differentiation-associated gene 5 (MDA5) in HIBECs. Conclusions TLR3 expression by biliary epithelial cells increased at sites of ductular reaction in diseased livers; further study will be necessary to characterize it's in vivo physiological role.</Abstract>
    <JournalRelease>1936-0533</JournalRelease>
    <Pages>222-30</Pages>
    <Affiliation>Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Kubara 2-1001-1, Omura, Nagasaki, 856-8562, Japan, nakamuram@nmc.hosp.go.jp.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19669308&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18439848</PMID>
    <AuthorListID>196</AuthorListID>
    <Title>TRADD protein is an essential component of the RIG-like helicase antiviral pathway.</Title>
    <PubDate>20080424</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.immuni.2008.03.013</doi>
    <Abstract>Upon detection of viral RNA, the helicases RIG-I and/or MDA5 trigger, via their adaptor Cardif (also known as IPS-1, MAVS, or VISA), the activation of the transcription factors NF-kappaB and IRF3, which collaborate to induce an antiviral type I interferon (IFN) response. FADD and RIP1, known as mediators of death-receptor signaling, are implicated in this antiviral pathway; however, the link between death-receptor and antiviral signaling is not known. Here we showed that TRADD, a crucial adaptor of tumor necrosis factor receptor (TNFRI), was important in RIG-like helicase (RLH)-mediated signal transduction. TRADD is recruited to Cardif and orchestrated complex formation with the E3 ubiquitin ligase TRAF3 and TANK and with FADD and RIP1, leading to the activation of IRF3 and NF-kappaB. Loss of TRADD prevented Cardif-dependent activation of IFN-beta, reduced the production of IFN-beta in response to RNA viruses, and enhanced vesicular stomatitis virus replication. Thus, TRADD is not only an essential component of proinflammatory TNFRI signaling, but is also required for RLH-Cardif-dependent antiviral immune responses.</Abstract>
    <JournalRelease>1097-4180</JournalRelease>
    <Pages>651-61</Pages>
    <Affiliation>Department of Biochemistry, University of Lausanne, Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18439848&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18397740</PMID>
    <AuthorListID>197</AuthorListID>
    <Title>Innate immunity: squelching anti-viral signalling with NLRX1.</Title>
    <Language>eng</Language>
    <doi>10.1016/j.cub.2008.02.021</doi>
    <Abstract>Innate immunity to viruses involves receptors such as RIG-I, which senses viral RNA and triggers a signalling pathway involving the outer mitochondrial membrane protein MAVS. Recent work has identified that NLRX1, a member of another class of innate immune receptors, sequesters MAVS away from RIG-I and thereby prevents mitochondrial anti-viral immunity.</Abstract>
    <JournalRelease>0960-9822</JournalRelease>
    <Pages>R302-4</Pages>
    <Affiliation>School of Biochemistry and Immunology, Trinity College Dublin, Ireland. laoneill@tcd.ie</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18397740&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18337166</PMID>
    <AuthorListID>198</AuthorListID>
    <Title>Spontaneous resolution of hepatitis C virus infection is not due to a mutation at Cys-508 of MAVS/VISA/IPS-1/CARDIF.</Title>
    <PubDate>20080311</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.jcv.2008.01.010</doi>
    <JournalRelease>1386-6532</JournalRelease>
    <Pages>229-30</Pages>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18337166&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18307765</PMID>
    <AuthorListID>199</AuthorListID>
    <Title>Crystal structure of human IPS-1/MAVS/VISA/Cardif caspase activation recruitment domain.</Title>
    <PubDate>20080228</PubDate>
    <Language>eng</Language>
    <doi>10.1186/1472-6807-8-11</doi>
    <Abstract>IPS-1/MAVS/VISA/Cardif is an adaptor protein that plays a crucial role in the induction of interferons in response to viral infection. In the initial stage of the intracellular antiviral response two RNA helicases, retinoic acid inducible gene-I (RIG-I) and melanoma differentiation-association gene 5 (MDA5), are independently able to bind viral RNA in the cytoplasm. The 62 kDa protein IPS-1/MAVS/VISA/Cardif contains an N-terminal caspase activation and recruitment (CARD) domain that associates with the CARD regions of RIG-I and MDA5, ultimately leading to the induction of type I interferons. As a first step towards understanding the molecular basis of this important adaptor protein we have undertaken structural studies of the IPS-1 MAVS/VISA/Cardif CARD region.The crystal structure of human IPS-1/MAVS/VISA/Cardif CARD has been determined to 2.1A resolution. The protein was expressed and crystallized as a maltose-binding protein (MBP) fusion protein. The MBP and IPS-1 components each form a distinct domain within the structure. IPS-1/MAVS/VISA/Cardif CARD adopts a characteristic six-helix bundle with a Greek-key topology and, in common with a number of other known CARD structures, contains two major polar surfaces on opposite sides of the molecule. One face has a surface-exposed, disordered tryptophan residue that may explain the poor solubility of untagged expression constructs.The IPS-1/MAVS/VISA/Cardif CARD domain adopts the classic CARD fold with an asymmetric surface charge distribution that is typical of CARD domains involved in homotypic protein-protein interactions. The location of the two polar areas on IPS-1/MAVS/VISA/Cardif CARD suggest possible types of associations that this domain makes with the two CARD domains of MDA5 or RIG-I. The N-terminal CARD domains of RIG-I and MDA5 share greatest sequence similarity with IPS-1/MAVS/VISA/Cardif CARD and this has allowed modelling of their structures. These models show a very different charge profile for the equivalent surfaces compared to IPS-1/MAVS/VISA/Cardif CARD.</Abstract>
    <JournalRelease>1472-6807</JournalRelease>
    <Pages>11</Pages>
    <Affiliation>Centre for Biomolecular Sciences, University of St Andrews, St Andrews, Fife, KY16 9ST, UK. jap7@st-andrews.ac.uk</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18307765&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18250407</PMID>
    <AuthorListID>200</AuthorListID>
    <Title>Cutting edge: innate immune response triggered by influenza A virus is negatively regulated by SOCS1 and SOCS3 through a RIG-I/IFNAR1-dependent pathway.</Title>
    <Language>eng</Language>
    <Abstract>Influenza A virus (IAV) triggers a contagious respiratory disease that produces considerable lethality. Although this lethality is likely due to an excessive host inflammatory response, the negative feedback mechanisms aimed at regulating such a response are unknown. In this study, we investigated the role of the eight "suppressor of cytokine signaling" (SOCS) regulatory proteins in IAV-triggered cytokine expression in human respiratory epithelial cells. SOCS1 to SOCS7, but not cytokine-inducible Src homology 2-containing protein (CIS), are constitutively expressed in these cells and only SOCS1 and SOCS3 expressions are up-regulated upon IAV challenge. Using distinct approaches affecting the expression and/or the function of the IFNalphabeta receptor (IFNAR)1, the viral sensors TLR3 and retinoic acid-inducible gene I (RIG-I) as well as the mitochondrial antiviral signaling protein (MAVS, a RIG-I signaling intermediate), we demonstrated that SOCS1 and SOCS3 up-regulation requires a TLR3-independent, RIG-I/MAVS/IFNAR1-dependent pathway. Importantly, by using vectors overexpressing SOCS1 and SOCS3 we revealed that while both molecules inhibit antiviral responses, they differentially modulate inflammatory signaling pathways.</Abstract>
    <JournalRelease>0022-1767</JournalRelease>
    <Pages>2034-8</Pages>
    <Affiliation>UnitÃ© DÃ©fense InnÃ©e et Inflammation, INSERM U874, Institut Pasteur, 25 Rue du Dr. Roux, Paris, France.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18250407&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18207245</PMID>
    <AuthorListID>201</AuthorListID>
    <Title>Identification of MAVS splicing variants that interfere with RIGI/MAVS pathway signaling.</Title>
    <PubDate>20080122</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.molimm.2007.11.018</doi>
    <Abstract>The mitochondrial anti-viral signaling protein (MAVS), also known as CARDIF, IPS-1, KIAA1271 and VISA, is a mitochondria associated protein that regulates type I interferon production through coordinated activation of NF-kappaB and IRF3. The N-terminal CARD domain of MAVS interacts with RIGI helicase of upcapped RNA detection and the putative TRAF2 and TRAF6 binding motifs modulate protein interaction for NF-kappaB activation. MAVS is encoded by a single gene composed of 6 exons but is generally detected as multiple protein bands after separation by SDS-PAGE. In an effort to identify MAVS variants with diverse biological functions, we isolated three splicing variants and named them MAVS 1a (exon 2 deletion), 1b (exon 3 deletion) and 1c (exon 6 deletion), respectively. MAVS 1a and 1b, due to a frame shift by exon deletion, encode 131 and 124 aa residues, respectively. Except the first 39 aa residues encoded by exon 1, MAVS 1a does not share sequence homology with known proteins, it instead contains a putative TRAF2-binding motif and interacts with TRAF2 and RIP1. MAVS 1b shares the first 97 residues with wt MAVS and 27 aa residues of unknown protein. Unlike MAVS that activates both NF-kappaB and IRF3 pathways, expression of MAVS 1b selectively activates an IFNbeta but not an IL8 promoter. MAVS 1b interacts with RIP1 and FADD and exhibits anti-viral activity against VSV infection. This study uncovers MAVS splicing variants of diverse biological function.</Abstract>
    <JournalRelease>0161-5890</JournalRelease>
    <Pages>2277-87</Pages>
    <Affiliation>Department of Immunology, The Scripps Research Institute, 10550 N. Torrey Pines Rd., La Jolla, CA 92037, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18207245&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18200010</PMID>
    <AuthorListID>202</AuthorListID>
    <Title>NLRX1 is a regulator of mitochondrial antiviral immunity.</Title>
    <PubDate>20080116</PubDate>
    <Language>eng</Language>
    <doi>10.1038/nature06501</doi>
    <Abstract>The RIG-like helicase (RLH) family of intracellular receptors detect viral nucleic acid and signal through the mitochondrial antiviral signalling adaptor MAVS (also known as Cardif, VISA and IPS-1) during a viral infection. MAVS activation leads to the rapid production of antiviral cytokines, including type 1 interferons. Although MAVS is vital to antiviral immunity, its regulation from within the mitochondria remains unknown. Here we describe human NLRX1, a highly conserved nucleotide-binding domain (NBD)- and leucine-rich-repeat (LRR)-containing family member (known as NLR) that localizes to the mitochondrial outer membrane and interacts with MAVS. Expression of NLRX1 results in the potent inhibition of RLH- and MAVS-mediated interferon-beta promoter activity and in the disruption of virus-induced RLH-MAVS interactions. Depletion of NLRX1 with small interference RNA promotes virus-induced type I interferon production and decreases viral replication. This work identifies NLRX1 as a check against mitochondrial antiviral responses and represents an intersection of three ancient cellular processes: NLR signalling, intracellular virus detection and the use of mitochondria as a platform for anti-pathogen signalling. This represents a conceptual advance, in that NLRX1 is a modulator of pathogen-associated molecular pattern receptors rather than a receptor, and identifies a key therapeutic target for enhancing antiviral responses.</Abstract>
    <JournalRelease>1476-4687</JournalRelease>
    <Pages>573-7</Pages>
    <Affiliation>Department of Microbiology-Immunology, University of North Carolina, Chapel Hill, North Carolina 27599, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18200010&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>17602886</PMID>
    <AuthorListID>203</AuthorListID>
    <Title>Subsidence and malplacement with the Oblique Maverick Lumbar Disc Arthroplasty: technical note.</Title>
    <PubDate>20070522</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.spinee.2007.03.010</doi>
    <Abstract>The A-Mav (Medtronic, Sofamor Danek, Memphis, TN) is a well-established lumbar total disc arthroplasty device. The O-Mav (Medtronic) is a more recent innovation designed to minimize the potential vascular complications associated with A-Mav insertion at L4/5. No study has hitherto studied the relative accuracy or safety of the two techniques.To compare the accuracy of lumbar disc arthroplasty placement by using the anterior technique (A-Mav) with the oblique (O-Mav) technique.Technical report.Fourteen patients.Implant placement accuracy on high-resolution computed tomography scan. Comparative morbidity, mortality, blood loss, and operating time were also assessed.Patients were considered for lumbar disc arthroplasty who had suffered chronic discogenic low back pain unresponsive to nonoperative management for at least 6 months. All patients were operated on at the L4/5 level. A-Mavs were inserted in 7 patients and O-Mavs in 7. Implant placement was analyzed postoperatively by using computer software on high-resolution computed tomography scan with respect to four parameters: (1) off-center malplacement, (2) axial rotational malplacement, (3) coronal tilt, and (4) vertebral body susbsidence. Comparative morbidity, mortality, blood loss, and operating time were also assessed.Subsidence, off-center malplacement, and rotational malplacement were significantly increased in O-Mavs compared with A-Mavs (4.3+/-0.6 mm vs. 1.6+/-0.6 mm, p=.008; 3.1+/-0.4 mm vs. 1.3+/-0.4 mm, p=.006; 6.5 degrees +/-1.2 degrees vs. 3.8 degrees +/-0.4 degrees , p=.046). No significant differences were found between O-Mavs and A-Mavs in tilt, operating time, blood loss, or morbidity and mortality.O-Mav insertion appears to be complicated by significantly greater vertebral body subsidence and malplacement than A-Mav insertion. A-Mav insertion therefore appears to be more accurate and less complicated yet equally as safe as O-Mav insertion.</Abstract>
    <JournalRelease>1529-9430</JournalRelease>
    <Pages>650-5</Pages>
    <Affiliation>Department of Spinal Surgery, University Hospital of North Tees, Hardwick, Stockton North Tees, TS19 8PE. l.a.g.marshman@btinternet.com</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=17602886&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>17552028</PMID>
    <AuthorListID>204</AuthorListID>
    <Title>The interferon inducing pathways and the hepatitis C virus.</Title>
    <Language>eng</Language>
    <Abstract>The innate immune response is triggered by a variety of pathogens, including viruses, and requires rapid induction of type I interferons (IFN), such as IFNbeta and IFNalpha. IFN induction occurs when specific pathogen motifs bind to specific cellular receptors. In non-professional immune, virally-infected cells, IFN induction is essentially initiated after the binding of dsRNA structures to TLR3 receptors or to intracytosolic RNA helicases, such as RIG-I/MDA5. This leads to the recruitment of specific adaptors, such as TRIF for TLR3 and the mitochondrial-associated IPS-1/VISA/MAVS/CARDIF adapter protein for the RNA helicases, and the ultimate recruitment of kinases, such as MAPKs, the canonical IKK complex and the TBK1/IKKepsilon kinases, which activate the transcription factors ATF-2/c-jun, NF-kappaB and IRF3, respectively. The coordinated action of these transcription factors leads to induction of IFN and of pro-inflammatory cytokines and to the establishment of the innate immune response. HCV can cleave both the adapters TRIF and IPS-1/VISA/MAVS/CARDIF through the action of its NS3/4A protease. This provokes abrogation of the induction of the IFN and cytokine pathways and favours viral propagation and presumably HCV chronic infection.</Abstract>
    <JournalRelease>1007-9327</JournalRelease>
    <Pages>2446-54</Pages>
    <Affiliation>Hepacivirus Unit, Department of Virology, Pasteur Institute, 28 rue du Dr Roux, 75724 Paris Cedex 15, France. emeurs@pasteur.fr</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=17552028&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>17517627</PMID>
    <AuthorListID>205</AuthorListID>
    <Title>Double-stranded DNA and double-stranded RNA induce a common antiviral signaling pathway in human cells.</Title>
    <PubDate>20070515</PubDate>
    <Language>eng</Language>
    <doi>10.1073/pnas.0703285104</doi>
    <Abstract>Virus infection triggers IFN immune defenses in infected cells in part through viral nucleic acid interactions, but the pathways by which dsDNA and DNA viruses trigger innate defenses are only partially understood. Here we present evidence that both retinoic acid-induced gene I (RIG-I) and mitochondrial antiviral signaling protein (MAVS) are required for dsDNA-induced IFN-beta promoter activation in a human hepatoma cell line (Huh-7), and that activation is efficiently blocked by the hepatitis C virus NS3/4A protease, which is known to block dsRNA signaling by cleaving MAVS. These findings suggest that dsDNA and dsRNA share a common pathway to trigger the innate antiviral defense response in human cells, although dsDNA appears to trigger that pathway upstream of the dsRNA-interacting protein RIG-I.</Abstract>
    <JournalRelease>0027-8424</JournalRelease>
    <Pages>9035-40</Pages>
    <Affiliation>Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=17517627&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>17473309</PMID>
    <AuthorListID>206</AuthorListID>
    <Title>Regulation of interferon production by RIG-I and LGP2: a lesson in self-control.</Title>
    <PubDate>20070501</PubDate>
    <Language>eng</Language>
    <doi>10.1126/stke.3842007pe20</doi>
    <Abstract>The cytoplasmic CARD-containing DExD/H box RNA helicases RIG-I and MDA5 act as sensors of viral infections through recognition of viral double-stranded (ds) RNAs. They both associate with the mitochondrial adaptor IPS-1 (also referred to as MAVS, VISA, and CARDIF) through homotypic CARD-CARD interactions. IPS-1, in turn, triggers signaling pathways, including activation of the protein kinases TBK1 and IKKepsilon, responsible for the phosphorylation of IRF3, a key transcription factor involved in interferon (IFN) synthesis, one essential element of the innate immune response. RIG-I remains in an autoinhibited state in the absence of dsRNA, through an internal repressor domain (RD) that binds within both its CARD and its RNA helicase domains and therefore acts in cis to control its multimerization and interaction with IPS-1. Ectopic expression of the RD prevents signaling and increases cell permissiveness to viruses, including hepatitis C virus. LGP2, which is another DExD/H RNA helicase of the RIG-I and MDA5 family and which is devoid of CARD domain, negatively controls IFN induction at different levels: by sequestering dsRNA, by blocking RIG-I's multimerization in trans through a domain analogous to the RIG-I RD, and by competing with the protein kinase IKKepsilon for a common interaction site on IPS-1. The ability of RIG-I and LGP2 to exert such a feedback control at the earliest steps of IFN synthesis allows the cells to exert a tight regulation of the induction of the innate immune response.</Abstract>
    <JournalRelease>1525-8882</JournalRelease>
    <Pages>pe20</Pages>
    <Affiliation>Hepacivirus Unit, Pasteur Institute, Paris Cedex 15, France.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=17473309&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>17468758</PMID>
    <AuthorListID>207</AuthorListID>
    <Title>The NEMO adaptor bridges the nuclear factor-kappaB and interferon regulatory factor signaling pathways.</Title>
    <PubDate>20070429</PubDate>
    <Language>eng</Language>
    <doi>10.1038/ni1465</doi>
    <Abstract>Intracellular detection of RNA virus infection is mediated by the RNA helicase RIG-I, which is recruited to mitochondria by the adaptor protein MAVS and triggers activation of the transcription factors NF-kappaB, IRF3 and IRF7. Here we demonstrate that virus-induced activation of IRF3 and IRF7 depended on the NF-kappaB modulator NEMO, which acted 'upstream' of the kinases TBK1 and IKKepsilon. IRF3 phosphorylation, formation of IRF3 dimers and DNA binding, as well as IRF3-dependent gene expression, were abrogated in NEMO-deficient cells. IRF3 phosphorylation and interferon production were restored by ectopic expression of NEMO. Thus, NEMO, like MAVS, acts as an adaptor protein that allows RIG-I to activate both the NF-kappaB and IRF signaling pathways.</Abstract>
    <JournalRelease>1529-2908</JournalRelease>
    <Pages>592-600</Pages>
    <Affiliation>Terry Fox Molecular Oncology Group, Lady Davis Institute for Medical Research, McGill University, Montreal H3T 1E2, Canada.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=17468758&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>17438296</PMID>
    <AuthorListID>208</AuthorListID>
    <Title>Disruption of innate immunity due to mitochondrial targeting of a picornaviral protease precursor.</Title>
    <PubDate>20070416</PubDate>
    <Language>eng</Language>
    <doi>10.1073/pnas.0611506104</doi>
    <Abstract>Mitochondrial antiviral signaling protein (MAVS) is an essential component of virus-activated signaling pathways that induce protective IFN responses. Its localization to the outer mitochondrial membrane suggests an important yet unexplained role for mitochondria in innate immunity. Here, we show that hepatitis A virus (HAV), a hepatotropic picornavirus, ablates type 1 IFN responses by targeting the 3ABC precursor of its 3C(pro) cysteine protease to mitochondria where it colocalizes with and cleaves MAVS, thereby disrupting activation of IRF3 through the MDA5 pathway. The 3ABC cleavage of MAVS requires both the protease activity of 3C(pro) and a transmembrane domain in 3A that directs 3ABC to mitochondria. Lacking this domain, mature 3C(pro) protease is incapable of MAVS proteolysis. HAV thus disrupts host signaling by a mechanism that parallels that of the serine NS3/4A protease of hepatitis C virus, but differs in its use of a stable, catalytically active polyprotein processing intermediate. The unique requirement for mitochondrial localization of 3ABC underscores the importance of mitochondria to host control of virus infections within the liver.</Abstract>
    <JournalRelease>0027-8424</JournalRelease>
    <Pages>7253-8</Pages>
    <Affiliation>Center for Hepatitis Research, Institute for Human Infections and Immunity, Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555-1019, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=17438296&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>17392790</PMID>
    <AuthorListID>209</AuthorListID>
    <Title>TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity.</Title>
    <Language>eng</Language>
    <doi>10.1038/nature05732</doi>
    <Abstract>Retinoic-acid-inducible gene-I (RIG-I; also called DDX58) is a cytosolic viral RNA receptor that interacts with MAVS (also called VISA, IPS-1 or Cardif) to induce type I interferon-mediated host protective innate immunity against viral infection. Furthermore, members of the tripartite motif (TRIM) protein family, which contain a cluster of a RING-finger domain, a B box/coiled-coil domain and a SPRY domain, are involved in various cellular processes, including cell proliferation and antiviral activity. Here we report that the amino-terminal caspase recruitment domains (CARDs) of RIG-I undergo robust ubiquitination induced by TRIM25 in mammalian cells. The carboxy-terminal SPRY domain of TRIM25 interacts with the N-terminal CARDs of RIG-I; this interaction effectively delivers the Lys 63-linked ubiquitin moiety to the N-terminal CARDs of RIG-I, resulting in a marked increase in RIG-I downstream signalling activity. The Lys 172 residue of RIG-I is critical for efficient TRIM25-mediated ubiquitination and for MAVS binding, as well as the ability of RIG-I to induce antiviral signal transduction. Furthermore, gene targeting demonstrates that TRIM25 is essential not only for RIG-I ubiquitination but also for RIG-I-mediated interferon- production and antiviral activity in response to RNA virus infection. Thus, we demonstrate that TRIM25 E3 ubiquitin ligase induces the Lys 63-linked ubiquitination of RIG-I, which is crucial for the cytosolic RIG-I signalling pathway to elicit host antiviral innate immunity.</Abstract>
    <JournalRelease>1476-4687</JournalRelease>
    <Pages>916-920</Pages>
    <Affiliation>Department of Microbiology and Molecular Genetics and Tumor Virology Division, New England Primate Research Center, Harvard Medical School, 1 Pine Hill Drive, Southborough, Massachusetts 01772, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=17392790&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>17339430</PMID>
    <AuthorListID>210</AuthorListID>
    <Title>Cutting Edge: Influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells.</Title>
    <Language>eng</Language>
    <Abstract>Influenza A virus (IAV) triggers a contagious acute respiratory disease that causes considerable mortality annually. Recently, we established a role for the pattern-recognition TLR3 in the response of lung epithelial cells to IAV-derived dsRNA. However, additional nucleic acid-recognition proteins have lately been implicated as key viral sensors, including the RNA helicases retinoic acid-inducible gene-I (RIG-I) and melanoma differentiation-associated gene (MDA)-5. In this study, we investigated the respective role of TLR3 vs RIG-I/MDA-5 signaling in human respiratory epithelial cells infected by IAV using BEAS-2B cells transfected with vectors encoding either a dominant-negative form of TLR3 or of mitochondrial antiviral signaling protein (MAVS; a signaling intermediate of RIG-I and MDA-5), or with plasmids overexpressing functional RIG-I or MDA-5. We demonstrate that the sensing of IAV by TLR3 primarily regulates a proinflammatory response, whereas RIG-I (but not MDA-5) mediates both a type I IFN-dependent antiviral signaling and a proinflammatory response.</Abstract>
    <JournalRelease>0022-1767</JournalRelease>
    <Pages>3368-72</Pages>
    <Affiliation>UnitÃ© de DÃ©fense InnÃ©e et Inflammation, INSERM UnitÃ© 874, Institut Pasteur, 25 Rue du Dr. Roux, 75015 Paris, France.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=17339430&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>17327220</PMID>
    <AuthorListID>211</AuthorListID>
    <Title>Modulation of the interferon antiviral response by the TBK1/IKKi adaptor protein TANK.</Title>
    <PubDate>20070226</PubDate>
    <Language>eng</Language>
    <doi>10.1074/jbc.M700017200</doi>
    <Abstract>Induction of type I interferons can be triggered by viral components through Toll-like receptors or intracellular viral receptors such as retinoic acid-inducible gene I. Here, we demonstrate that the TRAF (tumor necrosis factor receptor-associated factor) family member-associated NF-kappaB activator (TANK) plays an important role in interferon induction through both retinoic acid-inducible gene I- and Toll-like receptor-dependent pathways. TANK forms complexes with both upstream signal mediators, such as Cardif/MAVS/IPS-1/VISA, TRIF (Toll-interleukin-1 receptor domain-containing adaptor inducing interferon-beta), and TRAF3 and downstream mediators TANK-binding kinase 1, inducible IkappaB kinase, and interferon regulatory factor 3. In addition, it synergizes with these signaling components in interferon induction. Specific knockdown of TANK results in reduced type I interferon production, increased viral titers, and enhanced cell sensitivity to viral infection. Thus, TANK may be a critical adaptor that regulates the assembly of the TANK-binding kinase 1-inducible IkappaB kinase complex with upstream signaling molecules in multiple antiviral pathways.</Abstract>
    <JournalRelease>0021-9258</JournalRelease>
    <Pages>11817-26</Pages>
    <Affiliation>Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, California 90095, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=17327220&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>17142768</PMID>
    <AuthorListID>212</AuthorListID>
    <Title>NAK-associated protein 1 participates in both the TLR3 and the cytoplasmic pathways in type I IFN induction.</Title>
    <Language>eng</Language>
    <Abstract>TLR3 and the cytoplasmic helicase family proteins (retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated gene 5 (MDA5)) serve as dsRNA pattern-recognition receptors. In response to poly(I:C), a representative of dsRNA, and viral infection, they have been shown to activate the transcription factor IFN regulatory factor (IRF)-3, which in turn induces activation of the IFN-beta promoter. RIG-I/MDA5 recognizes dsRNA in the cytoplasm, whereas TLR3 resides in the cell surface membrane or endosomes to engage in extracytoplasmic recognition of dsRNA. Recent reports suggest that TLR3 induces cellular responses in epithelial cells in response to respiratory syncytial virus (RSV). The modus for TLR3 activation by RSV, however, remains unresolved. By small interference RNA gene-silencing technology and human cell transfectants, we have revealed that knockdown of NAK-associated protein 1 (NAP1) leads to the down-regulation of IFN-beta promoter activation &gt;24 h after poly(I:C) or virus (RSV and vesicular stomatitis virus) treatment. NAP1 is located downstream of the adapter Toll-IL-1R homology domain-containing adapter molecule (TICAM)-1 (Toll/IL-1R domain-containing adapter-inducing IFN-beta) in the TLR3 pathway, but TICAM-1 and TLR3 did not participate in the IRF-3 and IFN-beta promoter activation by RSV infection. Virus-mediated activation of the IFN-beta promoter was largely abrogated by the gene silencing of IFN-beta promoter stimulator-1 (mitochondria antiviral signaling (MAVS), VISA, Cardif), the adapter of the RIG-I/MDA5 dsRNA-recognition proteins. In both the TLR and virus-mediated IFN-inducing pathways, IkappaB kinase-related kinase epsilon and TANK-binding kinase 1 participated in IFN-beta induction. Thus, RSV as well as other viruses induces replication-mediated activation of the IFN-beta promoter, which is intracellularly initiated by the RIG-I/MDA5 but not the TLR3 pathway. Both the cytoplasmic and TLR3-mediated dsRNA recognition pathways converge upon NAP1 for the activation of the IRF-3 and IFN-beta promoter.</Abstract>
    <JournalRelease>0022-1767</JournalRelease>
    <Pages>8676-83</Pages>
    <Affiliation>Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Kita-ku, Sapporo 060-8638, Japan.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=17142768&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>17093192</PMID>
    <AuthorListID>213</AuthorListID>
    <Title>GB virus B disrupts RIG-I signaling by NS3/4A-mediated cleavage of the adaptor protein MAVS.</Title>
    <PubDate>20061108</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.02076-06</doi>
    <Abstract>Understanding the mechanisms of hepatitis C virus (HCV) pathogenesis and persistence has been hampered by the lack of small, convenient animal models. GB virus B (GBV-B) is phylogenetically the closest related virus to HCV. It causes generally acute and occasionally chronic hepatitis in small primates and is used as a surrogate model for HCV. It is not known, however, whether GBV-B has evolved strategies to circumvent host innate defenses similar to those of HCV, a property that may contribute to HCV persistence in vivo. We show here in cultured tamarin hepatocytes that GBV-B NS3/4A protease, but not a related catalytically inactive mutant, effectively blocks innate intracellular antiviral responses signaled through the RNA helicase, retinoic acid-inducible gene I (RIG-I), an essential sensor molecule that initiates host defenses against many RNA viruses, including HCV. GBV-B NS3/4A protease specifically cleaves mitochondrial antiviral signaling protein (MAVS; also known as IPS-1/Cardif/VISA) and dislodges it from mitochondria, thereby disrupting its function as a RIG-I adaptor and blocking downstream activation of both interferon regulatory factor 3 and nuclear factor kappa B. MAVS cleavage and abrogation of virus-induced interferon responses were also observed in Huh7 cells supporting autonomous replication of subgenomic GBV-B RNAs. Our data indicate that, as in the case of HCV, GBV-B has evolved to utilize its major protease to disrupt RIG-I signaling and impede innate antiviral defenses. These data provide further support for the use of GBV-B infection in small primates as an accurate surrogate model for deciphering virus-host interactions in hepacivirus pathogenesis.</Abstract>
    <JournalRelease>0022-538X</JournalRelease>
    <Pages>964-76</Pages>
    <Affiliation>Department of Microbiology &amp; Immunology, Center for Hepatitis Research, Institute for Human Infections &amp; Immunity, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-1019, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=17093192&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>17070177</PMID>
    <AuthorListID>214</AuthorListID>
    <Title>The effects of perioperative beta-blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial.</Title>
    <Language>eng</Language>
    <doi>10.1016/j.ahj.2006.07.024</doi>
    <Abstract>Patients undergoing vascular surgery comprise the highest risk group for perioperative cardiac mortality and morbidity after noncardiac procedures. Many current guidelines recommend the use of beta-blockers in all patients undergoing vascular surgery. We report a trial of the perioperative administration of metoprolol and its effects on the incidence of cardiac complications at 30 days and 6 months after vascular surgery.Patients undergoing abdominal aortic surgery and infrainguinal or axillofemoral revascularizations were recruited to a double-blind randomized controlled trial of perioperative metoprolol versus placebo. Patients were randomized to receive study medication, starting 2 hours preoperatively until hospital discharge or maximum of 5 days postoperatively. Primary outcome were postoperative 30-day composite incidence of nonfatal myocardial infarction, unstable angina, new congestive heart failure, new atrial or ventricular dysrhythmia requiring treatment, or cardiac death.Patients were randomized to receive either metoprolol (n = 246) or placebo (n = 250). Primary outcome events at 30 days postoperative occurred in 25 (10.2%) versus 30 (12.0%) (P = .57) in metoprolol and placebo groups, respectively (relative risk reduction 15.3%, 95% CI -38.3% to 48.2%). Observed effects at 6 months were not significantly different (P = .81) (relative risk reduction 6.2%, 95% CI% -58.4% to 43.8%). Intraoperative bradycardia requiring treatment was more frequent in the metoprolol group (53/246 vs 19/250, P = .00001), as was intraoperative hypotension requiring treatment (114/246 vs 84/250, P = .0045).Our results showed metoprolol was not effective in reducing the 30-day and 6-month postoperative cardiac event rates. Prophylactic use of perioperative beta-blockers in all vascular patients is not indicated.</Abstract>
    <JournalRelease>1097-6744</JournalRelease>
    <Pages>983-90</Pages>
    <Affiliation>Department of Anesthesiology, University of Ottawa, Ottawa, Canada.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=17070177&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>17020950</PMID>
    <AuthorListID>215</AuthorListID>
    <Title>RNA- and virus-independent inhibition of antiviral signaling by RNA helicase LGP2.</Title>
    <PubDate>20061004</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JVI.01325-06</doi>
    <Abstract>Antiviral innate immune responses can be triggered by accumulation of intracellular nucleic acids resulting from virus infections. Double-stranded RNA (dsRNA) can be detected by the cytoplasmic RNA helicase proteins RIG-I and MDA5, two proteins that share sequence similarities within a caspase recruitment domain (CARD) and a DExD/H box RNA helicase domain. These proteins are considered dsRNA sensors and are thought to transmit the signal to the mitochondrial adapter, IPS-1 (also known as MAVS, VISA, or CARDIF) via CARD interactions. IPS-1 coordinates the activity of protein kinases that activate transcription factors needed to induce beta interferon (IFN-beta) gene transcription. Another helicase protein, LGP2, lacks the CARD region and does not activate IFN-beta gene expression. LGP2 mRNA is induced by interferon, dsRNA treatments, or Sendai virus infection and acts as a feedback inhibitor for antiviral signaling. Results indicate that LGP2 can inhibit antiviral signaling independently of dsRNA or virus infection intermediates by engaging in a protein complex with IPS-1. Experiments suggest that LGP2 can compete with the kinase IKKi (also known as IKKepsilon) for a common interaction site on IPS-1. These results provide the first demonstration of protein interaction as an element of negative-feedback regulation of intracellular antiviral signaling by LGP2.</Abstract>
    <JournalRelease>0022-538X</JournalRelease>
    <Pages>12332-42</Pages>
    <Affiliation>Pancoe-ENH Research Pavilion, Northwestern University, 2200 Campus Drive, Evanston, IL 60208, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=17020950&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>16945160</PMID>
    <AuthorListID>216</AuthorListID>
    <Title>Hepatitis C virus NS2 and NS3/4A proteins are potent inhibitors of host cell cytokine/chemokine gene expression.</Title>
    <PubDate>20060901</PubDate>
    <Language>eng</Language>
    <doi>10.1186/1743-422X-3-66</doi>
    <Abstract>Hepatitis C virus (HCV) encodes several proteins that interfere with the host cell antiviral response. Previously, the serine protease NS3/4A was shown to inhibit IFN-beta gene expression by blocking dsRNA-activated retinoic acid-inducible gene I (RIG-I) and Toll-like receptor 3 (TLR3)-mediated signaling pathways.In the present work, we systematically studied the effect of all HCV proteins on IFN gene expression. NS2 and NS3/4A inhibited IFN gene activation. NS3/4A inhibited the Sendai virus-induced expression of multiple IFN (IFN-alpha, IFN-beta and IFN-lambda1/IL-29) and chemokine (CCL5, CXCL8 and CXCL10) gene promoters. NS2 and NS3/4A, but not its proteolytically inactive form NS3/4A-S139A, were found to inhibit promoter activity induced by RIG-I or its adaptor protein Cardif (or IPS-1/MAVS/VISA). Both endogenous and transfected Cardif were proteolytically cleaved by NS3/4A but not by NS2 indicating different mechanisms of inhibition of host cell cytokine production by these HCV encoded proteases. Cardif also strongly colocalized with NS3/4A at the mitochondrial membrane, implicating the mitochondrial membrane as the site for proteolytic cleavage. In many experimental systems, IFN priming dramatically enhances RNA virus-induced IFN gene expression; pretreatment of HEK293 cells with IFN-alpha strongly enhanced RIG-I expression, but failed to protect Cardif from NS3/4A-mediated cleavage and failed to restore Sendai virus-induced IFN-beta gene expression.HCV NS2 and NS3/4A proteins were identified as potent inhibitors of cytokine gene expression suggesting an important role for HCV proteases in counteracting host cell antiviral response.</Abstract>
    <JournalRelease>1743-422X</JournalRelease>
    <Pages>66</Pages>
    <Affiliation>Department of Viral Diseases and Immunology, National Public Health Institute, Helsinki, Finland. pasi.kaukinen@ktl.fi</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=16945160&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>16914100</PMID>
    <AuthorListID>217</AuthorListID>
    <Title>Induction of IRF-3 and IRF-7 phosphorylation following activation of the RIG-I pathway.</Title>
    <PubDate>20060515</PubDate>
    <Language>eng</Language>
    <Abstract>The induction of type I interferon (IFN) and the development of the innate antiviral response are mediated by the activation of interferon regulatory factor (IRF)-3 and IRF-7 under the control of the non-canonical kinases TBK-1 and IKKepsilon. The initial sensing of infection by RNA viruses is mediated by the cytoplasmic, retinoic acid inducible gene I (RIG-I), via a Toll-like receptor (TLR) independent signaling pathway. In the present study, we identify key residues involved in IRF-3 and IRF-7 phosphorylation using TAP-tag purification of TBK-1 and IKKepsilon proteins. Based on the identification of an extended sequence motif--SxSxxxS--common to both IRF-3 and IRF-7, an IRF-7 pSer477/479 phosphospecific antibody was generated. Virus infection, TBK-1/IKKepsilon expression or co-expression of different signaling adaptors such as RIG-I, MAVS and TRIF, all stimulated pSer477/479 phosphorylation. Furthermore, the newly identified adaptor of the RIG-I pathway (MAVS/IPS-1/VISA/Cardif) was able to induce IRF and NF-kappaB dependent promoter activity as efficiently as the constitutively active form of RIG-I (DeltaRIG-I). Co-expression of the NS3/4A protease activity of hepatitis C virus however blocked MAVS-mediated gene activation in a dose dependent manner. These studies link RIG-I sensing of viral RNA to downstream kinase signaling and phosphorylation of IRF-3 and IRF-7 via the MAVS/IPS/VISA/Cardif adaptor.</Abstract>
    <JournalRelease>1165-158X</JournalRelease>
    <Pages>17-28</Pages>
    <Affiliation>Terry Fox Molecular Oncology Group, Lady Davis Institute for Medical Research, 3755 Cote Ste. Catherine, Montreal, Quebec, Canada H3T 1E2.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=16914100&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>16876765</PMID>
    <AuthorListID>218</AuthorListID>
    <Title>Recruitment of an interferon molecular signaling complex to the mitochondrial membrane: disruption by hepatitis C virus NS3-4A protease.</Title>
    <PubDate>20060731</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.bcp.2006.06.030</doi>
    <Abstract>Recent advances in the understanding of the signaling pathways leading to the host antiviral response to hepatitis C virus (HCV), the mechanisms used by HCV to evade the immune response, and the development of small molecule inhibitors of HCV have generated optimism that novel therapeutic approaches to control HCV disease may soon be available. HCV infection is detected by the cytoplasmic, RNA helicase RIG-I that plays an essential role in signaling to the host antiviral response. Recently the adapter molecule that links RIG-I sensing of incoming viral RNA to downstream signaling and gene activation events was characterized by four different groups: MAVS/IPS-1-1/VISA/Cardif contains an amino-terminal CARD domain and carboxyl-terminal mitochondrial transmembrane sequence that localizes to the mitochondrial membrane. Furthermore, the hepatitis C virus NS3-4A protease complex specifically targets MAVS/IPS-1/VISA/Cardif for cleavage as part of its immune evasion strategy. Using a combination of biochemical analysis, subcellular fractionation and confocal microscopy, we demonstrate that: (1) NS3-4A cleavage of MAVS/IPS-1/VISA/Cardif causes relocation from the mitochondrial membrane to the cytosolic fraction, resulting in disruption of signaling to the antiviral immune response; (2) disruption requires a function NS3-4A protease; (3) a point mutant of MAVS/IPS-1/VISA/Cardif (Cys508Ala) is not cleaved from the mitochondria by active protease; and (4) the virus-induced IKK epsilon kinase, but not TBK1, co-localizes strongly with MAVS at the mitochondrial membrane and the localization of both molecules is disrupted by NS3-4A expression. These observations provide an outline of the mechanism by which HCV evades the IFN antiviral response.</Abstract>
    <JournalRelease>0006-2952</JournalRelease>
    <Pages>1477-84</Pages>
    <Affiliation>Lady Davis Institute for Medical Research-Jewish General Hospital, Department of Microbiology &amp; Immunology, McGill University, Montreal, Canada H3T 1E2. john.hiscott@mcgill.ca</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=16876765&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>16849320</PMID>
    <AuthorListID>219</AuthorListID>
    <Title>Toll-like receptor-dependent and -independent viperin gene expression and counter-regulation by PRDI-binding factor-1/BLIMP1.</Title>
    <PubDate>20060718</PubDate>
    <Language>eng</Language>
    <doi>10.1074/jbc.M604516200</doi>
    <Abstract>Here we identify Viperin as a highly inducible gene in response to lipopolysaccharide (LPS), double-stranded RNA (poly(I-C)) or Sendai virus (SV). The only known function of Viperin relates to its ability to inhibit human Cytomegalovirus replication. Very little data are available on the regulation of this gene. In silico analysis of the promoter identified two interferon (IFN)-stimulated response elements (ISRE), which in other genes bind IRF3 or the IFN-stimulated gene factor-3 (ISGF3) complex. LPS and poly(I-C) induce very high levels of Viperin in wild type cells but not in cells deficient in TRIF, TBK1, IRF3, or the type I IFNalpha/betaR. SV-induced Viperin gene expression was mediated independently of Toll-like receptor (TLR) signaling by retinoic acid-inducible gene (RIG-I) and the downstream adapter, mitochondrial anti-viral signaling (MAVS). Virus-induced Viperin expression was not attenuated in macrophages deficient in either TBK1 or IKKepsilon alone. Moreover, IRF3-deficient, but not IFNalpha/betaR deficient, macrophages still induced Viperin in response to SV. Promoter reporter studies combined with DNA immunoprecipitation assays identified the ISGF3 complex as the key regulator of Viperin gene expression. Moreover, positive regulatory domain I-binding factor 1 (PRDI-BF1, also called BLIMP1) binds the ISRE sites and competes with ISGF3 binding in a virus inducible manner to inhibit Viperin transcription. Collectively, these studies identify Viperin as a tightly regulated ISGF3 target gene, which is counter-regulated by PRDI-BF1.</Abstract>
    <JournalRelease>0021-9258</JournalRelease>
    <Pages>26188-95</Pages>
    <Affiliation>Division of Infectious Disease and Immunology, Department of Medicine, The University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=16849320&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>16731946</PMID>
    <AuthorListID>220</AuthorListID>
    <Title>Dissociation of a MAVS/IPS-1/VISA/Cardif-IKKepsilon molecular complex from the mitochondrial outer membrane by hepatitis C virus NS3-4A proteolytic cleavage.</Title>
    <Language>eng</Language>
    <doi>10.1128/JVI.02495-05</doi>
    <Abstract>Intracellular RNA virus infection is detected by the cytoplasmic RNA helicase RIG-I that plays an essential role in signaling to the host antiviral response. Recently, the adapter molecule that links RIG-I sensing of incoming viral RNA to downstream signaling and gene activation events was characterized by four different groups; MAVS/IPS-1-1/VISA/Cardif contains an amino-terminal CARD domain and a carboxyl-terminal mitochondrial transmembrane sequence that localizes to the mitochondrial membrane. Furthermore, the hepatitis C virus NS3-4A protease complex specifically targets MAVS/IPS-1/VISA/Cardif for cleavage as part of its immune evasion strategy. With a novel search program written in python, we also identified an uncharacterized protein, KIAA1271 (K1271), containing a single CARD-like domain at the N terminus and a Leu-Val-rich C terminus that is identical to that of MAVS/IPS-1/VISA/Cardif. Using a combination of biochemical analysis, subcellular fractionation, and confocal microscopy, we now demonstrate that NS3-4A cleavage of MAVS/IPS-1/VISA/Cardif/K1271 results in its dissociation from the mitochondrial membrane and disrupts signaling to the antiviral immune response. Furthermore, virus-induced IKKepsilon kinase, but not TBK1, colocalized strongly with MAVS at the mitochondrial membrane, and the localization of both molecules was disrupted by NS3-4A expression. Mutation of the critical cysteine 508 to alanine was sufficient to maintain mitochondrial localization of MAVS/IPS-1/VISA/Cardif and IKKepsilon in the presence of NS3-4A. These observations provide an outline of the mechanism by which hepatitis C virus evades the interferon antiviral response.</Abstract>
    <JournalRelease>0022-538X</JournalRelease>
    <Pages>6072-83</Pages>
    <Affiliation>Lady Davis Institute for Medical Research, McGill University, Montreal H3T 1E2, Quebec, Canada. rongtuan.lin@mcgill.ca</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=16731946&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>16707574</PMID>
    <AuthorListID>221</AuthorListID>
    <Title>Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease-dependent and -independent mechanisms.</Title>
    <PubDate>20060517</PubDate>
    <Language>eng</Language>
    <doi>10.1073/pnas.0602957103</doi>
    <Abstract>The recent establishment of a robust hepatitis C virus (HCV) cell culture system permits analysis of virus-host interactions during HCV infection. Here, we report that HCV genotype 2a (JFH-1) infection fails to induce IFN-beta or IFN-stimulated gene expression in Huh-7 cells, and that it blocks IFN-beta and IFN-stimulated gene production after transfection of synthetic dsRNA. Overexpression of individual components of the dsRNA-signaling pathway in HCV-infected and uninfected cells indicates that HCV inhibits IFN-beta promoter activity by inactivating the mitochondrial antiviral signaling protein/IFN-beta promoter stimulator 1 (MAVS/IPS-1), while leaving the IFN-induced Janus kinases-signal transducers and activators of transcription (JAK-STAT) signaling pathway intact. We also show that MAVS/IPS-1-dependent IFN-beta promoter activity in HCV-infected cells is fully restored by the nonstructural protein 3 (NS3) protease inhibitor BILN2061. In contrast, synthetic dsRNA-induced IFN-beta promoter activity is not restored by BILN2061, although it is partially restored by overexpression of RIG-I. These results support recently reported evidence that the HCV NS3 protease blunts the ability of HCV to induce IFN-beta promoter activity by proteolytically cleaving MAVS/IPS-1. The results also suggest that HCV blocks the synthetic dsRNA-induced signaling pathway at a point upstream of MAVS/IPS-1, and that it does so by an NS3-independent mechanism.</Abstract>
    <JournalRelease>0027-8424</JournalRelease>
    <Pages>8499-504</Pages>
    <Affiliation>Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=16707574&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>16406812</PMID>
    <AuthorListID>222</AuthorListID>
    <Title>MasterCARD: a priceless link to innate immunity.</Title>
    <PubDate>20060106</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.molmed.2005.12.003</doi>
    <Abstract>Intracellular viral infection is detected by the cytoplasmic RNA helicase RIG-I, which has an essential role in initiating the host antiviral response. The adaptor molecule that connects RIG-I sensing of incoming viral RNA to downstream signaling and gene activation has recently been elucidated by four independent research groups, and has been ascribed four different names: MAVS, IPS-1, VISA and Cardif. The fact that MAVS/IPS-1/VISA/Cardif localizes to the mitochondrial membrane suggests a link between viral infection, mitochondrial function and development of innate immunity. Furthermore, the hepatitis C virus NS3/4A protease specifically cleaves MAVS/IPS-1/VISA/Cardif as part of its immune-evasion strategy. These studies highlight a novel role for the mitochondria and for caspase activation and recruitment domain (CARD)-containing proteins in coordinating immune and apoptotic responses.</Abstract>
    <JournalRelease>1471-4914</JournalRelease>
    <Pages>53-6</Pages>
    <Affiliation>Lady Davis Institute for Medical Research--Jewish General Hospital, Department of Microbiology &amp; Immunology, McGill University, Montreal, QC, H3T 1E2, Canada. john.hiscott@mcgill.ca</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=16406812&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>16309964</PMID>
    <AuthorListID>223</AuthorListID>
    <Title>CARD games between virus and host get a new player.</Title>
    <PubDate>20051123</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.it.2005.11.004</doi>
    <Abstract>A growing family of cellular proteins encoding the caspase activation and recruitment domain (CARD) has a crucial role in immunity by sensing virus infection and signaling antiviral immune defenses. Four independent studies have identified a novel CARD-containing protein, variously called IPS-1, MAVS, VISA and Cardif, which is an essential signaling adaptor of the host defense mediating CARD-CARD interactions with retinoic acid inducible gene-I (RIG-I) and melanoma differentiation-associated gene 5 (MDAS), sensors of virus infection. Disruption of this novel signaling pathway by hepatitis C virus (HCV) might provide a foundation for viral persistence.</Abstract>
    <JournalRelease>1471-4906</JournalRelease>
    <Pages>1-4</Pages>
    <Affiliation>Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=16309964&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>16301520</PMID>
    <AuthorListID>224</AuthorListID>
    <Title>Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity.</Title>
    <PubDate>20051121</PubDate>
    <Language>eng</Language>
    <doi>10.1073/pnas.0508531102</doi>
    <Abstract>Hepatitis C virus (HCV) is a global epidemic manifested mainly by chronic infection. One strategy that HCV employs to establish chronic infection is to use the viral Ser protease NS3/4A to cleave some unknown cellular targets involved in innate immunity. Here we show that the target of NS3/4A is the mitochondrial antiviral signaling protein, MAVS, that activates NF-kappaB and IFN regulatory factor 3 to induce type-I interferons. NS3/4A cleaves MAVS at Cys-508, resulting in the dislocation of the N-terminal fragment of MAVS from the mitochondria. Remarkably, a point mutation of MAVS at Cys-508 renders MAVS resistant to cleavage by NS3/4A, thus maintaining the ability of MAVS to induce interferons in HCV replicon cells. NS3/4A binds to and colocalizes with MAVS in the mitochondrial membrane, and it can cleave MAVS directly in vitro. These results provide an example of host-pathogen interaction in which the virus evades innate immunity by dislodging a pivotal antiviral protein from the mitochondria and suggest that blocking the cleavage of MAVS by NS3/4A may be applied to the prevention and treatment of HCV.</Abstract>
    <JournalRelease>0027-8424</JournalRelease>
    <Pages>17717-22</Pages>
    <Affiliation>Howard Hughes Medical Institute, Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9148, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=16301520&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>16294425</PMID>
    <AuthorListID>225</AuthorListID>
    <Title>Anti-virus breakthrough on the horizon. MAVs proteins may play major new role in the human immune system.</Title>
    <Language>eng</Language>
    <JournalRelease>1081-5880</JournalRelease>
    <Pages>3-4</Pages>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=16294425&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>16143094</PMID>
    <AuthorListID>226</AuthorListID>
    <Title>Connecting mitochondria and innate immunity.</Title>
    <Language>eng</Language>
    <doi>10.1016/j.cell.2005.08.026</doi>
    <Abstract>Viral infection results in the activation of multiple signaling pathways, but how these pathways are coordinated remains a mystery. Two studies, one published in this issue of Cell (Seth et al., 2005) and the other in Molecular Cell (Xu et al., 2005), identify a new intracellular signaling protein that is required for activating type I interferon expression in response to viral infection. In addition,Seth et al. (2005) show that the function of this protein, which they call MAVS, requires that it be localized to the mitochondria. This observation establishes an unexpected link between innate immunity and an organelle with evolutionary origins in aerobic bacteria.</Abstract>
    <JournalRelease>0092-8674</JournalRelease>
    <Pages>645-7</Pages>
    <Affiliation>Department of Molecular and Cellular Biology, Harvard University, Cambridge, Massachusetts 02138, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=16143094&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>16125763</PMID>
    <AuthorListID>227</AuthorListID>
    <Title>Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3.</Title>
    <Language>eng</Language>
    <doi>10.1016/j.cell.2005.08.012</doi>
    <Abstract>Viral infection triggers host innate immune responses through activation of the transcription factors NF-kappaB and IRF 3, which coordinately regulate the expression of type-I interferons such as interferon-beta (IFN-beta). Herein, we report the identification of a novel protein termed MAVS (mitochondrial antiviral signaling), which mediates the activation of NF-kappaB and IRF 3 in response to viral infection. Silencing of MAVS expression through RNA interference abolishes the activation of NF-kappaB and IRF 3 by viruses, thereby permitting viral replication. Conversely, overexpression of MAVS induces the expression of IFN-beta through activation of NF-kappaB and IRF 3, thus boosting antiviral immunity. Epistasis experiments show that MAVS is required for the phosphorylation of IRF 3 and IkappaB and functions downstream of RIG-I, an intracellular receptor for viral RNA. MAVS contains an N-terminal CARD-like domain and a C-terminal transmembrane domain, both of which are essential for MAVS signaling. The transmembrane domain targets MAVS to the mitochondria, implicating a new role of mitochondria in innate immunity.</Abstract>
    <JournalRelease>0092-8674</JournalRelease>
    <Pages>669-82</Pages>
    <Affiliation>Howard Hughes Medical Institute, Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=16125763&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>11868065</PMID>
    <AuthorListID>228</AuthorListID>
    <Title>Early systolic mitral annular motion velocities responses to dobutamine infusion predict myocardial viability in patients with previous myocardial infarction.</Title>
    <Language>eng</Language>
    <Abstract>This study was undertaken for the determination of the correlation between myocardial viability and regional systolic mitral annular motion velocity (MAV) response to dobutamine stress in patients with previous myocardial infarction (MI) with pulsed tissue Doppler scan imaging.The study included 45 patients (mean age, 65 +/- 12 years) with previous MI with 1 major coronary lesion and 30 healthy individuals (mean age, 61 +/- 14 years). 99mTc-methoxyisobutylisonitrile scintigraphy was performed to divide the patients into 2 groups: the viability (+) group (n = 25) and the viability (-) group (n = 20). Dobutamine was infused (at 2, 5, 10, and 20 microg/kg/min), and the peak first and second systolic MAVs (Sw1 and Sw2, respectively) were measured at the level of the mitral annulus corresponding to the infarct regions in the MI group and to the 6 mitral annular sites in the control group. In addition, the left ventricular wall motion score index (WMSI) was determined with 2-dimensional echocardiography.At baseline, the WMSI was significantly greater and the mean Sw1 and Sw2 were significantly lower in both the viability (+) and (-) groups than in the control group, but there were no significant differences between the viability (+) and (-) groups. After dobutamine infusion, the WMSI improved only in the viability (+) group. The mean Sw1 and Sw2 increased significantly with 2 microg/kg/min and 5 microg/kg/min of dobutamine, respectively, in the viability (+) group. With an increase in Sw1 of 2.0 cm/s or more with 5 microg/kg/min of dobutamine, viable myocardium was detected, with a sensitivity of 92% and a specificity of 90%. There were no significant increases in Sw1 or Sw2 in the viability (-) group with dobutamine infusion.Viable left ventricular myocardium is identified with peak early systolic MAV during dobutamine infusion.</Abstract>
    <JournalRelease>1097-6744</JournalRelease>
    <Pages>552-8</Pages>
    <Affiliation>Second Department of Internal Medicine, School of Medicine, The University of Tokushima, Tokushima, Japan.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=11868065&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>11562841</PMID>
    <AuthorListID>229</AuthorListID>
    <Title>[Arteriovenous malformations of the posterior fossa. Clinical features, treatment and results].</Title>
    <Language>spa</Language>
    <Abstract>We present our experience of 20 cases of arteriovenous malformations (MAV) of the posterior fossa.During the period 1991 1999 we prospectively collected radiological and therapeutic clinical data and the results obtained in all cases of adults whose arterio venous malformations were treated. We selected 20 of those who had MAV of the posterior fossa.The average age was 39.6 years (15 64). Thirteen (65%) were men. Most patients, 16 cases (80%) presented clinically with cerebellar haemorrhage, subarachnoid and/or intraventricular haemorrhage and 6 (30%) of the patients were admitted in coma. On the Spetzler and Martin scale: grade 1, 1 patient (5%); grade 11, 8 patients (40%); grade 111, 8 patients (40%) and grade 1V, 3 patients (15%). One patient had an associated pedicular aneurysm, another a supratentorial MAV and another patient had several cavernomas. Nine patients required external ventricular drainage, which in 4 cases became a permanent CSF drainage system. Endovascular treatment was used in 8 patients, radiosurgery in 2 and surgery in 9. Complete resection of the MAV was only possible in the patients treated by surgery (two patients had been treated previously by embolizations and radiosurgery). In this series there was a mortality of 20%, in all four cases due to recurrence of bleeding. Good results were obtained in 11 (55%) of the patients, but in the other 5 (25%) there were sequelas.The high percentage with haemorrhages as the form of presentation, with a much higher mortality than that of supratentorial MAVs makes more aggressive treatment necessary.</Abstract>
    <JournalRelease>0210-0010</JournalRelease>
    <Pages>1124-8</Pages>
    <Affiliation>Servicio de NeurocirugÃ­a; Hospital Universitario de la Vall d'Hebron, Barcelona, 08035, EspaÃ±a. 13659jvc@comb.es</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=11562841&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>7793635</PMID>
    <AuthorListID>230</AuthorListID>
    <Title>Solid-phase hybridization capture of low-abundance target DNA sequences: application to the polymerase chain reaction detection of Mycobacterium paratuberculosis and Mycobacterium avium subsp. silvaticum.</Title>
    <Language>eng</Language>
    <Abstract>Polymerase chain reaction (PCR) has been widely applied to the detection of microorganisms. Overall sensitivity of PCR tests may be substantially reduced due to a large excess of nontarget DNA and inhibitory substances in the sample. We used a 5'-biotinylated 513-bp probe from the 3' region of the IS 900 element specific for Mycobacterium paratuberculosis (Mptb) to capture target Mptb DNA from crude sample DNA extracts. Captured target DNA was separated using streptavidin-coated magnetic particles (Dynal). Since the IS 900 element shares homology over this region with IS 902 in Mycobacterium avium subsp. silvaticum (Mavs), target DNA from this other pathogen was also retained. Highly specific PCR for the detection of either organism directed to the 5' regions of IS 900 or IS 902 was then performed directly on the solid phase. Hybridization capture of target DNA using sequence adjacent to the desired specific PCR site applied to Mptb increased overall sensitivity of detection in tissue and fecal extracts 10- to 100-fold. False positives due to contamination artifact were substantially excluded since the capture probe did not retain amplicons from the detection PCR. Development of the method to involve covalent 5' immobilization of capture probes on heat-resistant polymers should, in the future, provide a simple system with broad potential applications.</Abstract>
    <JournalRelease>0003-2697</JournalRelease>
    <Pages>325-30</Pages>
    <Affiliation>Department of Surgery, St. Georges Hospital Medical School, London, United Kingdom.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=7793635&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>6230074</PMID>
    <AuthorListID>231</AuthorListID>
    <Title>Helicopter pilot back pain: a preliminary study.</Title>
    <Language>eng</Language>
    <Abstract>Because of the high prevalence of back pain experienced by U.S. Army helicopter pilots, a study was conducted to ascertain the feasibility of reproducing these symptoms in the laboratory. A mock-up of a UH-1H seat and control configuration was mounted to a multi-axis vibration simulator (MAVS). Eleven subjects were tested on the apparatus for two 120-min periods. During one period, the MAVS was programmed to reproduce vibrations recorded from a UH-1H in cruise flight. The subjects received no vibration during the other test period. All subjects reported back pain which they described as identical to the pain they experience during flight, during one or more of their test periods. There was no statistical difference between the vibration and nonvibration test conditions (p greater than 0.05) in terms of time of onset of pain or intensity of pain as measured by a visual analog scale. It appears the vibration at the frequencies and amplitudes tested plays little or no role in the etiology of the back symptoms reported by these pilots. It is proposed that the primary etiological factor for these symptoms is the poor posture pilots are obliged to assume for extended periods while operating helicopters.</Abstract>
    <JournalRelease>0095-6562</JournalRelease>
    <Pages>117-21</Pages>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=6230074&amp;retmode=xml</URL>
  </T_Article>
  <T_AuthorList>
    <PMID>24183820</PMID>
    <AuthorListID>1</AuthorListID>
    <AuthorID>1</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>24183820</PMID>
    <AuthorListID>1</AuthorListID>
    <AuthorID>2</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>24183820</PMID>
    <AuthorListID>1</AuthorListID>
    <AuthorID>3</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>24183820</PMID>
    <AuthorListID>1</AuthorListID>
    <AuthorID>4</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>24183820</PMID>
    <AuthorListID>1</AuthorListID>
    <AuthorID>5</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>24183820</PMID>
    <AuthorListID>1</AuthorListID>
    <AuthorID>6</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>24128418</PMID>
    <AuthorListID>2</AuthorListID>
    <AuthorID>7</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>24128418</PMID>
    <AuthorListID>2</AuthorListID>
    <AuthorID>8</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>24128418</PMID>
    <AuthorListID>2</AuthorListID>
    <AuthorID>9</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>24096085</PMID>
    <AuthorListID>3</AuthorListID>
    <AuthorID>10</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>24096085</PMID>
    <AuthorListID>3</AuthorListID>
    <AuthorID>11</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>24096085</PMID>
    <AuthorListID>3</AuthorListID>
    <AuthorID>12</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>24096085</PMID>
    <AuthorListID>3</AuthorListID>
    <AuthorID>13</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>24096085</PMID>
    <AuthorListID>3</AuthorListID>
    <AuthorID>14</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>24096085</PMID>
    <AuthorListID>3</AuthorListID>
    <AuthorID>15</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>24096085</PMID>
    <AuthorListID>3</AuthorListID>
    <AuthorID>16</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>24096085</PMID>
    <AuthorListID>3</AuthorListID>
    <AuthorID>17</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>24096085</PMID>
    <AuthorListID>3</AuthorListID>
    <AuthorID>18</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>24078691</PMID>
    <AuthorListID>4</AuthorListID>
    <AuthorID>19</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>24078691</PMID>
    <AuthorListID>4</AuthorListID>
    <AuthorID>20</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23962476</PMID>
    <AuthorListID>5</AuthorListID>
    <AuthorID>21</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23951545</PMID>
    <AuthorListID>6</AuthorListID>
    <AuthorID>22</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23951545</PMID>
    <AuthorListID>6</AuthorListID>
    <AuthorID>23</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23951545</PMID>
    <AuthorListID>6</AuthorListID>
    <AuthorID>24</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23951545</PMID>
    <AuthorListID>6</AuthorListID>
    <AuthorID>25</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23951545</PMID>
    <AuthorListID>6</AuthorListID>
    <AuthorID>26</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23951545</PMID>
    <AuthorListID>6</AuthorListID>
    <AuthorID>27</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23951545</PMID>
    <AuthorListID>6</AuthorListID>
    <AuthorID>28</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23951545</PMID>
    <AuthorListID>6</AuthorListID>
    <AuthorID>29</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23942572</PMID>
    <AuthorListID>7</AuthorListID>
    <AuthorID>30</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23942572</PMID>
    <AuthorListID>7</AuthorListID>
    <AuthorID>31</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23942572</PMID>
    <AuthorListID>7</AuthorListID>
    <AuthorID>32</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23942572</PMID>
    <AuthorListID>7</AuthorListID>
    <AuthorID>33</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23873628</PMID>
    <AuthorListID>8</AuthorListID>
    <AuthorID>34</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23873628</PMID>
    <AuthorListID>8</AuthorListID>
    <AuthorID>35</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23873628</PMID>
    <AuthorListID>8</AuthorListID>
    <AuthorID>36</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23873628</PMID>
    <AuthorListID>8</AuthorListID>
    <AuthorID>37</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23873628</PMID>
    <AuthorListID>8</AuthorListID>
    <AuthorID>38</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23873628</PMID>
    <AuthorListID>8</AuthorListID>
    <AuthorID>39</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23873628</PMID>
    <AuthorListID>8</AuthorListID>
    <AuthorID>40</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23873628</PMID>
    <AuthorListID>8</AuthorListID>
    <AuthorID>41</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23873628</PMID>
    <AuthorListID>8</AuthorListID>
    <AuthorID>42</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23873628</PMID>
    <AuthorListID>8</AuthorListID>
    <AuthorID>43</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23873628</PMID>
    <AuthorListID>8</AuthorListID>
    <AuthorID>44</AuthorID>
    <AuthorOrder>11</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23873628</PMID>
    <AuthorListID>8</AuthorListID>
    <AuthorID>45</AuthorID>
    <AuthorOrder>12</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23873628</PMID>
    <AuthorListID>8</AuthorListID>
    <AuthorID>46</AuthorID>
    <AuthorOrder>13</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23873628</PMID>
    <AuthorListID>8</AuthorListID>
    <AuthorID>47</AuthorID>
    <AuthorOrder>14</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23843640</PMID>
    <AuthorListID>9</AuthorListID>
    <AuthorID>48</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23843640</PMID>
    <AuthorListID>9</AuthorListID>
    <AuthorID>49</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23843640</PMID>
    <AuthorListID>9</AuthorListID>
    <AuthorID>50</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23843640</PMID>
    <AuthorListID>9</AuthorListID>
    <AuthorID>51</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23843640</PMID>
    <AuthorListID>9</AuthorListID>
    <AuthorID>52</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23843640</PMID>
    <AuthorListID>9</AuthorListID>
    <AuthorID>53</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23843640</PMID>
    <AuthorListID>9</AuthorListID>
    <AuthorID>54</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23843640</PMID>
    <AuthorListID>9</AuthorListID>
    <AuthorID>55</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23810392</PMID>
    <AuthorListID>10</AuthorListID>
    <AuthorID>56</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23810392</PMID>
    <AuthorListID>10</AuthorListID>
    <AuthorID>57</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23810392</PMID>
    <AuthorListID>10</AuthorListID>
    <AuthorID>58</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23810392</PMID>
    <AuthorListID>10</AuthorListID>
    <AuthorID>59</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23810392</PMID>
    <AuthorListID>10</AuthorListID>
    <AuthorID>60</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23770038</PMID>
    <AuthorListID>11</AuthorListID>
    <AuthorID>61</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23770038</PMID>
    <AuthorListID>11</AuthorListID>
    <AuthorID>62</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23770038</PMID>
    <AuthorListID>11</AuthorListID>
    <AuthorID>63</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23770038</PMID>
    <AuthorListID>11</AuthorListID>
    <AuthorID>64</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23770038</PMID>
    <AuthorListID>11</AuthorListID>
    <AuthorID>65</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23770038</PMID>
    <AuthorListID>11</AuthorListID>
    <AuthorID>66</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23770038</PMID>
    <AuthorListID>11</AuthorListID>
    <AuthorID>67</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23770038</PMID>
    <AuthorListID>11</AuthorListID>
    <AuthorID>68</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23770038</PMID>
    <AuthorListID>11</AuthorListID>
    <AuthorID>69</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23770038</PMID>
    <AuthorListID>11</AuthorListID>
    <AuthorID>70</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23770038</PMID>
    <AuthorListID>11</AuthorListID>
    <AuthorID>71</AuthorID>
    <AuthorOrder>11</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23702035</PMID>
    <AuthorListID>12</AuthorListID>
    <AuthorID>72</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23702035</PMID>
    <AuthorListID>12</AuthorListID>
    <AuthorID>73</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23702035</PMID>
    <AuthorListID>12</AuthorListID>
    <AuthorID>74</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23702035</PMID>
    <AuthorListID>12</AuthorListID>
    <AuthorID>75</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23702035</PMID>
    <AuthorListID>12</AuthorListID>
    <AuthorID>76</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23702035</PMID>
    <AuthorListID>12</AuthorListID>
    <AuthorID>77</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23702035</PMID>
    <AuthorListID>12</AuthorListID>
    <AuthorID>78</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23702035</PMID>
    <AuthorListID>12</AuthorListID>
    <AuthorID>79</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23702035</PMID>
    <AuthorListID>12</AuthorListID>
    <AuthorID>80</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23702035</PMID>
    <AuthorListID>12</AuthorListID>
    <AuthorID>81</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23702035</PMID>
    <AuthorListID>12</AuthorListID>
    <AuthorID>82</AuthorID>
    <AuthorOrder>11</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23702035</PMID>
    <AuthorListID>12</AuthorListID>
    <AuthorID>83</AuthorID>
    <AuthorOrder>12</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23702035</PMID>
    <AuthorListID>12</AuthorListID>
    <AuthorID>84</AuthorID>
    <AuthorOrder>13</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23671700</PMID>
    <AuthorListID>13</AuthorListID>
    <AuthorID>85</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23671700</PMID>
    <AuthorListID>13</AuthorListID>
    <AuthorID>86</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23671700</PMID>
    <AuthorListID>13</AuthorListID>
    <AuthorID>87</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23671700</PMID>
    <AuthorListID>13</AuthorListID>
    <AuthorID>88</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23653683</PMID>
    <AuthorListID>14</AuthorListID>
    <AuthorID>89</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23653683</PMID>
    <AuthorListID>14</AuthorListID>
    <AuthorID>90</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23653683</PMID>
    <AuthorListID>14</AuthorListID>
    <AuthorID>91</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23653683</PMID>
    <AuthorListID>14</AuthorListID>
    <AuthorID>92</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23653683</PMID>
    <AuthorListID>14</AuthorListID>
    <AuthorID>93</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23653683</PMID>
    <AuthorListID>14</AuthorListID>
    <AuthorID>94</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23653683</PMID>
    <AuthorListID>14</AuthorListID>
    <AuthorID>95</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23653683</PMID>
    <AuthorListID>14</AuthorListID>
    <AuthorID>96</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23653683</PMID>
    <AuthorListID>14</AuthorListID>
    <AuthorID>97</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23653683</PMID>
    <AuthorListID>14</AuthorListID>
    <AuthorID>98</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23653683</PMID>
    <AuthorListID>14</AuthorListID>
    <AuthorID>99</AuthorID>
    <AuthorOrder>11</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23653683</PMID>
    <AuthorListID>14</AuthorListID>
    <AuthorID>100</AuthorID>
    <AuthorOrder>12</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23653683</PMID>
    <AuthorListID>14</AuthorListID>
    <AuthorID>101</AuthorID>
    <AuthorOrder>13</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23626834</PMID>
    <AuthorListID>15</AuthorListID>
    <AuthorID>102</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23626834</PMID>
    <AuthorListID>15</AuthorListID>
    <AuthorID>103</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23626834</PMID>
    <AuthorListID>15</AuthorListID>
    <AuthorID>104</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23626834</PMID>
    <AuthorListID>15</AuthorListID>
    <AuthorID>105</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23626834</PMID>
    <AuthorListID>15</AuthorListID>
    <AuthorID>106</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23626834</PMID>
    <AuthorListID>15</AuthorListID>
    <AuthorID>107</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23611287</PMID>
    <AuthorListID>16</AuthorListID>
    <AuthorID>108</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23611287</PMID>
    <AuthorListID>16</AuthorListID>
    <AuthorID>109</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23592984</PMID>
    <AuthorListID>17</AuthorListID>
    <AuthorID>110</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23592984</PMID>
    <AuthorListID>17</AuthorListID>
    <AuthorID>111</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23592984</PMID>
    <AuthorListID>17</AuthorListID>
    <AuthorID>112</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23592984</PMID>
    <AuthorListID>17</AuthorListID>
    <AuthorID>113</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23592984</PMID>
    <AuthorListID>17</AuthorListID>
    <AuthorID>114</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23592984</PMID>
    <AuthorListID>17</AuthorListID>
    <AuthorID>115</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23592984</PMID>
    <AuthorListID>17</AuthorListID>
    <AuthorID>116</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23582325</PMID>
    <AuthorListID>18</AuthorListID>
    <AuthorID>117</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23582325</PMID>
    <AuthorListID>18</AuthorListID>
    <AuthorID>118</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23582325</PMID>
    <AuthorListID>18</AuthorListID>
    <AuthorID>119</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23582325</PMID>
    <AuthorListID>18</AuthorListID>
    <AuthorID>120</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23582325</PMID>
    <AuthorListID>18</AuthorListID>
    <AuthorID>121</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23555725</PMID>
    <AuthorListID>19</AuthorListID>
    <AuthorID>122</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23555725</PMID>
    <AuthorListID>19</AuthorListID>
    <AuthorID>123</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23555725</PMID>
    <AuthorListID>19</AuthorListID>
    <AuthorID>124</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23555725</PMID>
    <AuthorListID>19</AuthorListID>
    <AuthorID>125</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23555725</PMID>
    <AuthorListID>19</AuthorListID>
    <AuthorID>126</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23555725</PMID>
    <AuthorListID>19</AuthorListID>
    <AuthorID>127</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23555725</PMID>
    <AuthorListID>19</AuthorListID>
    <AuthorID>128</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23555725</PMID>
    <AuthorListID>19</AuthorListID>
    <AuthorID>129</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23555725</PMID>
    <AuthorListID>19</AuthorListID>
    <AuthorID>130</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23555725</PMID>
    <AuthorListID>19</AuthorListID>
    <AuthorID>131</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23555725</PMID>
    <AuthorListID>19</AuthorListID>
    <AuthorID>132</AuthorID>
    <AuthorOrder>11</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23555725</PMID>
    <AuthorListID>19</AuthorListID>
    <AuthorID>133</AuthorID>
    <AuthorOrder>12</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23555725</PMID>
    <AuthorListID>19</AuthorListID>
    <AuthorID>134</AuthorID>
    <AuthorOrder>13</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23555725</PMID>
    <AuthorListID>19</AuthorListID>
    <AuthorID>135</AuthorID>
    <AuthorOrder>14</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23555725</PMID>
    <AuthorListID>19</AuthorListID>
    <AuthorID>136</AuthorID>
    <AuthorOrder>15</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23555725</PMID>
    <AuthorListID>19</AuthorListID>
    <AuthorID>137</AuthorID>
    <AuthorOrder>16</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23555247</PMID>
    <AuthorListID>20</AuthorListID>
    <AuthorID>138</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23555247</PMID>
    <AuthorListID>20</AuthorListID>
    <AuthorID>139</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23555247</PMID>
    <AuthorListID>20</AuthorListID>
    <AuthorID>140</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23555247</PMID>
    <AuthorListID>20</AuthorListID>
    <AuthorID>141</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23555247</PMID>
    <AuthorListID>20</AuthorListID>
    <AuthorID>142</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23555247</PMID>
    <AuthorListID>20</AuthorListID>
    <AuthorID>143</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23555247</PMID>
    <AuthorListID>20</AuthorListID>
    <AuthorID>144</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23555247</PMID>
    <AuthorListID>20</AuthorListID>
    <AuthorID>145</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23545497</PMID>
    <AuthorListID>21</AuthorListID>
    <AuthorID>146</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23545497</PMID>
    <AuthorListID>21</AuthorListID>
    <AuthorID>147</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23545497</PMID>
    <AuthorListID>21</AuthorListID>
    <AuthorID>148</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23545497</PMID>
    <AuthorListID>21</AuthorListID>
    <AuthorID>149</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23545497</PMID>
    <AuthorListID>21</AuthorListID>
    <AuthorID>150</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23545497</PMID>
    <AuthorListID>21</AuthorListID>
    <AuthorID>151</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23545497</PMID>
    <AuthorListID>21</AuthorListID>
    <AuthorID>152</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23545497</PMID>
    <AuthorListID>21</AuthorListID>
    <AuthorID>153</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23545497</PMID>
    <AuthorListID>21</AuthorListID>
    <AuthorID>154</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23545497</PMID>
    <AuthorListID>21</AuthorListID>
    <AuthorID>155</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23544010</PMID>
    <AuthorListID>22</AuthorListID>
    <AuthorID>156</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23544010</PMID>
    <AuthorListID>22</AuthorListID>
    <AuthorID>157</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23544010</PMID>
    <AuthorListID>22</AuthorListID>
    <AuthorID>158</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23544010</PMID>
    <AuthorListID>22</AuthorListID>
    <AuthorID>159</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23544010</PMID>
    <AuthorListID>22</AuthorListID>
    <AuthorID>160</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23544010</PMID>
    <AuthorListID>22</AuthorListID>
    <AuthorID>161</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23544010</PMID>
    <AuthorListID>22</AuthorListID>
    <AuthorID>162</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23544010</PMID>
    <AuthorListID>22</AuthorListID>
    <AuthorID>163</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23544010</PMID>
    <AuthorListID>22</AuthorListID>
    <AuthorID>164</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23542348</PMID>
    <AuthorListID>23</AuthorListID>
    <AuthorID>165</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23542348</PMID>
    <AuthorListID>23</AuthorListID>
    <AuthorID>166</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23542348</PMID>
    <AuthorListID>23</AuthorListID>
    <AuthorID>167</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23542348</PMID>
    <AuthorListID>23</AuthorListID>
    <AuthorID>168</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23542348</PMID>
    <AuthorListID>23</AuthorListID>
    <AuthorID>169</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23542348</PMID>
    <AuthorListID>23</AuthorListID>
    <AuthorID>170</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23542348</PMID>
    <AuthorListID>23</AuthorListID>
    <AuthorID>171</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23542348</PMID>
    <AuthorListID>23</AuthorListID>
    <AuthorID>172</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23526820</PMID>
    <AuthorListID>24</AuthorListID>
    <AuthorID>173</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23526820</PMID>
    <AuthorListID>24</AuthorListID>
    <AuthorID>174</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23526820</PMID>
    <AuthorListID>24</AuthorListID>
    <AuthorID>175</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23526820</PMID>
    <AuthorListID>24</AuthorListID>
    <AuthorID>176</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23503762</PMID>
    <AuthorListID>25</AuthorListID>
    <AuthorID>177</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23503762</PMID>
    <AuthorListID>25</AuthorListID>
    <AuthorID>178</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23503762</PMID>
    <AuthorListID>25</AuthorListID>
    <AuthorID>179</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23503762</PMID>
    <AuthorListID>25</AuthorListID>
    <AuthorID>180</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23499490</PMID>
    <AuthorListID>26</AuthorListID>
    <AuthorID>181</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23499490</PMID>
    <AuthorListID>26</AuthorListID>
    <AuthorID>182</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23499490</PMID>
    <AuthorListID>26</AuthorListID>
    <AuthorID>183</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23499490</PMID>
    <AuthorListID>26</AuthorListID>
    <AuthorID>184</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23498958</PMID>
    <AuthorListID>27</AuthorListID>
    <AuthorID>185</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23498958</PMID>
    <AuthorListID>27</AuthorListID>
    <AuthorID>186</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23498958</PMID>
    <AuthorListID>27</AuthorListID>
    <AuthorID>187</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23498958</PMID>
    <AuthorListID>27</AuthorListID>
    <AuthorID>188</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23498958</PMID>
    <AuthorListID>27</AuthorListID>
    <AuthorID>189</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23498958</PMID>
    <AuthorListID>27</AuthorListID>
    <AuthorID>190</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23498958</PMID>
    <AuthorListID>27</AuthorListID>
    <AuthorID>191</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23498958</PMID>
    <AuthorListID>27</AuthorListID>
    <AuthorID>192</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23498958</PMID>
    <AuthorListID>27</AuthorListID>
    <AuthorID>193</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23498958</PMID>
    <AuthorListID>27</AuthorListID>
    <AuthorID>194</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23498958</PMID>
    <AuthorListID>27</AuthorListID>
    <AuthorID>195</AuthorID>
    <AuthorOrder>11</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23498958</PMID>
    <AuthorListID>27</AuthorListID>
    <AuthorID>196</AuthorID>
    <AuthorOrder>12</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23432157</PMID>
    <AuthorListID>28</AuthorListID>
    <AuthorID>197</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23432157</PMID>
    <AuthorListID>28</AuthorListID>
    <AuthorID>198</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23432157</PMID>
    <AuthorListID>28</AuthorListID>
    <AuthorID>199</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23432157</PMID>
    <AuthorListID>28</AuthorListID>
    <AuthorID>200</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23432157</PMID>
    <AuthorListID>28</AuthorListID>
    <AuthorID>201</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23432157</PMID>
    <AuthorListID>28</AuthorListID>
    <AuthorID>202</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23419645</PMID>
    <AuthorListID>29</AuthorListID>
    <AuthorID>203</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23419645</PMID>
    <AuthorListID>29</AuthorListID>
    <AuthorID>204</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23419645</PMID>
    <AuthorListID>29</AuthorListID>
    <AuthorID>205</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23419645</PMID>
    <AuthorListID>29</AuthorListID>
    <AuthorID>206</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23419645</PMID>
    <AuthorListID>29</AuthorListID>
    <AuthorID>207</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23419645</PMID>
    <AuthorListID>29</AuthorListID>
    <AuthorID>208</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23419645</PMID>
    <AuthorListID>29</AuthorListID>
    <AuthorID>209</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23419645</PMID>
    <AuthorListID>29</AuthorListID>
    <AuthorID>210</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23419645</PMID>
    <AuthorListID>29</AuthorListID>
    <AuthorID>211</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23419645</PMID>
    <AuthorListID>29</AuthorListID>
    <AuthorID>212</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23419645</PMID>
    <AuthorListID>29</AuthorListID>
    <AuthorID>213</AuthorID>
    <AuthorOrder>11</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23419645</PMID>
    <AuthorListID>29</AuthorListID>
    <AuthorID>214</AuthorID>
    <AuthorOrder>12</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23414438</PMID>
    <AuthorListID>30</AuthorListID>
    <AuthorID>215</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23408632</PMID>
    <AuthorListID>31</AuthorListID>
    <AuthorID>216</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23408632</PMID>
    <AuthorListID>31</AuthorListID>
    <AuthorID>217</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23408632</PMID>
    <AuthorListID>31</AuthorListID>
    <AuthorID>218</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23408632</PMID>
    <AuthorListID>31</AuthorListID>
    <AuthorID>219</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23408632</PMID>
    <AuthorListID>31</AuthorListID>
    <AuthorID>220</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23408632</PMID>
    <AuthorListID>31</AuthorListID>
    <AuthorID>221</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23408632</PMID>
    <AuthorListID>31</AuthorListID>
    <AuthorID>222</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23408632</PMID>
    <AuthorListID>31</AuthorListID>
    <AuthorID>223</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23408632</PMID>
    <AuthorListID>31</AuthorListID>
    <AuthorID>224</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23408632</PMID>
    <AuthorListID>31</AuthorListID>
    <AuthorID>225</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23408632</PMID>
    <AuthorListID>31</AuthorListID>
    <AuthorID>226</AuthorID>
    <AuthorOrder>11</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23408632</PMID>
    <AuthorListID>31</AuthorListID>
    <AuthorID>227</AuthorID>
    <AuthorOrder>12</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23367207</PMID>
    <AuthorListID>32</AuthorListID>
    <AuthorID>228</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23367207</PMID>
    <AuthorListID>32</AuthorListID>
    <AuthorID>229</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23367207</PMID>
    <AuthorListID>32</AuthorListID>
    <AuthorID>230</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23367207</PMID>
    <AuthorListID>32</AuthorListID>
    <AuthorID>231</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23367207</PMID>
    <AuthorListID>32</AuthorListID>
    <AuthorID>232</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23367207</PMID>
    <AuthorListID>32</AuthorListID>
    <AuthorID>233</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23367207</PMID>
    <AuthorListID>32</AuthorListID>
    <AuthorID>234</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23367207</PMID>
    <AuthorListID>32</AuthorListID>
    <AuthorID>235</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23337771</PMID>
    <AuthorListID>33</AuthorListID>
    <AuthorID>236</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23337771</PMID>
    <AuthorListID>33</AuthorListID>
    <AuthorID>237</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23337771</PMID>
    <AuthorListID>33</AuthorListID>
    <AuthorID>238</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23337771</PMID>
    <AuthorListID>33</AuthorListID>
    <AuthorID>239</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23337771</PMID>
    <AuthorListID>33</AuthorListID>
    <AuthorID>240</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23337771</PMID>
    <AuthorListID>33</AuthorListID>
    <AuthorID>241</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23337771</PMID>
    <AuthorListID>33</AuthorListID>
    <AuthorID>242</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23321557</PMID>
    <AuthorListID>34</AuthorListID>
    <AuthorID>243</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23321557</PMID>
    <AuthorListID>34</AuthorListID>
    <AuthorID>244</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23321557</PMID>
    <AuthorListID>34</AuthorListID>
    <AuthorID>245</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23320079</PMID>
    <AuthorListID>35</AuthorListID>
    <AuthorID>246</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23320079</PMID>
    <AuthorListID>35</AuthorListID>
    <AuthorID>247</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23320079</PMID>
    <AuthorListID>35</AuthorListID>
    <AuthorID>248</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23320079</PMID>
    <AuthorListID>35</AuthorListID>
    <AuthorID>249</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23320079</PMID>
    <AuthorListID>35</AuthorListID>
    <AuthorID>250</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23320079</PMID>
    <AuthorListID>35</AuthorListID>
    <AuthorID>251</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23320079</PMID>
    <AuthorListID>35</AuthorListID>
    <AuthorID>252</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23320079</PMID>
    <AuthorListID>35</AuthorListID>
    <AuthorID>253</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23320079</PMID>
    <AuthorListID>35</AuthorListID>
    <AuthorID>254</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23308256</PMID>
    <AuthorListID>36</AuthorListID>
    <AuthorID>255</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23308256</PMID>
    <AuthorListID>36</AuthorListID>
    <AuthorID>256</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23308256</PMID>
    <AuthorListID>36</AuthorListID>
    <AuthorID>257</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23308256</PMID>
    <AuthorListID>36</AuthorListID>
    <AuthorID>258</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23308256</PMID>
    <AuthorListID>36</AuthorListID>
    <AuthorID>259</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23308256</PMID>
    <AuthorListID>36</AuthorListID>
    <AuthorID>260</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23308256</PMID>
    <AuthorListID>36</AuthorListID>
    <AuthorID>261</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23308256</PMID>
    <AuthorListID>36</AuthorListID>
    <AuthorID>262</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23308256</PMID>
    <AuthorListID>36</AuthorListID>
    <AuthorID>263</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23308256</PMID>
    <AuthorListID>36</AuthorListID>
    <AuthorID>264</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23308066</PMID>
    <AuthorListID>37</AuthorListID>
    <AuthorID>265</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23308066</PMID>
    <AuthorListID>37</AuthorListID>
    <AuthorID>266</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23308066</PMID>
    <AuthorListID>37</AuthorListID>
    <AuthorID>267</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23308066</PMID>
    <AuthorListID>37</AuthorListID>
    <AuthorID>268</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23308066</PMID>
    <AuthorListID>37</AuthorListID>
    <AuthorID>269</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23308066</PMID>
    <AuthorListID>37</AuthorListID>
    <AuthorID>270</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23308066</PMID>
    <AuthorListID>37</AuthorListID>
    <AuthorID>271</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23301932</PMID>
    <AuthorListID>38</AuthorListID>
    <AuthorID>272</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23301932</PMID>
    <AuthorListID>38</AuthorListID>
    <AuthorID>273</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23301932</PMID>
    <AuthorListID>38</AuthorListID>
    <AuthorID>274</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23292079</PMID>
    <AuthorListID>39</AuthorListID>
    <AuthorID>275</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23292079</PMID>
    <AuthorListID>39</AuthorListID>
    <AuthorID>276</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23273991</PMID>
    <AuthorListID>40</AuthorListID>
    <AuthorID>277</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23273991</PMID>
    <AuthorListID>40</AuthorListID>
    <AuthorID>278</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23273991</PMID>
    <AuthorListID>40</AuthorListID>
    <AuthorID>279</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23273991</PMID>
    <AuthorListID>40</AuthorListID>
    <AuthorID>280</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23273991</PMID>
    <AuthorListID>40</AuthorListID>
    <AuthorID>281</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23273991</PMID>
    <AuthorListID>40</AuthorListID>
    <AuthorID>282</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23273991</PMID>
    <AuthorListID>40</AuthorListID>
    <AuthorID>283</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23273991</PMID>
    <AuthorListID>40</AuthorListID>
    <AuthorID>284</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23273991</PMID>
    <AuthorListID>40</AuthorListID>
    <AuthorID>285</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23264040</PMID>
    <AuthorListID>41</AuthorListID>
    <AuthorID>286</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23264040</PMID>
    <AuthorListID>41</AuthorListID>
    <AuthorID>287</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23264040</PMID>
    <AuthorListID>41</AuthorListID>
    <AuthorID>288</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23264040</PMID>
    <AuthorListID>41</AuthorListID>
    <AuthorID>289</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23264040</PMID>
    <AuthorListID>41</AuthorListID>
    <AuthorID>290</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23264040</PMID>
    <AuthorListID>41</AuthorListID>
    <AuthorID>291</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23264040</PMID>
    <AuthorListID>41</AuthorListID>
    <AuthorID>292</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23264040</PMID>
    <AuthorListID>41</AuthorListID>
    <AuthorID>293</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23264040</PMID>
    <AuthorListID>41</AuthorListID>
    <AuthorID>294</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23264040</PMID>
    <AuthorListID>41</AuthorListID>
    <AuthorID>295</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23249700</PMID>
    <AuthorListID>42</AuthorListID>
    <AuthorID>296</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23249700</PMID>
    <AuthorListID>42</AuthorListID>
    <AuthorID>297</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23249700</PMID>
    <AuthorListID>42</AuthorListID>
    <AuthorID>298</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23249700</PMID>
    <AuthorListID>42</AuthorListID>
    <AuthorID>299</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23249700</PMID>
    <AuthorListID>42</AuthorListID>
    <AuthorID>300</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23249700</PMID>
    <AuthorListID>42</AuthorListID>
    <AuthorID>301</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23249700</PMID>
    <AuthorListID>42</AuthorListID>
    <AuthorID>302</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23249700</PMID>
    <AuthorListID>42</AuthorListID>
    <AuthorID>303</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23249700</PMID>
    <AuthorListID>42</AuthorListID>
    <AuthorID>304</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23249700</PMID>
    <AuthorListID>42</AuthorListID>
    <AuthorID>305</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23246644</PMID>
    <AuthorListID>43</AuthorListID>
    <AuthorID>306</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23246644</PMID>
    <AuthorListID>43</AuthorListID>
    <AuthorID>307</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23246644</PMID>
    <AuthorListID>43</AuthorListID>
    <AuthorID>308</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23096996</PMID>
    <AuthorListID>44</AuthorListID>
    <AuthorID>309</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23096996</PMID>
    <AuthorListID>44</AuthorListID>
    <AuthorID>310</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23096996</PMID>
    <AuthorListID>44</AuthorListID>
    <AuthorID>311</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23096996</PMID>
    <AuthorListID>44</AuthorListID>
    <AuthorID>312</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23096996</PMID>
    <AuthorListID>44</AuthorListID>
    <AuthorID>313</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23090998</PMID>
    <AuthorListID>45</AuthorListID>
    <AuthorID>314</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23090998</PMID>
    <AuthorListID>45</AuthorListID>
    <AuthorID>315</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23090998</PMID>
    <AuthorListID>45</AuthorListID>
    <AuthorID>316</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23090998</PMID>
    <AuthorListID>45</AuthorListID>
    <AuthorID>317</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23087404</PMID>
    <AuthorListID>46</AuthorListID>
    <AuthorID>318</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23087404</PMID>
    <AuthorListID>46</AuthorListID>
    <AuthorID>319</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23087404</PMID>
    <AuthorListID>46</AuthorListID>
    <AuthorID>320</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23077300</PMID>
    <AuthorListID>47</AuthorListID>
    <AuthorID>321</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23077300</PMID>
    <AuthorListID>47</AuthorListID>
    <AuthorID>322</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23077300</PMID>
    <AuthorListID>47</AuthorListID>
    <AuthorID>323</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23077300</PMID>
    <AuthorListID>47</AuthorListID>
    <AuthorID>324</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23077300</PMID>
    <AuthorListID>47</AuthorListID>
    <AuthorID>325</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23077300</PMID>
    <AuthorListID>47</AuthorListID>
    <AuthorID>326</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23077300</PMID>
    <AuthorListID>47</AuthorListID>
    <AuthorID>327</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23063572</PMID>
    <AuthorListID>48</AuthorListID>
    <AuthorID>328</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23028806</PMID>
    <AuthorListID>49</AuthorListID>
    <AuthorID>329</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23028806</PMID>
    <AuthorListID>49</AuthorListID>
    <AuthorID>330</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23028806</PMID>
    <AuthorListID>49</AuthorListID>
    <AuthorID>331</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23028806</PMID>
    <AuthorListID>49</AuthorListID>
    <AuthorID>332</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23028806</PMID>
    <AuthorListID>49</AuthorListID>
    <AuthorID>333</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23028806</PMID>
    <AuthorListID>49</AuthorListID>
    <AuthorID>334</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23028469</PMID>
    <AuthorListID>50</AuthorListID>
    <AuthorID>335</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23028469</PMID>
    <AuthorListID>50</AuthorListID>
    <AuthorID>336</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23028469</PMID>
    <AuthorListID>50</AuthorListID>
    <AuthorID>337</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23015697</PMID>
    <AuthorListID>51</AuthorListID>
    <AuthorID>338</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23015697</PMID>
    <AuthorListID>51</AuthorListID>
    <AuthorID>339</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23015697</PMID>
    <AuthorListID>51</AuthorListID>
    <AuthorID>340</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23015697</PMID>
    <AuthorListID>51</AuthorListID>
    <AuthorID>341</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23014529</PMID>
    <AuthorListID>52</AuthorListID>
    <AuthorID>342</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23014529</PMID>
    <AuthorListID>52</AuthorListID>
    <AuthorID>343</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23014529</PMID>
    <AuthorListID>52</AuthorListID>
    <AuthorID>344</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23014529</PMID>
    <AuthorListID>52</AuthorListID>
    <AuthorID>345</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23014529</PMID>
    <AuthorListID>52</AuthorListID>
    <AuthorID>346</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23014529</PMID>
    <AuthorListID>52</AuthorListID>
    <AuthorID>347</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23014529</PMID>
    <AuthorListID>52</AuthorListID>
    <AuthorID>348</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23014529</PMID>
    <AuthorListID>52</AuthorListID>
    <AuthorID>349</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22996173</PMID>
    <AuthorListID>53</AuthorListID>
    <AuthorID>350</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22996173</PMID>
    <AuthorListID>53</AuthorListID>
    <AuthorID>351</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22908223</PMID>
    <AuthorListID>54</AuthorListID>
    <AuthorID>352</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22908223</PMID>
    <AuthorListID>54</AuthorListID>
    <AuthorID>353</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22908223</PMID>
    <AuthorListID>54</AuthorListID>
    <AuthorID>354</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22901541</PMID>
    <AuthorListID>55</AuthorListID>
    <AuthorID>355</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22901541</PMID>
    <AuthorListID>55</AuthorListID>
    <AuthorID>356</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22901541</PMID>
    <AuthorListID>55</AuthorListID>
    <AuthorID>357</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22901541</PMID>
    <AuthorListID>55</AuthorListID>
    <AuthorID>358</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22901541</PMID>
    <AuthorListID>55</AuthorListID>
    <AuthorID>359</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22901541</PMID>
    <AuthorListID>55</AuthorListID>
    <AuthorID>360</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22901541</PMID>
    <AuthorListID>55</AuthorListID>
    <AuthorID>361</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22901541</PMID>
    <AuthorListID>55</AuthorListID>
    <AuthorID>362</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22870331</PMID>
    <AuthorListID>56</AuthorListID>
    <AuthorID>363</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22870331</PMID>
    <AuthorListID>56</AuthorListID>
    <AuthorID>364</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22870331</PMID>
    <AuthorListID>56</AuthorListID>
    <AuthorID>365</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22870331</PMID>
    <AuthorListID>56</AuthorListID>
    <AuthorID>366</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22870331</PMID>
    <AuthorListID>56</AuthorListID>
    <AuthorID>367</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22844514</PMID>
    <AuthorListID>57</AuthorListID>
    <AuthorID>368</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22844514</PMID>
    <AuthorListID>57</AuthorListID>
    <AuthorID>369</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22844514</PMID>
    <AuthorListID>57</AuthorListID>
    <AuthorID>370</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22844514</PMID>
    <AuthorListID>57</AuthorListID>
    <AuthorID>371</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22844514</PMID>
    <AuthorListID>57</AuthorListID>
    <AuthorID>372</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22844514</PMID>
    <AuthorListID>57</AuthorListID>
    <AuthorID>373</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22844514</PMID>
    <AuthorListID>57</AuthorListID>
    <AuthorID>374</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22844514</PMID>
    <AuthorListID>57</AuthorListID>
    <AuthorID>375</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22844514</PMID>
    <AuthorListID>57</AuthorListID>
    <AuthorID>376</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22844514</PMID>
    <AuthorListID>57</AuthorListID>
    <AuthorID>377</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22844514</PMID>
    <AuthorListID>57</AuthorListID>
    <AuthorID>378</AuthorID>
    <AuthorOrder>11</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22844514</PMID>
    <AuthorListID>57</AuthorListID>
    <AuthorID>379</AuthorID>
    <AuthorOrder>12</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22844514</PMID>
    <AuthorListID>57</AuthorListID>
    <AuthorID>380</AuthorID>
    <AuthorOrder>13</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22844514</PMID>
    <AuthorListID>57</AuthorListID>
    <AuthorID>381</AuthorID>
    <AuthorOrder>14</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22844514</PMID>
    <AuthorListID>57</AuthorListID>
    <AuthorID>382</AuthorID>
    <AuthorOrder>15</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22844514</PMID>
    <AuthorListID>57</AuthorListID>
    <AuthorID>383</AuthorID>
    <AuthorOrder>16</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22844514</PMID>
    <AuthorListID>57</AuthorListID>
    <AuthorID>384</AuthorID>
    <AuthorOrder>17</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22844514</PMID>
    <AuthorListID>57</AuthorListID>
    <AuthorID>385</AuthorID>
    <AuthorOrder>18</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22792062</PMID>
    <AuthorListID>58</AuthorListID>
    <AuthorID>386</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22792062</PMID>
    <AuthorListID>58</AuthorListID>
    <AuthorID>387</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22792062</PMID>
    <AuthorListID>58</AuthorListID>
    <AuthorID>388</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22792062</PMID>
    <AuthorListID>58</AuthorListID>
    <AuthorID>389</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22792062</PMID>
    <AuthorListID>58</AuthorListID>
    <AuthorID>390</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22792062</PMID>
    <AuthorListID>58</AuthorListID>
    <AuthorID>391</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22792062</PMID>
    <AuthorListID>58</AuthorListID>
    <AuthorID>392</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22792062</PMID>
    <AuthorListID>58</AuthorListID>
    <AuthorID>393</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22792062</PMID>
    <AuthorListID>58</AuthorListID>
    <AuthorID>394</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22792062</PMID>
    <AuthorListID>58</AuthorListID>
    <AuthorID>395</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22792062</PMID>
    <AuthorListID>58</AuthorListID>
    <AuthorID>396</AuthorID>
    <AuthorOrder>11</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22792062</PMID>
    <AuthorListID>58</AuthorListID>
    <AuthorID>397</AuthorID>
    <AuthorOrder>12</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22749352</PMID>
    <AuthorListID>59</AuthorListID>
    <AuthorID>398</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22749352</PMID>
    <AuthorListID>59</AuthorListID>
    <AuthorID>399</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22749352</PMID>
    <AuthorListID>59</AuthorListID>
    <AuthorID>400</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22749352</PMID>
    <AuthorListID>59</AuthorListID>
    <AuthorID>401</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22749352</PMID>
    <AuthorListID>59</AuthorListID>
    <AuthorID>402</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22749352</PMID>
    <AuthorListID>59</AuthorListID>
    <AuthorID>403</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22749352</PMID>
    <AuthorListID>59</AuthorListID>
    <AuthorID>404</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22749352</PMID>
    <AuthorListID>59</AuthorListID>
    <AuthorID>405</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22749352</PMID>
    <AuthorListID>59</AuthorListID>
    <AuthorID>406</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22749352</PMID>
    <AuthorListID>59</AuthorListID>
    <AuthorID>407</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22749352</PMID>
    <AuthorListID>59</AuthorListID>
    <AuthorID>408</AuthorID>
    <AuthorOrder>11</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22749352</PMID>
    <AuthorListID>59</AuthorListID>
    <AuthorID>409</AuthorID>
    <AuthorOrder>12</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22749352</PMID>
    <AuthorListID>59</AuthorListID>
    <AuthorID>410</AuthorID>
    <AuthorOrder>13</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22674996</PMID>
    <AuthorListID>60</AuthorListID>
    <AuthorID>411</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22674996</PMID>
    <AuthorListID>60</AuthorListID>
    <AuthorID>412</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22674996</PMID>
    <AuthorListID>60</AuthorListID>
    <AuthorID>413</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22674996</PMID>
    <AuthorListID>60</AuthorListID>
    <AuthorID>414</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22664327</PMID>
    <AuthorListID>61</AuthorListID>
    <AuthorID>415</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22664327</PMID>
    <AuthorListID>61</AuthorListID>
    <AuthorID>416</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22626058</PMID>
    <AuthorListID>62</AuthorListID>
    <AuthorID>417</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22626058</PMID>
    <AuthorListID>62</AuthorListID>
    <AuthorID>418</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22626058</PMID>
    <AuthorListID>62</AuthorListID>
    <AuthorID>419</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22626058</PMID>
    <AuthorListID>62</AuthorListID>
    <AuthorID>420</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22626058</PMID>
    <AuthorListID>62</AuthorListID>
    <AuthorID>421</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22623799</PMID>
    <AuthorListID>63</AuthorListID>
    <AuthorID>422</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22623799</PMID>
    <AuthorListID>63</AuthorListID>
    <AuthorID>423</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22623799</PMID>
    <AuthorListID>63</AuthorListID>
    <AuthorID>424</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22623799</PMID>
    <AuthorListID>63</AuthorListID>
    <AuthorID>425</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22623799</PMID>
    <AuthorListID>63</AuthorListID>
    <AuthorID>426</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22623799</PMID>
    <AuthorListID>63</AuthorListID>
    <AuthorID>427</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22623799</PMID>
    <AuthorListID>63</AuthorListID>
    <AuthorID>428</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22623799</PMID>
    <AuthorListID>63</AuthorListID>
    <AuthorID>429</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22623799</PMID>
    <AuthorListID>63</AuthorListID>
    <AuthorID>430</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22623799</PMID>
    <AuthorListID>63</AuthorListID>
    <AuthorID>431</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22623799</PMID>
    <AuthorListID>63</AuthorListID>
    <AuthorID>432</AuthorID>
    <AuthorOrder>11</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22623799</PMID>
    <AuthorListID>63</AuthorListID>
    <AuthorID>433</AuthorID>
    <AuthorOrder>12</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22623799</PMID>
    <AuthorListID>63</AuthorListID>
    <AuthorID>434</AuthorID>
    <AuthorOrder>13</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22623799</PMID>
    <AuthorListID>63</AuthorListID>
    <AuthorID>435</AuthorID>
    <AuthorOrder>14</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22623778</PMID>
    <AuthorListID>64</AuthorListID>
    <AuthorID>436</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22623778</PMID>
    <AuthorListID>64</AuthorListID>
    <AuthorID>437</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22623778</PMID>
    <AuthorListID>64</AuthorListID>
    <AuthorID>438</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22623778</PMID>
    <AuthorListID>64</AuthorListID>
    <AuthorID>439</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22623778</PMID>
    <AuthorListID>64</AuthorListID>
    <AuthorID>440</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22623778</PMID>
    <AuthorListID>64</AuthorListID>
    <AuthorID>441</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22607805</PMID>
    <AuthorListID>65</AuthorListID>
    <AuthorID>442</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22607805</PMID>
    <AuthorListID>65</AuthorListID>
    <AuthorID>443</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22607805</PMID>
    <AuthorListID>65</AuthorListID>
    <AuthorID>444</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22607805</PMID>
    <AuthorListID>65</AuthorListID>
    <AuthorID>445</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22558311</PMID>
    <AuthorListID>66</AuthorListID>
    <AuthorID>446</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22558311</PMID>
    <AuthorListID>66</AuthorListID>
    <AuthorID>447</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22558311</PMID>
    <AuthorListID>66</AuthorListID>
    <AuthorID>448</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22558311</PMID>
    <AuthorListID>66</AuthorListID>
    <AuthorID>449</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22558311</PMID>
    <AuthorListID>66</AuthorListID>
    <AuthorID>450</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22532683</PMID>
    <AuthorListID>67</AuthorListID>
    <AuthorID>451</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22532683</PMID>
    <AuthorListID>67</AuthorListID>
    <AuthorID>452</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22532683</PMID>
    <AuthorListID>67</AuthorListID>
    <AuthorID>453</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22532683</PMID>
    <AuthorListID>67</AuthorListID>
    <AuthorID>454</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22532683</PMID>
    <AuthorListID>67</AuthorListID>
    <AuthorID>455</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22532683</PMID>
    <AuthorListID>67</AuthorListID>
    <AuthorID>456</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22532683</PMID>
    <AuthorListID>67</AuthorListID>
    <AuthorID>457</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22427742</PMID>
    <AuthorListID>69</AuthorListID>
    <AuthorID>458</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22427742</PMID>
    <AuthorListID>69</AuthorListID>
    <AuthorID>459</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22383950</PMID>
    <AuthorListID>70</AuthorListID>
    <AuthorID>460</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22383950</PMID>
    <AuthorListID>70</AuthorListID>
    <AuthorID>461</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22383950</PMID>
    <AuthorListID>70</AuthorListID>
    <AuthorID>462</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22383950</PMID>
    <AuthorListID>70</AuthorListID>
    <AuthorID>463</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22383950</PMID>
    <AuthorListID>70</AuthorListID>
    <AuthorID>464</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22383950</PMID>
    <AuthorListID>70</AuthorListID>
    <AuthorID>465</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22383950</PMID>
    <AuthorListID>70</AuthorListID>
    <AuthorID>466</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22345667</PMID>
    <AuthorListID>71</AuthorListID>
    <AuthorID>467</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22345667</PMID>
    <AuthorListID>71</AuthorListID>
    <AuthorID>468</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22341464</PMID>
    <AuthorListID>72</AuthorListID>
    <AuthorID>469</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22341464</PMID>
    <AuthorListID>72</AuthorListID>
    <AuthorID>470</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22341464</PMID>
    <AuthorListID>72</AuthorListID>
    <AuthorID>471</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22341464</PMID>
    <AuthorListID>72</AuthorListID>
    <AuthorID>472</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22341464</PMID>
    <AuthorListID>72</AuthorListID>
    <AuthorID>473</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22341464</PMID>
    <AuthorListID>72</AuthorListID>
    <AuthorID>474</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22341464</PMID>
    <AuthorListID>72</AuthorListID>
    <AuthorID>475</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22341464</PMID>
    <AuthorListID>72</AuthorListID>
    <AuthorID>476</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22312431</PMID>
    <AuthorListID>73</AuthorListID>
    <AuthorID>477</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22312431</PMID>
    <AuthorListID>73</AuthorListID>
    <AuthorID>478</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22312431</PMID>
    <AuthorListID>73</AuthorListID>
    <AuthorID>479</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22312431</PMID>
    <AuthorListID>73</AuthorListID>
    <AuthorID>480</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22312431</PMID>
    <AuthorListID>73</AuthorListID>
    <AuthorID>481</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22312431</PMID>
    <AuthorListID>73</AuthorListID>
    <AuthorID>482</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22312431</PMID>
    <AuthorListID>73</AuthorListID>
    <AuthorID>483</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22312431</PMID>
    <AuthorListID>73</AuthorListID>
    <AuthorID>484</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22312431</PMID>
    <AuthorListID>73</AuthorListID>
    <AuthorID>485</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22312431</PMID>
    <AuthorListID>73</AuthorListID>
    <AuthorID>486</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22312267</PMID>
    <AuthorListID>74</AuthorListID>
    <AuthorID>487</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22312267</PMID>
    <AuthorListID>74</AuthorListID>
    <AuthorID>488</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22312267</PMID>
    <AuthorListID>74</AuthorListID>
    <AuthorID>489</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22312267</PMID>
    <AuthorListID>74</AuthorListID>
    <AuthorID>490</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22312267</PMID>
    <AuthorListID>74</AuthorListID>
    <AuthorID>491</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22312267</PMID>
    <AuthorListID>74</AuthorListID>
    <AuthorID>492</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22312267</PMID>
    <AuthorListID>74</AuthorListID>
    <AuthorID>493</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22301138</PMID>
    <AuthorListID>75</AuthorListID>
    <AuthorID>494</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22301138</PMID>
    <AuthorListID>75</AuthorListID>
    <AuthorID>495</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22301138</PMID>
    <AuthorListID>75</AuthorListID>
    <AuthorID>496</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22301138</PMID>
    <AuthorListID>75</AuthorListID>
    <AuthorID>497</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22278390</PMID>
    <AuthorListID>76</AuthorListID>
    <AuthorID>498</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22278390</PMID>
    <AuthorListID>76</AuthorListID>
    <AuthorID>499</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22278390</PMID>
    <AuthorListID>76</AuthorListID>
    <AuthorID>500</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22278390</PMID>
    <AuthorListID>76</AuthorListID>
    <AuthorID>501</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22278390</PMID>
    <AuthorListID>76</AuthorListID>
    <AuthorID>502</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22278390</PMID>
    <AuthorListID>76</AuthorListID>
    <AuthorID>503</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22254549</PMID>
    <AuthorListID>78</AuthorListID>
    <AuthorID>504</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22254549</PMID>
    <AuthorListID>78</AuthorListID>
    <AuthorID>505</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22254549</PMID>
    <AuthorListID>78</AuthorListID>
    <AuthorID>506</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22254549</PMID>
    <AuthorListID>78</AuthorListID>
    <AuthorID>507</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22254549</PMID>
    <AuthorListID>78</AuthorListID>
    <AuthorID>508</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22254549</PMID>
    <AuthorListID>78</AuthorListID>
    <AuthorID>509</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22254549</PMID>
    <AuthorListID>78</AuthorListID>
    <AuthorID>510</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22238314</PMID>
    <AuthorListID>79</AuthorListID>
    <AuthorID>511</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22235281</PMID>
    <AuthorListID>80</AuthorListID>
    <AuthorID>512</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22235281</PMID>
    <AuthorListID>80</AuthorListID>
    <AuthorID>513</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22235281</PMID>
    <AuthorListID>80</AuthorListID>
    <AuthorID>514</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22235281</PMID>
    <AuthorListID>80</AuthorListID>
    <AuthorID>515</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22235281</PMID>
    <AuthorListID>80</AuthorListID>
    <AuthorID>516</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22235281</PMID>
    <AuthorListID>80</AuthorListID>
    <AuthorID>517</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22235281</PMID>
    <AuthorListID>80</AuthorListID>
    <AuthorID>518</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22235281</PMID>
    <AuthorListID>80</AuthorListID>
    <AuthorID>519</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22235281</PMID>
    <AuthorListID>80</AuthorListID>
    <AuthorID>520</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22235281</PMID>
    <AuthorListID>80</AuthorListID>
    <AuthorID>521</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22235281</PMID>
    <AuthorListID>80</AuthorListID>
    <AuthorID>522</AuthorID>
    <AuthorOrder>11</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22235281</PMID>
    <AuthorListID>80</AuthorListID>
    <AuthorID>523</AuthorID>
    <AuthorOrder>12</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22152002</PMID>
    <AuthorListID>81</AuthorListID>
    <AuthorID>524</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22152002</PMID>
    <AuthorListID>81</AuthorListID>
    <AuthorID>525</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22152002</PMID>
    <AuthorListID>81</AuthorListID>
    <AuthorID>526</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22152002</PMID>
    <AuthorListID>81</AuthorListID>
    <AuthorID>527</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22152002</PMID>
    <AuthorListID>81</AuthorListID>
    <AuthorID>528</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22152002</PMID>
    <AuthorListID>81</AuthorListID>
    <AuthorID>529</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22152002</PMID>
    <AuthorListID>81</AuthorListID>
    <AuthorID>530</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22131337</PMID>
    <AuthorListID>82</AuthorListID>
    <AuthorID>531</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22131337</PMID>
    <AuthorListID>82</AuthorListID>
    <AuthorID>532</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22131337</PMID>
    <AuthorListID>82</AuthorListID>
    <AuthorID>533</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22131337</PMID>
    <AuthorListID>82</AuthorListID>
    <AuthorID>534</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22131337</PMID>
    <AuthorListID>82</AuthorListID>
    <AuthorID>535</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22131337</PMID>
    <AuthorListID>82</AuthorListID>
    <AuthorID>536</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22110409</PMID>
    <AuthorListID>83</AuthorListID>
    <AuthorID>537</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22110409</PMID>
    <AuthorListID>83</AuthorListID>
    <AuthorID>538</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22105485</PMID>
    <AuthorListID>84</AuthorListID>
    <AuthorID>539</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22050228</PMID>
    <AuthorListID>85</AuthorListID>
    <AuthorID>540</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22050228</PMID>
    <AuthorListID>85</AuthorListID>
    <AuthorID>541</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22050228</PMID>
    <AuthorListID>85</AuthorListID>
    <AuthorID>542</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22050228</PMID>
    <AuthorListID>85</AuthorListID>
    <AuthorID>543</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22050228</PMID>
    <AuthorListID>85</AuthorListID>
    <AuthorID>544</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22050228</PMID>
    <AuthorListID>85</AuthorListID>
    <AuthorID>545</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22050228</PMID>
    <AuthorListID>85</AuthorListID>
    <AuthorID>546</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22039483</PMID>
    <AuthorListID>86</AuthorListID>
    <AuthorID>547</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22039483</PMID>
    <AuthorListID>86</AuthorListID>
    <AuthorID>548</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22039483</PMID>
    <AuthorListID>86</AuthorListID>
    <AuthorID>549</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22039483</PMID>
    <AuthorListID>86</AuthorListID>
    <AuthorID>550</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22039483</PMID>
    <AuthorListID>86</AuthorListID>
    <AuthorID>551</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22039483</PMID>
    <AuthorListID>86</AuthorListID>
    <AuthorID>552</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22039483</PMID>
    <AuthorListID>86</AuthorListID>
    <AuthorID>553</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22032846</PMID>
    <AuthorListID>87</AuthorListID>
    <AuthorID>554</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22032846</PMID>
    <AuthorListID>87</AuthorListID>
    <AuthorID>555</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22032846</PMID>
    <AuthorListID>87</AuthorListID>
    <AuthorID>556</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22032846</PMID>
    <AuthorListID>87</AuthorListID>
    <AuthorID>557</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22032846</PMID>
    <AuthorListID>87</AuthorListID>
    <AuthorID>558</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22032846</PMID>
    <AuthorListID>87</AuthorListID>
    <AuthorID>559</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22032846</PMID>
    <AuthorListID>87</AuthorListID>
    <AuthorID>560</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22032846</PMID>
    <AuthorListID>87</AuthorListID>
    <AuthorID>561</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22022264</PMID>
    <AuthorListID>88</AuthorListID>
    <AuthorID>562</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22022264</PMID>
    <AuthorListID>88</AuthorListID>
    <AuthorID>563</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22022264</PMID>
    <AuthorListID>88</AuthorListID>
    <AuthorID>564</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22022264</PMID>
    <AuthorListID>88</AuthorListID>
    <AuthorID>565</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22022264</PMID>
    <AuthorListID>88</AuthorListID>
    <AuthorID>566</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22022264</PMID>
    <AuthorListID>88</AuthorListID>
    <AuthorID>567</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22022264</PMID>
    <AuthorListID>88</AuthorListID>
    <AuthorID>568</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22022264</PMID>
    <AuthorListID>88</AuthorListID>
    <AuthorID>569</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21997372</PMID>
    <AuthorListID>89</AuthorListID>
    <AuthorID>570</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21997372</PMID>
    <AuthorListID>89</AuthorListID>
    <AuthorID>571</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21997372</PMID>
    <AuthorListID>89</AuthorListID>
    <AuthorID>572</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21997372</PMID>
    <AuthorListID>89</AuthorListID>
    <AuthorID>573</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21937652</PMID>
    <AuthorListID>90</AuthorListID>
    <AuthorID>574</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21937652</PMID>
    <AuthorListID>90</AuthorListID>
    <AuthorID>575</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21937652</PMID>
    <AuthorListID>90</AuthorListID>
    <AuthorID>576</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21937652</PMID>
    <AuthorListID>90</AuthorListID>
    <AuthorID>577</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21937652</PMID>
    <AuthorListID>90</AuthorListID>
    <AuthorID>578</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21937652</PMID>
    <AuthorListID>90</AuthorListID>
    <AuthorID>579</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21937652</PMID>
    <AuthorListID>90</AuthorListID>
    <AuthorID>580</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21931545</PMID>
    <AuthorListID>91</AuthorListID>
    <AuthorID>581</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21931545</PMID>
    <AuthorListID>91</AuthorListID>
    <AuthorID>582</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21931545</PMID>
    <AuthorListID>91</AuthorListID>
    <AuthorID>583</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21931545</PMID>
    <AuthorListID>91</AuthorListID>
    <AuthorID>584</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21931545</PMID>
    <AuthorListID>91</AuthorListID>
    <AuthorID>585</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21931545</PMID>
    <AuthorListID>91</AuthorListID>
    <AuthorID>586</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21931357</PMID>
    <AuthorListID>92</AuthorListID>
    <AuthorID>587</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21931357</PMID>
    <AuthorListID>92</AuthorListID>
    <AuthorID>588</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21931357</PMID>
    <AuthorListID>92</AuthorListID>
    <AuthorID>589</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21899695</PMID>
    <AuthorListID>93</AuthorListID>
    <AuthorID>590</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21899695</PMID>
    <AuthorListID>93</AuthorListID>
    <AuthorID>591</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21899695</PMID>
    <AuthorListID>93</AuthorListID>
    <AuthorID>592</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21844353</PMID>
    <AuthorListID>95</AuthorListID>
    <AuthorID>593</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21813773</PMID>
    <AuthorListID>96</AuthorListID>
    <AuthorID>594</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21813773</PMID>
    <AuthorListID>96</AuthorListID>
    <AuthorID>595</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21813773</PMID>
    <AuthorListID>96</AuthorListID>
    <AuthorID>596</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21806875</PMID>
    <AuthorListID>97</AuthorListID>
    <AuthorID>597</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21806875</PMID>
    <AuthorListID>97</AuthorListID>
    <AuthorID>598</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21806875</PMID>
    <AuthorListID>97</AuthorListID>
    <AuthorID>599</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21806875</PMID>
    <AuthorListID>97</AuthorListID>
    <AuthorID>600</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21806875</PMID>
    <AuthorListID>97</AuthorListID>
    <AuthorID>601</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21806875</PMID>
    <AuthorListID>97</AuthorListID>
    <AuthorID>602</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21799518</PMID>
    <AuthorListID>98</AuthorListID>
    <AuthorID>603</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21799518</PMID>
    <AuthorListID>98</AuthorListID>
    <AuthorID>604</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21799518</PMID>
    <AuthorListID>98</AuthorListID>
    <AuthorID>605</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21782231</PMID>
    <AuthorListID>100</AuthorListID>
    <AuthorID>606</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21782231</PMID>
    <AuthorListID>100</AuthorListID>
    <AuthorID>607</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21782231</PMID>
    <AuthorListID>100</AuthorListID>
    <AuthorID>608</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21782231</PMID>
    <AuthorListID>100</AuthorListID>
    <AuthorID>609</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21703540</PMID>
    <AuthorListID>101</AuthorListID>
    <AuthorID>610</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21703540</PMID>
    <AuthorListID>101</AuthorListID>
    <AuthorID>611</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21703540</PMID>
    <AuthorListID>101</AuthorListID>
    <AuthorID>612</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21703540</PMID>
    <AuthorListID>101</AuthorListID>
    <AuthorID>613</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21703540</PMID>
    <AuthorListID>101</AuthorListID>
    <AuthorID>614</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21703540</PMID>
    <AuthorListID>101</AuthorListID>
    <AuthorID>615</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21703540</PMID>
    <AuthorListID>101</AuthorListID>
    <AuthorID>616</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21703540</PMID>
    <AuthorListID>101</AuthorListID>
    <AuthorID>617</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21703540</PMID>
    <AuthorListID>101</AuthorListID>
    <AuthorID>618</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21703540</PMID>
    <AuthorListID>101</AuthorListID>
    <AuthorID>619</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21703540</PMID>
    <AuthorListID>101</AuthorListID>
    <AuthorID>620</AuthorID>
    <AuthorOrder>11</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21698224</PMID>
    <AuthorListID>102</AuthorListID>
    <AuthorID>621</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21698224</PMID>
    <AuthorListID>102</AuthorListID>
    <AuthorID>622</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21698224</PMID>
    <AuthorListID>102</AuthorListID>
    <AuthorID>623</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21698224</PMID>
    <AuthorListID>102</AuthorListID>
    <AuthorID>624</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21698224</PMID>
    <AuthorListID>102</AuthorListID>
    <AuthorID>625</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21698224</PMID>
    <AuthorListID>102</AuthorListID>
    <AuthorID>626</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21698224</PMID>
    <AuthorListID>102</AuthorListID>
    <AuthorID>627</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21698224</PMID>
    <AuthorListID>102</AuthorListID>
    <AuthorID>628</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21698224</PMID>
    <AuthorListID>102</AuthorListID>
    <AuthorID>629</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21698224</PMID>
    <AuthorListID>102</AuthorListID>
    <AuthorID>630</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21698224</PMID>
    <AuthorListID>102</AuthorListID>
    <AuthorID>631</AuthorID>
    <AuthorOrder>11</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21695240</PMID>
    <AuthorListID>103</AuthorListID>
    <AuthorID>632</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21695240</PMID>
    <AuthorListID>103</AuthorListID>
    <AuthorID>633</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21695240</PMID>
    <AuthorListID>103</AuthorListID>
    <AuthorID>634</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21695240</PMID>
    <AuthorListID>103</AuthorListID>
    <AuthorID>635</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21626268</PMID>
    <AuthorListID>104</AuthorListID>
    <AuthorID>636</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21626268</PMID>
    <AuthorListID>104</AuthorListID>
    <AuthorID>637</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21617692</PMID>
    <AuthorListID>105</AuthorListID>
    <AuthorID>638</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21617692</PMID>
    <AuthorListID>105</AuthorListID>
    <AuthorID>639</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21617692</PMID>
    <AuthorListID>105</AuthorListID>
    <AuthorID>640</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21617692</PMID>
    <AuthorListID>105</AuthorListID>
    <AuthorID>641</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21617692</PMID>
    <AuthorListID>105</AuthorListID>
    <AuthorID>642</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21617692</PMID>
    <AuthorListID>105</AuthorListID>
    <AuthorID>643</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21527281</PMID>
    <AuthorListID>106</AuthorListID>
    <AuthorID>644</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21527281</PMID>
    <AuthorListID>106</AuthorListID>
    <AuthorID>645</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21527281</PMID>
    <AuthorListID>106</AuthorListID>
    <AuthorID>646</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21527281</PMID>
    <AuthorListID>106</AuthorListID>
    <AuthorID>647</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21527281</PMID>
    <AuthorListID>106</AuthorListID>
    <AuthorID>648</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21527281</PMID>
    <AuthorListID>106</AuthorListID>
    <AuthorID>649</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21527281</PMID>
    <AuthorListID>106</AuthorListID>
    <AuthorID>650</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21527281</PMID>
    <AuthorListID>106</AuthorListID>
    <AuthorID>651</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21527281</PMID>
    <AuthorListID>106</AuthorListID>
    <AuthorID>652</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21527281</PMID>
    <AuthorListID>106</AuthorListID>
    <AuthorID>653</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21527281</PMID>
    <AuthorListID>106</AuthorListID>
    <AuthorID>654</AuthorID>
    <AuthorOrder>11</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21507982</PMID>
    <AuthorListID>107</AuthorListID>
    <AuthorID>655</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21507982</PMID>
    <AuthorListID>107</AuthorListID>
    <AuthorID>656</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21507982</PMID>
    <AuthorListID>107</AuthorListID>
    <AuthorID>657</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21507982</PMID>
    <AuthorListID>107</AuthorListID>
    <AuthorID>658</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21507982</PMID>
    <AuthorListID>107</AuthorListID>
    <AuthorID>659</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21507982</PMID>
    <AuthorListID>107</AuthorListID>
    <AuthorID>660</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21436888</PMID>
    <AuthorListID>109</AuthorListID>
    <AuthorID>661</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21436888</PMID>
    <AuthorListID>109</AuthorListID>
    <AuthorID>662</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21436888</PMID>
    <AuthorListID>109</AuthorListID>
    <AuthorID>663</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21436888</PMID>
    <AuthorListID>109</AuthorListID>
    <AuthorID>664</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21436888</PMID>
    <AuthorListID>109</AuthorListID>
    <AuthorID>665</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21425308</PMID>
    <AuthorListID>110</AuthorListID>
    <AuthorID>666</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21425308</PMID>
    <AuthorListID>110</AuthorListID>
    <AuthorID>667</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21425308</PMID>
    <AuthorListID>110</AuthorListID>
    <AuthorID>668</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21425308</PMID>
    <AuthorListID>110</AuthorListID>
    <AuthorID>669</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21425308</PMID>
    <AuthorListID>110</AuthorListID>
    <AuthorID>670</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21425308</PMID>
    <AuthorListID>110</AuthorListID>
    <AuthorID>671</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21425308</PMID>
    <AuthorListID>110</AuthorListID>
    <AuthorID>672</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21425308</PMID>
    <AuthorListID>110</AuthorListID>
    <AuthorID>673</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21285412</PMID>
    <AuthorListID>111</AuthorListID>
    <AuthorID>674</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21285412</PMID>
    <AuthorListID>111</AuthorListID>
    <AuthorID>675</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21268286</PMID>
    <AuthorListID>112</AuthorListID>
    <AuthorID>676</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21268286</PMID>
    <AuthorListID>112</AuthorListID>
    <AuthorID>677</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21268286</PMID>
    <AuthorListID>112</AuthorListID>
    <AuthorID>678</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21268286</PMID>
    <AuthorListID>112</AuthorListID>
    <AuthorID>679</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21268286</PMID>
    <AuthorListID>112</AuthorListID>
    <AuthorID>680</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21216621</PMID>
    <AuthorListID>114</AuthorListID>
    <AuthorID>681</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21216621</PMID>
    <AuthorListID>114</AuthorListID>
    <AuthorID>682</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21216621</PMID>
    <AuthorListID>114</AuthorListID>
    <AuthorID>683</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21216621</PMID>
    <AuthorListID>114</AuthorListID>
    <AuthorID>684</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21216621</PMID>
    <AuthorListID>114</AuthorListID>
    <AuthorID>685</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21216621</PMID>
    <AuthorListID>114</AuthorListID>
    <AuthorID>686</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21200404</PMID>
    <AuthorListID>115</AuthorListID>
    <AuthorID>687</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21200404</PMID>
    <AuthorListID>115</AuthorListID>
    <AuthorID>688</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21200404</PMID>
    <AuthorListID>115</AuthorListID>
    <AuthorID>689</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21200404</PMID>
    <AuthorListID>115</AuthorListID>
    <AuthorID>690</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21200404</PMID>
    <AuthorListID>115</AuthorListID>
    <AuthorID>691</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21200404</PMID>
    <AuthorListID>115</AuthorListID>
    <AuthorID>692</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21187438</PMID>
    <AuthorListID>116</AuthorListID>
    <AuthorID>693</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21187438</PMID>
    <AuthorListID>116</AuthorListID>
    <AuthorID>694</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21187438</PMID>
    <AuthorListID>116</AuthorListID>
    <AuthorID>695</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21187438</PMID>
    <AuthorListID>116</AuthorListID>
    <AuthorID>696</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21170385</PMID>
    <AuthorListID>117</AuthorListID>
    <AuthorID>697</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21170385</PMID>
    <AuthorListID>117</AuthorListID>
    <AuthorID>698</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21170385</PMID>
    <AuthorListID>117</AuthorListID>
    <AuthorID>699</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21170385</PMID>
    <AuthorListID>117</AuthorListID>
    <AuthorID>700</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21170385</PMID>
    <AuthorListID>117</AuthorListID>
    <AuthorID>701</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21105190</PMID>
    <AuthorListID>118</AuthorListID>
    <AuthorID>702</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21105190</PMID>
    <AuthorListID>118</AuthorListID>
    <AuthorID>703</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21105190</PMID>
    <AuthorListID>118</AuthorListID>
    <AuthorID>704</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21105190</PMID>
    <AuthorListID>118</AuthorListID>
    <AuthorID>705</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21105190</PMID>
    <AuthorListID>118</AuthorListID>
    <AuthorID>706</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21105190</PMID>
    <AuthorListID>118</AuthorListID>
    <AuthorID>707</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21105190</PMID>
    <AuthorListID>118</AuthorListID>
    <AuthorID>708</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21105190</PMID>
    <AuthorListID>118</AuthorListID>
    <AuthorID>709</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20832207</PMID>
    <AuthorListID>120</AuthorListID>
    <AuthorID>710</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20832207</PMID>
    <AuthorListID>120</AuthorListID>
    <AuthorID>711</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20832207</PMID>
    <AuthorListID>120</AuthorListID>
    <AuthorID>712</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20832207</PMID>
    <AuthorListID>120</AuthorListID>
    <AuthorID>713</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20824343</PMID>
    <AuthorListID>121</AuthorListID>
    <AuthorID>714</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20824343</PMID>
    <AuthorListID>121</AuthorListID>
    <AuthorID>715</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20824343</PMID>
    <AuthorListID>121</AuthorListID>
    <AuthorID>716</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20824343</PMID>
    <AuthorListID>121</AuthorListID>
    <AuthorID>717</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20824343</PMID>
    <AuthorListID>121</AuthorListID>
    <AuthorID>718</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20824343</PMID>
    <AuthorListID>121</AuthorListID>
    <AuthorID>719</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20824343</PMID>
    <AuthorListID>121</AuthorListID>
    <AuthorID>720</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20824343</PMID>
    <AuthorListID>121</AuthorListID>
    <AuthorID>721</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20739519</PMID>
    <AuthorListID>123</AuthorListID>
    <AuthorID>722</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20739519</PMID>
    <AuthorListID>123</AuthorListID>
    <AuthorID>723</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20699406</PMID>
    <AuthorListID>124</AuthorListID>
    <AuthorID>724</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20699406</PMID>
    <AuthorListID>124</AuthorListID>
    <AuthorID>725</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20699406</PMID>
    <AuthorListID>124</AuthorListID>
    <AuthorID>726</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20686657</PMID>
    <AuthorListID>125</AuthorListID>
    <AuthorID>727</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20686657</PMID>
    <AuthorListID>125</AuthorListID>
    <AuthorID>728</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20686657</PMID>
    <AuthorListID>125</AuthorListID>
    <AuthorID>729</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20686657</PMID>
    <AuthorListID>125</AuthorListID>
    <AuthorID>730</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20686657</PMID>
    <AuthorListID>125</AuthorListID>
    <AuthorID>731</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20661427</PMID>
    <AuthorListID>126</AuthorListID>
    <AuthorID>732</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20661427</PMID>
    <AuthorListID>126</AuthorListID>
    <AuthorID>733</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20661427</PMID>
    <AuthorListID>126</AuthorListID>
    <AuthorID>734</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20661427</PMID>
    <AuthorListID>126</AuthorListID>
    <AuthorID>735</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20643110</PMID>
    <AuthorListID>127</AuthorListID>
    <AuthorID>736</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20643110</PMID>
    <AuthorListID>127</AuthorListID>
    <AuthorID>737</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20643110</PMID>
    <AuthorListID>127</AuthorListID>
    <AuthorID>738</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20628368</PMID>
    <AuthorListID>128</AuthorListID>
    <AuthorID>739</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20610716</PMID>
    <AuthorListID>129</AuthorListID>
    <AuthorID>740</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20610716</PMID>
    <AuthorListID>129</AuthorListID>
    <AuthorID>741</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20592086</PMID>
    <AuthorListID>130</AuthorListID>
    <AuthorID>742</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20592086</PMID>
    <AuthorListID>130</AuthorListID>
    <AuthorID>743</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20592086</PMID>
    <AuthorListID>130</AuthorListID>
    <AuthorID>744</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20592086</PMID>
    <AuthorListID>130</AuthorListID>
    <AuthorID>745</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20592086</PMID>
    <AuthorListID>130</AuthorListID>
    <AuthorID>746</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20554965</PMID>
    <AuthorListID>131</AuthorListID>
    <AuthorID>747</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20554965</PMID>
    <AuthorListID>131</AuthorListID>
    <AuthorID>748</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20554965</PMID>
    <AuthorListID>131</AuthorListID>
    <AuthorID>749</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20554965</PMID>
    <AuthorListID>131</AuthorListID>
    <AuthorID>750</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20554965</PMID>
    <AuthorListID>131</AuthorListID>
    <AuthorID>751</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20554965</PMID>
    <AuthorListID>131</AuthorListID>
    <AuthorID>752</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20554965</PMID>
    <AuthorListID>131</AuthorListID>
    <AuthorID>753</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20554965</PMID>
    <AuthorListID>131</AuthorListID>
    <AuthorID>754</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20554965</PMID>
    <AuthorListID>131</AuthorListID>
    <AuthorID>755</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20554965</PMID>
    <AuthorListID>131</AuthorListID>
    <AuthorID>756</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20554965</PMID>
    <AuthorListID>131</AuthorListID>
    <AuthorID>757</AuthorID>
    <AuthorOrder>11</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20538852</PMID>
    <AuthorListID>132</AuthorListID>
    <AuthorID>758</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20538852</PMID>
    <AuthorListID>132</AuthorListID>
    <AuthorID>759</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20538852</PMID>
    <AuthorListID>132</AuthorListID>
    <AuthorID>760</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20538852</PMID>
    <AuthorListID>132</AuthorListID>
    <AuthorID>761</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20538852</PMID>
    <AuthorListID>132</AuthorListID>
    <AuthorID>762</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20538852</PMID>
    <AuthorListID>132</AuthorListID>
    <AuthorID>763</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20538852</PMID>
    <AuthorListID>132</AuthorListID>
    <AuthorID>764</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20532218</PMID>
    <AuthorListID>133</AuthorListID>
    <AuthorID>765</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20532218</PMID>
    <AuthorListID>133</AuthorListID>
    <AuthorID>766</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20532218</PMID>
    <AuthorListID>133</AuthorListID>
    <AuthorID>767</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20532218</PMID>
    <AuthorListID>133</AuthorListID>
    <AuthorID>768</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20532218</PMID>
    <AuthorListID>133</AuthorListID>
    <AuthorID>769</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20532218</PMID>
    <AuthorListID>133</AuthorListID>
    <AuthorID>770</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20532218</PMID>
    <AuthorListID>133</AuthorListID>
    <AuthorID>771</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20532218</PMID>
    <AuthorListID>133</AuthorListID>
    <AuthorID>772</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20532218</PMID>
    <AuthorListID>133</AuthorListID>
    <AuthorID>773</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20485506</PMID>
    <AuthorListID>134</AuthorListID>
    <AuthorID>774</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20485506</PMID>
    <AuthorListID>134</AuthorListID>
    <AuthorID>775</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20485506</PMID>
    <AuthorListID>134</AuthorListID>
    <AuthorID>776</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20485506</PMID>
    <AuthorListID>134</AuthorListID>
    <AuthorID>777</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20485506</PMID>
    <AuthorListID>134</AuthorListID>
    <AuthorID>778</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20451243</PMID>
    <AuthorListID>135</AuthorListID>
    <AuthorID>779</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20451243</PMID>
    <AuthorListID>135</AuthorListID>
    <AuthorID>780</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20451243</PMID>
    <AuthorListID>135</AuthorListID>
    <AuthorID>781</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20451243</PMID>
    <AuthorListID>135</AuthorListID>
    <AuthorID>782</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20451243</PMID>
    <AuthorListID>135</AuthorListID>
    <AuthorID>783</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20451243</PMID>
    <AuthorListID>135</AuthorListID>
    <AuthorID>784</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20451243</PMID>
    <AuthorListID>135</AuthorListID>
    <AuthorID>785</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20451243</PMID>
    <AuthorListID>135</AuthorListID>
    <AuthorID>786</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20451243</PMID>
    <AuthorListID>135</AuthorListID>
    <AuthorID>787</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20451243</PMID>
    <AuthorListID>135</AuthorListID>
    <AuthorID>788</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20434986</PMID>
    <AuthorListID>136</AuthorListID>
    <AuthorID>789</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20434986</PMID>
    <AuthorListID>136</AuthorListID>
    <AuthorID>790</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20434986</PMID>
    <AuthorListID>136</AuthorListID>
    <AuthorID>791</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20434986</PMID>
    <AuthorListID>136</AuthorListID>
    <AuthorID>792</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20434986</PMID>
    <AuthorListID>136</AuthorListID>
    <AuthorID>793</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20434986</PMID>
    <AuthorListID>136</AuthorListID>
    <AuthorID>794</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20434986</PMID>
    <AuthorListID>136</AuthorListID>
    <AuthorID>795</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20434986</PMID>
    <AuthorListID>136</AuthorListID>
    <AuthorID>796</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20434986</PMID>
    <AuthorListID>136</AuthorListID>
    <AuthorID>797</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20434986</PMID>
    <AuthorListID>136</AuthorListID>
    <AuthorID>798</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20410276</PMID>
    <AuthorListID>137</AuthorListID>
    <AuthorID>799</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20410276</PMID>
    <AuthorListID>137</AuthorListID>
    <AuthorID>800</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20407122</PMID>
    <AuthorListID>138</AuthorListID>
    <AuthorID>801</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20406818</PMID>
    <AuthorListID>139</AuthorListID>
    <AuthorID>802</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20406818</PMID>
    <AuthorListID>139</AuthorListID>
    <AuthorID>803</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20406818</PMID>
    <AuthorListID>139</AuthorListID>
    <AuthorID>804</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20406818</PMID>
    <AuthorListID>139</AuthorListID>
    <AuthorID>805</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20406818</PMID>
    <AuthorListID>139</AuthorListID>
    <AuthorID>806</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20406818</PMID>
    <AuthorListID>139</AuthorListID>
    <AuthorID>807</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20406818</PMID>
    <AuthorListID>139</AuthorListID>
    <AuthorID>808</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20406818</PMID>
    <AuthorListID>139</AuthorListID>
    <AuthorID>809</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20403326</PMID>
    <AuthorListID>140</AuthorListID>
    <AuthorID>810</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20403326</PMID>
    <AuthorListID>140</AuthorListID>
    <AuthorID>811</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20403326</PMID>
    <AuthorListID>140</AuthorListID>
    <AuthorID>812</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20403326</PMID>
    <AuthorListID>140</AuthorListID>
    <AuthorID>813</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20386371</PMID>
    <AuthorListID>141</AuthorListID>
    <AuthorID>814</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20223737</PMID>
    <AuthorListID>142</AuthorListID>
    <AuthorID>815</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20223737</PMID>
    <AuthorListID>142</AuthorListID>
    <AuthorID>816</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20223737</PMID>
    <AuthorListID>142</AuthorListID>
    <AuthorID>817</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20223737</PMID>
    <AuthorListID>142</AuthorListID>
    <AuthorID>818</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20206303</PMID>
    <AuthorListID>143</AuthorListID>
    <AuthorID>819</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20161788</PMID>
    <AuthorListID>144</AuthorListID>
    <AuthorID>820</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20161788</PMID>
    <AuthorListID>144</AuthorListID>
    <AuthorID>821</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20154210</PMID>
    <AuthorListID>145</AuthorListID>
    <AuthorID>822</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20154210</PMID>
    <AuthorListID>145</AuthorListID>
    <AuthorID>823</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20154210</PMID>
    <AuthorListID>145</AuthorListID>
    <AuthorID>824</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20154210</PMID>
    <AuthorListID>145</AuthorListID>
    <AuthorID>825</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20154210</PMID>
    <AuthorListID>145</AuthorListID>
    <AuthorID>826</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20154210</PMID>
    <AuthorListID>145</AuthorListID>
    <AuthorID>827</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20154210</PMID>
    <AuthorListID>145</AuthorListID>
    <AuthorID>828</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20154210</PMID>
    <AuthorListID>145</AuthorListID>
    <AuthorID>829</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20154210</PMID>
    <AuthorListID>145</AuthorListID>
    <AuthorID>830</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20044805</PMID>
    <AuthorListID>147</AuthorListID>
    <AuthorID>831</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20044805</PMID>
    <AuthorListID>147</AuthorListID>
    <AuthorID>832</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20044805</PMID>
    <AuthorListID>147</AuthorListID>
    <AuthorID>833</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20044805</PMID>
    <AuthorListID>147</AuthorListID>
    <AuthorID>834</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20044805</PMID>
    <AuthorListID>147</AuthorListID>
    <AuthorID>835</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20044805</PMID>
    <AuthorListID>147</AuthorListID>
    <AuthorID>836</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20044805</PMID>
    <AuthorListID>147</AuthorListID>
    <AuthorID>837</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20044805</PMID>
    <AuthorListID>147</AuthorListID>
    <AuthorID>838</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20044805</PMID>
    <AuthorListID>147</AuthorListID>
    <AuthorID>839</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20044805</PMID>
    <AuthorListID>147</AuthorListID>
    <AuthorID>840</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20044805</PMID>
    <AuthorListID>147</AuthorListID>
    <AuthorID>841</AuthorID>
    <AuthorOrder>11</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20032188</PMID>
    <AuthorListID>148</AuthorListID>
    <AuthorID>842</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20032188</PMID>
    <AuthorListID>148</AuthorListID>
    <AuthorID>843</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20032188</PMID>
    <AuthorListID>148</AuthorListID>
    <AuthorID>844</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20032188</PMID>
    <AuthorListID>148</AuthorListID>
    <AuthorID>845</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20032188</PMID>
    <AuthorListID>148</AuthorListID>
    <AuthorID>846</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20007272</PMID>
    <AuthorListID>150</AuthorListID>
    <AuthorID>847</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20007272</PMID>
    <AuthorListID>150</AuthorListID>
    <AuthorID>848</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20007272</PMID>
    <AuthorListID>150</AuthorListID>
    <AuthorID>849</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19956647</PMID>
    <AuthorListID>151</AuthorListID>
    <AuthorID>850</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19956647</PMID>
    <AuthorListID>151</AuthorListID>
    <AuthorID>851</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19956647</PMID>
    <AuthorListID>151</AuthorListID>
    <AuthorID>852</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19956647</PMID>
    <AuthorListID>151</AuthorListID>
    <AuthorID>853</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19956647</PMID>
    <AuthorListID>151</AuthorListID>
    <AuthorID>854</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19915568</PMID>
    <AuthorListID>152</AuthorListID>
    <AuthorID>855</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19915568</PMID>
    <AuthorListID>152</AuthorListID>
    <AuthorID>856</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19915568</PMID>
    <AuthorListID>152</AuthorListID>
    <AuthorID>857</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19915568</PMID>
    <AuthorListID>152</AuthorListID>
    <AuthorID>858</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19915568</PMID>
    <AuthorListID>152</AuthorListID>
    <AuthorID>859</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19915568</PMID>
    <AuthorListID>152</AuthorListID>
    <AuthorID>860</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19915568</PMID>
    <AuthorListID>152</AuthorListID>
    <AuthorID>861</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19915568</PMID>
    <AuthorListID>152</AuthorListID>
    <AuthorID>862</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19915568</PMID>
    <AuthorListID>152</AuthorListID>
    <AuthorID>863</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19915568</PMID>
    <AuthorListID>152</AuthorListID>
    <AuthorID>864</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19915568</PMID>
    <AuthorListID>152</AuthorListID>
    <AuthorID>865</AuthorID>
    <AuthorOrder>11</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19915568</PMID>
    <AuthorListID>152</AuthorListID>
    <AuthorID>866</AuthorID>
    <AuthorOrder>12</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19914245</PMID>
    <AuthorListID>153</AuthorListID>
    <AuthorID>867</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19893624</PMID>
    <AuthorListID>154</AuthorListID>
    <AuthorID>868</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19893624</PMID>
    <AuthorListID>154</AuthorListID>
    <AuthorID>869</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19893624</PMID>
    <AuthorListID>154</AuthorListID>
    <AuthorID>870</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19893624</PMID>
    <AuthorListID>154</AuthorListID>
    <AuthorID>871</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19893624</PMID>
    <AuthorListID>154</AuthorListID>
    <AuthorID>872</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19881509</PMID>
    <AuthorListID>155</AuthorListID>
    <AuthorID>873</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19881509</PMID>
    <AuthorListID>155</AuthorListID>
    <AuthorID>874</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19881509</PMID>
    <AuthorListID>155</AuthorListID>
    <AuthorID>875</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19881509</PMID>
    <AuthorListID>155</AuthorListID>
    <AuthorID>876</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19859543</PMID>
    <AuthorListID>156</AuthorListID>
    <AuthorID>877</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19859543</PMID>
    <AuthorListID>156</AuthorListID>
    <AuthorID>878</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19859543</PMID>
    <AuthorListID>156</AuthorListID>
    <AuthorID>879</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19859543</PMID>
    <AuthorListID>156</AuthorListID>
    <AuthorID>880</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19859543</PMID>
    <AuthorListID>156</AuthorListID>
    <AuthorID>881</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19859543</PMID>
    <AuthorListID>156</AuthorListID>
    <AuthorID>882</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19859543</PMID>
    <AuthorListID>156</AuthorListID>
    <AuthorID>883</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19859543</PMID>
    <AuthorListID>156</AuthorListID>
    <AuthorID>884</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19859543</PMID>
    <AuthorListID>156</AuthorListID>
    <AuthorID>885</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19859543</PMID>
    <AuthorListID>156</AuthorListID>
    <AuthorID>886</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19859543</PMID>
    <AuthorListID>156</AuthorListID>
    <AuthorID>887</AuthorID>
    <AuthorOrder>11</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19846534</PMID>
    <AuthorListID>158</AuthorListID>
    <AuthorID>888</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19846534</PMID>
    <AuthorListID>158</AuthorListID>
    <AuthorID>889</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19846534</PMID>
    <AuthorListID>158</AuthorListID>
    <AuthorID>890</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19846534</PMID>
    <AuthorListID>158</AuthorListID>
    <AuthorID>891</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19734229</PMID>
    <AuthorListID>159</AuthorListID>
    <AuthorID>892</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19734229</PMID>
    <AuthorListID>159</AuthorListID>
    <AuthorID>893</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19706715</PMID>
    <AuthorListID>160</AuthorListID>
    <AuthorID>894</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19706715</PMID>
    <AuthorListID>160</AuthorListID>
    <AuthorID>895</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19701189</PMID>
    <AuthorListID>161</AuthorListID>
    <AuthorID>896</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19701189</PMID>
    <AuthorListID>161</AuthorListID>
    <AuthorID>897</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19701189</PMID>
    <AuthorListID>161</AuthorListID>
    <AuthorID>898</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19701189</PMID>
    <AuthorListID>161</AuthorListID>
    <AuthorID>899</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19701189</PMID>
    <AuthorListID>161</AuthorListID>
    <AuthorID>900</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19701189</PMID>
    <AuthorListID>161</AuthorListID>
    <AuthorID>901</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19701189</PMID>
    <AuthorListID>161</AuthorListID>
    <AuthorID>902</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19701189</PMID>
    <AuthorListID>161</AuthorListID>
    <AuthorID>903</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19692591</PMID>
    <AuthorListID>162</AuthorListID>
    <AuthorID>904</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19690333</PMID>
    <AuthorListID>163</AuthorListID>
    <AuthorID>905</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19631370</PMID>
    <AuthorListID>164</AuthorListID>
    <AuthorID>906</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19631370</PMID>
    <AuthorListID>164</AuthorListID>
    <AuthorID>907</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19561593</PMID>
    <AuthorListID>166</AuthorListID>
    <AuthorID>908</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19561593</PMID>
    <AuthorListID>166</AuthorListID>
    <AuthorID>909</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19561593</PMID>
    <AuthorListID>166</AuthorListID>
    <AuthorID>910</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19546225</PMID>
    <AuthorListID>167</AuthorListID>
    <AuthorID>911</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19546225</PMID>
    <AuthorListID>167</AuthorListID>
    <AuthorID>912</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19546225</PMID>
    <AuthorListID>167</AuthorListID>
    <AuthorID>913</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19543380</PMID>
    <AuthorListID>168</AuthorListID>
    <AuthorID>914</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19543380</PMID>
    <AuthorListID>168</AuthorListID>
    <AuthorID>915</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19543380</PMID>
    <AuthorListID>168</AuthorListID>
    <AuthorID>916</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19543380</PMID>
    <AuthorListID>168</AuthorListID>
    <AuthorID>917</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19543380</PMID>
    <AuthorListID>168</AuthorListID>
    <AuthorID>918</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19543380</PMID>
    <AuthorListID>168</AuthorListID>
    <AuthorID>919</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19543380</PMID>
    <AuthorListID>168</AuthorListID>
    <AuthorID>920</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19543380</PMID>
    <AuthorListID>168</AuthorListID>
    <AuthorID>921</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19543380</PMID>
    <AuthorListID>168</AuthorListID>
    <AuthorID>922</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19543380</PMID>
    <AuthorListID>168</AuthorListID>
    <AuthorID>923</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19543380</PMID>
    <AuthorListID>168</AuthorListID>
    <AuthorID>924</AuthorID>
    <AuthorOrder>11</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19535268</PMID>
    <AuthorListID>169</AuthorListID>
    <AuthorID>925</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19507289</PMID>
    <AuthorListID>170</AuthorListID>
    <AuthorID>926</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19507289</PMID>
    <AuthorListID>170</AuthorListID>
    <AuthorID>927</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19507289</PMID>
    <AuthorListID>170</AuthorListID>
    <AuthorID>928</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19507289</PMID>
    <AuthorListID>170</AuthorListID>
    <AuthorID>929</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19419966</PMID>
    <AuthorListID>172</AuthorListID>
    <AuthorID>930</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19419966</PMID>
    <AuthorListID>172</AuthorListID>
    <AuthorID>931</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19419966</PMID>
    <AuthorListID>172</AuthorListID>
    <AuthorID>932</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19419966</PMID>
    <AuthorListID>172</AuthorListID>
    <AuthorID>933</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19404494</PMID>
    <AuthorListID>173</AuthorListID>
    <AuthorID>934</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19404494</PMID>
    <AuthorListID>173</AuthorListID>
    <AuthorID>935</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19404494</PMID>
    <AuthorListID>173</AuthorListID>
    <AuthorID>936</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19380815</PMID>
    <AuthorListID>174</AuthorListID>
    <AuthorID>937</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19380815</PMID>
    <AuthorListID>174</AuthorListID>
    <AuthorID>938</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19380815</PMID>
    <AuthorListID>174</AuthorListID>
    <AuthorID>939</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19380491</PMID>
    <AuthorListID>175</AuthorListID>
    <AuthorID>940</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19380491</PMID>
    <AuthorListID>175</AuthorListID>
    <AuthorID>941</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19380491</PMID>
    <AuthorListID>175</AuthorListID>
    <AuthorID>942</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19380491</PMID>
    <AuthorListID>175</AuthorListID>
    <AuthorID>943</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19281641</PMID>
    <AuthorListID>176</AuthorListID>
    <AuthorID>944</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19281641</PMID>
    <AuthorListID>176</AuthorListID>
    <AuthorID>945</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19281641</PMID>
    <AuthorListID>176</AuthorListID>
    <AuthorID>946</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19193793</PMID>
    <AuthorListID>177</AuthorListID>
    <AuthorID>947</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19193793</PMID>
    <AuthorListID>177</AuthorListID>
    <AuthorID>948</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19193793</PMID>
    <AuthorListID>177</AuthorListID>
    <AuthorID>949</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19164550</PMID>
    <AuthorListID>179</AuthorListID>
    <AuthorID>950</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19164550</PMID>
    <AuthorListID>179</AuthorListID>
    <AuthorID>951</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19164550</PMID>
    <AuthorListID>179</AuthorListID>
    <AuthorID>952</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19036819</PMID>
    <AuthorListID>182</AuthorListID>
    <AuthorID>953</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19036819</PMID>
    <AuthorListID>182</AuthorListID>
    <AuthorID>954</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19036819</PMID>
    <AuthorListID>182</AuthorListID>
    <AuthorID>955</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19017982</PMID>
    <AuthorListID>183</AuthorListID>
    <AuthorID>956</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19017982</PMID>
    <AuthorListID>183</AuthorListID>
    <AuthorID>957</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19017982</PMID>
    <AuthorListID>183</AuthorListID>
    <AuthorID>958</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19017982</PMID>
    <AuthorListID>183</AuthorListID>
    <AuthorID>959</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19017631</PMID>
    <AuthorListID>184</AuthorListID>
    <AuthorID>960</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18948594</PMID>
    <AuthorListID>185</AuthorListID>
    <AuthorID>961</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18948594</PMID>
    <AuthorListID>185</AuthorListID>
    <AuthorID>962</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18948594</PMID>
    <AuthorListID>185</AuthorListID>
    <AuthorID>963</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18948594</PMID>
    <AuthorListID>185</AuthorListID>
    <AuthorID>964</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18948594</PMID>
    <AuthorListID>185</AuthorListID>
    <AuthorID>965</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18948594</PMID>
    <AuthorListID>185</AuthorListID>
    <AuthorID>966</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18780793</PMID>
    <AuthorListID>186</AuthorListID>
    <AuthorID>967</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18780793</PMID>
    <AuthorListID>186</AuthorListID>
    <AuthorID>968</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18780793</PMID>
    <AuthorListID>186</AuthorListID>
    <AuthorID>969</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18780793</PMID>
    <AuthorListID>186</AuthorListID>
    <AuthorID>970</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18780793</PMID>
    <AuthorListID>186</AuthorListID>
    <AuthorID>971</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18780793</PMID>
    <AuthorListID>186</AuthorListID>
    <AuthorID>972</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18780793</PMID>
    <AuthorListID>186</AuthorListID>
    <AuthorID>973</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18780793</PMID>
    <AuthorListID>186</AuthorListID>
    <AuthorID>974</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18756281</PMID>
    <AuthorListID>187</AuthorListID>
    <AuthorID>975</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18725224</PMID>
    <AuthorListID>188</AuthorListID>
    <AuthorID>976</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18725224</PMID>
    <AuthorListID>188</AuthorListID>
    <AuthorID>977</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18725224</PMID>
    <AuthorListID>188</AuthorListID>
    <AuthorID>978</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18725224</PMID>
    <AuthorListID>188</AuthorListID>
    <AuthorID>979</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18725224</PMID>
    <AuthorListID>188</AuthorListID>
    <AuthorID>980</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18725224</PMID>
    <AuthorListID>188</AuthorListID>
    <AuthorID>981</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18725224</PMID>
    <AuthorListID>188</AuthorListID>
    <AuthorID>982</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18725224</PMID>
    <AuthorListID>188</AuthorListID>
    <AuthorID>983</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18715932</PMID>
    <AuthorListID>189</AuthorListID>
    <AuthorID>984</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18715932</PMID>
    <AuthorListID>189</AuthorListID>
    <AuthorID>985</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18715932</PMID>
    <AuthorListID>189</AuthorListID>
    <AuthorID>986</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18715932</PMID>
    <AuthorListID>189</AuthorListID>
    <AuthorID>987</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18715932</PMID>
    <AuthorListID>189</AuthorListID>
    <AuthorID>988</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18715932</PMID>
    <AuthorListID>189</AuthorListID>
    <AuthorID>989</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18715932</PMID>
    <AuthorListID>189</AuthorListID>
    <AuthorID>990</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18715932</PMID>
    <AuthorListID>189</AuthorListID>
    <AuthorID>991</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18715932</PMID>
    <AuthorListID>189</AuthorListID>
    <AuthorID>992</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18692023</PMID>
    <AuthorListID>190</AuthorListID>
    <AuthorID>993</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18689426</PMID>
    <AuthorListID>191</AuthorListID>
    <AuthorID>994</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18689426</PMID>
    <AuthorListID>191</AuthorListID>
    <AuthorID>995</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18689426</PMID>
    <AuthorListID>191</AuthorListID>
    <AuthorID>996</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18689426</PMID>
    <AuthorListID>191</AuthorListID>
    <AuthorID>997</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18689426</PMID>
    <AuthorListID>191</AuthorListID>
    <AuthorID>998</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18689426</PMID>
    <AuthorListID>191</AuthorListID>
    <AuthorID>999</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18689426</PMID>
    <AuthorListID>191</AuthorListID>
    <AuthorID>1000</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18689426</PMID>
    <AuthorListID>191</AuthorListID>
    <AuthorID>1001</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18689426</PMID>
    <AuthorListID>191</AuthorListID>
    <AuthorID>1002</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18689426</PMID>
    <AuthorListID>191</AuthorListID>
    <AuthorID>1003</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18689426</PMID>
    <AuthorListID>191</AuthorListID>
    <AuthorID>1004</AuthorID>
    <AuthorOrder>11</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18632970</PMID>
    <AuthorListID>192</AuthorListID>
    <AuthorID>1005</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18632970</PMID>
    <AuthorListID>192</AuthorListID>
    <AuthorID>1006</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18632970</PMID>
    <AuthorListID>192</AuthorListID>
    <AuthorID>1007</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18632970</PMID>
    <AuthorListID>192</AuthorListID>
    <AuthorID>1008</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18632970</PMID>
    <AuthorListID>192</AuthorListID>
    <AuthorID>1009</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18632970</PMID>
    <AuthorListID>192</AuthorListID>
    <AuthorID>1010</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18632970</PMID>
    <AuthorListID>192</AuthorListID>
    <AuthorID>1011</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18586328</PMID>
    <AuthorListID>193</AuthorListID>
    <AuthorID>1012</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18586328</PMID>
    <AuthorListID>193</AuthorListID>
    <AuthorID>1013</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18586328</PMID>
    <AuthorListID>193</AuthorListID>
    <AuthorID>1014</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18586328</PMID>
    <AuthorListID>193</AuthorListID>
    <AuthorID>1015</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18586328</PMID>
    <AuthorListID>193</AuthorListID>
    <AuthorID>1016</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18586328</PMID>
    <AuthorListID>193</AuthorListID>
    <AuthorID>1017</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18586328</PMID>
    <AuthorListID>193</AuthorListID>
    <AuthorID>1018</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18586328</PMID>
    <AuthorListID>193</AuthorListID>
    <AuthorID>1019</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19669308</PMID>
    <AuthorListID>195</AuthorListID>
    <AuthorID>1020</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19669308</PMID>
    <AuthorListID>195</AuthorListID>
    <AuthorID>1021</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19669308</PMID>
    <AuthorListID>195</AuthorListID>
    <AuthorID>1022</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19669308</PMID>
    <AuthorListID>195</AuthorListID>
    <AuthorID>1023</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19669308</PMID>
    <AuthorListID>195</AuthorListID>
    <AuthorID>1024</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19669308</PMID>
    <AuthorListID>195</AuthorListID>
    <AuthorID>1025</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19669308</PMID>
    <AuthorListID>195</AuthorListID>
    <AuthorID>1026</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19669308</PMID>
    <AuthorListID>195</AuthorListID>
    <AuthorID>1027</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19669308</PMID>
    <AuthorListID>195</AuthorListID>
    <AuthorID>1028</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19669308</PMID>
    <AuthorListID>195</AuthorListID>
    <AuthorID>1029</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19669308</PMID>
    <AuthorListID>195</AuthorListID>
    <AuthorID>1030</AuthorID>
    <AuthorOrder>11</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19669308</PMID>
    <AuthorListID>195</AuthorListID>
    <AuthorID>1031</AuthorID>
    <AuthorOrder>12</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19669308</PMID>
    <AuthorListID>195</AuthorListID>
    <AuthorID>1032</AuthorID>
    <AuthorOrder>13</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19669308</PMID>
    <AuthorListID>195</AuthorListID>
    <AuthorID>1033</AuthorID>
    <AuthorOrder>14</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18439848</PMID>
    <AuthorListID>196</AuthorListID>
    <AuthorID>1034</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18439848</PMID>
    <AuthorListID>196</AuthorListID>
    <AuthorID>1035</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18439848</PMID>
    <AuthorListID>196</AuthorListID>
    <AuthorID>1036</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18439848</PMID>
    <AuthorListID>196</AuthorListID>
    <AuthorID>1037</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18439848</PMID>
    <AuthorListID>196</AuthorListID>
    <AuthorID>1038</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18439848</PMID>
    <AuthorListID>196</AuthorListID>
    <AuthorID>1039</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18397740</PMID>
    <AuthorListID>197</AuthorListID>
    <AuthorID>1040</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18337166</PMID>
    <AuthorListID>198</AuthorListID>
    <AuthorID>1041</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18337166</PMID>
    <AuthorListID>198</AuthorListID>
    <AuthorID>1042</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18337166</PMID>
    <AuthorListID>198</AuthorListID>
    <AuthorID>1043</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18337166</PMID>
    <AuthorListID>198</AuthorListID>
    <AuthorID>1044</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18307765</PMID>
    <AuthorListID>199</AuthorListID>
    <AuthorID>1045</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18307765</PMID>
    <AuthorListID>199</AuthorListID>
    <AuthorID>1046</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18307765</PMID>
    <AuthorListID>199</AuthorListID>
    <AuthorID>1047</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18207245</PMID>
    <AuthorListID>201</AuthorListID>
    <AuthorID>1048</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18207245</PMID>
    <AuthorListID>201</AuthorListID>
    <AuthorID>1049</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18207245</PMID>
    <AuthorListID>201</AuthorListID>
    <AuthorID>1050</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18207245</PMID>
    <AuthorListID>201</AuthorListID>
    <AuthorID>1051</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18207245</PMID>
    <AuthorListID>201</AuthorListID>
    <AuthorID>1052</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18200010</PMID>
    <AuthorListID>202</AuthorListID>
    <AuthorID>1053</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18200010</PMID>
    <AuthorListID>202</AuthorListID>
    <AuthorID>1054</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18200010</PMID>
    <AuthorListID>202</AuthorListID>
    <AuthorID>1055</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18200010</PMID>
    <AuthorListID>202</AuthorListID>
    <AuthorID>1056</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18200010</PMID>
    <AuthorListID>202</AuthorListID>
    <AuthorID>1057</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18200010</PMID>
    <AuthorListID>202</AuthorListID>
    <AuthorID>1058</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18200010</PMID>
    <AuthorListID>202</AuthorListID>
    <AuthorID>1059</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17602886</PMID>
    <AuthorListID>203</AuthorListID>
    <AuthorID>1060</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17602886</PMID>
    <AuthorListID>203</AuthorListID>
    <AuthorID>1061</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17602886</PMID>
    <AuthorListID>203</AuthorListID>
    <AuthorID>1062</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17602886</PMID>
    <AuthorListID>203</AuthorListID>
    <AuthorID>1063</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17602886</PMID>
    <AuthorListID>203</AuthorListID>
    <AuthorID>1064</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17552028</PMID>
    <AuthorListID>204</AuthorListID>
    <AuthorID>1065</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17517627</PMID>
    <AuthorListID>205</AuthorListID>
    <AuthorID>1066</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17517627</PMID>
    <AuthorListID>205</AuthorListID>
    <AuthorID>1067</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17517627</PMID>
    <AuthorListID>205</AuthorListID>
    <AuthorID>1068</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17468758</PMID>
    <AuthorListID>207</AuthorListID>
    <AuthorID>1069</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17438296</PMID>
    <AuthorListID>208</AuthorListID>
    <AuthorID>1070</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17438296</PMID>
    <AuthorListID>208</AuthorListID>
    <AuthorID>1071</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17392790</PMID>
    <AuthorListID>209</AuthorListID>
    <AuthorID>1072</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17392790</PMID>
    <AuthorListID>209</AuthorListID>
    <AuthorID>1073</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17339430</PMID>
    <AuthorListID>210</AuthorListID>
    <AuthorID>1074</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17339430</PMID>
    <AuthorListID>210</AuthorListID>
    <AuthorID>1075</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17327220</PMID>
    <AuthorListID>211</AuthorListID>
    <AuthorID>1076</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17327220</PMID>
    <AuthorListID>211</AuthorListID>
    <AuthorID>1077</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17142768</PMID>
    <AuthorListID>212</AuthorListID>
    <AuthorID>1078</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17093192</PMID>
    <AuthorListID>213</AuthorListID>
    <AuthorID>1079</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17093192</PMID>
    <AuthorListID>213</AuthorListID>
    <AuthorID>1080</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17093192</PMID>
    <AuthorListID>213</AuthorListID>
    <AuthorID>1081</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17093192</PMID>
    <AuthorListID>213</AuthorListID>
    <AuthorID>1082</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17093192</PMID>
    <AuthorListID>213</AuthorListID>
    <AuthorID>1083</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17093192</PMID>
    <AuthorListID>213</AuthorListID>
    <AuthorID>1084</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17093192</PMID>
    <AuthorListID>213</AuthorListID>
    <AuthorID>1085</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17093192</PMID>
    <AuthorListID>213</AuthorListID>
    <AuthorID>1086</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17070177</PMID>
    <AuthorListID>214</AuthorListID>
    <AuthorID>1087</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17070177</PMID>
    <AuthorListID>214</AuthorListID>
    <AuthorID>1088</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17070177</PMID>
    <AuthorListID>214</AuthorListID>
    <AuthorID>1089</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17070177</PMID>
    <AuthorListID>214</AuthorListID>
    <AuthorID>1090</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17070177</PMID>
    <AuthorListID>214</AuthorListID>
    <AuthorID>1091</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17020950</PMID>
    <AuthorListID>215</AuthorListID>
    <AuthorID>1092</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17020950</PMID>
    <AuthorListID>215</AuthorListID>
    <AuthorID>1093</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16945160</PMID>
    <AuthorListID>216</AuthorListID>
    <AuthorID>1094</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16914100</PMID>
    <AuthorListID>217</AuthorListID>
    <AuthorID>1095</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16914100</PMID>
    <AuthorListID>217</AuthorListID>
    <AuthorID>1096</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16914100</PMID>
    <AuthorListID>217</AuthorListID>
    <AuthorID>1097</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16914100</PMID>
    <AuthorListID>217</AuthorListID>
    <AuthorID>1098</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16914100</PMID>
    <AuthorListID>217</AuthorListID>
    <AuthorID>1099</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16914100</PMID>
    <AuthorListID>217</AuthorListID>
    <AuthorID>1100</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16914100</PMID>
    <AuthorListID>217</AuthorListID>
    <AuthorID>1101</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16914100</PMID>
    <AuthorListID>217</AuthorListID>
    <AuthorID>1102</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16849320</PMID>
    <AuthorListID>219</AuthorListID>
    <AuthorID>1103</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16849320</PMID>
    <AuthorListID>219</AuthorListID>
    <AuthorID>1104</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16731946</PMID>
    <AuthorListID>220</AuthorListID>
    <AuthorID>1105</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16309964</PMID>
    <AuthorListID>223</AuthorListID>
    <AuthorID>1106</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16301520</PMID>
    <AuthorListID>224</AuthorListID>
    <AuthorID>1107</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16301520</PMID>
    <AuthorListID>224</AuthorListID>
    <AuthorID>1108</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16301520</PMID>
    <AuthorListID>224</AuthorListID>
    <AuthorID>1109</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16143094</PMID>
    <AuthorListID>226</AuthorListID>
    <AuthorID>1110</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16143094</PMID>
    <AuthorListID>226</AuthorListID>
    <AuthorID>1111</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16143094</PMID>
    <AuthorListID>226</AuthorListID>
    <AuthorID>1112</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16125763</PMID>
    <AuthorListID>227</AuthorListID>
    <AuthorID>1113</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11868065</PMID>
    <AuthorListID>228</AuthorListID>
    <AuthorID>1114</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11868065</PMID>
    <AuthorListID>228</AuthorListID>
    <AuthorID>1115</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11868065</PMID>
    <AuthorListID>228</AuthorListID>
    <AuthorID>1116</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11868065</PMID>
    <AuthorListID>228</AuthorListID>
    <AuthorID>1117</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11868065</PMID>
    <AuthorListID>228</AuthorListID>
    <AuthorID>1118</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11868065</PMID>
    <AuthorListID>228</AuthorListID>
    <AuthorID>1119</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11868065</PMID>
    <AuthorListID>228</AuthorListID>
    <AuthorID>1120</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11562841</PMID>
    <AuthorListID>229</AuthorListID>
    <AuthorID>1121</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11562841</PMID>
    <AuthorListID>229</AuthorListID>
    <AuthorID>1122</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11562841</PMID>
    <AuthorListID>229</AuthorListID>
    <AuthorID>1123</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11562841</PMID>
    <AuthorListID>229</AuthorListID>
    <AuthorID>1124</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11562841</PMID>
    <AuthorListID>229</AuthorListID>
    <AuthorID>1125</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11562841</PMID>
    <AuthorListID>229</AuthorListID>
    <AuthorID>1126</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>7793635</PMID>
    <AuthorListID>230</AuthorListID>
    <AuthorID>1127</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>7793635</PMID>
    <AuthorListID>230</AuthorListID>
    <AuthorID>1128</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>7793635</PMID>
    <AuthorListID>230</AuthorListID>
    <AuthorID>1129</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>7793635</PMID>
    <AuthorListID>230</AuthorListID>
    <AuthorID>1130</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>7793635</PMID>
    <AuthorListID>230</AuthorListID>
    <AuthorID>1131</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>6230074</PMID>
    <AuthorListID>231</AuthorListID>
    <AuthorID>1132</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>6230074</PMID>
    <AuthorListID>231</AuthorListID>
    <AuthorID>1133</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_Authors>
    <AuthorID>1</AuthorID>
    <LastName>Nie</LastName>
    <ForeName>Li</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>2</AuthorID>
    <LastName>Xiong</LastName>
    <ForeName>Ran</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>3</AuthorID>
    <LastName>Zhang</LastName>
    <ForeName>Ying-Sheng</ForeName>
    <Initials>YS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>4</AuthorID>
    <LastName>Zhu</LastName>
    <ForeName>Lv-Yun</ForeName>
    <Initials>LY</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>5</AuthorID>
    <LastName>Shao</LastName>
    <ForeName>Jian-Zhong</ForeName>
    <Initials>JZ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>6</AuthorID>
    <LastName>Xiang</LastName>
    <ForeName>Li-Xin</ForeName>
    <Initials>LX</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>7</AuthorID>
    <LastName>Mailly</LastName>
    <ForeName>Laurent</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>8</AuthorID>
    <LastName>Zeisel</LastName>
    <ForeName>Mirjam B</ForeName>
    <Initials>MB</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>9</AuthorID>
    <LastName>Baumert</LastName>
    <ForeName>Thomas F</ForeName>
    <Initials>TF</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>10</AuthorID>
    <LastName>Takaki</LastName>
    <ForeName>Hiromi</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>11</AuthorID>
    <LastName>Honda</LastName>
    <ForeName>Kenya</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>12</AuthorID>
    <LastName>Atarashi</LastName>
    <ForeName>Koji</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>13</AuthorID>
    <LastName>Kobayashi</LastName>
    <ForeName>Fukiko</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>14</AuthorID>
    <LastName>Ebihara</LastName>
    <ForeName>Takashi</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>15</AuthorID>
    <LastName>Oshiumi</LastName>
    <ForeName>Hiroyuki</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>16</AuthorID>
    <LastName>Matsumoto</LastName>
    <ForeName>Misako</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>17</AuthorID>
    <LastName>Shingai</LastName>
    <ForeName>Masashi</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>18</AuthorID>
    <LastName>Seya</LastName>
    <ForeName>Tsukasa</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>19</AuthorID>
    <LastName>Takeda</LastName>
    <ForeName>Makoto</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>20</AuthorID>
    <LastName>Tahara</LastName>
    <ForeName>Maino</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>21</AuthorID>
    <LastName>Unterholzner</LastName>
    <ForeName>Leonie</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>22</AuthorID>
    <LastName>Liu</LastName>
    <ForeName>Siqi</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>23</AuthorID>
    <LastName>Chen</LastName>
    <ForeName>Jueqi</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>24</AuthorID>
    <LastName>Cai</LastName>
    <ForeName>Xin</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>25</AuthorID>
    <LastName>Wu</LastName>
    <ForeName>Jiaxi</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>26</AuthorID>
    <LastName>Chen</LastName>
    <ForeName>Xiang</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>27</AuthorID>
    <LastName>Wu</LastName>
    <ForeName>You-Tong</ForeName>
    <Initials>YT</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>28</AuthorID>
    <LastName>Sun</LastName>
    <ForeName>Lijun</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>29</AuthorID>
    <LastName>Chen</LastName>
    <ForeName>Zhijian J</ForeName>
    <Initials>ZJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>30</AuthorID>
    <LastName>Zhang</LastName>
    <ForeName>Bianhong</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>31</AuthorID>
    <LastName>Liu</LastName>
    <ForeName>Xinyi</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>32</AuthorID>
    <LastName>Chen</LastName>
    <ForeName>Wei</ForeName>
    <Initials>W</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>33</AuthorID>
    <LastName>Chen</LastName>
    <ForeName>Liang</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>34</AuthorID>
    <LastName>Frentzen</LastName>
    <ForeName>Anne</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>35</AuthorID>
    <LastName>Kusuma</LastName>
    <ForeName>Angga</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>36</AuthorID>
    <LastName>Guerlevik</LastName>
    <ForeName>Engin</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>37</AuthorID>
    <LastName>Hueging</LastName>
    <ForeName>Kathrin</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>38</AuthorID>
    <LastName>Knocke</LastName>
    <ForeName>Sarah</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>39</AuthorID>
    <LastName>Ginkel</LastName>
    <ForeName>Corinne</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>40</AuthorID>
    <LastName>Brown</LastName>
    <ForeName>Richard J P</ForeName>
    <Initials>RJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>41</AuthorID>
    <LastName>Heim</LastName>
    <ForeName>Markus</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>42</AuthorID>
    <LastName>Dill</LastName>
    <ForeName>Michael T</ForeName>
    <Initials>MT</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>43</AuthorID>
    <LastName>KrÃ¶ger</LastName>
    <ForeName>Andrea</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>44</AuthorID>
    <LastName>Kalinke</LastName>
    <ForeName>Ulrich</ForeName>
    <Initials>U</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>45</AuthorID>
    <LastName>Kaderali</LastName>
    <ForeName>Lars</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>46</AuthorID>
    <LastName>Kuehnel</LastName>
    <ForeName>Florian</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>47</AuthorID>
    <LastName>Pietschmann</LastName>
    <ForeName>Thomas</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>48</AuthorID>
    <LastName>Li</LastName>
    <ForeName>Meng-Tong</ForeName>
    <Initials>MT</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>49</AuthorID>
    <LastName>Di</LastName>
    <ForeName>Wei</ForeName>
    <Initials>W</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>50</AuthorID>
    <LastName>Xu</LastName>
    <ForeName>Hao</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>51</AuthorID>
    <LastName>Yang</LastName>
    <ForeName>Yong-Kang</ForeName>
    <Initials>YK</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>52</AuthorID>
    <LastName>Chen</LastName>
    <ForeName>Hai-Wei</ForeName>
    <Initials>HW</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>53</AuthorID>
    <LastName>Zhang</LastName>
    <ForeName>Fei-Xiong</ForeName>
    <Initials>FX</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>54</AuthorID>
    <LastName>Zhai</LastName>
    <ForeName>Zhong-He</ForeName>
    <Initials>ZH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>55</AuthorID>
    <LastName>Chen</LastName>
    <ForeName>Dan-Ying</ForeName>
    <Initials>DY</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>56</AuthorID>
    <LastName>Lee</LastName>
    <ForeName>Na-Rae</ForeName>
    <Initials>NR</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>57</AuthorID>
    <LastName>Shin</LastName>
    <ForeName>Han-Bo</ForeName>
    <Initials>HB</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>58</AuthorID>
    <LastName>Kim</LastName>
    <ForeName>Hye-In</ForeName>
    <Initials>HI</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>59</AuthorID>
    <LastName>Choi</LastName>
    <ForeName>Myung-Soo</ForeName>
    <Initials>MS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>60</AuthorID>
    <LastName>Inn</LastName>
    <ForeName>Kyung-Soo</ForeName>
    <Initials>KS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>61</AuthorID>
    <LastName>Brownell</LastName>
    <ForeName>Jessica</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>62</AuthorID>
    <LastName>Wagoner</LastName>
    <ForeName>Jessica</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>63</AuthorID>
    <LastName>Lovelace</LastName>
    <ForeName>Erica S</ForeName>
    <Initials>ES</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>64</AuthorID>
    <LastName>Thirstrup</LastName>
    <ForeName>Derek</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>65</AuthorID>
    <LastName>Mohar</LastName>
    <ForeName>Isaac</ForeName>
    <Initials>I</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>66</AuthorID>
    <LastName>Smith</LastName>
    <ForeName>Wesley</ForeName>
    <Initials>W</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>67</AuthorID>
    <LastName>Giugliano</LastName>
    <ForeName>Silvia</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>68</AuthorID>
    <LastName>Li</LastName>
    <ForeName>Kui</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>69</AuthorID>
    <LastName>Crispe</LastName>
    <ForeName>I Nicholas</ForeName>
    <Initials>IN</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>70</AuthorID>
    <LastName>Rosen</LastName>
    <ForeName>Hugo R</ForeName>
    <Initials>HR</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>71</AuthorID>
    <LastName>Polyak</LastName>
    <ForeName>Stephen J</ForeName>
    <Initials>SJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>72</AuthorID>
    <LastName>Li</LastName>
    <ForeName>Yujun</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>73</AuthorID>
    <LastName>Song</LastName>
    <ForeName>Wuqi</ForeName>
    <Initials>W</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>74</AuthorID>
    <LastName>Wu</LastName>
    <ForeName>Jing</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>75</AuthorID>
    <LastName>Zhang</LastName>
    <ForeName>Qingmeng</ForeName>
    <Initials>Q</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>76</AuthorID>
    <LastName>He</LastName>
    <ForeName>Junming</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>77</AuthorID>
    <LastName>Li</LastName>
    <ForeName>Aimei</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>78</AuthorID>
    <LastName>Qian</LastName>
    <ForeName>Jun</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>79</AuthorID>
    <LastName>Zhai</LastName>
    <ForeName>Aixia</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>80</AuthorID>
    <LastName>Hu</LastName>
    <ForeName>Yunlong</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>81</AuthorID>
    <LastName>Kao</LastName>
    <ForeName>Wenping</ForeName>
    <Initials>W</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>82</AuthorID>
    <LastName>Wei</LastName>
    <ForeName>Lanlan</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>83</AuthorID>
    <LastName>Zhang</LastName>
    <ForeName>Fengmin</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>84</AuthorID>
    <LastName>Xu</LastName>
    <ForeName>Dakang</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>85</AuthorID>
    <LastName>Devhare</LastName>
    <ForeName>Pradip B</ForeName>
    <Initials>PB</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>86</AuthorID>
    <LastName>Chatterjee</LastName>
    <ForeName>Subhashis N</ForeName>
    <Initials>SN</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>87</AuthorID>
    <LastName>Arankalle</LastName>
    <ForeName>Vidya A</ForeName>
    <Initials>VA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>88</AuthorID>
    <LastName>Lole</LastName>
    <ForeName>Kavita S</ForeName>
    <Initials>KS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>89</AuthorID>
    <LastName>Hagmann</LastName>
    <ForeName>Cristina Amparo</ForeName>
    <Initials>CA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>90</AuthorID>
    <LastName>Herzner</LastName>
    <ForeName>Anna Maria</ForeName>
    <Initials>AM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>91</AuthorID>
    <LastName>Abdullah</LastName>
    <ForeName>Zeinab</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>92</AuthorID>
    <LastName>Zillinger</LastName>
    <ForeName>Thomas</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>93</AuthorID>
    <LastName>Jakobs</LastName>
    <ForeName>Christopher</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>94</AuthorID>
    <LastName>Schuberth</LastName>
    <ForeName>Christine</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>95</AuthorID>
    <LastName>Coch</LastName>
    <ForeName>Christoph</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>96</AuthorID>
    <LastName>Higgins</LastName>
    <ForeName>Paul G</ForeName>
    <Initials>PG</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>97</AuthorID>
    <LastName>Wisplinghoff</LastName>
    <ForeName>Hilmar</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>98</AuthorID>
    <LastName>Barchet</LastName>
    <ForeName>Winfried</ForeName>
    <Initials>W</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>99</AuthorID>
    <LastName>Hornung</LastName>
    <ForeName>Veit</ForeName>
    <Initials>V</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>100</AuthorID>
    <LastName>Hartmann</LastName>
    <ForeName>Gunther</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>101</AuthorID>
    <LastName>Schlee</LastName>
    <ForeName>Martin</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>102</AuthorID>
    <LastName>Bao</LastName>
    <ForeName>Xiaoyong</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>103</AuthorID>
    <LastName>Kolli</LastName>
    <ForeName>Deepthi</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>104</AuthorID>
    <LastName>Ren</LastName>
    <ForeName>Junping</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>105</AuthorID>
    <LastName>Liu</LastName>
    <ForeName>Tianshuang</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>106</AuthorID>
    <LastName>Garofalo</LastName>
    <ForeName>Roberto P</ForeName>
    <Initials>RP</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>107</AuthorID>
    <LastName>Casola</LastName>
    <ForeName>Antonella</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>108</AuthorID>
    <LastName>Dixit</LastName>
    <ForeName>Evelyn</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>109</AuthorID>
    <LastName>Kagan</LastName>
    <ForeName>Jonathan C</ForeName>
    <Initials>JC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>110</AuthorID>
    <LastName>Pothlichet</LastName>
    <ForeName>Julien</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>111</AuthorID>
    <LastName>Meunier</LastName>
    <ForeName>Isabelle</ForeName>
    <Initials>I</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>112</AuthorID>
    <LastName>Davis</LastName>
    <ForeName>Beckley K</ForeName>
    <Initials>BK</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>113</AuthorID>
    <LastName>Ting</LastName>
    <ForeName>Jenny P-Y</ForeName>
    <Initials>JP</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>114</AuthorID>
    <LastName>Skamene</LastName>
    <ForeName>Emil</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>115</AuthorID>
    <LastName>von Messling</LastName>
    <ForeName>Veronika</ForeName>
    <Initials>V</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>116</AuthorID>
    <LastName>Vidal</LastName>
    <ForeName>Silvia M</ForeName>
    <Initials>SM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>117</AuthorID>
    <LastName>Subramanian</LastName>
    <ForeName>Naeha</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>118</AuthorID>
    <LastName>Natarajan</LastName>
    <ForeName>Kannan</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>119</AuthorID>
    <LastName>Clatworthy</LastName>
    <ForeName>Menna R</ForeName>
    <Initials>MR</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>120</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Ze</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>121</AuthorID>
    <LastName>Germain</LastName>
    <ForeName>Ronald N</ForeName>
    <Initials>RN</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>122</AuthorID>
    <LastName>Nakagawa</LastName>
    <ForeName>Shin-ichiro</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>123</AuthorID>
    <LastName>Hirata</LastName>
    <ForeName>Yuichi</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>124</AuthorID>
    <LastName>Kameyama</LastName>
    <ForeName>Takeshi</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>125</AuthorID>
    <LastName>Tokunaga</LastName>
    <ForeName>Yuko</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>126</AuthorID>
    <LastName>Nishito</LastName>
    <ForeName>Yasumasa</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>127</AuthorID>
    <LastName>Hirabayashi</LastName>
    <ForeName>Kazuko</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>128</AuthorID>
    <LastName>Yano</LastName>
    <ForeName>Junichi</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>129</AuthorID>
    <LastName>Ochiya</LastName>
    <ForeName>Takahiro</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>130</AuthorID>
    <LastName>Tateno</LastName>
    <ForeName>Chise</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>131</AuthorID>
    <LastName>Tanaka</LastName>
    <ForeName>Yasuhito</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>132</AuthorID>
    <LastName>Mizokami</LastName>
    <ForeName>Masashi</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>133</AuthorID>
    <LastName>Tsukiyama-Kohara</LastName>
    <ForeName>Kyoko</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>134</AuthorID>
    <LastName>Inoue</LastName>
    <ForeName>Kazuaki</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>135</AuthorID>
    <LastName>Yoshiba</LastName>
    <ForeName>Makoto</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>136</AuthorID>
    <LastName>Takaoka</LastName>
    <ForeName>Akinori</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>137</AuthorID>
    <LastName>Kohara</LastName>
    <ForeName>Michinori</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>138</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Bei</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>139</AuthorID>
    <LastName>Xi</LastName>
    <ForeName>Xueyan</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>140</AuthorID>
    <LastName>Lei</LastName>
    <ForeName>Xiaobo</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>141</AuthorID>
    <LastName>Zhang</LastName>
    <ForeName>Xiaoyan</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>142</AuthorID>
    <LastName>Cui</LastName>
    <ForeName>Sheng</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>143</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Jianwei</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>144</AuthorID>
    <LastName>Jin</LastName>
    <ForeName>Qi</ForeName>
    <Initials>Q</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>145</AuthorID>
    <LastName>Zhao</LastName>
    <ForeName>Zhendong</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>146</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Penghua</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>147</AuthorID>
    <LastName>Yang</LastName>
    <ForeName>Long</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>148</AuthorID>
    <LastName>Cheng</LastName>
    <ForeName>Gong</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>149</AuthorID>
    <LastName>Yang</LastName>
    <ForeName>Guang</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>150</AuthorID>
    <LastName>Xu</LastName>
    <ForeName>Zhengyun</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>151</AuthorID>
    <LastName>You</LastName>
    <ForeName>Fuping</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>152</AuthorID>
    <LastName>Sun</LastName>
    <ForeName>Qiang</ForeName>
    <Initials>Q</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>153</AuthorID>
    <LastName>Lin</LastName>
    <ForeName>Rongtuan</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>154</AuthorID>
    <LastName>Fikrig</LastName>
    <ForeName>Erol</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>155</AuthorID>
    <LastName>Sutton</LastName>
    <ForeName>Richard E</ForeName>
    <Initials>RE</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>156</AuthorID>
    <LastName>Suthar</LastName>
    <ForeName>Mehul S</ForeName>
    <Initials>MS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>157</AuthorID>
    <LastName>Brassil</LastName>
    <ForeName>Margaret M</ForeName>
    <Initials>MM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>158</AuthorID>
    <LastName>Blahnik</LastName>
    <ForeName>Gabriele</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>159</AuthorID>
    <LastName>McMillan</LastName>
    <ForeName>Aimee</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>160</AuthorID>
    <LastName>Ramos</LastName>
    <ForeName>Hilario J</ForeName>
    <Initials>HJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>161</AuthorID>
    <LastName>Proll</LastName>
    <ForeName>Sean C</ForeName>
    <Initials>SC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>162</AuthorID>
    <LastName>Belisle</LastName>
    <ForeName>Sarah E</ForeName>
    <Initials>SE</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>163</AuthorID>
    <LastName>Katze</LastName>
    <ForeName>Michael G</ForeName>
    <Initials>MG</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>164</AuthorID>
    <Suffix>Jr</Suffix>
    <LastName>Gale</LastName>
    <ForeName>Michael</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>165</AuthorID>
    <LastName>Ding</LastName>
    <ForeName>Qiang</ForeName>
    <Initials>Q</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>166</AuthorID>
    <LastName>Cao</LastName>
    <ForeName>Xuezhi</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>167</AuthorID>
    <LastName>Lu</LastName>
    <ForeName>Jie</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>168</AuthorID>
    <LastName>Huang</LastName>
    <ForeName>Bing</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>169</AuthorID>
    <LastName>Liu</LastName>
    <ForeName>Yong-Jun</ForeName>
    <Initials>YJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>170</AuthorID>
    <LastName>Kato</LastName>
    <ForeName>Nobuyuki</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>171</AuthorID>
    <LastName>Shu</LastName>
    <ForeName>Hong-Bing</ForeName>
    <Initials>HB</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>172</AuthorID>
    <LastName>Zhong</LastName>
    <ForeName>Jin</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>173</AuthorID>
    <LastName>Graham</LastName>
    <ForeName>Amy C</ForeName>
    <Initials>AC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>174</AuthorID>
    <LastName>Hilmer</LastName>
    <ForeName>Kimberly M</ForeName>
    <Initials>KM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>175</AuthorID>
    <LastName>Zickovich</LastName>
    <ForeName>Julianne M</ForeName>
    <Initials>JM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>176</AuthorID>
    <LastName>Obar</LastName>
    <ForeName>Joshua J</ForeName>
    <Initials>JJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>177</AuthorID>
    <LastName>Buskiewicz</LastName>
    <ForeName>Iwona A</ForeName>
    <Initials>IA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>178</AuthorID>
    <LastName>Koenig</LastName>
    <ForeName>Andreas</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>179</AuthorID>
    <LastName>Huber</LastName>
    <ForeName>Sally A</ForeName>
    <Initials>SA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>180</AuthorID>
    <LastName>Budd</LastName>
    <ForeName>Ralph C</ForeName>
    <Initials>RC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>181</AuthorID>
    <LastName>Mukherjee</LastName>
    <ForeName>Piyali</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>182</AuthorID>
    <LastName>Woods</LastName>
    <ForeName>Tyson A</ForeName>
    <Initials>TA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>183</AuthorID>
    <LastName>Moore</LastName>
    <ForeName>Roger A</ForeName>
    <Initials>RA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>184</AuthorID>
    <LastName>Peterson</LastName>
    <ForeName>Karin E</ForeName>
    <Initials>KE</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>185</AuthorID>
    <LastName>Weber</LastName>
    <ForeName>Michaela</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>186</AuthorID>
    <LastName>Gawanbacht</LastName>
    <ForeName>Ali</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>187</AuthorID>
    <LastName>Habjan</LastName>
    <ForeName>Matthias</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>188</AuthorID>
    <LastName>Rang</LastName>
    <ForeName>Andreas</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>189</AuthorID>
    <LastName>Borner</LastName>
    <ForeName>Christoph</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>190</AuthorID>
    <LastName>Schmidt</LastName>
    <ForeName>Anna Mareike</ForeName>
    <Initials>AM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>191</AuthorID>
    <LastName>Veitinger</LastName>
    <ForeName>Sophie</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>192</AuthorID>
    <LastName>Jacob</LastName>
    <ForeName>Ralf</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>193</AuthorID>
    <LastName>Devignot</LastName>
    <ForeName>StÃ©phanie</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>194</AuthorID>
    <LastName>Kochs</LastName>
    <ForeName>Georg</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>195</AuthorID>
    <LastName>GarcÃ­a-Sastre</LastName>
    <ForeName>Adolfo</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>196</AuthorID>
    <LastName>Weber</LastName>
    <ForeName>Friedemann</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>197</AuthorID>
    <LastName>Boga</LastName>
    <ForeName>Jose A</ForeName>
    <Initials>JA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>198</AuthorID>
    <LastName>de OÃ±a</LastName>
    <ForeName>Maria</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>199</AuthorID>
    <LastName>Melon</LastName>
    <ForeName>Santiago</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>200</AuthorID>
    <LastName>Alvarez-Arguelles</LastName>
    <ForeName>Marta E</ForeName>
    <Initials>ME</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>201</AuthorID>
    <LastName>Morilla</LastName>
    <ForeName>Ana</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>202</AuthorID>
    <LastName>Coto-Montes</LastName>
    <ForeName>Ana</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>203</AuthorID>
    <LastName>Wadajkar</LastName>
    <ForeName>Aniket S</ForeName>
    <Initials>AS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>204</AuthorID>
    <LastName>Menon</LastName>
    <ForeName>Jyothi U</ForeName>
    <Initials>JU</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>205</AuthorID>
    <LastName>Tsai</LastName>
    <ForeName>Yuh-Shyan</ForeName>
    <Initials>YS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>206</AuthorID>
    <LastName>Gore</LastName>
    <ForeName>Crystal</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>207</AuthorID>
    <LastName>Dobin</LastName>
    <ForeName>Timothy</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>208</AuthorID>
    <LastName>Gandee</LastName>
    <ForeName>Leah</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>209</AuthorID>
    <LastName>Kangasniemi</LastName>
    <ForeName>Kim</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>210</AuthorID>
    <LastName>Takahashi</LastName>
    <ForeName>Masaya</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>211</AuthorID>
    <LastName>Manandhar</LastName>
    <ForeName>Bikash</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>212</AuthorID>
    <LastName>Ahn</LastName>
    <ForeName>Jung-Mo</ForeName>
    <Initials>JM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>213</AuthorID>
    <LastName>Hsieh</LastName>
    <ForeName>Jer-Tsong</ForeName>
    <Initials>JT</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>214</AuthorID>
    <LastName>Nguyen</LastName>
    <ForeName>Kytai T</ForeName>
    <Initials>KT</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>215</AuthorID>
    <LastName>Azuma</LastName>
    <ForeName>Masahiro</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>216</AuthorID>
    <LastName>Ermler</LastName>
    <ForeName>Megan E</ForeName>
    <Initials>ME</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>217</AuthorID>
    <LastName>Yerukhim</LastName>
    <ForeName>Ekaterina</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>218</AuthorID>
    <LastName>Schriewer</LastName>
    <ForeName>Jill</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>219</AuthorID>
    <LastName>Schattgen</LastName>
    <ForeName>Stefan</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>220</AuthorID>
    <LastName>Traylor</LastName>
    <ForeName>Zachary</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>221</AuthorID>
    <LastName>Wespiser</LastName>
    <ForeName>Adam R</ForeName>
    <Initials>AR</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>222</AuthorID>
    <LastName>Caffrey</LastName>
    <ForeName>Daniel R</ForeName>
    <Initials>DR</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>223</AuthorID>
    <LastName>King</LastName>
    <ForeName>Charles H</ForeName>
    <Initials>CH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>224</AuthorID>
    <LastName>Colonna</LastName>
    <ForeName>Marco</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>225</AuthorID>
    <LastName>Fitzgerald</LastName>
    <ForeName>Katherine A</ForeName>
    <Initials>KA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>226</AuthorID>
    <LastName>Buller</LastName>
    <ForeName>R Mark L</ForeName>
    <Initials>RM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>227</AuthorID>
    <LastName>Hise</LastName>
    <ForeName>Amy G</ForeName>
    <Initials>AG</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>228</AuthorID>
    <LastName>Alex</LastName>
    <ForeName>Raichel</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>229</AuthorID>
    <LastName>Bhave</LastName>
    <ForeName>Gauri</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>230</AuthorID>
    <LastName>Al-Abed</LastName>
    <ForeName>Mohammad A</ForeName>
    <Initials>MA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>231</AuthorID>
    <LastName>Bashaboyina</LastName>
    <ForeName>Aditya</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>232</AuthorID>
    <LastName>Iyer</LastName>
    <ForeName>Swathi</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>233</AuthorID>
    <LastName>Watenpaugh</LastName>
    <ForeName>Donald E</ForeName>
    <Initials>DE</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>234</AuthorID>
    <LastName>Zhang</LastName>
    <ForeName>Rong</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>235</AuthorID>
    <LastName>Behbehani</LastName>
    <ForeName>Khosrow</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>236</AuthorID>
    <LastName>Sasaki</LastName>
    <ForeName>Osamu</ForeName>
    <Initials>O</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>237</AuthorID>
    <LastName>Yoshizumi</LastName>
    <ForeName>Takuma</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>238</AuthorID>
    <LastName>Kuboyama</LastName>
    <ForeName>Misa</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>239</AuthorID>
    <LastName>Ishihara</LastName>
    <ForeName>Takeshi</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>240</AuthorID>
    <LastName>Suzuki</LastName>
    <ForeName>Emiko</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>241</AuthorID>
    <LastName>Kawabata</LastName>
    <ForeName>Shun-ichiro</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>242</AuthorID>
    <LastName>Koshiba</LastName>
    <ForeName>Takumi</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>243</AuthorID>
    <LastName>Lei</LastName>
    <ForeName>Yu</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>244</AuthorID>
    <LastName>Wen</LastName>
    <ForeName>Haitao</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>245</AuthorID>
    <LastName>Ting</LastName>
    <ForeName>Jenny P Y</ForeName>
    <Initials>JP</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>246</AuthorID>
    <LastName>Jin</LastName>
    <ForeName>Rui</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>247</AuthorID>
    <LastName>Zhu</LastName>
    <ForeName>Wandi</ForeName>
    <Initials>W</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>248</AuthorID>
    <LastName>Cao</LastName>
    <ForeName>Shengbo</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>249</AuthorID>
    <LastName>Chen</LastName>
    <ForeName>Rui</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>250</AuthorID>
    <LastName>Jin</LastName>
    <ForeName>Hui</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>251</AuthorID>
    <LastName>Liu</LastName>
    <ForeName>Yang</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>252</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Shaobo</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>253</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Wei</ForeName>
    <Initials>W</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>254</AuthorID>
    <LastName>Xiao</LastName>
    <ForeName>Gengfu</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>255</AuthorID>
    <LastName>Takamatsu</LastName>
    <ForeName>Shiori</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>256</AuthorID>
    <LastName>Onoguchi</LastName>
    <ForeName>Kazuhide</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>257</AuthorID>
    <LastName>Onomoto</LastName>
    <ForeName>Koji</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>258</AuthorID>
    <LastName>Narita</LastName>
    <ForeName>Ryo</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>259</AuthorID>
    <LastName>Takahasi</LastName>
    <ForeName>Kiyohiro</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>260</AuthorID>
    <LastName>Ishidate</LastName>
    <ForeName>Fumiyoshi</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>261</AuthorID>
    <LastName>Fujiwara</LastName>
    <ForeName>Takahiro K</ForeName>
    <Initials>TK</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>262</AuthorID>
    <LastName>Yoneyama</LastName>
    <ForeName>Mitsutoshi</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>263</AuthorID>
    <LastName>Kato</LastName>
    <ForeName>Hiroki</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>264</AuthorID>
    <LastName>Fujita</LastName>
    <ForeName>Takashi</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>265</AuthorID>
    <LastName>Zhao</LastName>
    <ForeName>Yuanyuan</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>266</AuthorID>
    <LastName>Sun</LastName>
    <ForeName>Xiaofeng</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>267</AuthorID>
    <LastName>Nie</LastName>
    <ForeName>Xuanli</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>268</AuthorID>
    <LastName>Sun</LastName>
    <ForeName>Liwei</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>269</AuthorID>
    <LastName>Tang</LastName>
    <ForeName>Tie-Shan</ForeName>
    <Initials>TS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>270</AuthorID>
    <LastName>Chen</LastName>
    <ForeName>Dahua</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>271</AuthorID>
    <LastName>Sun</LastName>
    <ForeName>Qinmiao</ForeName>
    <Initials>Q</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>272</AuthorID>
    <LastName>Ruiz</LastName>
    <ForeName>Erika</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>273</AuthorID>
    <LastName>Aguirre</LastName>
    <ForeName>Regina T P</ForeName>
    <Initials>RT</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>274</AuthorID>
    <LastName>Mitschke</LastName>
    <ForeName>Diane B</ForeName>
    <Initials>DB</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>275</AuthorID>
    <LastName>Funami</LastName>
    <ForeName>Kenji</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>276</AuthorID>
    <LastName>Aly</LastName>
    <ForeName>Hussein H</ForeName>
    <Initials>HH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>277</AuthorID>
    <LastName>Wu</LastName>
    <ForeName>Bin</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>278</AuthorID>
    <LastName>Peisley</LastName>
    <ForeName>Alys</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>279</AuthorID>
    <LastName>Richards</LastName>
    <ForeName>Claire</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>280</AuthorID>
    <LastName>Yao</LastName>
    <ForeName>Hui</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>281</AuthorID>
    <LastName>Zeng</LastName>
    <ForeName>Xiaohui</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>282</AuthorID>
    <LastName>Lin</LastName>
    <ForeName>Cecilie</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>283</AuthorID>
    <LastName>Chu</LastName>
    <ForeName>Feixia</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>284</AuthorID>
    <LastName>Walz</LastName>
    <ForeName>Thomas</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>285</AuthorID>
    <LastName>Hur</LastName>
    <ForeName>Sun</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>286</AuthorID>
    <LastName>Feng</LastName>
    <ForeName>Miao</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>287</AuthorID>
    <LastName>Ding</LastName>
    <ForeName>Zhanyu</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>288</AuthorID>
    <LastName>Xu</LastName>
    <ForeName>Liang</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>289</AuthorID>
    <LastName>Kong</LastName>
    <ForeName>Liangliang</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>290</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Wenjia</ForeName>
    <Initials>W</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>291</AuthorID>
    <LastName>Jiao</LastName>
    <ForeName>Shi</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>292</AuthorID>
    <LastName>Shi</LastName>
    <ForeName>Zhubing</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>293</AuthorID>
    <LastName>Greene</LastName>
    <ForeName>Mark I</ForeName>
    <Initials>MI</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>294</AuthorID>
    <LastName>Cong</LastName>
    <ForeName>Yao</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>295</AuthorID>
    <LastName>Zhou</LastName>
    <ForeName>Zhaocai</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>296</AuthorID>
    <LastName>Zhang</LastName>
    <ForeName>Qing-Meng</ForeName>
    <Initials>QM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>297</AuthorID>
    <LastName>Song</LastName>
    <ForeName>Wu-Qi</ForeName>
    <Initials>WQ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>298</AuthorID>
    <LastName>Li</LastName>
    <ForeName>Yu-Jun</ForeName>
    <Initials>YJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>299</AuthorID>
    <LastName>Zhai</LastName>
    <ForeName>Ai-Xia</ForeName>
    <Initials>AX</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>300</AuthorID>
    <LastName>Li</LastName>
    <ForeName>Ai-Mei</ForeName>
    <Initials>AM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>301</AuthorID>
    <LastName>He</LastName>
    <ForeName>Jun-Ming</ForeName>
    <Initials>JM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>302</AuthorID>
    <LastName>Zhao</LastName>
    <ForeName>Jin-Yun</ForeName>
    <Initials>JY</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>303</AuthorID>
    <LastName>Yu</LastName>
    <ForeName>Xin</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>304</AuthorID>
    <LastName>Wei</LastName>
    <ForeName>Lan-Lan</ForeName>
    <Initials>LL</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>305</AuthorID>
    <LastName>Zhang</LastName>
    <ForeName>Feng-Min</ForeName>
    <Initials>FM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>306</AuthorID>
    <LastName>Patel</LastName>
    <ForeName>Deendayal</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>307</AuthorID>
    <LastName>Schultz</LastName>
    <ForeName>L Wayne</ForeName>
    <Initials>LW</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>308</AuthorID>
    <LastName>Umland</LastName>
    <ForeName>Timothy C</ForeName>
    <Initials>TC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>309</AuthorID>
    <LastName>Kaukinen</LastName>
    <ForeName>Pasi</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>310</AuthorID>
    <LastName>SillanpÃ¤Ã¤</LastName>
    <ForeName>Maarit</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>311</AuthorID>
    <LastName>Nousiainen</LastName>
    <ForeName>Laura</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>312</AuthorID>
    <LastName>MelÃ©n</LastName>
    <ForeName>Krister</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>313</AuthorID>
    <LastName>Julkunen</LastName>
    <ForeName>Ilkka</ForeName>
    <Initials>I</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>314</AuthorID>
    <LastName>Berke</LastName>
    <ForeName>Ian C</ForeName>
    <Initials>IC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>315</AuthorID>
    <LastName>Yu</LastName>
    <ForeName>Xiong</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>316</AuthorID>
    <LastName>Modis</LastName>
    <ForeName>Yorgo</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>317</AuthorID>
    <LastName>Egelman</LastName>
    <ForeName>Edward H</ForeName>
    <Initials>EH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>318</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Yetao</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>319</AuthorID>
    <LastName>Tong</LastName>
    <ForeName>Xiaomei</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>320</AuthorID>
    <LastName>Ye</LastName>
    <ForeName>Xin</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>321</AuthorID>
    <LastName>Uchil</LastName>
    <ForeName>Pradeep D</ForeName>
    <Initials>PD</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>322</AuthorID>
    <LastName>Hinz</LastName>
    <ForeName>Angelika</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>323</AuthorID>
    <LastName>Siegel</LastName>
    <ForeName>Steven</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>324</AuthorID>
    <LastName>Coenen-Stass</LastName>
    <ForeName>Anna</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>325</AuthorID>
    <LastName>Pertel</LastName>
    <ForeName>Thomas</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>326</AuthorID>
    <LastName>Luban</LastName>
    <ForeName>Jeremy</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>327</AuthorID>
    <LastName>Mothes</LastName>
    <ForeName>Walther</ForeName>
    <Initials>W</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>328</AuthorID>
    <LastName>Heim</LastName>
    <ForeName>Markus H</ForeName>
    <Initials>MH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>329</AuthorID>
    <LastName>Xing</LastName>
    <ForeName>Fei</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>330</AuthorID>
    <LastName>Matsumiya</LastName>
    <ForeName>Tomoh</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>331</AuthorID>
    <LastName>Hayakari</LastName>
    <ForeName>Ryo</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>332</AuthorID>
    <LastName>Imaizumi</LastName>
    <ForeName>Tadaatsu</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>333</AuthorID>
    <LastName>Yoshida</LastName>
    <ForeName>Hidemi</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>334</AuthorID>
    <LastName>Satoh</LastName>
    <ForeName>Kei</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>335</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Lingyan</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>336</AuthorID>
    <LastName>Li</LastName>
    <ForeName>Shitao</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>337</AuthorID>
    <LastName>Dorf</LastName>
    <ForeName>Martin E</ForeName>
    <Initials>ME</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>338</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Qingrong</ForeName>
    <Initials>Q</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>339</AuthorID>
    <LastName>Prusak</LastName>
    <ForeName>Deborah J</ForeName>
    <Initials>DJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>340</AuthorID>
    <LastName>Tseng</LastName>
    <ForeName>Chien-Te K</ForeName>
    <Initials>CT</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>341</AuthorID>
    <LastName>Wood</LastName>
    <ForeName>Thomas G</ForeName>
    <Initials>TG</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>342</AuthorID>
    <LastName>Matsushima-Miyagi</LastName>
    <ForeName>Taeko</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>343</AuthorID>
    <LastName>Hatano</LastName>
    <ForeName>Koji</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>344</AuthorID>
    <LastName>Nomura</LastName>
    <ForeName>Motonari</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>345</AuthorID>
    <LastName>Li-Wen</LastName>
    <ForeName>Liu</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>346</AuthorID>
    <LastName>Nishikawa</LastName>
    <ForeName>Tomoyuki</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>347</AuthorID>
    <LastName>Saga</LastName>
    <ForeName>Kotaro</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>348</AuthorID>
    <LastName>Shimbo</LastName>
    <ForeName>Takashi</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>349</AuthorID>
    <LastName>Kaneda</LastName>
    <ForeName>Yasufumi</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>350</AuthorID>
    <LastName>Chen</LastName>
    <ForeName>Huihui</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>351</AuthorID>
    <LastName>Jiang</LastName>
    <ForeName>Zhengfan</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>352</AuthorID>
    <LastName>Omoregie</LastName>
    <ForeName>Ehimwenma Sheena</ForeName>
    <Initials>ES</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>353</AuthorID>
    <LastName>Liu</LastName>
    <ForeName>Wenjun</ForeName>
    <Initials>W</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>354</AuthorID>
    <LastName>Meng</LastName>
    <ForeName>Songdong</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>355</AuthorID>
    <LastName>Belgnaoui</LastName>
    <ForeName>S Mehdi</ForeName>
    <Initials>SM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>356</AuthorID>
    <LastName>Paz</LastName>
    <ForeName>Suzanne</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>357</AuthorID>
    <LastName>Samuel</LastName>
    <ForeName>Sara</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>358</AuthorID>
    <LastName>Goulet</LastName>
    <ForeName>Marie-Line</ForeName>
    <Initials>ML</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>359</AuthorID>
    <LastName>Kikkert</LastName>
    <ForeName>Marjolein</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>360</AuthorID>
    <LastName>Iwai</LastName>
    <ForeName>Kazuhiro</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>361</AuthorID>
    <LastName>Dikic</LastName>
    <ForeName>Ivan</ForeName>
    <Initials>I</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>362</AuthorID>
    <LastName>Hiscott</LastName>
    <ForeName>John</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>363</AuthorID>
    <LastName>Parera</LastName>
    <ForeName>Mariona</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>364</AuthorID>
    <LastName>Martrus</LastName>
    <ForeName>Gloria</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>365</AuthorID>
    <LastName>Franco</LastName>
    <ForeName>Sandra</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>366</AuthorID>
    <LastName>Clotet</LastName>
    <ForeName>Bonaventura</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>367</AuthorID>
    <LastName>Martinez</LastName>
    <ForeName>Miguel Angel</ForeName>
    <Initials>MA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>368</AuthorID>
    <LastName>Wen</LastName>
    <ForeName>Chaoyang</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>369</AuthorID>
    <LastName>Yan</LastName>
    <ForeName>Zhifeng</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>370</AuthorID>
    <LastName>Yang</LastName>
    <ForeName>Xiaoli</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>371</AuthorID>
    <LastName>Guan</LastName>
    <ForeName>Kai</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>372</AuthorID>
    <LastName>Xu</LastName>
    <ForeName>Changzhi</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>373</AuthorID>
    <LastName>Song</LastName>
    <ForeName>Ting</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>374</AuthorID>
    <LastName>Zheng</LastName>
    <ForeName>Zirui</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>375</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Wenjun</ForeName>
    <Initials>W</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>376</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Ying</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>377</AuthorID>
    <LastName>Zhao</LastName>
    <ForeName>Man</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>378</AuthorID>
    <LastName>Zhang</LastName>
    <ForeName>Yanhong</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>379</AuthorID>
    <LastName>Xu</LastName>
    <ForeName>Tao</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>380</AuthorID>
    <LastName>Dou</LastName>
    <ForeName>Jianping</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>381</AuthorID>
    <LastName>Liu</LastName>
    <ForeName>Jingmei</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>382</AuthorID>
    <LastName>Xu</LastName>
    <ForeName>Quanbin</ForeName>
    <Initials>Q</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>383</AuthorID>
    <LastName>He</LastName>
    <ForeName>Xiang</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>384</AuthorID>
    <LastName>Wei</LastName>
    <ForeName>Congwen</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>385</AuthorID>
    <LastName>Zhong</LastName>
    <ForeName>Hui</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>386</AuthorID>
    <LastName>van Zuylen</LastName>
    <ForeName>Wendy J</ForeName>
    <Initials>WJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>387</AuthorID>
    <LastName>Doyon</LastName>
    <ForeName>Priscilla</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>388</AuthorID>
    <LastName>ClÃ©ment</LastName>
    <ForeName>Jean-FranÃ§ois</ForeName>
    <Initials>JF</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>389</AuthorID>
    <LastName>Khan</LastName>
    <ForeName>Kashif Aziz</ForeName>
    <Initials>KA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>390</AuthorID>
    <LastName>D'Ambrosio</LastName>
    <ForeName>Lisa M</ForeName>
    <Initials>LM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>391</AuthorID>
    <LastName>DÃ´</LastName>
    <ForeName>Florence</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>392</AuthorID>
    <LastName>St-Amant-Verret</LastName>
    <ForeName>Myriam</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>393</AuthorID>
    <LastName>Wissanji</LastName>
    <ForeName>Tasheen</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>394</AuthorID>
    <LastName>Emery</LastName>
    <ForeName>Gregory</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>395</AuthorID>
    <LastName>Gingras</LastName>
    <ForeName>Anne-Claude</ForeName>
    <Initials>AC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>396</AuthorID>
    <LastName>Meloche</LastName>
    <ForeName>Sylvain</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>397</AuthorID>
    <LastName>Servant</LastName>
    <ForeName>Marc J</ForeName>
    <Initials>MJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>398</AuthorID>
    <LastName>Yu</LastName>
    <ForeName>Yanbao</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>399</AuthorID>
    <LastName>Taxman</LastName>
    <ForeName>Debra J</ForeName>
    <Initials>DJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>400</AuthorID>
    <LastName>Zhang</LastName>
    <ForeName>Lu</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>401</AuthorID>
    <LastName>Widman</LastName>
    <ForeName>Douglas G</ForeName>
    <Initials>DG</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>402</AuthorID>
    <LastName>Swanson</LastName>
    <ForeName>Karen V</ForeName>
    <Initials>KV</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>403</AuthorID>
    <LastName>Wen</LastName>
    <ForeName>Kwun-Wah</ForeName>
    <Initials>KW</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>404</AuthorID>
    <LastName>Damania</LastName>
    <ForeName>Blossom</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>405</AuthorID>
    <LastName>Moore</LastName>
    <ForeName>Chris B</ForeName>
    <Initials>CB</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>406</AuthorID>
    <LastName>GiguÃ¨re</LastName>
    <ForeName>Patrick M</ForeName>
    <Initials>PM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>407</AuthorID>
    <LastName>Siderovski</LastName>
    <ForeName>David P</ForeName>
    <Initials>DP</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>408</AuthorID>
    <LastName>Razani</LastName>
    <ForeName>Babak</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>409</AuthorID>
    <LastName>Semenkovich</LastName>
    <ForeName>Clay F</ForeName>
    <Initials>CF</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>410</AuthorID>
    <LastName>Chen</LastName>
    <ForeName>Xian</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>411</AuthorID>
    <LastName>Varga</LastName>
    <ForeName>Zsuzsanna T</ForeName>
    <Initials>ZT</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>412</AuthorID>
    <LastName>Grant</LastName>
    <ForeName>Alesha</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>413</AuthorID>
    <LastName>Manicassamy</LastName>
    <ForeName>Balaji</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>414</AuthorID>
    <LastName>Palese</LastName>
    <ForeName>Peter</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>415</AuthorID>
    <LastName>Zemirli</LastName>
    <ForeName>Naima</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>416</AuthorID>
    <LastName>Arnoult</LastName>
    <ForeName>Damien</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>417</AuthorID>
    <LastName>Castanier</LastName>
    <ForeName>CÃ©line</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>418</AuthorID>
    <LastName>Portier</LastName>
    <ForeName>Alain</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>419</AuthorID>
    <LastName>Garcin</LastName>
    <ForeName>Dominique</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>420</AuthorID>
    <LastName>BidÃ¨re</LastName>
    <ForeName>Nicolas</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>421</AuthorID>
    <LastName>Vazquez</LastName>
    <ForeName>AimÃ©</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>422</AuthorID>
    <LastName>Qu</LastName>
    <ForeName>Bingqian</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>423</AuthorID>
    <LastName>Qi</LastName>
    <ForeName>Xian</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>424</AuthorID>
    <LastName>Wu</LastName>
    <ForeName>Xiaodong</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>425</AuthorID>
    <LastName>Liang</LastName>
    <ForeName>Mifang</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>426</AuthorID>
    <LastName>Li</LastName>
    <ForeName>Chuan</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>427</AuthorID>
    <LastName>Cardona</LastName>
    <ForeName>Carol J</ForeName>
    <Initials>CJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>428</AuthorID>
    <LastName>Xu</LastName>
    <ForeName>Wayne</ForeName>
    <Initials>W</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>429</AuthorID>
    <LastName>Tang</LastName>
    <ForeName>Fenyang</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>430</AuthorID>
    <LastName>Li</LastName>
    <ForeName>Zhifeng</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>431</AuthorID>
    <LastName>Wu</LastName>
    <ForeName>Bing</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>432</AuthorID>
    <LastName>Powell</LastName>
    <ForeName>Kira</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>433</AuthorID>
    <LastName>Wegner</LastName>
    <ForeName>Marta</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>434</AuthorID>
    <LastName>Li</LastName>
    <ForeName>Dexin</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>435</AuthorID>
    <LastName>Xing</LastName>
    <ForeName>Zheng</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>436</AuthorID>
    <LastName>Lifland</LastName>
    <ForeName>Aaron W</ForeName>
    <Initials>AW</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>437</AuthorID>
    <LastName>Jung</LastName>
    <ForeName>Jeenah</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>438</AuthorID>
    <LastName>Alonas</LastName>
    <ForeName>Eric</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>439</AuthorID>
    <LastName>Zurla</LastName>
    <ForeName>Chiara</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>440</AuthorID>
    <Suffix>Jr</Suffix>
    <LastName>Crowe</LastName>
    <ForeName>James E</ForeName>
    <Initials>JE</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>441</AuthorID>
    <LastName>Santangelo</LastName>
    <ForeName>Philip J</ForeName>
    <Initials>PJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>442</AuthorID>
    <LastName>Liu</LastName>
    <ForeName>Helene Minyi</ForeName>
    <Initials>HM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>443</AuthorID>
    <LastName>Loo</LastName>
    <ForeName>Yueh-Ming</ForeName>
    <Initials>YM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>444</AuthorID>
    <LastName>Horner</LastName>
    <ForeName>Stacy M</ForeName>
    <Initials>SM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>445</AuthorID>
    <LastName>Zornetzer</LastName>
    <ForeName>Gregory A</ForeName>
    <Initials>GA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>446</AuthorID>
    <LastName>Chhatwal</LastName>
    <ForeName>Patrick</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>447</AuthorID>
    <LastName>Bankwitz</LastName>
    <ForeName>Dorothea</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>448</AuthorID>
    <LastName>Gentzsch</LastName>
    <ForeName>Juliane</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>449</AuthorID>
    <LastName>Schult</LastName>
    <ForeName>Philipp</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>450</AuthorID>
    <LastName>Lohmann</LastName>
    <ForeName>Volker</ForeName>
    <Initials>V</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>451</AuthorID>
    <LastName>Pythoud</LastName>
    <ForeName>Christelle</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>452</AuthorID>
    <LastName>Rodrigo</LastName>
    <ForeName>W W Shanaka I</ForeName>
    <Initials>WW</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>453</AuthorID>
    <LastName>Pasqual</LastName>
    <ForeName>Giulia</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>454</AuthorID>
    <LastName>Rothenberger</LastName>
    <ForeName>Sylvia</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>455</AuthorID>
    <LastName>MartÃ­nez-Sobrido</LastName>
    <ForeName>Luis</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>456</AuthorID>
    <LastName>de la Torre</LastName>
    <ForeName>Juan Carlos</ForeName>
    <Initials>JC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>457</AuthorID>
    <LastName>Kunz</LastName>
    <ForeName>Stefan</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>458</AuthorID>
    <LastName>Patel</LastName>
    <ForeName>Maulik R</ForeName>
    <Initials>MR</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>459</AuthorID>
    <LastName>Malik</LastName>
    <ForeName>Harmit S</ForeName>
    <Initials>HS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>460</AuthorID>
    <LastName>Boyapalle</LastName>
    <ForeName>Sandhya</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>461</AuthorID>
    <LastName>Wong</LastName>
    <ForeName>Terianne</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>462</AuthorID>
    <LastName>Garay</LastName>
    <ForeName>Julio</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>463</AuthorID>
    <LastName>Teng</LastName>
    <ForeName>Michael</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>464</AuthorID>
    <LastName>San Juan-Vergara</LastName>
    <ForeName>Homero</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>465</AuthorID>
    <LastName>Mohapatra</LastName>
    <ForeName>Subhra</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>466</AuthorID>
    <LastName>Mohapatra</LastName>
    <ForeName>Shyam</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>467</AuthorID>
    <LastName>Xiang</LastName>
    <ForeName>Li-xin</ForeName>
    <Initials>LX</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>468</AuthorID>
    <LastName>Shao</LastName>
    <ForeName>Jian-zhong</ForeName>
    <Initials>JZ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>469</AuthorID>
    <LastName>Bozym</LastName>
    <ForeName>Rebecca A</ForeName>
    <Initials>RA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>470</AuthorID>
    <LastName>Delorme-Axford</LastName>
    <ForeName>Elizabeth</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>471</AuthorID>
    <LastName>Harris</LastName>
    <ForeName>Katharine</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>472</AuthorID>
    <LastName>Morosky</LastName>
    <ForeName>Stefanie</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>473</AuthorID>
    <LastName>Ikizler</LastName>
    <ForeName>Mine</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>474</AuthorID>
    <LastName>Dermody</LastName>
    <ForeName>Terence S</ForeName>
    <Initials>TS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>475</AuthorID>
    <LastName>Sarkar</LastName>
    <ForeName>Saumendra N</ForeName>
    <Initials>SN</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>476</AuthorID>
    <LastName>Coyne</LastName>
    <ForeName>Carolyn B</ForeName>
    <Initials>CB</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>477</AuthorID>
    <LastName>Sun</LastName>
    <ForeName>Li</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>478</AuthorID>
    <LastName>Xing</LastName>
    <ForeName>Yaling</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>479</AuthorID>
    <LastName>Chen</LastName>
    <ForeName>Xiaojuan</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>480</AuthorID>
    <LastName>Zheng</LastName>
    <ForeName>Yang</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>481</AuthorID>
    <LastName>Yang</LastName>
    <ForeName>Yudong</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>482</AuthorID>
    <LastName>Nichols</LastName>
    <ForeName>Daniel B</ForeName>
    <Initials>DB</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>483</AuthorID>
    <LastName>Clementz</LastName>
    <ForeName>Mark A</ForeName>
    <Initials>MA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>484</AuthorID>
    <LastName>Banach</LastName>
    <ForeName>Bridget S</ForeName>
    <Initials>BS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>485</AuthorID>
    <LastName>Baker</LastName>
    <ForeName>Susan C</ForeName>
    <Initials>SC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>486</AuthorID>
    <LastName>Chen</LastName>
    <ForeName>Zhongbin</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>487</AuthorID>
    <LastName>Huang</LastName>
    <ForeName>Zhiqing</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>488</AuthorID>
    <LastName>Chen</LastName>
    <ForeName>Xiaoling</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>489</AuthorID>
    <LastName>Zhang</LastName>
    <ForeName>Keying</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>490</AuthorID>
    <LastName>Yu</LastName>
    <ForeName>Bing</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>491</AuthorID>
    <LastName>Mao</LastName>
    <ForeName>Xiangbing</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>492</AuthorID>
    <LastName>Zhao</LastName>
    <ForeName>Ye</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>493</AuthorID>
    <LastName>Chen</LastName>
    <ForeName>Daiwen</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>494</AuthorID>
    <LastName>Xing</LastName>
    <ForeName>Junji</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>495</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Shuai</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>496</AuthorID>
    <LastName>Mossman</LastName>
    <ForeName>Karen L</ForeName>
    <Initials>KL</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>497</AuthorID>
    <LastName>Zheng</LastName>
    <ForeName>Chunfu</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>498</AuthorID>
    <LastName>Ikuta</LastName>
    <ForeName>Yasushi</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>499</AuthorID>
    <LastName>Matsuda</LastName>
    <ForeName>Yuji</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>500</AuthorID>
    <LastName>Yamada</LastName>
    <ForeName>Yosuke</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>501</AuthorID>
    <LastName>Kida</LastName>
    <ForeName>Noriyuki</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>502</AuthorID>
    <LastName>Oda</LastName>
    <ForeName>Shingo</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>503</AuthorID>
    <LastName>Moritani</LastName>
    <ForeName>Toshio</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>504</AuthorID>
    <LastName>Giampalmo</LastName>
    <ForeName>Susan L</ForeName>
    <Initials>SL</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>505</AuthorID>
    <LastName>Absher</LastName>
    <ForeName>Benjamin F</ForeName>
    <Initials>BF</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>506</AuthorID>
    <LastName>Bourne</LastName>
    <ForeName>W Tucker</ForeName>
    <Initials>WT</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>507</AuthorID>
    <LastName>Steves</LastName>
    <ForeName>Lida E</ForeName>
    <Initials>LE</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>508</AuthorID>
    <LastName>Vodenski</LastName>
    <ForeName>Vassil V</ForeName>
    <Initials>VV</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>509</AuthorID>
    <LastName>O'Donnell</LastName>
    <ForeName>Peter M</ForeName>
    <Initials>PM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>510</AuthorID>
    <LastName>Erickson</LastName>
    <ForeName>Jonathan C</ForeName>
    <Initials>JC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>511</AuthorID>
    <LastName>Park</LastName>
    <ForeName>Hae Soo</ForeName>
    <Initials>HS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>512</AuthorID>
    <LastName>Berg</LastName>
    <ForeName>Randi K</ForeName>
    <Initials>RK</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>513</AuthorID>
    <LastName>Melchjorsen</LastName>
    <ForeName>Jesper</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>514</AuthorID>
    <LastName>Rintahaka</LastName>
    <ForeName>Johanna</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>515</AuthorID>
    <LastName>Diget</LastName>
    <ForeName>Elisabeth</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>516</AuthorID>
    <LastName>SÃ¸by</LastName>
    <ForeName>Stine</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>517</AuthorID>
    <LastName>Horan</LastName>
    <ForeName>Kristy A</ForeName>
    <Initials>KA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>518</AuthorID>
    <LastName>Gorelick</LastName>
    <ForeName>Robert J</ForeName>
    <Initials>RJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>519</AuthorID>
    <LastName>Matikainen</LastName>
    <ForeName>Sampsa</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>520</AuthorID>
    <LastName>Larsen</LastName>
    <ForeName>Carsten S</ForeName>
    <Initials>CS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>521</AuthorID>
    <LastName>Ostergaard</LastName>
    <ForeName>Lars</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>522</AuthorID>
    <LastName>Paludan</LastName>
    <ForeName>SÃ¸ren R</ForeName>
    <Initials>SR</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>523</AuthorID>
    <LastName>Mogensen</LastName>
    <ForeName>Trine H</ForeName>
    <Initials>TH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>524</AuthorID>
    <LastName>Qin</LastName>
    <ForeName>Lan</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>525</AuthorID>
    <LastName>Ren</LastName>
    <ForeName>Lili</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>526</AuthorID>
    <LastName>Zhou</LastName>
    <ForeName>Zhuo</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>527</AuthorID>
    <LastName>Chen</LastName>
    <ForeName>Lan</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>528</AuthorID>
    <LastName>Xue</LastName>
    <ForeName>Qinghua</ForeName>
    <Initials>Q</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>529</AuthorID>
    <LastName>Liu</LastName>
    <ForeName>Xinlei</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>530</AuthorID>
    <LastName>Hung</LastName>
    <ForeName>Tao</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>531</AuthorID>
    <LastName>Huang</LastName>
    <ForeName>Yuefeng</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>532</AuthorID>
    <LastName>Liu</LastName>
    <ForeName>Heng</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>533</AuthorID>
    <LastName>Ge</LastName>
    <ForeName>Rui</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>534</AuthorID>
    <LastName>Zhou</LastName>
    <ForeName>Yi</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>535</AuthorID>
    <LastName>Lou</LastName>
    <ForeName>Xiwen</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>536</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Chen</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>537</AuthorID>
    <LastName>Dong</LastName>
    <ForeName>Xiaonan</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>538</AuthorID>
    <LastName>Feng</LastName>
    <ForeName>Pinghui</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>539</AuthorID>
    <LastName>Zhou</LastName>
    <ForeName>Xiang</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>540</AuthorID>
    <LastName>Dudek</LastName>
    <ForeName>Sabine E</ForeName>
    <Initials>SE</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>541</AuthorID>
    <LastName>Wixler</LastName>
    <ForeName>Ludmilla</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>542</AuthorID>
    <LastName>Nordhoff</LastName>
    <ForeName>Carolin</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>543</AuthorID>
    <LastName>Nordmann</LastName>
    <ForeName>Alexandra</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>544</AuthorID>
    <LastName>Anhlan</LastName>
    <ForeName>Darisuren</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>545</AuthorID>
    <LastName>Wixler</LastName>
    <ForeName>Viktor</ForeName>
    <Initials>V</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>546</AuthorID>
    <LastName>Ludwig</LastName>
    <ForeName>Stephan</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>547</AuthorID>
    <LastName>Jia</LastName>
    <ForeName>Shuaizheng</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>548</AuthorID>
    <LastName>Peng</LastName>
    <ForeName>Jianchun</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>549</AuthorID>
    <LastName>Gao</LastName>
    <ForeName>Bo</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>550</AuthorID>
    <LastName>Zhou</LastName>
    <ForeName>Yong</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>551</AuthorID>
    <LastName>Fu</LastName>
    <ForeName>Qiuxia</ForeName>
    <Initials>Q</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>552</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Haiping</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>553</AuthorID>
    <LastName>Zhan</LastName>
    <ForeName>Linsheng</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>554</AuthorID>
    <LastName>Kasama</LastName>
    <ForeName>Yuri</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>555</AuthorID>
    <LastName>Saito</LastName>
    <ForeName>Makoto</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>556</AuthorID>
    <LastName>Takano</LastName>
    <ForeName>Takashi</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>557</AuthorID>
    <LastName>Nishimura</LastName>
    <ForeName>Tomohiro</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>558</AuthorID>
    <LastName>Satoh</LastName>
    <ForeName>Masaaki</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>559</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Zhongzhi</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>560</AuthorID>
    <LastName>Ali</LastName>
    <ForeName>Salem Nagla Elwy Salem</ForeName>
    <Initials>SN</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>561</AuthorID>
    <LastName>Harada</LastName>
    <ForeName>Shinji</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>562</AuthorID>
    <LastName>Arnaud</LastName>
    <ForeName>NoÃ«lla</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>563</AuthorID>
    <LastName>Dabo</LastName>
    <ForeName>StÃ©phanie</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>564</AuthorID>
    <LastName>Akazawa</LastName>
    <ForeName>Daisuke</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>565</AuthorID>
    <LastName>Fukasawa</LastName>
    <ForeName>Masayoshi</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>566</AuthorID>
    <LastName>Shinkai-Ouchi</LastName>
    <ForeName>Fumiko</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>567</AuthorID>
    <LastName>Hugon</LastName>
    <ForeName>Jacques</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>568</AuthorID>
    <LastName>Wakita</LastName>
    <ForeName>Takaji</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>569</AuthorID>
    <LastName>Meurs</LastName>
    <ForeName>Eliane F</ForeName>
    <Initials>EF</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>570</AuthorID>
    <LastName>Sun</LastName>
    <ForeName>Jiaren</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>571</AuthorID>
    <LastName>Desai</LastName>
    <ForeName>Mayura M</ForeName>
    <Initials>MM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>572</AuthorID>
    <LastName>Soong</LastName>
    <ForeName>Lynn</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>573</AuthorID>
    <LastName>Ou</LastName>
    <ForeName>J H James</ForeName>
    <Initials>JH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>574</AuthorID>
    <LastName>Cotter</LastName>
    <ForeName>Christopher R</ForeName>
    <Initials>CR</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>575</AuthorID>
    <LastName>Kim</LastName>
    <ForeName>Won-keun</ForeName>
    <Initials>WK</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>576</AuthorID>
    <LastName>Nguyen</LastName>
    <ForeName>Marie L</ForeName>
    <Initials>ML</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>577</AuthorID>
    <LastName>Yount</LastName>
    <ForeName>Jacob S</ForeName>
    <Initials>JS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>578</AuthorID>
    <LastName>LÃ³pez</LastName>
    <ForeName>Carolina B</ForeName>
    <Initials>CB</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>579</AuthorID>
    <LastName>Blaho</LastName>
    <ForeName>John A</ForeName>
    <Initials>JA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>580</AuthorID>
    <LastName>Moran</LastName>
    <ForeName>Thomas M</ForeName>
    <Initials>TM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>581</AuthorID>
    <LastName>Qu</LastName>
    <ForeName>Lin</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>582</AuthorID>
    <LastName>Feng</LastName>
    <ForeName>Zongdi</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>583</AuthorID>
    <LastName>Yamane</LastName>
    <ForeName>Daisuke</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>584</AuthorID>
    <LastName>Liang</LastName>
    <ForeName>Yuqiong</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>585</AuthorID>
    <LastName>Lanford</LastName>
    <ForeName>Robert E</ForeName>
    <Initials>RE</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>586</AuthorID>
    <LastName>Lemon</LastName>
    <ForeName>Stanley M</ForeName>
    <Initials>SM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>587</AuthorID>
    <LastName>Moresco</LastName>
    <ForeName>Eva Marie Y</ForeName>
    <Initials>EM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>588</AuthorID>
    <LastName>Vine</LastName>
    <ForeName>Diantha La</ForeName>
    <Initials>DL</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>589</AuthorID>
    <LastName>Beutler</LastName>
    <ForeName>Bruce</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>590</AuthorID>
    <LastName>Hrincius</LastName>
    <ForeName>Eike R</ForeName>
    <Initials>ER</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>591</AuthorID>
    <LastName>Dierkes</LastName>
    <ForeName>RÃ¼diger</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>592</AuthorID>
    <LastName>Ehrhardt</LastName>
    <ForeName>Christina</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>593</AuthorID>
    <LastName>Briley</LastName>
    <ForeName>Jessica</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>594</AuthorID>
    <LastName>Liu</LastName>
    <ForeName>Xin-Yi</ForeName>
    <Initials>XY</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>595</AuthorID>
    <LastName>Wei</LastName>
    <ForeName>Bo</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>596</AuthorID>
    <LastName>Shan</LastName>
    <ForeName>Yu-Fei</ForeName>
    <Initials>YF</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>597</AuthorID>
    <LastName>Sun</LastName>
    <ForeName>Ting</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>598</AuthorID>
    <LastName>Su</LastName>
    <ForeName>Wen-li</ForeName>
    <Initials>WL</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>599</AuthorID>
    <LastName>Bai</LastName>
    <ForeName>Ji-wei</ForeName>
    <Initials>JW</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>600</AuthorID>
    <LastName>Ling</LastName>
    <ForeName>Yan</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>601</AuthorID>
    <LastName>Yuan</LastName>
    <ForeName>Jing</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>602</AuthorID>
    <LastName>Li</LastName>
    <ForeName>Yong-mei</ForeName>
    <Initials>YM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>603</AuthorID>
    <LastName>Soares</LastName>
    <ForeName>Fraser</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>604</AuthorID>
    <LastName>Tattoli</LastName>
    <ForeName>Ivan</ForeName>
    <Initials>I</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>605</AuthorID>
    <LastName>Girardin</LastName>
    <ForeName>Stephen E</ForeName>
    <Initials>SE</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>606</AuthorID>
    <LastName>Hou</LastName>
    <ForeName>Fajian</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>607</AuthorID>
    <LastName>Zheng</LastName>
    <ForeName>Hui</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>608</AuthorID>
    <LastName>Skaug</LastName>
    <ForeName>Brian</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>609</AuthorID>
    <LastName>Jiang</LastName>
    <ForeName>Qiu-Xing</ForeName>
    <Initials>QX</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>610</AuthorID>
    <LastName>Allen</LastName>
    <ForeName>Irving C</ForeName>
    <Initials>IC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>611</AuthorID>
    <LastName>Schneider</LastName>
    <ForeName>Monika</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>612</AuthorID>
    <LastName>Scull</LastName>
    <ForeName>Margaret A</ForeName>
    <Initials>MA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>613</AuthorID>
    <LastName>Gris</LastName>
    <ForeName>Denis</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>614</AuthorID>
    <LastName>Roney</LastName>
    <ForeName>Kelly E</ForeName>
    <Initials>KE</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>615</AuthorID>
    <LastName>Zimmermann</LastName>
    <ForeName>Albert G</ForeName>
    <Initials>AG</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>616</AuthorID>
    <LastName>Bowzard</LastName>
    <ForeName>John B</ForeName>
    <Initials>JB</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>617</AuthorID>
    <LastName>Ranjan</LastName>
    <ForeName>Priya</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>618</AuthorID>
    <LastName>Monroe</LastName>
    <ForeName>Kathryn M</ForeName>
    <Initials>KM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>619</AuthorID>
    <LastName>Pickles</LastName>
    <ForeName>Raymond J</ForeName>
    <Initials>RJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>620</AuthorID>
    <LastName>Sambhara</LastName>
    <ForeName>Suryaprakash</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>621</AuthorID>
    <LastName>Eitz Ferrer</LastName>
    <ForeName>Pedro</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>622</AuthorID>
    <LastName>Potthoff</LastName>
    <ForeName>Stephanie</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>623</AuthorID>
    <LastName>Kirschnek</LastName>
    <ForeName>Susanne</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>624</AuthorID>
    <LastName>Gasteiger</LastName>
    <ForeName>Georg</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>625</AuthorID>
    <LastName>KastenmÃ¼ller</LastName>
    <ForeName>Wolfgang</ForeName>
    <Initials>W</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>626</AuthorID>
    <LastName>Ludwig</LastName>
    <ForeName>Holger</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>627</AuthorID>
    <LastName>Paschen</LastName>
    <ForeName>Stefan A</ForeName>
    <Initials>SA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>628</AuthorID>
    <LastName>Villunger</LastName>
    <ForeName>Andreas</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>629</AuthorID>
    <LastName>Sutter</LastName>
    <ForeName>Gerd</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>630</AuthorID>
    <LastName>Drexler</LastName>
    <ForeName>Ingo</ForeName>
    <Initials>I</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>631</AuthorID>
    <LastName>HÃ¤cker</LastName>
    <ForeName>Georg</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>632</AuthorID>
    <LastName>Ramos</LastName>
    <ForeName>Irene</ForeName>
    <Initials>I</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>633</AuthorID>
    <LastName>Hai</LastName>
    <ForeName>Rong</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>634</AuthorID>
    <LastName>Schmolke</LastName>
    <ForeName>Mirco</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>635</AuthorID>
    <LastName>Fernandez-Sesma</LastName>
    <ForeName>Ana</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>636</AuthorID>
    <LastName>Liu</LastName>
    <ForeName>Feng</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>637</AuthorID>
    <LastName>Gu</LastName>
    <ForeName>Jun</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>638</AuthorID>
    <LastName>Rebsamen</LastName>
    <ForeName>M</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>639</AuthorID>
    <LastName>Vazquez</LastName>
    <ForeName>J</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>640</AuthorID>
    <LastName>Tardivel</LastName>
    <ForeName>A</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>641</AuthorID>
    <LastName>Guarda</LastName>
    <ForeName>G</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>642</AuthorID>
    <LastName>Curran</LastName>
    <ForeName>J</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>643</AuthorID>
    <LastName>Tschopp</LastName>
    <ForeName>J</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>644</AuthorID>
    <LastName>Xiang</LastName>
    <ForeName>Zhiming</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>645</AuthorID>
    <LastName>Qi</LastName>
    <ForeName>Lin</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>646</AuthorID>
    <LastName>Chen</LastName>
    <ForeName>Weijian</ForeName>
    <Initials>W</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>647</AuthorID>
    <LastName>Dong</LastName>
    <ForeName>Chuanfu</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>648</AuthorID>
    <LastName>Liu</LastName>
    <ForeName>Zhaoyu</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>649</AuthorID>
    <LastName>Liu</LastName>
    <ForeName>Dong</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>650</AuthorID>
    <LastName>Huang</LastName>
    <ForeName>Mengli</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>651</AuthorID>
    <LastName>Li</LastName>
    <ForeName>Wei</ForeName>
    <Initials>W</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>652</AuthorID>
    <LastName>Yang</LastName>
    <ForeName>Gan</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>653</AuthorID>
    <LastName>Weng</LastName>
    <ForeName>Shaoping</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>654</AuthorID>
    <LastName>He</LastName>
    <ForeName>Jianguo</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>655</AuthorID>
    <LastName>Romano</LastName>
    <ForeName>Keith P</ForeName>
    <Initials>KP</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>656</AuthorID>
    <LastName>Laine</LastName>
    <ForeName>Jennifer M</ForeName>
    <Initials>JM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>657</AuthorID>
    <LastName>Deveau</LastName>
    <ForeName>Laura M</ForeName>
    <Initials>LM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>658</AuthorID>
    <LastName>Cao</LastName>
    <ForeName>Hong</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>659</AuthorID>
    <LastName>Massi</LastName>
    <ForeName>Francesca</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>660</AuthorID>
    <LastName>Schiffer</LastName>
    <ForeName>Celia A</ForeName>
    <Initials>CA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>661</AuthorID>
    <LastName>Mukherjee</LastName>
    <ForeName>Amitava</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>662</AuthorID>
    <LastName>Morosky</LastName>
    <ForeName>Stefanie A</ForeName>
    <Initials>SA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>663</AuthorID>
    <LastName>Dybdahl-Sissoko</LastName>
    <ForeName>Naomi</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>664</AuthorID>
    <LastName>Oberste</LastName>
    <ForeName>M Steven</ForeName>
    <Initials>MS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>665</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Tianyi</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>666</AuthorID>
    <LastName>Csak</LastName>
    <ForeName>Timea</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>667</AuthorID>
    <LastName>Dolganiuc</LastName>
    <ForeName>Angela</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>668</AuthorID>
    <LastName>Kodys</LastName>
    <ForeName>Karen</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>669</AuthorID>
    <LastName>Nath</LastName>
    <ForeName>Bharath</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>670</AuthorID>
    <LastName>Petrasek</LastName>
    <ForeName>Jan</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>671</AuthorID>
    <LastName>Bala</LastName>
    <ForeName>Shashi</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>672</AuthorID>
    <LastName>Lippai</LastName>
    <ForeName>Dora</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>673</AuthorID>
    <LastName>Szabo</LastName>
    <ForeName>Gyongyi</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>674</AuthorID>
    <LastName>Yasukawa</LastName>
    <ForeName>Kai</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>675</AuthorID>
    <LastName>Yanagi</LastName>
    <ForeName>Yusuke</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>676</AuthorID>
    <LastName>Niewold</LastName>
    <ForeName>Timothy B</ForeName>
    <Initials>TB</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>677</AuthorID>
    <LastName>Vitour</LastName>
    <ForeName>Damien</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>678</AuthorID>
    <LastName>Solhonne</LastName>
    <ForeName>Brigitte</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>679</AuthorID>
    <LastName>Crow</LastName>
    <ForeName>Mary K</ForeName>
    <Initials>MK</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>680</AuthorID>
    <LastName>Si-Tahar</LastName>
    <ForeName>Mustapha</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>681</AuthorID>
    <LastName>Baur</LastName>
    <ForeName>Heiner</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>682</AuthorID>
    <LastName>MÃ¼ller</LastName>
    <ForeName>Steffen</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>683</AuthorID>
    <LastName>HirschmÃ¼ller</LastName>
    <ForeName>Anja</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>684</AuthorID>
    <LastName>Cassel</LastName>
    <ForeName>Michael</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>685</AuthorID>
    <LastName>Weber</LastName>
    <ForeName>Josefine</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>686</AuthorID>
    <LastName>Mayer</LastName>
    <ForeName>Frank</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>687</AuthorID>
    <LastName>Vilasco</LastName>
    <ForeName>Myriam</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>688</AuthorID>
    <LastName>Werden</LastName>
    <ForeName>Steven J</ForeName>
    <Initials>SJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>689</AuthorID>
    <LastName>Arguello</LastName>
    <ForeName>Meztli</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>690</AuthorID>
    <LastName>Joseph-Pillai</LastName>
    <ForeName>Deshanthe</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>691</AuthorID>
    <LastName>Zhao</LastName>
    <ForeName>Tiejun</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>692</AuthorID>
    <LastName>Nguyen</LastName>
    <ForeName>Thi Lien-Anh</ForeName>
    <Initials>TL</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>693</AuthorID>
    <LastName>Broquet</LastName>
    <ForeName>Alexis H</ForeName>
    <Initials>AH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>694</AuthorID>
    <LastName>Hirata</LastName>
    <ForeName>Yoshihiro</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>695</AuthorID>
    <LastName>McAllister</LastName>
    <ForeName>Christopher S</ForeName>
    <Initials>CS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>696</AuthorID>
    <LastName>Kagnoff</LastName>
    <ForeName>Martin F</ForeName>
    <Initials>MF</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>697</AuthorID>
    <LastName>Ikeda</LastName>
    <ForeName>Masanori</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>698</AuthorID>
    <LastName>Watanabe</LastName>
    <ForeName>Ayako</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>699</AuthorID>
    <LastName>Takeuchi</LastName>
    <ForeName>Osamu</ForeName>
    <Initials>O</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>700</AuthorID>
    <LastName>Akira</LastName>
    <ForeName>Shizuo</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>701</AuthorID>
    <LastName>Shimotohno</LastName>
    <ForeName>Kunitada</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>702</AuthorID>
    <LastName>Fu</LastName>
    <ForeName>Qiu-Xia</ForeName>
    <Initials>QX</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>703</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Li-Cui</ForeName>
    <Initials>LC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>704</AuthorID>
    <LastName>Jia</LastName>
    <ForeName>Shuai-Zheng</ForeName>
    <Initials>SZ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>705</AuthorID>
    <LastName>Du</LastName>
    <ForeName>Juan</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>706</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Ying-Li</ForeName>
    <Initials>YL</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>707</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Xiao-Hui</ForeName>
    <Initials>XH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>708</AuthorID>
    <LastName>Peng</LastName>
    <ForeName>Jian-Chun</ForeName>
    <Initials>JC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>709</AuthorID>
    <LastName>Zhan</LastName>
    <ForeName>Lin-Sheng</ForeName>
    <Initials>LS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>710</AuthorID>
    <LastName>Spencer</LastName>
    <ForeName>Sandra E</ForeName>
    <Initials>SE</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>711</AuthorID>
    <LastName>Kim</LastName>
    <ForeName>Sin Young</ForeName>
    <Initials>SY</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>712</AuthorID>
    <LastName>Kim</LastName>
    <ForeName>Seoung Bum</ForeName>
    <Initials>SB</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>713</AuthorID>
    <LastName>Schug</LastName>
    <ForeName>Kevin A</ForeName>
    <Initials>KA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>714</AuthorID>
    <LastName>Farajidavar</LastName>
    <ForeName>Aydin</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>715</AuthorID>
    <LastName>Seifert</LastName>
    <ForeName>Jennifer L</ForeName>
    <Initials>JL</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>716</AuthorID>
    <LastName>Bell</LastName>
    <ForeName>Jennifer E S</ForeName>
    <Initials>JE</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>717</AuthorID>
    <LastName>Seo</LastName>
    <ForeName>Young-Sik</ForeName>
    <Initials>YS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>718</AuthorID>
    <LastName>Delgado</LastName>
    <ForeName>Mauricio R</ForeName>
    <Initials>MR</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>719</AuthorID>
    <LastName>Sparagana</LastName>
    <ForeName>Steven</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>720</AuthorID>
    <LastName>Romero</LastName>
    <ForeName>Mario I</ForeName>
    <Initials>MI</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>721</AuthorID>
    <LastName>Chiao</LastName>
    <ForeName>J-C</ForeName>
    <Initials>JC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>722</AuthorID>
    <LastName>Poltajainen</LastName>
    <ForeName>Alina</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>723</AuthorID>
    <LastName>Ã˜stergaard</LastName>
    <ForeName>Lars</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>724</AuthorID>
    <LastName>Lyons</LastName>
    <ForeName>Patricia A</ForeName>
    <Initials>PA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>725</AuthorID>
    <LastName>Kenworthy</LastName>
    <ForeName>Jared B</ForeName>
    <Initials>JB</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>726</AuthorID>
    <LastName>Popan</LastName>
    <ForeName>Jason R</ForeName>
    <Initials>JR</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>727</AuthorID>
    <LastName>Feng</LastName>
    <ForeName>Hao</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>728</AuthorID>
    <LastName>Li</LastName>
    <ForeName>Haiyan</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>729</AuthorID>
    <LastName>Wu</LastName>
    <ForeName>Ting-Ting</ForeName>
    <Initials>TT</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>730</AuthorID>
    <LastName>Sun</LastName>
    <ForeName>Ren</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>731</AuthorID>
    <LastName>Tibbetts</LastName>
    <ForeName>Scott A</ForeName>
    <Initials>SA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>732</AuthorID>
    <LastName>Jogi</LastName>
    <ForeName>Michihiko</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>733</AuthorID>
    <LastName>Takemura</LastName>
    <ForeName>Azumi</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>734</AuthorID>
    <LastName>Morimoto</LastName>
    <ForeName>Shiho</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>735</AuthorID>
    <LastName>Namiki</LastName>
    <ForeName>Hideo</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>736</AuthorID>
    <LastName>Lecat</LastName>
    <ForeName>Aurore</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>737</AuthorID>
    <LastName>Piette</LastName>
    <ForeName>Jacques</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>738</AuthorID>
    <LastName>Legrand-Poels</LastName>
    <ForeName>Sylvie</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>739</AuthorID>
    <LastName>Shi</LastName>
    <ForeName>He-Xin</ForeName>
    <Initials>HX</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>740</AuthorID>
    <LastName>Stavrou</LastName>
    <ForeName>Spyridon</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>741</AuthorID>
    <LastName>Roos</LastName>
    <ForeName>Raymond P</ForeName>
    <Initials>RP</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>742</AuthorID>
    <LastName>Zhou</LastName>
    <ForeName>Shenghua</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>743</AuthorID>
    <LastName>Cerny</LastName>
    <ForeName>Anna M</ForeName>
    <Initials>AM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>744</AuthorID>
    <LastName>Zacharia</LastName>
    <ForeName>An</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>745</AuthorID>
    <LastName>Kurt-Jones</LastName>
    <ForeName>Evelyn A</ForeName>
    <Initials>EA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>746</AuthorID>
    <LastName>Finberg</LastName>
    <ForeName>Robert W</ForeName>
    <Initials>RW</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>747</AuthorID>
    <LastName>Ni</LastName>
    <ForeName>Caifei</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>748</AuthorID>
    <LastName>Liu</LastName>
    <ForeName>Yu</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>749</AuthorID>
    <LastName>Yang</LastName>
    <ForeName>XiaoLi</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>750</AuthorID>
    <LastName>Jia</LastName>
    <ForeName>Yongxia</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>751</AuthorID>
    <LastName>Yuan</LastName>
    <ForeName>Yuan</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>752</AuthorID>
    <LastName>Xu</LastName>
    <ForeName>Yang</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>753</AuthorID>
    <LastName>Cheng</LastName>
    <ForeName>Xiaozhong</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>754</AuthorID>
    <LastName>Yang</LastName>
    <ForeName>Xiao</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>755</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Youliang</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>756</AuthorID>
    <LastName>Wu</LastName>
    <ForeName>Qing</ForeName>
    <Initials>Q</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>757</AuthorID>
    <LastName>Shi</LastName>
    <ForeName>Wei</ForeName>
    <Initials>W</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>758</AuthorID>
    <LastName>Graef</LastName>
    <ForeName>Katy M</ForeName>
    <Initials>KM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>759</AuthorID>
    <LastName>Vreede</LastName>
    <ForeName>Frank T</ForeName>
    <Initials>FT</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>760</AuthorID>
    <LastName>Lau</LastName>
    <ForeName>Yuk-Fai</ForeName>
    <Initials>YF</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>761</AuthorID>
    <LastName>McCall</LastName>
    <ForeName>Amber W</ForeName>
    <Initials>AW</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>762</AuthorID>
    <LastName>Carr</LastName>
    <ForeName>Simon M</ForeName>
    <Initials>SM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>763</AuthorID>
    <LastName>Subbarao</LastName>
    <ForeName>Kanta</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>764</AuthorID>
    <LastName>Fodor</LastName>
    <ForeName>Ervin</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>765</AuthorID>
    <LastName>Soucy-Faulkner</LastName>
    <ForeName>Anton</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>766</AuthorID>
    <LastName>Mukawera</LastName>
    <ForeName>EspÃ©rance</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>767</AuthorID>
    <LastName>Fink</LastName>
    <ForeName>Karin</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>768</AuthorID>
    <LastName>Martel</LastName>
    <ForeName>Alexis</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>769</AuthorID>
    <LastName>Jouan</LastName>
    <ForeName>Loubna</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>770</AuthorID>
    <LastName>Nzengue</LastName>
    <ForeName>Yves</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>771</AuthorID>
    <LastName>Lamarre</LastName>
    <ForeName>Daniel</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>772</AuthorID>
    <LastName>Vande Velde</LastName>
    <ForeName>Christine</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>773</AuthorID>
    <LastName>Grandvaux</LastName>
    <ForeName>Nathalie</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>774</AuthorID>
    <LastName>Maillard</LastName>
    <ForeName>Patrick</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>775</AuthorID>
    <LastName>Budkowska</LastName>
    <ForeName>Agata</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>776</AuthorID>
    <LastName>Kalliampakou</LastName>
    <ForeName>Katerina I</ForeName>
    <Initials>KI</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>777</AuthorID>
    <LastName>Mavromara</LastName>
    <ForeName>Penelope</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>778</AuthorID>
    <LastName>Gatignol</LastName>
    <ForeName>Anne</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>779</AuthorID>
    <LastName>Boulant</LastName>
    <ForeName>Steeve</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>780</AuthorID>
    <LastName>Zhang</LastName>
    <ForeName>Yijing</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>781</AuthorID>
    <LastName>Lee</LastName>
    <ForeName>Amy S Y</ForeName>
    <Initials>AS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>782</AuthorID>
    <LastName>Odendall</LastName>
    <ForeName>Charlotte</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>783</AuthorID>
    <LastName>Shum</LastName>
    <ForeName>Bennett</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>784</AuthorID>
    <LastName>Hacohen</LastName>
    <ForeName>Nir</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>785</AuthorID>
    <LastName>Whelan</LastName>
    <ForeName>Sean P</ForeName>
    <Initials>SP</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>786</AuthorID>
    <LastName>Fransen</LastName>
    <ForeName>Marc</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>787</AuthorID>
    <LastName>Nibert</LastName>
    <ForeName>Max L</ForeName>
    <Initials>ML</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>788</AuthorID>
    <LastName>Superti-Furga</LastName>
    <ForeName>Giulio</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>789</AuthorID>
    <LastName>Cui</LastName>
    <ForeName>Jun</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>790</AuthorID>
    <LastName>Zhu</LastName>
    <ForeName>Liang</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>791</AuthorID>
    <LastName>Xia</LastName>
    <ForeName>Xiaojun</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>792</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Helen Y</ForeName>
    <Initials>HY</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>793</AuthorID>
    <LastName>Legras</LastName>
    <ForeName>Xavier</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>794</AuthorID>
    <LastName>Hong</LastName>
    <ForeName>Jun</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>795</AuthorID>
    <LastName>Ji</LastName>
    <ForeName>Jiabing</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>796</AuthorID>
    <LastName>Shen</LastName>
    <ForeName>Pingping</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>797</AuthorID>
    <LastName>Zheng</LastName>
    <ForeName>Shu</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>798</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Rong-Fu</ForeName>
    <Initials>RF</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>799</AuthorID>
    <LastName>Yoboua</LastName>
    <ForeName>Fabrice</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>800</AuthorID>
    <LastName>Duval</LastName>
    <ForeName>Annick</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>801</AuthorID>
    <LastName>Munir</LastName>
    <ForeName>Muhammad</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>802</AuthorID>
    <LastName>Nistal-VillÃ¡n</LastName>
    <ForeName>Estanislao</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>803</AuthorID>
    <LastName>Gack</LastName>
    <ForeName>Michaela U</ForeName>
    <Initials>MU</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>804</AuthorID>
    <LastName>MartÃ­nez-Delgado</LastName>
    <ForeName>Gustavo</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>805</AuthorID>
    <LastName>Maharaj</LastName>
    <ForeName>Natalya P</ForeName>
    <Initials>NP</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>806</AuthorID>
    <LastName>Yang</LastName>
    <ForeName>Heyi</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>807</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Rong</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>808</AuthorID>
    <LastName>Aggarwal</LastName>
    <ForeName>Aneel K</ForeName>
    <Initials>AK</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>809</AuthorID>
    <LastName>Jung</LastName>
    <ForeName>Jae U</ForeName>
    <Initials>JU</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>810</AuthorID>
    <LastName>Zeng</LastName>
    <ForeName>Wenwen</ForeName>
    <Initials>W</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>811</AuthorID>
    <LastName>Jiang</LastName>
    <ForeName>Xiaomo</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>812</AuthorID>
    <LastName>Adhikari</LastName>
    <ForeName>Anirban</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>813</AuthorID>
    <LastName>Xu</LastName>
    <ForeName>Ming</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>814</AuthorID>
    <LastName>Spillers</LastName>
    <ForeName>Jana</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>815</AuthorID>
    <LastName>Singh</LastName>
    <ForeName>Abanish</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>816</AuthorID>
    <LastName>Keswani</LastName>
    <ForeName>Umeshkumar</ForeName>
    <Initials>U</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>817</AuthorID>
    <LastName>Levine</LastName>
    <ForeName>David</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>818</AuthorID>
    <LastName>Feschotte</LastName>
    <ForeName>Cedric</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>819</AuthorID>
    <LastName>Scott</LastName>
    <ForeName>Iain</ForeName>
    <Initials>I</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>820</AuthorID>
    <LastName>Tang</LastName>
    <ForeName>Eric D</ForeName>
    <Initials>ED</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>821</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Cun-Yu</ForeName>
    <Initials>CY</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>822</AuthorID>
    <LastName>Buss</LastName>
    <ForeName>Claudia</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>823</AuthorID>
    <LastName>Opitz</LastName>
    <ForeName>Bastian</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>824</AuthorID>
    <LastName>Hocke</LastName>
    <ForeName>Andreas C</ForeName>
    <Initials>AC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>825</AuthorID>
    <LastName>Lippmann</LastName>
    <ForeName>Juliane</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>826</AuthorID>
    <LastName>van Laak</LastName>
    <ForeName>Vincent</ForeName>
    <Initials>V</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>827</AuthorID>
    <LastName>Hippenstiel</LastName>
    <ForeName>Stefan</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>828</AuthorID>
    <LastName>KrÃ¼ll</LastName>
    <ForeName>Matthias</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>829</AuthorID>
    <LastName>Suttorp</LastName>
    <ForeName>Norbert</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>830</AuthorID>
    <LastName>Eitel</LastName>
    <ForeName>Julia</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>831</AuthorID>
    <LastName>Bellecave</LastName>
    <ForeName>Pantxika</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>832</AuthorID>
    <LastName>Sarasin-Filipowicz</LastName>
    <ForeName>Magdalena</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>833</AuthorID>
    <LastName>DonzÃ©</LastName>
    <ForeName>Olivier</ForeName>
    <Initials>O</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>834</AuthorID>
    <LastName>Kennel</LastName>
    <ForeName>Audrey</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>835</AuthorID>
    <LastName>Gouttenoire</LastName>
    <ForeName>JÃ©rÃ´me</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>836</AuthorID>
    <LastName>Meylan</LastName>
    <ForeName>Etienne</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>837</AuthorID>
    <LastName>Terracciano</LastName>
    <ForeName>Luigi</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>838</AuthorID>
    <LastName>Tschopp</LastName>
    <ForeName>JÃ¼rg</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>839</AuthorID>
    <LastName>Sarrazin</LastName>
    <ForeName>Christoph</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>840</AuthorID>
    <LastName>Berg</LastName>
    <ForeName>Thomas</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>841</AuthorID>
    <LastName>Moradpour</LastName>
    <ForeName>Darius</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>842</AuthorID>
    <LastName>Yu</LastName>
    <ForeName>Chia-Yi</ForeName>
    <Initials>CY</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>843</AuthorID>
    <LastName>Chiang</LastName>
    <ForeName>Ruei-Lin</ForeName>
    <Initials>RL</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>844</AuthorID>
    <LastName>Chang</LastName>
    <ForeName>Tsung-Hsien</ForeName>
    <Initials>TH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>845</AuthorID>
    <LastName>Liao</LastName>
    <ForeName>Ching-Len</ForeName>
    <Initials>CL</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>846</AuthorID>
    <LastName>Lin</LastName>
    <ForeName>Yi-Ling</ForeName>
    <Initials>YL</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>847</AuthorID>
    <LastName>Fan</LastName>
    <ForeName>Lina</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>848</AuthorID>
    <LastName>Briese</LastName>
    <ForeName>Thomas</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>849</AuthorID>
    <LastName>Lipkin</LastName>
    <ForeName>W Ian</ForeName>
    <Initials>WI</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>850</AuthorID>
    <LastName>Liu</LastName>
    <ForeName>Ping</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>851</AuthorID>
    <LastName>Lu</LastName>
    <ForeName>Muping</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>852</AuthorID>
    <LastName>Tian</LastName>
    <ForeName>Bing</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>853</AuthorID>
    <LastName>Prusak</LastName>
    <ForeName>Deborah</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>854</AuthorID>
    <LastName>Brasier</LastName>
    <ForeName>Allan R</ForeName>
    <Initials>AR</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>855</AuthorID>
    <LastName>Poeck</LastName>
    <ForeName>Hendrik</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>856</AuthorID>
    <LastName>Bscheider</LastName>
    <ForeName>Michael</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>857</AuthorID>
    <LastName>Gross</LastName>
    <ForeName>Olaf</ForeName>
    <Initials>O</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>858</AuthorID>
    <LastName>Finger</LastName>
    <ForeName>Katrin</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>859</AuthorID>
    <LastName>Roth</LastName>
    <ForeName>Susanne</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>860</AuthorID>
    <LastName>Rebsamen</LastName>
    <ForeName>Manuele</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>861</AuthorID>
    <LastName>HannesschlÃ¤ger</LastName>
    <ForeName>Nicole</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>862</AuthorID>
    <LastName>Rothenfusser</LastName>
    <ForeName>Simon</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>863</AuthorID>
    <LastName>Inoue</LastName>
    <ForeName>Satoshi</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>864</AuthorID>
    <LastName>Endres</LastName>
    <ForeName>Stefan</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>865</AuthorID>
    <LastName>Peschel</LastName>
    <ForeName>Christian</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>866</AuthorID>
    <LastName>Ruland</LastName>
    <ForeName>JÃ¼rgen</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>867</AuthorID>
    <LastName>Ma</LastName>
    <ForeName>Qingjun</ForeName>
    <Initials>Q</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>868</AuthorID>
    <LastName>Nakhaei</LastName>
    <ForeName>Peyman</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>869</AuthorID>
    <LastName>Mesplede</LastName>
    <ForeName>Thibault</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>870</AuthorID>
    <LastName>Solis</LastName>
    <ForeName>Mayra</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>871</AuthorID>
    <LastName>Chuang</LastName>
    <ForeName>Tsung-Hsien</ForeName>
    <Initials>TH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>872</AuthorID>
    <LastName>Ware</LastName>
    <ForeName>Carl F</ForeName>
    <Initials>CF</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>873</AuthorID>
    <LastName>Sun</LastName>
    <ForeName>Hui</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>874</AuthorID>
    <LastName>Sun</LastName>
    <ForeName>Wenxiang</ForeName>
    <Initials>W</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>875</AuthorID>
    <LastName>Liang</LastName>
    <ForeName>Shimin</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>876</AuthorID>
    <LastName>Zhai</LastName>
    <ForeName>Zhonghe</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>877</AuthorID>
    <LastName>Burtey</LastName>
    <ForeName>Anne</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>878</AuthorID>
    <LastName>Kubarenko</LastName>
    <ForeName>Andriy V</ForeName>
    <Initials>AV</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>879</AuthorID>
    <LastName>Caignard</LastName>
    <ForeName>Gregory</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>880</AuthorID>
    <LastName>Tangy</LastName>
    <ForeName>FrÃ©dÃ©ric</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>881</AuthorID>
    <LastName>Ben-Ali</LastName>
    <ForeName>Meriem</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>882</AuthorID>
    <LastName>Quintana-Murci</LastName>
    <ForeName>Lluis</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>883</AuthorID>
    <LastName>Heinzmann</LastName>
    <ForeName>Andrea</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>884</AuthorID>
    <LastName>Chiche</LastName>
    <ForeName>Jean-Daniel</ForeName>
    <Initials>JD</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>885</AuthorID>
    <LastName>Vidalain</LastName>
    <ForeName>Pierre-Olivier</ForeName>
    <Initials>PO</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>886</AuthorID>
    <LastName>Weber</LastName>
    <ForeName>Alexander N R</ForeName>
    <Initials>AN</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>887</AuthorID>
    <LastName>Chignard</LastName>
    <ForeName>Michel</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>888</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Jennifer P</ForeName>
    <Initials>JP</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>889</AuthorID>
    <LastName>Cerny</LastName>
    <ForeName>Anna</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>890</AuthorID>
    <LastName>Asher</LastName>
    <ForeName>Damon R</ForeName>
    <Initials>DR</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>891</AuthorID>
    <LastName>Bronson</LastName>
    <ForeName>Roderick T</ForeName>
    <Initials>RT</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>892</AuthorID>
    <LastName>Ma</LastName>
    <ForeName>Hongfang</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>893</AuthorID>
    <LastName>Li</LastName>
    <ForeName>Li</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>894</AuthorID>
    <LastName>Jamaluddin</LastName>
    <ForeName>Mohammad</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>895</AuthorID>
    <LastName>Boldogh</LastName>
    <ForeName>Istvan</ForeName>
    <Initials>I</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>896</AuthorID>
    <LastName>Sabbah</LastName>
    <ForeName>Ahmed</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>897</AuthorID>
    <LastName>Chang</LastName>
    <ForeName>Te Hung</ForeName>
    <Initials>TH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>898</AuthorID>
    <LastName>Harnack</LastName>
    <ForeName>Rosalinda</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>899</AuthorID>
    <LastName>Frohlich</LastName>
    <ForeName>Victoria</ForeName>
    <Initials>V</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>900</AuthorID>
    <LastName>Tominaga</LastName>
    <ForeName>Kaoru</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>901</AuthorID>
    <LastName>Dube</LastName>
    <ForeName>Peter H</ForeName>
    <Initials>PH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>902</AuthorID>
    <LastName>Xiang</LastName>
    <ForeName>Yan</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>903</AuthorID>
    <LastName>Bose</LastName>
    <ForeName>Santanu</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>904</AuthorID>
    <LastName>Philpott</LastName>
    <ForeName>Dana J</ForeName>
    <Initials>DJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>905</AuthorID>
    <LastName>Ishihara</LastName>
    <ForeName>Naotada</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>906</AuthorID>
    <LastName>Chiu</LastName>
    <ForeName>Yu-Hsin</ForeName>
    <Initials>YH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>907</AuthorID>
    <LastName>Macmillan</LastName>
    <ForeName>John B</ForeName>
    <Initials>JB</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>908</AuthorID>
    <LastName>Okabe</LastName>
    <ForeName>Yasutaka</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>909</AuthorID>
    <LastName>Sano</LastName>
    <ForeName>Teruyuki</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>910</AuthorID>
    <LastName>Nagata</LastName>
    <ForeName>Shigekazu</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>911</AuthorID>
    <LastName>Ahmadi Pour</LastName>
    <ForeName>Malek</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>912</AuthorID>
    <LastName>Jacob</LastName>
    <ForeName>Yves</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>913</AuthorID>
    <LastName>Mezel-Lemoine</LastName>
    <ForeName>Mariana</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>914</AuthorID>
    <LastName>Delaloye</LastName>
    <ForeName>Julie</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>915</AuthorID>
    <LastName>Roger</LastName>
    <ForeName>Thierry</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>916</AuthorID>
    <LastName>Steiner-Tardivel</LastName>
    <ForeName>Quynh-Giao</ForeName>
    <Initials>QG</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>917</AuthorID>
    <LastName>Le Roy</LastName>
    <ForeName>Didier</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>918</AuthorID>
    <LastName>Knaup Reymond</LastName>
    <ForeName>Marlies</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>919</AuthorID>
    <LastName>Petrilli</LastName>
    <ForeName>Virginie</ForeName>
    <Initials>V</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>920</AuthorID>
    <LastName>Gomez</LastName>
    <ForeName>Carmen E</ForeName>
    <Initials>CE</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>921</AuthorID>
    <LastName>Perdiguero</LastName>
    <ForeName>Beatriz</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>922</AuthorID>
    <LastName>Pantaleo</LastName>
    <ForeName>Giuseppe</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>923</AuthorID>
    <LastName>Esteban</LastName>
    <ForeName>Mariano</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>924</AuthorID>
    <LastName>Calandra</LastName>
    <ForeName>Thierry</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>925</AuthorID>
    <LastName>Carneiro</LastName>
    <ForeName>Leticia</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>926</AuthorID>
    <LastName>Nguyen</LastName>
    <ForeName>Nha</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>927</AuthorID>
    <LastName>Huang</LastName>
    <ForeName>Heng</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>928</AuthorID>
    <LastName>Oraintara</LastName>
    <ForeName>Soontorn</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>929</AuthorID>
    <LastName>Vo</LastName>
    <ForeName>An</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>930</AuthorID>
    <LastName>Johnsen</LastName>
    <ForeName>Ingvild B</ForeName>
    <Initials>IB</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>931</AuthorID>
    <LastName>Nguyen</LastName>
    <ForeName>Thuy Thanh</ForeName>
    <Initials>TT</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>932</AuthorID>
    <LastName>Bergstroem</LastName>
    <ForeName>Bjarte</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>933</AuthorID>
    <LastName>Anthonsen</LastName>
    <ForeName>Marit W</ForeName>
    <Initials>MW</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>934</AuthorID>
    <LastName>Liesman</LastName>
    <ForeName>Rachael M</ForeName>
    <Initials>RM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>935</AuthorID>
    <LastName>O'Connor</LastName>
    <ForeName>Brian P</ForeName>
    <Initials>BP</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>936</AuthorID>
    <LastName>Bergstralh</LastName>
    <ForeName>Daniel T</ForeName>
    <Initials>DT</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>937</AuthorID>
    <LastName>Ohman</LastName>
    <ForeName>Tiina</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>938</AuthorID>
    <LastName>Kalkkinen</LastName>
    <ForeName>Nisse</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>939</AuthorID>
    <LastName>Nyman</LastName>
    <ForeName>Tuula A</ForeName>
    <Initials>TA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>940</AuthorID>
    <LastName>Lacoste</LastName>
    <ForeName>Judith</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>941</AuthorID>
    <LastName>Shestakova</LastName>
    <ForeName>Elena A</ForeName>
    <Initials>EA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>942</AuthorID>
    <LastName>Zaari</LastName>
    <ForeName>Scott</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>943</AuthorID>
    <LastName>Bibeau-Poirier</LastName>
    <ForeName>Annie</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>944</AuthorID>
    <LastName>Cutler</LastName>
    <ForeName>Patrick J</ForeName>
    <Initials>PJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>945</AuthorID>
    <LastName>Haaland</LastName>
    <ForeName>David M</ForeName>
    <Initials>DM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>946</AuthorID>
    <LastName>Gemperline</LastName>
    <ForeName>Paul J</ForeName>
    <Initials>PJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>947</AuthorID>
    <LastName>Ling</LastName>
    <ForeName>Zhenhua</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>948</AuthorID>
    <LastName>Tran</LastName>
    <ForeName>Kim C</ForeName>
    <Initials>KC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>949</AuthorID>
    <LastName>Teng</LastName>
    <ForeName>Michael N</ForeName>
    <Initials>MN</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>950</AuthorID>
    <LastName>Xu</LastName>
    <ForeName>Lijuan</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>951</AuthorID>
    <LastName>Xiao</LastName>
    <ForeName>Nengming</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>952</AuthorID>
    <LastName>Ren</LastName>
    <ForeName>Hongwei</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>953</AuthorID>
    <LastName>Baril</LastName>
    <ForeName>Martin</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>954</AuthorID>
    <LastName>Racine</LastName>
    <ForeName>Marie-Eve</ForeName>
    <Initials>ME</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>955</AuthorID>
    <LastName>Penin</LastName>
    <ForeName>FranÃ§ois</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>956</AuthorID>
    <LastName>Chessler</LastName>
    <ForeName>Anne-Danielle C</ForeName>
    <Initials>AD</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>957</AuthorID>
    <LastName>Ferreira</LastName>
    <ForeName>Ludmila R P</ForeName>
    <Initials>LR</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>958</AuthorID>
    <LastName>Chang</LastName>
    <ForeName>Tun-Han</ForeName>
    <Initials>TH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>959</AuthorID>
    <LastName>Burleigh</LastName>
    <ForeName>Barbara A</ForeName>
    <Initials>BA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>960</AuthorID>
    <LastName>Hatakeyama</LastName>
    <ForeName>Shigetsugu</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>961</AuthorID>
    <LastName>Kirchhofer</LastName>
    <ForeName>Axel</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>962</AuthorID>
    <LastName>Shin</LastName>
    <ForeName>Young C</ForeName>
    <Initials>YC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>963</AuthorID>
    <LastName>Liang</LastName>
    <ForeName>Chengyu</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>964</AuthorID>
    <LastName>Myong</LastName>
    <ForeName>Sua</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>965</AuthorID>
    <LastName>Ha</LastName>
    <ForeName>Taekjip</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>966</AuthorID>
    <LastName>Hopfner</LastName>
    <ForeName>Karl-Peter</ForeName>
    <Initials>KP</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>967</AuthorID>
    <LastName>Bhoj</LastName>
    <ForeName>Vijay G</ForeName>
    <Initials>VG</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>968</AuthorID>
    <LastName>Bhoj</LastName>
    <ForeName>Elizabeth J</ForeName>
    <Initials>EJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>969</AuthorID>
    <LastName>Somers</LastName>
    <ForeName>Cynthia</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>970</AuthorID>
    <LastName>Torres</LastName>
    <ForeName>Juan-Pablo</ForeName>
    <Initials>JP</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>971</AuthorID>
    <LastName>Mejias</LastName>
    <ForeName>Asuncion</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>972</AuthorID>
    <LastName>Gomez</LastName>
    <ForeName>Ana M</ForeName>
    <Initials>AM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>973</AuthorID>
    <LastName>Jafri</LastName>
    <ForeName>Hasan</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>974</AuthorID>
    <LastName>Ramilo</LastName>
    <ForeName>Octavio</ForeName>
    <Initials>O</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>975</AuthorID>
    <LastName>Meylan</LastName>
    <ForeName>E</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>976</AuthorID>
    <LastName>Ishida</LastName>
    <ForeName>Hisashi</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>977</AuthorID>
    <LastName>Lenz</LastName>
    <ForeName>Oliver</ForeName>
    <Initials>O</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>978</AuthorID>
    <LastName>Lin</LastName>
    <ForeName>Tse-I</ForeName>
    <Initials>TI</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>979</AuthorID>
    <LastName>Nyanguile</LastName>
    <ForeName>OrigÃ¨ne</ForeName>
    <Initials>O</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>980</AuthorID>
    <LastName>Simmen</LastName>
    <ForeName>Kenny</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>981</AuthorID>
    <LastName>Pyles</LastName>
    <ForeName>Richard B</ForeName>
    <Initials>RB</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>982</AuthorID>
    <LastName>Bourne</LastName>
    <ForeName>Nigel</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>983</AuthorID>
    <LastName>Yi</LastName>
    <ForeName>Minkyung</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>984</AuthorID>
    <LastName>Deng</LastName>
    <ForeName>Liang</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>985</AuthorID>
    <LastName>Dai</LastName>
    <ForeName>Peihong</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>986</AuthorID>
    <LastName>Parikh</LastName>
    <ForeName>Tanvi</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>987</AuthorID>
    <LastName>Cao</LastName>
    <ForeName>Hua</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>988</AuthorID>
    <LastName>Bhoj</LastName>
    <ForeName>Vijay</ForeName>
    <Initials>V</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>989</AuthorID>
    <LastName>Chen</LastName>
    <ForeName>Zhijian</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>990</AuthorID>
    <LastName>Merghoub</LastName>
    <ForeName>Taha</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>991</AuthorID>
    <LastName>Houghton</LastName>
    <ForeName>Alan</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>992</AuthorID>
    <LastName>Shuman</LastName>
    <ForeName>Stewart</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>993</AuthorID>
    <LastName>Norris</LastName>
    <ForeName>Kristi L</ForeName>
    <Initials>KL</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>994</AuthorID>
    <LastName>AhlÃ©n</LastName>
    <ForeName>G</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>995</AuthorID>
    <LastName>Derk</LastName>
    <ForeName>E</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>996</AuthorID>
    <LastName>Weiland</LastName>
    <ForeName>M</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>997</AuthorID>
    <LastName>Jiao</LastName>
    <ForeName>J</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>998</AuthorID>
    <LastName>Rahbin</LastName>
    <ForeName>N</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>999</AuthorID>
    <LastName>Aleman</LastName>
    <ForeName>S</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1000</AuthorID>
    <LastName>Peterson</LastName>
    <ForeName>D L</ForeName>
    <Initials>DL</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1001</AuthorID>
    <LastName>Pokrovskaja</LastName>
    <ForeName>K</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1002</AuthorID>
    <LastName>GrandÃ©r</LastName>
    <ForeName>D</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1003</AuthorID>
    <LastName>Frelin</LastName>
    <ForeName>L</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1004</AuthorID>
    <LastName>SÃ¤llberg</LastName>
    <ForeName>M</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1005</AuthorID>
    <LastName>Liao</LastName>
    <ForeName>S</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1006</AuthorID>
    <LastName>Bao</LastName>
    <ForeName>X</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1007</AuthorID>
    <LastName>Liu</LastName>
    <ForeName>T</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1008</AuthorID>
    <LastName>Lai</LastName>
    <ForeName>S</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1009</AuthorID>
    <LastName>Li</LastName>
    <ForeName>K</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1010</AuthorID>
    <LastName>Garofalo</LastName>
    <ForeName>R P</ForeName>
    <Initials>RP</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1011</AuthorID>
    <LastName>Casola</LastName>
    <ForeName>A</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1012</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Dang</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1013</AuthorID>
    <LastName>Fang</LastName>
    <ForeName>Liurong</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1014</AuthorID>
    <LastName>Li</LastName>
    <ForeName>Tingting</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1015</AuthorID>
    <LastName>Luo</LastName>
    <ForeName>Rui</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1016</AuthorID>
    <LastName>Xie</LastName>
    <ForeName>Lilan</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1017</AuthorID>
    <LastName>Jiang</LastName>
    <ForeName>Yunbo</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1018</AuthorID>
    <LastName>Chen</LastName>
    <ForeName>Huanchun</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1019</AuthorID>
    <LastName>Xiao</LastName>
    <ForeName>Shaobo</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1020</AuthorID>
    <LastName>Nakamura</LastName>
    <ForeName>Minoru</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1021</AuthorID>
    <LastName>Komori</LastName>
    <ForeName>Atsumasa</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1022</AuthorID>
    <LastName>Yokoyama</LastName>
    <ForeName>Terufumi</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1023</AuthorID>
    <LastName>Aiba</LastName>
    <ForeName>Yoshihiro</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1024</AuthorID>
    <LastName>Araki</LastName>
    <ForeName>Aiko</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1025</AuthorID>
    <LastName>Takii</LastName>
    <ForeName>Yasushi</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1026</AuthorID>
    <LastName>Ito</LastName>
    <ForeName>Masahiro</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1027</AuthorID>
    <LastName>Matsuyama</LastName>
    <ForeName>Mutsumi</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1028</AuthorID>
    <LastName>Koyabu</LastName>
    <ForeName>Makiko</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1029</AuthorID>
    <LastName>Migita</LastName>
    <ForeName>Kiyoshi</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1030</AuthorID>
    <LastName>Taniguchi</LastName>
    <ForeName>Ken</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1031</AuthorID>
    <LastName>Fujioka</LastName>
    <ForeName>Hikaru</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1032</AuthorID>
    <LastName>Yatsuhashi</LastName>
    <ForeName>Hiroshi</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1033</AuthorID>
    <LastName>Ishibashi</LastName>
    <ForeName>Hiromi</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1034</AuthorID>
    <LastName>Michallet</LastName>
    <ForeName>Marie-CÃ©cile</ForeName>
    <Initials>MC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1035</AuthorID>
    <LastName>Ermolaeva</LastName>
    <ForeName>Maria A</ForeName>
    <Initials>MA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1036</AuthorID>
    <LastName>Vazquez</LastName>
    <ForeName>Jessica</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1037</AuthorID>
    <LastName>Curran</LastName>
    <ForeName>Joseph</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1038</AuthorID>
    <LastName>KÃ¶nig</LastName>
    <ForeName>Martin</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1039</AuthorID>
    <LastName>Pasparakis</LastName>
    <ForeName>Manolis</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1040</AuthorID>
    <LastName>O'Neill</LastName>
    <ForeName>Luke A J</ForeName>
    <Initials>LA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1041</AuthorID>
    <LastName>Huang</LastName>
    <ForeName>Kenneth H</ForeName>
    <Initials>KH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1042</AuthorID>
    <LastName>Bruneau</LastName>
    <ForeName>Julie</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1043</AuthorID>
    <LastName>Shoukry</LastName>
    <ForeName>Naglaa</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1044</AuthorID>
    <LastName>Bernard</LastName>
    <ForeName>Nicole F</ForeName>
    <Initials>NF</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1045</AuthorID>
    <LastName>Potter</LastName>
    <ForeName>Jane A</ForeName>
    <Initials>JA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1046</AuthorID>
    <LastName>Randall</LastName>
    <ForeName>Richard E</ForeName>
    <Initials>RE</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1047</AuthorID>
    <LastName>Taylor</LastName>
    <ForeName>Garry L</ForeName>
    <Initials>GL</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1048</AuthorID>
    <LastName>Lad</LastName>
    <ForeName>Sonya P</ForeName>
    <Initials>SP</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1049</AuthorID>
    <LastName>Scott</LastName>
    <ForeName>David A</ForeName>
    <Initials>DA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1050</AuthorID>
    <LastName>Chao</LastName>
    <ForeName>Ta-Hsiang</ForeName>
    <Initials>TH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1051</AuthorID>
    <LastName>Correia</LastName>
    <ForeName>Jean da Silva</ForeName>
    <Initials>Jda S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1052</AuthorID>
    <LastName>Li</LastName>
    <ForeName>Erguang</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1053</AuthorID>
    <LastName>Duncan</LastName>
    <ForeName>Joseph A</ForeName>
    <Initials>JA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1054</AuthorID>
    <LastName>Morrison</LastName>
    <ForeName>Thomas E</ForeName>
    <Initials>TE</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1055</AuthorID>
    <LastName>Accavitti-Loper</LastName>
    <ForeName>Mary A</ForeName>
    <Initials>MA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1056</AuthorID>
    <LastName>Madden</LastName>
    <ForeName>Victoria J</ForeName>
    <Initials>VJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1057</AuthorID>
    <LastName>Ye</LastName>
    <ForeName>Zhengmao</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1058</AuthorID>
    <LastName>Lich</LastName>
    <ForeName>John D</ForeName>
    <Initials>JD</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1059</AuthorID>
    <LastName>Heise</LastName>
    <ForeName>Mark T</ForeName>
    <Initials>MT</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1060</AuthorID>
    <LastName>Marshman</LastName>
    <ForeName>Laurence A G</ForeName>
    <Initials>LA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1061</AuthorID>
    <LastName>Friesem</LastName>
    <ForeName>Tai</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1062</AuthorID>
    <LastName>Rampersaud</LastName>
    <ForeName>Y Raja</ForeName>
    <Initials>YR</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1063</AuthorID>
    <LastName>Le Huec</LastName>
    <ForeName>Jean-Charles</ForeName>
    <Initials>JC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1064</AuthorID>
    <LastName>Krishna</LastName>
    <ForeName>Manoj</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1065</AuthorID>
    <LastName>Breiman</LastName>
    <ForeName>Adrien</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1066</AuthorID>
    <LastName>Cheng</LastName>
    <ForeName>Guofeng</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1067</AuthorID>
    <LastName>Chung</LastName>
    <ForeName>Josan</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1068</AuthorID>
    <LastName>Chisari</LastName>
    <ForeName>Francis V</ForeName>
    <Initials>FV</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1069</AuthorID>
    <LastName>Ballard</LastName>
    <ForeName>Dean W</ForeName>
    <Initials>DW</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1070</AuthorID>
    <LastName>Yang</LastName>
    <ForeName>Yan</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1071</AuthorID>
    <LastName>Chen</LastName>
    <ForeName>Zeming</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1072</AuthorID>
    <LastName>Joo</LastName>
    <ForeName>Chul-Hyun</ForeName>
    <Initials>CH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1073</AuthorID>
    <LastName>Urano</LastName>
    <ForeName>Tomohiko</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1074</AuthorID>
    <LastName>Le Goffic</LastName>
    <ForeName>Ronan</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1075</AuthorID>
    <LastName>Meurs</LastName>
    <ForeName>Eliane</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1076</AuthorID>
    <LastName>Guo</LastName>
    <ForeName>Beichu</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1077</AuthorID>
    <LastName>Cheng</LastName>
    <ForeName>Genhong</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1078</AuthorID>
    <LastName>Sasai</LastName>
    <ForeName>Miwa</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1079</AuthorID>
    <LastName>Chen</LastName>
    <ForeName>Zihong</ForeName>
    <Initials>Z</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1080</AuthorID>
    <LastName>Benureau</LastName>
    <ForeName>Yann</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1081</AuthorID>
    <LastName>Rijnbrand</LastName>
    <ForeName>Rene</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1082</AuthorID>
    <LastName>Yi</LastName>
    <ForeName>Jianzhong</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1083</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Ting</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1084</AuthorID>
    <LastName>Warter</LastName>
    <ForeName>Lucile</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1085</AuthorID>
    <LastName>Weinman</LastName>
    <ForeName>Steven A</ForeName>
    <Initials>SA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1086</AuthorID>
    <LastName>Martin</LastName>
    <ForeName>Annette</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1087</AuthorID>
    <LastName>Yang</LastName>
    <ForeName>Homer</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1088</AuthorID>
    <LastName>Raymer</LastName>
    <ForeName>Karen</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1089</AuthorID>
    <LastName>Butler</LastName>
    <ForeName>Ron</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1090</AuthorID>
    <LastName>Parlow</LastName>
    <ForeName>Joel</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1091</AuthorID>
    <LastName>Roberts</LastName>
    <ForeName>Robin</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1092</AuthorID>
    <LastName>Komuro</LastName>
    <ForeName>Akihiko</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1093</AuthorID>
    <LastName>Horvath</LastName>
    <ForeName>Curt M</ForeName>
    <Initials>CM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1094</AuthorID>
    <LastName>Kotenko</LastName>
    <ForeName>Sergei</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1095</AuthorID>
    <LastName>Paz</LastName>
    <ForeName>S</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1096</AuthorID>
    <LastName>Sun</LastName>
    <ForeName>Q</ForeName>
    <Initials>Q</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1097</AuthorID>
    <LastName>Nakhaei</LastName>
    <ForeName>P</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1098</AuthorID>
    <LastName>Romieu-Mourez</LastName>
    <ForeName>R</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1099</AuthorID>
    <LastName>Goubau</LastName>
    <ForeName>D</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1100</AuthorID>
    <LastName>Julkunen</LastName>
    <ForeName>I</ForeName>
    <Initials>I</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1101</AuthorID>
    <LastName>Lin</LastName>
    <ForeName>R</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1102</AuthorID>
    <LastName>Hiscott</LastName>
    <ForeName>J</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1103</AuthorID>
    <LastName>Severa</LastName>
    <ForeName>Martina</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1104</AuthorID>
    <LastName>Coccia</LastName>
    <ForeName>Eliana M</ForeName>
    <Initials>EM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1105</AuthorID>
    <LastName>Wilkinson</LastName>
    <ForeName>Peter</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1106</AuthorID>
    <LastName>Johnson</LastName>
    <ForeName>Cynthia L</ForeName>
    <Initials>CL</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1107</AuthorID>
    <LastName>Li</LastName>
    <ForeName>Xiao-Dong</ForeName>
    <Initials>XD</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1108</AuthorID>
    <LastName>Seth</LastName>
    <ForeName>Rashu B</ForeName>
    <Initials>RB</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1109</AuthorID>
    <LastName>Pineda</LastName>
    <ForeName>Gabriel</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1110</AuthorID>
    <LastName>McWhirter</LastName>
    <ForeName>Sarah M</ForeName>
    <Initials>SM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1111</AuthorID>
    <LastName>Tenoever</LastName>
    <ForeName>Benjamin R</ForeName>
    <Initials>BR</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1112</AuthorID>
    <LastName>Maniatis</LastName>
    <ForeName>Tom</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1113</AuthorID>
    <LastName>Ea</LastName>
    <ForeName>Chee-Kwee</ForeName>
    <Initials>CK</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1114</AuthorID>
    <LastName>Matsuoka</LastName>
    <ForeName>Masako</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1115</AuthorID>
    <LastName>Oki</LastName>
    <ForeName>Takashi</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1116</AuthorID>
    <LastName>Mishiro</LastName>
    <ForeName>Yuichiro</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1117</AuthorID>
    <LastName>Yamada</LastName>
    <ForeName>Hirotsugu</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1118</AuthorID>
    <LastName>Tabata</LastName>
    <ForeName>Tomotsugu</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1119</AuthorID>
    <LastName>Wakatsuki</LastName>
    <ForeName>Tetsuzo</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1120</AuthorID>
    <LastName>Ito</LastName>
    <ForeName>Susumu</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1121</AuthorID>
    <LastName>Vilalta</LastName>
    <ForeName>J</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1122</AuthorID>
    <LastName>Topezewski</LastName>
    <ForeName>T</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1123</AuthorID>
    <LastName>AÃ±ez</LastName>
    <ForeName>J D</ForeName>
    <Initials>JD</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1124</AuthorID>
    <LastName>Arikan</LastName>
    <ForeName>F</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1125</AuthorID>
    <LastName>Guitart</LastName>
    <ForeName>J M</ForeName>
    <Initials>JM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1126</AuthorID>
    <LastName>Rubio</LastName>
    <ForeName>E</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1127</AuthorID>
    <LastName>Millar</LastName>
    <ForeName>D S</ForeName>
    <Initials>DS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1128</AuthorID>
    <LastName>Withey</LastName>
    <ForeName>S J</ForeName>
    <Initials>SJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1129</AuthorID>
    <LastName>Tizard</LastName>
    <ForeName>M L</ForeName>
    <Initials>ML</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1130</AuthorID>
    <LastName>Ford</LastName>
    <ForeName>J G</ForeName>
    <Initials>JG</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1131</AuthorID>
    <LastName>Hermon-Taylor</LastName>
    <ForeName>J</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1132</AuthorID>
    <LastName>Shanahan</LastName>
    <ForeName>D F</ForeName>
    <Initials>DF</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>1133</AuthorID>
    <LastName>Reading</LastName>
    <ForeName>T E</ForeName>
    <Initials>TE</Initials>
  </T_Authors>
  <T_Journals>
    <JournalID>1</JournalID>
    <Title>Developmental and comparative immunology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>2</JournalID>
    <Title>Journal of hepatology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>3</JournalID>
    <Title>Molecular immunology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>4</JournalID>
    <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>5</JournalID>
    <Title>Immunobiology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>6</JournalID>
    <Title>eLife</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>7</JournalID>
    <Title>Acta biochimica et biophysica Sinica</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>8</JournalID>
    <Title>Hepatology (Baltimore, Md.)</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>9</JournalID>
    <Title>Journal of virology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>10</JournalID>
    <Title>Biochemical and biophysical research communications</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>11</JournalID>
    <Title>The international journal of biochemistry &amp; cell biology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>12</JournalID>
    <Title>PloS one</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>13</JournalID>
    <Title>Advances in immunology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>14</JournalID>
    <Title>PLoS pathogens</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>15</JournalID>
    <Title>Cell</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>16</JournalID>
    <Title>Cell reports</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>17</JournalID>
    <Title>Future virology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>18</JournalID>
    <Title>Immunity</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>19</JournalID>
    <Title>Cell host &amp; microbe</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>20</JournalID>
    <Title>Recent patents on endocrine, metabolic &amp; immune drug discovery</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>21</JournalID>
    <Title>Biomaterials</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>22</JournalID>
    <Title>Expert opinion on therapeutic targets</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>23</JournalID>
    <Title>Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Conference</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>24</JournalID>
    <Title>Biochimica et biophysica acta</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>25</JournalID>
    <Title>Autophagy</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>26</JournalID>
    <Title>Social work in health care</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>27</JournalID>
    <Title>Archivum immunologiae et therapiae experimentalis</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>28</JournalID>
    <Title>Protein &amp; cell</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>29</JournalID>
    <Title>Virology journal</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>30</JournalID>
    <Title>Virus research</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>31</JournalID>
    <Title>Journal of medical virology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>32</JournalID>
    <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>33</JournalID>
    <Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>34</JournalID>
    <Title>The Journal of biological chemistry</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>35</JournalID>
    <Title>BMC biology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>36</JournalID>
    <Title>PLoS biology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>37</JournalID>
    <Title>International journal of molecular sciences</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>38</JournalID>
    <Title>European journal of applied physiology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>39</JournalID>
    <Title>Cell research</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>40</JournalID>
    <Title>Biological chemistry</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>41</JournalID>
    <Title>Cellular microbiology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>42</JournalID>
    <Title>Current opinion in immunology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>43</JournalID>
    <Title>Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>44</JournalID>
    <Title>EMBO reports</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>45</JournalID>
    <Title>Cell death and differentiation</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>46</JournalID>
    <Title>Science signaling</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>47</JournalID>
    <Title>EMBO molecular medicine</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>48</JournalID>
    <Title>Journal of electromyography and kinesiology : official journal of the International Society of Electrophysiological Kinesiology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>49</JournalID>
    <Title>World journal of gastroenterology : WJG</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>50</JournalID>
    <Title>Seminars in liver disease</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>51</JournalID>
    <Title>Forensic science international</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>52</JournalID>
    <Title>Annals of biomedical engineering</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>53</JournalID>
    <Title>Personality &amp; social psychology bulletin</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>54</JournalID>
    <Title>Biochemical pharmacology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>55</JournalID>
    <Title>Advances in neonatal care : official journal of the National Association of Neonatal Nurses</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>56</JournalID>
    <Title>International journal of bioinformatics research and applications</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>57</JournalID>
    <Title>Mitochondrion</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>58</JournalID>
    <Title>Nature immunology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>59</JournalID>
    <Title>FEBS letters</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>60</JournalID>
    <Title>Molecular cell</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>61</JournalID>
    <Title>Journal of cell science</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>62</JournalID>
    <Title>Microbes and infection / Institut Pasteur</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>63</JournalID>
    <Title>Nature</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>64</JournalID>
    <Title>Seminars in immunology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>65</JournalID>
    <Title>Journal of bioinformatics and computational biology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>66</JournalID>
    <Title>Molecular and cellular biology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>67</JournalID>
    <Title>Applied spectroscopy</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>68</JournalID>
    <Title>Immunological reviews</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>69</JournalID>
    <Title>Gastroenterology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>70</JournalID>
    <Title>Gut</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>71</JournalID>
    <Title>The Journal of general virology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>72</JournalID>
    <Title>Veterinary immunology and immunopathology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>73</JournalID>
    <Title>Hepatology international</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>74</JournalID>
    <Title>Current biology : CB</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>75</JournalID>
    <Title>Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>76</JournalID>
    <Title>BMC structural biology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>77</JournalID>
    <Title>The spine journal : official journal of the North American Spine Society</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>78</JournalID>
    <Title>Science's STKE : signal transduction knowledge environment</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>79</JournalID>
    <Title>American heart journal</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>80</JournalID>
    <Title>Cellular and molecular biology (Noisy-le-Grand, France)</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>81</JournalID>
    <Title>Trends in molecular medicine</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>82</JournalID>
    <Title>Trends in immunology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>83</JournalID>
    <Title>Health news (Waltham, Mass.)</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>84</JournalID>
    <Title>Revista de neurologia</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>85</JournalID>
    <Title>Analytical biochemistry</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>86</JournalID>
    <Title>Aviation, space, and environmental medicine</Title>
  </T_Journals>
  <T_JournalRelease>
    <JournalRelease>1879-0089</JournalRelease>
    <JournalID>1</JournalID>
    <Year>2013Oct29</Year>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1600-0641</JournalRelease>
    <JournalID>2</JournalID>
    <Year>2013Oct12</Year>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1872-9142</JournalRelease>
    <JournalID>3</JournalID>
    <Year>2013Oct3</Year>
    <Volume>57</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1550-6606</JournalRelease>
    <JournalID>4</JournalID>
    <Year>2013Nov1</Year>
    <Volume>191</Volume>
    <Issue>9</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1878-3279</JournalRelease>
    <JournalID>5</JournalID>
    <Year>2013Nov</Year>
    <Volume>218</Volume>
    <Issue>11</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>2050-084X</JournalRelease>
    <JournalID>6</JournalID>
    <Year>2013</Year>
    <Volume>2</Volume>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1745-7270</JournalRelease>
    <JournalID>7</JournalID>
    <Year>2013Oct</Year>
    <Volume>45</Volume>
    <Issue>10</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1527-3350</JournalRelease>
    <JournalID>8</JournalID>
    <Year>2013Jul19</Year>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1098-5514</JournalRelease>
    <JournalID>9</JournalID>
    <Year>2013Sep</Year>
    <Volume>87</Volume>
    <Issue>18</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1090-2104</JournalRelease>
    <JournalID>10</JournalID>
    <Year>2013Jul19</Year>
    <Volume>437</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1878-5875</JournalRelease>
    <JournalID>11</JournalID>
    <Year>2013Aug</Year>
    <Volume>45</Volume>
    <Issue>8</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1932-6203</JournalRelease>
    <JournalID>12</JournalID>
    <Year>2013</Year>
    <Volume>8</Volume>
    <Issue>5</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1557-8445</JournalRelease>
    <JournalID>13</JournalID>
    <Year>2013</Year>
    <Volume>117</Volume>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1553-7374</JournalRelease>
    <JournalID>14</JournalID>
    <Year>2013Apr</Year>
    <Volume>9</Volume>
    <Issue>4</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1097-4172</JournalRelease>
    <JournalID>15</JournalID>
    <Year>2013Apr11</Year>
    <Volume>153</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>2211-1247</JournalRelease>
    <JournalID>16</JournalID>
    <Year>2013Apr25</Year>
    <Volume>3</Volume>
    <Issue>4</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1746-0794</JournalRelease>
    <JournalID>17</JournalID>
    <Year>2012Dec</Year>
    <Volume>7</Volume>
    <Issue>12</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1097-4180</JournalRelease>
    <JournalID>18</JournalID>
    <Year>2013Apr18</Year>
    <Volume>38</Volume>
    <Issue>4</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1934-6069</JournalRelease>
    <JournalID>19</JournalID>
    <Year>2013Mar13</Year>
    <Volume>13</Volume>
    <Issue>3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1872-2148</JournalRelease>
    <JournalID>20</JournalID>
    <Year>2013May</Year>
    <Volume>7</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1878-5905</JournalRelease>
    <JournalID>21</JournalID>
    <Year>2013May</Year>
    <Volume>34</Volume>
    <Issue>14</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1744-7631</JournalRelease>
    <JournalID>22</JournalID>
    <Year>2013May</Year>
    <Volume>17</Volume>
    <Issue>5</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1557-170X</JournalRelease>
    <JournalID>23</JournalID>
    <Year>2012</Year>
    <Volume>2012</Volume>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0006-3002</JournalRelease>
    <JournalID>24</JournalID>
    <Year>2013May</Year>
    <Volume>1833</Volume>
    <Issue>5</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1554-8635</JournalRelease>
    <JournalID>25</JournalID>
    <Year>2013Mar</Year>
    <Volume>9</Volume>
    <Issue>3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1541-034X</JournalRelease>
    <JournalID>26</JournalID>
    <Year>2013</Year>
    <Volume>52</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1661-4917</JournalRelease>
    <JournalID>27</JournalID>
    <Year>2013Apr</Year>
    <Volume>61</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1674-8018</JournalRelease>
    <JournalID>28</JournalID>
    <Year>2013Feb</Year>
    <Volume>4</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1743-422X</JournalRelease>
    <JournalID>29</JournalID>
    <Year>2012</Year>
    <Volume>9</Volume>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1872-7492</JournalRelease>
    <JournalID>30</JournalID>
    <Year>2013Mar</Year>
    <Volume>172</Volume>
    <Issue>1-2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1096-9071</JournalRelease>
    <JournalID>31</JournalID>
    <Year>2013Jan</Year>
    <Volume>85</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1091-6490</JournalRelease>
    <JournalID>32</JournalID>
    <Year>2012Nov6</Year>
    <Volume>109</Volume>
    <Issue>45</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1078-0432</JournalRelease>
    <JournalID>33</JournalID>
    <Year>2012Nov15</Year>
    <Volume>18</Volume>
    <Issue>22</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1083-351X</JournalRelease>
    <JournalID>34</JournalID>
    <Year>2012Oct5</Year>
    <Volume>287</Volume>
    <Issue>41</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1741-7007</JournalRelease>
    <JournalID>35</JournalID>
    <Year>2012</Year>
    <Volume>10</Volume>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1545-7885</JournalRelease>
    <JournalID>36</JournalID>
    <Year>2012</Year>
    <Volume>10</Volume>
    <Issue>3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1422-0067</JournalRelease>
    <JournalID>37</JournalID>
    <Year>2012</Year>
    <Volume>13</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1439-6327</JournalRelease>
    <JournalID>38</JournalID>
    <Year>2012Sep</Year>
    <Volume>112</Volume>
    <Issue>9</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1748-7838</JournalRelease>
    <JournalID>39</JournalID>
    <Year>2012Apr</Year>
    <Volume>22</Volume>
    <Issue>4</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1437-4315</JournalRelease>
    <JournalID>40</JournalID>
    <Year>2011Dec</Year>
    <Volume>392</Volume>
    <Issue>12</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1462-5822</JournalRelease>
    <JournalID>41</JournalID>
    <Year>2011Dec</Year>
    <Volume>13</Volume>
    <Issue>12</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1879-0372</JournalRelease>
    <JournalID>42</JournalID>
    <Year>2011Oct</Year>
    <Volume>23</Volume>
    <Issue>5</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1007-8738</JournalRelease>
    <JournalID>43</JournalID>
    <Year>2011Aug</Year>
    <Volume>27</Volume>
    <Issue>8</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1469-3178</JournalRelease>
    <JournalID>44</JournalID>
    <Year>2011Sep</Year>
    <Volume>12</Volume>
    <Issue>9</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1476-5403</JournalRelease>
    <JournalID>45</JournalID>
    <Year>2011Aug</Year>
    <Volume>18</Volume>
    <Issue>8</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1937-9145</JournalRelease>
    <JournalID>46</JournalID>
    <Year>2011</Year>
    <Volume>4</Volume>
    <Issue>158</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1757-4684</JournalRelease>
    <JournalID>47</JournalID>
    <Year>2011Mar</Year>
    <Volume>3</Volume>
    <Issue>3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1873-5711</JournalRelease>
    <JournalID>48</JournalID>
    <Year>2011Jun</Year>
    <Volume>21</Volume>
    <Issue>3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1007-9327</JournalRelease>
    <JournalID>49</JournalID>
    <Year>2010Nov28</Year>
    <Volume>16</Volume>
    <Issue>44</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1098-8971</JournalRelease>
    <JournalID>50</JournalID>
    <Year>2010Nov</Year>
    <Volume>30</Volume>
    <Issue>4</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1872-6283</JournalRelease>
    <JournalID>51</JournalID>
    <Year>2011Apr15</Year>
    <Volume>207</Volume>
    <Issue>1-3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1573-9686</JournalRelease>
    <JournalID>52</JournalID>
    <Year>2011Jan</Year>
    <Volume>39</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1552-7433</JournalRelease>
    <JournalID>53</JournalID>
    <Year>2010Sep</Year>
    <Volume>36</Volume>
    <Issue>9</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1873-2968</JournalRelease>
    <JournalID>54</JournalID>
    <Year>2010Dec15</Year>
    <Volume>80</Volume>
    <Issue>12</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1536-0911</JournalRelease>
    <JournalID>55</JournalID>
    <Year>2010Apr</Year>
    <Volume>10</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1744-5485</JournalRelease>
    <JournalID>56</JournalID>
    <Year>2010</Year>
    <Volume>6</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1872-8278</JournalRelease>
    <JournalID>57</JournalID>
    <Year>2010Jun</Year>
    <Volume>10</Volume>
    <Issue>4</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1529-2916</JournalRelease>
    <JournalID>58</JournalID>
    <Year>2010Jan</Year>
    <Volume>11</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1873-3468</JournalRelease>
    <JournalID>59</JournalID>
    <Year>2010Jan4</Year>
    <Volume>584</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1097-4164</JournalRelease>
    <JournalID>60</JournalID>
    <Year>2009Oct23</Year>
    <Volume>36</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1477-9137</JournalRelease>
    <JournalID>61</JournalID>
    <Year>2009Sep1</Year>
    <Volume>122</Volume>
    <Issue>Pt 17</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1769-714X</JournalRelease>
    <JournalID>62</JournalID>
    <Year>2009Oct</Year>
    <Volume>11</Volume>
    <Issue>12</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1476-4687</JournalRelease>
    <JournalID>63</JournalID>
    <Year>2009Jul23</Year>
    <Volume>460</Volume>
    <Issue>7254</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0021-9258</JournalRelease>
    <JournalID>34</JournalID>
    <Year>2009Aug14</Year>
    <Volume>284</Volume>
    <Issue>33</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1096-3618</JournalRelease>
    <JournalID>64</JournalID>
    <Year>2009Aug</Year>
    <Volume>21</Volume>
    <Issue>4</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0219-7200</JournalRelease>
    <JournalID>65</JournalID>
    <Year>2009Jun</Year>
    <Volume>7</Volume>
    <Issue>3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1098-5549</JournalRelease>
    <JournalID>66</JournalID>
    <Year>2009Jun</Year>
    <Volume>29</Volume>
    <Issue>12</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0003-7028</JournalRelease>
    <JournalID>67</JournalID>
    <Year>2009Mar</Year>
    <Volume>63</Volume>
    <Issue>3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1001-0602</JournalRelease>
    <JournalID>39</JournalID>
    <Year>2008Sep</Year>
    <Volume>18</Volume>
    <Issue>9</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1600-065X</JournalRelease>
    <JournalID>68</JournalID>
    <Year>2009Jan</Year>
    <Volume>227</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1350-9047</JournalRelease>
    <JournalID>45</JournalID>
    <Year>2008Nov</Year>
    <Volume>15</Volume>
    <Issue>11</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1528-0012</JournalRelease>
    <JournalID>69</JournalID>
    <Year>2008Nov</Year>
    <Volume>135</Volume>
    <Issue>5</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1468-3288</JournalRelease>
    <JournalID>70</JournalID>
    <Year>2009Apr</Year>
    <Volume>58</Volume>
    <Issue>4</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0022-1317</JournalRelease>
    <JournalID>71</JournalID>
    <Year>2008Aug</Year>
    <Volume>89</Volume>
    <Issue>Pt 8</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0165-2427</JournalRelease>
    <JournalID>72</JournalID>
    <Year>2008Oct15</Year>
    <Volume>125</Volume>
    <Issue>3-4</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1936-0533</JournalRelease>
    <JournalID>73</JournalID>
    <Year>2008Jun</Year>
    <Volume>2</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0960-9822</JournalRelease>
    <JournalID>74</JournalID>
    <Year>2008Apr8</Year>
    <Volume>18</Volume>
    <Issue>7</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1386-6532</JournalRelease>
    <JournalID>75</JournalID>
    <Year>2008Jun</Year>
    <Volume>42</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1472-6807</JournalRelease>
    <JournalID>76</JournalID>
    <Year>2008</Year>
    <Volume>8</Volume>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0022-1767</JournalRelease>
    <JournalID>4</JournalID>
    <Year>2008Feb15</Year>
    <Volume>180</Volume>
    <Issue>4</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0161-5890</JournalRelease>
    <JournalID>3</JournalID>
    <Year>2008Apr</Year>
    <Volume>45</Volume>
    <Issue>8</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1529-9430</JournalRelease>
    <JournalID>77</JournalID>
    <Year>2008 Jul-Aug</Year>
    <Volume>8</Volume>
    <Issue>4</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0027-8424</JournalRelease>
    <JournalID>32</JournalID>
    <Year>2007May22</Year>
    <Volume>104</Volume>
    <Issue>21</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1525-8882</JournalRelease>
    <JournalID>78</JournalID>
    <Year>2007May1</Year>
    <Volume>2007</Volume>
    <Issue>384</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1529-2908</JournalRelease>
    <JournalID>58</JournalID>
    <Year>2007Jun</Year>
    <Volume>8</Volume>
    <Issue>6</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0022-538X</JournalRelease>
    <JournalID>9</JournalID>
    <Year>2007Jan</Year>
    <Volume>81</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1097-6744</JournalRelease>
    <JournalID>79</JournalID>
    <Year>2006Nov</Year>
    <Volume>152</Volume>
    <Issue>5</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1165-158X</JournalRelease>
    <JournalID>80</JournalID>
    <Year>2006</Year>
    <Volume>52</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0006-2952</JournalRelease>
    <JournalID>54</JournalID>
    <Year>2006Nov30</Year>
    <Volume>72</Volume>
    <Issue>11</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1471-4914</JournalRelease>
    <JournalID>81</JournalID>
    <Year>2006Feb</Year>
    <Volume>12</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1471-4906</JournalRelease>
    <JournalID>82</JournalID>
    <Year>2006Jan</Year>
    <Volume>27</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1081-5880</JournalRelease>
    <JournalID>83</JournalID>
    <Year>2005Nov</Year>
    <Volume>11</Volume>
    <Issue>11</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0092-8674</JournalRelease>
    <JournalID>15</JournalID>
    <Year>2005Sep9</Year>
    <Volume>122</Volume>
    <Issue>5</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0210-0010</JournalRelease>
    <JournalID>84</JournalID>
    <Year>2001 Jun 16-30</Year>
    <Volume>32</Volume>
    <Issue>12</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0003-2697</JournalRelease>
    <JournalID>85</JournalID>
    <Year>1995Apr10</Year>
    <Volume>226</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0095-6562</JournalRelease>
    <JournalID>86</JournalID>
    <Year>1984Feb</Year>
    <Volume>55</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
</QueryArticlesSet>